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Abstract  
Poor sleep and pain conditions present a major public health challenge due to their 
pervasive impact on well-being. Using a mix of experimental and observational 
methodologies, this thesis assesses sleep disruptions and its potential associations 
with the experience of pain. Chapter 4 comprises two experimental studies in healthy 
young adults (n = 57; n = 118) revealing that impairment in central pain inhibitory 
processes (conditioned pain modulation response) may be associated with self-
reported sleep disruptions. The studies also support the validity of the conditioned 
pain modulation response as a physiological marker of pain inhibition. Chapter 5 
presented a quasi-experimental study comparing chronic pain groups (Fibromyalgia n 
= 9; Chronic Back Pain n = 8) with healthy controls (n = 9) across range of self-reported 
and objective sleep and pain-related parameters. Findings revealed differences in 
patterns of self-reported sleep but not objective sleep between the two chronic pain 
conditions compared with healthy controls. The study also provided some extension 
of the findings from Chapter 4 by exploring the associations of objective sleep 
disturbance with less efficient pain inhibitory processes. To expand on these findings, 
the thesis adopted an epidemiological approach to explore the long-term 
interrelationship between sleep and pain-related outcomes in the general population. 
A systematic literature review (Chapter 6) of 16 longitudinal studies involving 61,000 
participants consolidated evidence that changes in sleep are associated with several 
dimensions of the pain experience (risk of developing a pain condition, elevations in 
levels of inflammatory markers, and a decline in self-reported physical health status). 
Finally, Chapter 7 presents an analysis of a sample of the UK population and revealed 
the association between four-year changes in different insomnia symptom (sleep 
onset latency, awakenings, and daytime sleepiness) and perceived physical and 
psychological well-being in the general population (n = 30,594) and a subgroup with 
arthritis (n = 4,300).  Overall, the findings from this thesis provide support for the 
associations of sleep disturbances with the processes underlying and shaping the 
experience of pain. The thesis highlights future research and beneficial interventions 
aimed at improving sleep and addressing associated pain-related health outcomes. 
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1 Introduction  
 
 
“Both symptoms are attributable to the same cause in the majority of cases. 
They are nature's danger signals, and he who would aim at merely relieving 
them by drugs may be compared to him who would cover up the red flag of 
danger on the railway with a white one, while the danger continued”  
 
John Haddon (1905) on pain and sleeplessness.  
 
  
The processes of sleep and pain are both intrinsic and essential for our survival 
as humans. The ability to perceive and react to pain is one of the most basic and 
beneficial physiological, psychological, and evolutionary response that we possess. 
Without this ability, the body becomes easily susceptible to different manners of 
physical threats and dangers. Sleep is also key to human survival and while it may be 
a behaviour that renders the individual into an unconscious state, it has evolved 
regardless to serve various important functions and we continue to depend on good 
sleep for optimum functioning. Neurobiological evidence shows that the systems 
regulating these two processes are overlapped and inextricably linked  (Foo & Mason, 
2003). This sets up an eventuality where problems in one system would affect or at 
least justify malfunction in the other. Dysregulation in the function of pain can alter 
and impede the ability of sleep to serve its necessary physiological function. Similarly, 
impaired sleep may lead to malfunction in the ability to perceive and manage pain.  
 
1.1 The process of sleep 
 
Sleep is a complex process regulated by various biological systems, which in turn 
can also impact different physiological processes in the body. Sleep depends on a 
network of brain activities across different neurobiological, neurophysiological, and 
 18 
neuroanatomical levels and engages numerous neurotransmitters, cellular and 
molecular interactions within the brain (Carskadon & Dement, 2011). Borbely, Daan, 
Wirz-Justice, and Deboer (2016) explains that sleep regulation depends on the action 
of two mechanisms that drives sleep and wakefulness; the body’s 24-hour circadian 
clock (Process C) which drives the timing of biological propensity to sleep and 
wakefulness and an arousal-dependent homeostatic system to drive sleep propensity, 
duration and intensity of sleep pressure build-up, and which measures and monitors 
sleep debt (Process S). The two processes usually work in a complimentary manner to 
drive wakefulness during the day and sleep at night. Other factors such as light, social 
activities, meal times and other behavioural and environmental factors can also 
regulate the two processes and drive sleep-wake activities (Dijk & Lazar, 2012). All 
these factors come together to bring about sleep through the activities of multiple 
brain regions. The suprachiasmatic nuclei (SCN) of the hypothalamus houses the 
internal 24-hour body clock and the ventrolateral preoptic nucleus (VLPO) which 
drives the action of associated genes, neurotransmitters, and the orexin, 
monoaminergic and cholinergic neurons (Dijk & Lazar, 2012). Also involved in the 
control of sleep are modulation hormones such as melatonin from the pineal gland, 
which regulates levels of alertness (Borbely et al., 2016; Peigneux, Urbain, & Schmitz, 
2012). 
 
Why we sleep is still not known. There is no grand overarching explanation, but 
several theories have suggested a role of sleep in maintaining optimal physiological 
and mental functioning. A set of theories propose that sleep allows us to function 
most efficiently during waking hours by carrying out tasks of neuronal maintenance 
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and memory consolidation during sleep (Harrison, 2012). There is also evidence to 
support that sleep is required for the process of learning, converting short-term to 
long-term memory and improving already existing long-term memories (Stickgold, 
2005). This is thought to be achieved by enhancing neuroplasticity and consolidation 
of neuronal circuity involved in learning, promoting learning-dependent synapse 
formation, and regulation of other higher cortical brain regions (Harrison, 2012; 
Stickgold, 2005; Yang et al., 2014). Another emerging theory is that deep slow wave 
sleep is when sleep-dependent hormones such as growth hormone and thyroid 
stimulating hormones are released and hence plays a role in ensuring cellular repair, 
maximal cell division, and protein synthesis (Tononi & Cirelli, 2014; Tung, Takase, 
Fornal, & Jacobs, 2005). Furthermore, it is thought that sleep is critical in ensuring 
metabolic homeostasis by engaging in the metabolic clearance task of ridding the 
central nervous system of potential neurotoxic by-products that accumulate during 
wakefulness, in particular proteins linked to neurodegenerative diseases such as -
amyloid (Xie et al., 2013). Immune signalling molecules and cytokines also interact 
within neurochemical systems in the brain influencing the regulation of normal sleep 
(Imeri & Opp, 2009). Regardless of the function sleep may serve, it appears that the 
process is key to both optimum physiological and cognitive functioning. A disruption 
in the normal process would subsequently impact both physiological and 
psychological well-being.  
 
1.2 What is chronic pain? 
 
International Association for the Study of Pain defines pain as ‘an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage 
 20 
or described in terms of such damage’ (Merskey & Bogduk, 1994). The most notable 
concept that has emerged from this definition is that pain is very much an affective 
emotional experience as well a physical one. Pain is inherently a subjective 
phenomenon and evidence reveals that perception of pain is not restricted to just 
localised sensations in body sites but rather a sum of various cortical processes and 
complex neurobiological pathways involving the somatosensory cortices, insula, 
limbic system, cingulate gyrus and prefrontal cortex (Apkarian et al., 2005). Pain 
invoked by injury or disease is generally perceived through a cumulative interaction 
of peripheral nocipceptive activation and different biochemical, physiological and 
psychological mechanisms involving a majority of the central nervous system. 
Ascending pathways are comprised of specialised sensory receptors responsible for 
the detection of noxious stimuli and the transformation of these stimuli into signals 
conducted to the central nervous system (Brooks & Tracey, 2005). From then on, the 
central nervous system can take on a pain inhibitory or facilitatory role in a number of 
ways. This can be at the spinal cord level, but there are also neural pathways that 
descend from the central structures of the nervous system and diminish pain signals 
(Brooks & Tracey, 2005). The outcome of the balance of these activities consequently 
determine the perception of pain by the individual.  
 
Acute feeling of pain serves an important bodily function of signalling injury and 
damage. In contrast, chronic pain persists beyond the expected time of healing from 
injury, illness or tissue damage, lasts beyond 3-6 months, and lacks the adaptive 
warning function that acute pain serves (Merskey & Bogduk, 1994). Chronic pain 
conditions are usually accompanied by notable emotional distress and/or significant 
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disabilities and interference with daily functioning and activities. The International 
Classification of Disease (ICD-11) categorisation for chronic pain (Treede et al., 2015), 
classifies chronic pain disorders into seven main categories. This includes chronic 
cancer pain (malignant cancer-related pain), chronic postsurgical and posttraumatic 
pain, chronic neuropathic pain (e.g., diabetic neuropathy), chronic headache and 
orofacial pain (e.g., migraines, temporomandibular joint disorder), chronic visceral 
pain (e.g., ischemia and thrombosis), chronic musculoskeletal pain that arises as part 
of a disease process directly affecting any  bone, joint, muscle, or related soft tissues 
(e.g., specific lower back pain, osteoarthritis, and rheumatoid arthritis), and chronic 
primary pain persisting or recurring in 1 or more anatomic regions for longer than 3 
months and not better explained by another chronic pain condition (e.g., fibromyalgia 
and conditions with idiopathic origin).  
 
Chronic pain further involves various degrees of dysfunction in peripheral and 
central sensitisation. Edwards (2005) explained that peripheral sensitisation is 
increased nociceptive input and dysfunction of pain regulating nociceptive signal in a 
way that heightens sensation of pain. Although compared to conditions such as 
osteoarthritis and back pain, idiopathic chronic pain conditions such as fibromyalgia 
and irritable bowel syndrome do not necessarily engage tissue or any peripheral 
damage to begin with. It is thought that in these cases, chronic pain is possibly rooted 
in dysfunction in central processes underlying pain functioning. Central sensitisation 
in chronic pain conditions refers to hypersensitivity that arise from a reduced 
threshold for pain facilitation and abnormal amplification of sensory signalling within 
the central nervous system, as well as reduced central pain inhibitory abilities 
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(Pergolizzi et al., 2013). Chronic pain may also result from neuroplastic changes over 
time at both spinal and supraspinal level, which results in amplified pain signal, surges 
in pain neurotransmitters, and dampened pain inhibitory responses (Edwards, 2005).  
 
1.3 Chronic pain conditions  
 
The discussions in this thesis focus on some of the most prevalent conditions 
(fibromyalgia, chronic back pain, and arthritis) in order to highlight and reflect the 
reality of pain and sleep disturbances as prevalent health burdens. These common 
primary and musculoskeletal pain conditions often account for the most primary care 
doctor’s visits and health care costs (Hoy, Brooks, Blyth, & Buchbinder, 2010; Marcus, 
2009) and are very briefly introduced below:  
 
1.3.1 Fibromyalgia  
 
Fibromyalgia (FM) is condition that typically presents with a combination of 
symptoms; pain at contralateral tender points all over the body, fatigue, memory 
problems, and sleep and mood disturbances. Global prevalence of FM is around 3% - 
8%, with 75% of affected individuals being women and aged between 30 – 50 years 
old (Clauw, 2014; Won & Kirsch, 2017). Diagnosis of FM is made according to the 2011 
Modification of the American College of Rheumatology Preliminary Diagnostic Criteria 
for Fibromyalgia. This diagnosis is based on an assessment of tender points, 
widespread pain index, and severity of accompanying symptoms (Wolfe et al., 2011; 
Wolfe & Hauser, 2011; Wolfe et al., 1990). 
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1.3.2 Chronic back pain  
 
Chronic back pain (CBP) is defined as back pain that lasts for longer than 3 – 6 
months and is commonly associated with a host of socioeconomic, work-related, 
psychological and psychosocial dysfunctions (Andersson, 1999). According to the 
latest findings from the Global Burden of Disease study, CBP is the leading cause of 
years lived in less than ideal health, measured as years lived with disability (YLDs). It 
also ranks among the top five illnesses contributing to disability-adjusted life years 
(DALYs) which combines data on mortality, measured as years of life lost due to 
premature mortality (YLLs) and YLDs (Institute for Health Metrics and Evaluation 
(IHME), 2016). This highlights the enormous global burden of low back pain as a 
prominent pain condition. The condition has a global prevalence estimated to be 
11.9%, with the highest prevalence among female individuals and those aged 40–80 
years (Buchbinder et al., 2013; Hoy et al., 2012; Hoy et al., 2010). A report based on 
Global Burden of Disease study findings revealed that in the UK, a third of all long-
term sickness absence from work, and nearly a fifth of any sick leave, is caused by 
musculoskeletal disorders such as chronic back and neck pain (Vos et al., 2016). A 
recent article also showed the increasing healthcare costs of chronic back pain. The 
condition costs the USA  about $88bn a year in personal healthcare which is the third 
highest bill for any health condition yet the prevalence, complaints, and burden of the 
condition persists for most individuals (Dieleman et al., 2016).  
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1.3.3 Arthritis  
 
Arthritis is a common chronic pain condition and a leading cause of health-
related disability worldwide and years lost to disabilities (YLD) (Institute for Health 
Metrics and Evaluation (IHME), 2016). It has two most common forms; rheumatoid 
(RA) and osteoarthritis (OA). RA is an inflammatory and autoimmune pain condition 
characterised by joint pain and joint swelling. Incidence of sleep problems in RA ranges 
from 54 to 70% (Abad, Sarinas, & Guilleminault, 2008). OA on the other hand is not 
associated with immune problems but is similarly characterised by musculoskeletal 
problems, joint pain, and joint stiffness. It is estimated that some 8.75 million in the 
UK have sought treatment for OA and around 400,000 have been diagnosed with RA 
(Arthritis Researh UK, 2013).  
 
1.4 The prevalence and impact of sleep and pain problems in the 
population  
 
 
Poor sleep and pain disorders are two of the biggest global health problems and 
present a major public health challenge with great economic and societal costs and 
burden to healthcare systems worldwide. Yet, understanding of the interrelationship 
between the two remains incomplete. Estimations and measures of health-related 
quality of life (HRQoL) and quality-adjusted life-year (QALY) also show that pain 
disorders in the general population are highly associated with disabilities. Namely, 
inability to engage in activities in daily living, limitations in social functioning, 
increased health-care utilisation, and risk of other comorbid disorders, morbidity and 
pre-mature mortality (Fernandez et al., 2010).  
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A diagnosis of insomnia often encompasses poor sleep quality. Insomnia is 
characterised by having difficulty initiating sleep, difficulty maintaining sleep and/or 
early morning awakenings with inability to return to sleep with those difficulties 
occurring despite adequate opportunity for sleep, and with accompanying daytime 
dysfunction (DSM-5, 2013; ICSD-3, 2014). Insomnia can either be a cause or 
consequence of poor physical and mental health. Studies have highlighted the 
negative association of both problems with insomnia (sleep quality) and problems 
with sleep quantity on morbidity and overall poor physical health. The implication of 
this can be seen on the biggest public health problems in society; sleep problems are 
linked to the development of depression (Riemann & Voderholzer, 2003), 
cardiovascular diseases (Cappuccio, Cooper, D'Elia, Strazzullo, & Miller, 2011), stroke 
(Leng et al., 2015), Type II diabetes (Cappuccio, D'Elia, Strazzullo, & Miller, 2010a), 
premature mortality (Cappuccio, D'Elia, Strazzullo, & Miller, 2010b), suicide and 
overall life satisfaction (Bernert, Turvey, Conwell, & Joiner, 2014), and chronic pain 
(Mork & Nilsen, 2012). Prevalence of insomnia symptoms in the general population 
ranges from 10 – 30% (Ohayon, 2002; Roth, 2007). Chronic pain prevalence can also 
range from 10 – 20% depending on different conditions and on how chronic pain is 
defined, if present for over three or six months (Breivik, Collett, Ventafidda, Cohen, & 
Gallacher, 2006; Goldberg & McGee, 2011).   
 
Sleep problems are a common presentation in individuals suffering from chronic 
pain. Data suggests that the prevalence of sleep complaints in chronic pain patients 
can be anything up to 50% in chronic back pain patients, 90% in those with 
 26 
fibromyalgia, and 65 – 70% in other mixed chronic conditions (Atkinson, Ancoli-Israel, 
Slater, Garfin, & Gillin, 1988; Morin, Gibson, & Wade, 1998; Pilowsky, Crettenden, & 
Townley, 1985; Tang, Wright, & Salkovskis, 2007; Theadom & Cropley, 2008). The 
National Health Interview Survey in America also revealed that 10.2 million of those 
with arthritis report insomnia, sleep disturbance, sleep duration of less than 6 hours 
and/or excessive daytime sleepiness (Louie, Tektonidou, Caban-Martinez, & Ward, 
2011). Ohayon (2005) ‘s  telephone survey of over 18,980 residents living in UK, 
Germany, Italy, Portugal, and Spain revealed a snapshot of the state of insomnia and 
painful conditions across Europe. This study assessed chronic painful physical 
conditions (CPPC) defined by pain lasting for at least six months and insomnia 
symptoms (difficulty initiating sleep, difficulty maintaining sleep, early morning 
awakening and non-restorative sleep, occurring for at least 1 month, more than three 
times a week and with daytime consequences). More than 40% of individuals with 
insomnia symptoms also reported at least one CPPC. Presence of a pain condition such 
as backaches and joint/arthritic diseases was a strong predictor of the presence 
insomnia symptoms with odds ratio (OR) ranging from 3.0 to 5.0. This relates to up to 
5 times higher the risk of reporting insomnia compared with those with no pain 
condition. Sivertsen, Krokstad, Overland, and Mykletun (2009) also reported the 
prevalence of insomnia in Norway from the HUNT-2 survey to be at 17% - 39.8% 
amongst individuals with a chronic pain condition. In addition, amongst the 47,700 
respondents, those with insomnia were more likely to report a co-occurring pain 
condition (mean ORs ranging from 1.24 – 2.75 across pain conditions). Since chronic 
pain is by definition intractable, focus has been on factors such as poor sleep quality 
that are either risk factors for developing long-lasting painful conditions, might 
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contribute to greater pain-related disability, or may be changeable factors that 
determine pain management and quality of life.  
 
1.5 Interrelationship between sleep and pain in chronic pain patients  
 
Not all patients with chronic pain have trouble sleeping, for example, in one 
study up to 35% of 105 chronic pain sample with high pain intensity still sleep normally 
and describe themselves as good sleepers (Morin et al., 1998). However, in those that 
do report problems, pain is believed by the patients to interfere with the ability to 
obtain adequate sleep and this disrupted sleep consequently worsens the experience 
of pain and related problems (Theadom & Cropley, 2008). Pain causes arousal and this 
arousal interferes with the ability to either initiate or maintain sleep, maintaining a 
vicious cycle of physical limitations and mental frustration (Drewes & Arendt-Nielsen, 
2001; Vitiello, Rybarczyk, Von Korff, & Stepanski, 2009). Notably, findings from recent 
studies using varied and sophisticated research designs are suggesting that sleep 
disturbance may have a stronger contributory effect on the experience, development, 
maintenance and perception of chronic pain than vice-versa. Research designs 
examining the temporal day-to-day variations have revealed the associations of  poor 
sleep quality with next-day pain (Tang, Goodchild, Sanborn, Howard, & Salkovskis, 
2012). Healthy women whose sleep continuity was disrupted using overnight forced 
awakenings reported decreased pain threshold and self-reported spontaneous painful 
somatic symptoms the next morning (Smith, Edwards, McCann, & Haythornthwaite, 
2007). Notably, prospective data in healthy populations have also revealed that 
complaints of non-restorative sleep or sleep disturbances are risk factors for the onset 
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and exacerbation of a host of chronic pain conditions (Campbell et al., 2013; McBeth, 
Lacey, & Wilkie, 2014; Mork & Nilsen, 2012; Nitter, Pripp, & Forseth, 2012).  
 
Finan, Goodin, and Smith (2013) expanded on these findings in their 
comprehensive review and urged more research to elucidate the directionality and 
potential mechanisms of the sleep and pain relationship. Aside from these initial 
findings, there is an overall lack of both extensive experimental and observational data 
in the area to substantiate the evidence that poor sleep and sleep disruptions 
activates symptoms of pain and contributes to the experience of chronic pain. It is 
possible that sleep problems may not just simply be a consequence of pain. Poor sleep 
itself may even alter central pain mechanisms and immune process implicated in the 
processing of pain and the pathophysiology of chronic pain. Disrupted sleep may also 
play a role in influencing not just the biological but also behavioural and psychological 
mechanisms that may perpetuate the pain experience.  
 
On the whole, sleep is emerging as an important aspect of the chronic pain 
condition; however, sleep is not currently routinely considered as a therapeutic target 
in chronic pain management. Proactive management of sleep disturbance would be 
beneficial to those individuals whose sleep quality may put them at greater risk for 
developing chronic pain conditions (Tang, 2009). Additionally, recent evidence also 
suggests that improving sleep quality may also alleviate the pain experience and 
consequently enhance health outcomes and quality of life for those living with chronic 
pain conditions (Tang, Lereya, et al., 2015).  
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1.6 Background and aim of thesis  
 
The aim of the thesis is to assess the specific mechanisms of sleep disruptions 
and its associations with pain processes. Additionally, the thesis aimed to explore if 
changes in sleep status are associated with pain-related health outcomes. Finan et al. 
(2013) and Smith and Haythornthwaite (2004) suggest the use of an integrated 
biopsychosocial model to investigate the different mechanisms, antecedents, and 
sequelae of the association between sleep and pain. They encourage basic and clinical 
research incorporating systematic and thorough measures of sleep and pain across 
both experimental and observational designs. Salkovskis (2002) also supports this 
manner of approach in clinical sciences; a model that incorporates a varied evidence 
base to support the biological understanding of health conditions and development 
of novel approaches to treatment. This further emphasises that the empirical basis of 
clinical interventions must come from validated theories and linked research studies. 
In light of this, this thesis adopted a multi-methodological approach that allows for a 
detailed multi-level investigation of the biological and psychological contingencies 
underlying the association between sleep disturbances and the pain experience. 
Notably, the thesis considers how much sleep contributes to the experience of pain 
and chronic pain both at the individual within-person and at the general population 
level. At the individual level, we need a deeper and better understanding of the 
biological interaction between impaired sleep and pain, to establish individual 
variations in sleep behaviours and pain processing in heathy individuals and clinical 
pain patients. At the population level, we need evidence to also demonstrate the long-
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term association of sleep and pain symptoms, in order to tackle and contain the 
societal impact of sleep and pain problems and their comorbidities.  
 
Using a mix of experimental and observational methodologies, this thesis seeks to: 
- Characterise sleep disturbances, pain inhibitory processes, and bio-
psychological functioning in healthy and clinical pain populations.  
- Explore the long-term association of changes in sleep status and pain-related 
health outcomes and general wellbeing in the general population and 
subgroups with chronic pain.   
 
The thesis is structured and presented as follows: 
Chapter 2 – An overview of measures and assessment of sleep (polysomnography and 
actigraphy), pain (quantitative sensory testing), and physiological biomarkers 
(inflammatory cytokines) discussed and explored in subsequent chapters. 
 
Chapter 3 – A brief overview of existing literature and research evidence on the 
different bio-behavioural aspects and mechanisms underlying the association 
between sleep and pain.  
 
Chapter 4 – An experimental study which assesses the validity of conditioned pain 
modulation (CPM) as a measure of central pain inhibitory processes and the 
association of CPM with self-reported sleep disturbances in healthy young adults.  
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Chapter 5 – A quasi-experimental study using self-report, actigraphy, and 
polysomnography to identify the characteristics of pain, sleep disturbance, 
inflammation, and psychological functioning in two chronic pain conditions 
(fibromyalgia and chronic back pain) compared with healthy controls. Specifically, 
with a focus on polysomnography assessment to examine both overnight sleep 
macroarchitecture and micro architecture. In addition, it forms a further exploration 
of the association of sleep disturbance with pain inhibitory processes in those with 
chronic pain.  
 
Chapter 6 – A systematic review and meta-analysis of prospective studies that have 
evaluated changes in sleep quality, sleep quantity, and insomnia symptoms, as well as 
their associations with pain-related health outcomes in the general population.  
 
Chapter 7 – A study to examine whether changes in sleep and insomnia symptoms 
over a four-year period are associated with psychological wellbeing and perceived 
physical functioning and mental health assessed at baseline and follow-up (four 
years). This was investigated in the general population and a subset of individuals with 
chronic pain within the general population.   
 
Chapter 8 – A summary and general discussion on the unique contributions of the 
thesis to the mechanisms and processes that shape the associations between sleep 
disturbance and pain experience. This chapter brings together results of all the 
studies, strengths and weaknesses of the thesis, and discusses general 
recommendations emerging from the findings.  
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2 Assessment of sleep, pain, and inflammation biomarkers 
 
 
This chapter provides an overview of measures and assessments applied in this 
thesis. The chapter considers the measurement of sleep (including polysomnography, 
actigraphy, and self-reported measures). The chapter then addresses the mechanism 
of human pain perception and use of quantitative sensory testing in the assessment 
of pain. Finally, the chapter presents an overview of physiological biomarkers 
(inflammatory cytokines) implicated in sleep and pain processes which are discussed 
and explored in subsequent chapters. 
 
2.1 Assessment of sleep        
                                                                                         
2.1.1 Polysomnography  
 
Sleep is a dynamic process involving changing electrical activity within the 
brain and accompanying physiological characteristics (Carskadon & Dement, 2011). 
Polysomnography (PSG) comprises of electroencephalography (EEG), 
electromyography (EMG), electrooculography (EOG), respiration measures, heart 
rate, and sometimes body temperature and is the gold standard method for the 
assessment of measuring sleep and sleep disturbances. PSG is an electrophysiological 
marker reflecting the sleep process and allows for analysis of both macrostructure 
(sleep continuity and sleep architecture, sleep stages) and microstructure (EEG wave 
form distribution using spectral analysis) of sleep. PSG recording montage (Berry et 
al., 2017) typically consists of six electroencephalography (EEG) electrodes attached 
to the scalp near the frontal (F3, F4), central (C3, C4), and occipital (O1, O2) cortices. 
Additional EEG electrodes are used as reference electrodes – these include Ground 
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(PGND) placed on the forehead (FPz) to maintain amplifier inputs within a small 
voltage range relative to the amplifier’s zero voltage level, Reference (REF) placed 
near the centre of the scalp (Cz) and M1 and M2 placed on the mastoid bone behind 
the left and right ear.  The EEG channels are referenced to each mastoid on the 
opposite side of the head (e.g., F3/M1, C4/M2). EEG electrodes are placed according 
to the ‘International 10-20 system’ for describing the location and application of scalp 
electrodes (Berry et al., 2017). Electrode sites are usually cleaned with a mild abrasive 
cream (e.g. Weaver NuPrep skin prep gel) and electrode application completed using 
GRASS 30” 78in/200cm gold EEG electrodes fixed with a conductive paste such as the 
Natus Grass EC2 electrode paste. See Figure 1 for electrodes placement and location 
used in this thesis.  
 
  
 
For the rest of PSG set up, electrooculography (EOG) electrodes E1 and E2 are 
placed around the eyes to detect eye movements during sleep. 
 
Notes: Electrode placement for standard EEG and PSG recording  
Figure reproduced from Embla S4500 clinical manual with permission.  
 
Figure 1 Sleep EEG Electrodes placement and location 
Figure 1 Electrodes placement and location  
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Electromyography (EMG) electrodes are used to detect electrical activity in the 
muscles. Three EMG electrodes are placed around the chin and two further electrodes 
on muscle of each leg to measure leg movements.  Two electrocardiography (ECG) 
electrodes are placed under the collarbone on each side of the chest to detect heart 
rate and cardiac activity.  Nasal and oral airflow and respiration rate are 
measured using a nasal cannula and airflow thermistor placed around the nostrils. In 
addition, respiratory effort is measured using belts placed around the chest and the 
abdomen, which expand and contract upon breathing effort. Pulse oximetry assesses 
blood oxygen levels and is measured using a pulse oximeter placed over the fingertip. 
Snoring can also be recorded using a snore microphone placed over the neck. In 
addition, for polysomnography recording, participants are usually monitored visually 
during the night using infra-red CCTV camera for sleep behavioural observations. Any 
sleep disruptions such as periodic limb movement disorder or parasomnias can thus 
be detected as part of PSG assessment.  
 
For the study described in Chapter 5 of this thesis, overnight sleep assessment 
was conducted to determine sleep macro- and micro-structure. The first night of PSG 
recording was used for screening and adaptation to the new sleeping environment 
and was not included in the analysis as per standard recommendations (Berry et al., 
2017).  Embla REMLogic 3.4 PSG software was used for PSG data recording, acquisition 
and later analysis, scoring and spectral analysis.  Impedance test and bio calibrations 
were carried out on the RemLogic software before each recording to check the 
amplifier settings and integrity of the electrodes and sensor. All impedance was kept 
below 5Ω or less to lessen the chances of noisy traces during the night. Acquisition of 
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the data on was relayed to the RemLogic PSG software via the M-Drive communication 
unit and Embla S4500 system. EEG traces and PSG signals were digitised, transmitted 
and viewed in real time on a Lenovo ThinkVision LT2934z 29-inch display computer 
monitor with a 2560 x 1080 resolution, minimum resolution for sleep scoring as per 
AASM recommendations is 1600 x 1200.  
 
Figure 2 Embla unit for PSG recording 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.1.1 Sleep Scoring  
 
Outputs from PSG recording is normally scored and summarised by a 
polysomnography technician according to standardised AASM criteria (Berry et al., 
2017). Scoring involves analysing each 30-second period of sleep (epochs) and the 
brain electrical wave patterns in each epoch for amplitude and frequency, as well as 
distinct markers of brain activity, eye movements, and muscle activity.  
Notes: Embla S4500 bedside unit and channel inputs for 
standard EEG and PSG recording used in the study. Figure 
reproduced from Embla S4500 clinical manual with permission.  
 36 
 
As described by the AASM (Berry et al., 2017), in adults, sleep typically consists 
of non-rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep 
periods. These parameters make up normal sleep architecture and macro-structure. 
In normal sleep physiology, transitions through these states of sleep occur 
approximately every 90 minutes and it is usual for an individual to pass through 4-5 
cycles overnight. Wakefulness with eyes closed is characterised by fast frequency 
alpha waves (8-12 Hz) seen on the EEG. NREM sleep has three distinct sleep stages 
and the initial short period following sleep onset is known as stage 1 (N1). This initial 
stage marks the disappearance of alpha waves and emergence of theta (4-7 Hz) waves. 
This is followed by stage 2 (N2) sleep which is characterised by a variety of wave 
frequency and distinct bursts of activities such as sleep spindles and K-
complexes. Sleep spindles are short burst of oscillatory electrical activity of beta and 
sigma frequency waves (12–16 Hz) and K-complexes precede sleep spindles. K-
complexes are large amplitude (>75 µV), low-frequency (0.5–2.0-Hz) biphasic wave-
forms with a brief negative high-voltage peak, followed by a slower positive electrical 
component. Following N2, Stage 3 (N3) sleep, also known as slow wave sleep (SWS) 
emerges and is characterised by low amplitude delta frequency (0.5-4.5 Hz) wave 
formations (Berry et al., 2017).  
 
REM sleep is characterised by mixed frequency theta and beta wave patterns 
with distinct sawtooth shapes, rapid eye movements picked up by EOG electrodes and 
decrease in muscle tone detected by EMG electrodes (Berry et al., 2017). During 
normal sleep in healthy individuals, REM sleep episodes come at the end of each sleep 
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cycle and become increasingly longer as the night progresses and as SWS conversely 
becomes less dominant especially in the last 2 sleep cycles (Carskadon & Dement, 
2011). Typically for an adult, a normal night of sleep would comprise approximately 
5% of N1, 50% of N2, 20% of N3 (SWS), and 25% of REM sleep.  
 
For the study described in Chapter 5, PSG sleep scoring was performed for the 
second night of PSG monitoring. Each night of data was analysed using the Embla 
RemLogic 3.4 software, traces were viewed and scored in 30-s epochs by the 
researcher using the AASM criteria (Berry et al., 2017). Variables derived from PSG 
and their definitions are displayed in Table 1.  The beginning of sleep scoring was 
determined by ‘lights out’ time and this was when participants depressed the light 
when going to sleep and ‘lights on’ was when they turned on the light in the morning 
to indicate getting out of bed. The scored sleep period was used for the definition of 
the values of: sleep onset latency, wake after sleep onset, sleep efficiency, total sleep 
time, time spent in each sleep stages, awakenings, and arousals. Arousals were 
computed automatically by the system; the sensitivity of detection was calibrated to 
be in accordance with AASM defined criteria; an abrupt shift in frequency lasting for 
at least 3 seconds with 10 seconds of stable sleep preceding (Berry et al., 2017). 
 
2.1.1.2 Spectral analysis  
 
Sleep macrostructure refers to the organisation of sleep stages as described 
above, whilst sleep microarchitecture focuses more on the EEG features and subtle 
alterations occurring during the course of sleep. This approach provides a deeper and 
more dynamic characterisation of the sleep process not reflected by simple 
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macrostructure sleep scoring. Spectral analysis involves mathematical  transformation 
of EEG signals into representations of power bands of different frequencies (Campbell, 
2009) and provides a way to quantify EEG activity. For the study described in this 
thesis, spectral analysis was applied to the second night of sleep EEG data. 
Additionally, the C4 - M1 channel was selected for spectral analysis as it was deemed 
to produce the most robust signal, C3 – M2 were also used in some cases when C4 – 
M1 was noisy and with a lot of artefacts (Campbell, 2009; Spiegelhalder et al., 2012).  
Analysis was conducted using the RemLogic 3.4 software. The software has an 
algorithm for artefact rejection and to discard outlier epochs with a lot of noise and 
artefacts from the computation of average spectral power. The software protocol for 
spectral analysis involves Fast Fourier Transform (FFT) as per Spiegelhalder et al. 
(2012). Each analysis window equates to 512 points (2.56 seconds) long, giving a 
frequency resolution of 1/2.56 = 0.39Hz and 22 overlapping windows cover each 30 
second epochs. Spectral power values were obtained from FFT bins with frequency 
within the frequency bands of Delta-1 (0.1-1Hz), Delta-2 (1-3.5Hz), Theta (3.5-8Hz), 
Alpha (8-12Hz), Sigma-1 (12- 16Hz), Beta-1 (16-24Hz), Beta-2 (24-32Hz) and Gamma 
(32-48Hz). These power bands were averaged over the whole night of sleep across all 
artefact-free epoch of scored sleep stages. The values were then log transformed 
(log10) for analysis. Frequency bands were analysed separately for NREM and REM 
periods and for sleep stages N2 and N3. Analysis was separated and examined 
separately for N2 and N3 to eliminate the influence of different frequencies of NREM 
sleep stage distribution across participants (Feige et al., 2013).  
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Table 1 Polysomnography (PSG) variables and definition 
PSG variables  Definition 
Time in Bed Analysis period from ‘lights off’ to ‘lights 
on’, beginning to end of sleep period 
Sleep onset latency Time (minutes) from start of analysis until 
first occurrence of 30secs of consecutive 
sleep events 
Sleep efficiency  Total sleep time/Time in bed*100 
Wake after sleep onset duration Time (minutes) spent awake during sleep 
period 
Total sleep time Total amount of time spent sleeping 
during sleep period 
Awakenings A duration of awakening during the sleep 
period that equates to 60 seconds or 
greater 
Arousal Automatic arousal analyser, based on 
criteria set by AASM, duration of 3 
seconds or longer, abrupt shift in EEG 
frequency greater than frequency band 
thresholds. RemLogic algorithm uses the 
following frequency bands: Delta 0.5-
4.0Hz, Theta 4.0-8.0Hz, Alpha 8.0-12.0Hz, 
Sigma 12.0-16.0Hz, Beta 16.0-20.0Hz 
Stage N1% Time (minutes) and percentage of time (as 
a function of total sleep time) spent in 
Stage N1 
Stage N2% Time (minutes) and percentage of time (as 
a function of total sleep time) spent in 
Stage N2 
Stage N3% Time (minutes) and percentage of time (as 
a function of total sleep time) spent in 
Stage N3 
Stage REM% Time (minutes) and percentage of time (as 
a function of total sleep time) spent in 
Stage REM 
Power Spectral Analysis 
Trace used (C4 – M1) 
Power bands: Delta-1 (0.1-1Hz), Delta-2 
(1-3.5Hz), Theta (3.5-8Hz), Alpha (8-12Hz), 
Sigma-1 (12- 16Hz), Beta-1 (16-24Hz), 
Beta-2 (24-32Hz) and Gamma (32-48Hz). 
Power spectrum computed in logarithmic 
scale and synced with predefined 30sec 
scoring epochs. A 512-point Fast Fourier 
Transform (FFT) was used and overlapped 
by 50% and average over 30sec epoch 
duration. 
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2.1.2 Actigraphy  
 
Actigraphy is a non-invasive method of sleep assessment that uses a 
wristwatch like device with an accelerometer to detect movements.  The devices 
usually come with an event marker with which the wearer can indicate time in bed, 
overnight awakenings, and wake time. The data collected is downloaded unto a 
computer and a corresponding analysis software can then use validated algorithms to 
provide information on sleep and wake patterns. This provides an interpretation and 
overview of participants’ sleep schedule and sleep pattern over a period of days and 
weeks. Actigraphy is relatively inexpensive and more convenient than PSG 
assessment. It can provide an ecologically valid assessment and estimate of sleep 
amounts and sleep continuity in the individual’s normal sleeping environment (Ancoli-
Israel et al., 2003).  Another advantage of actigraphy is that it can be used over a 
period of weeks (depending on battery length) as a non-invasive assessment of sleep 
and activity across different sleep disorders including insomnia and circadian rhythm 
disorders.  However, unlike PSG, actigraphy does not provide an assessment of sleep 
architecture and cannot provide a specific diagnosis of a sleep disorder such as sleep 
apnoea. Actigraphy sensitivity and specificity for sleep detection is usually good and 
often shows high agreement rates with PSG data for total sleep time and sleep 
efficiency variables in healthy individual but is more limited in detecting sleep onset 
latency for example (Kushida et al., 2001). It is often recommended to use self-
reported data as a supplement to actigraphy data (Ancoli-Israel et al., 2003). 
 
For the study described in Chapter 5, actigraphy monitoring involved the use 
of CamNTech Actiwatch 4 and corresponding activity and sleep analysis software. Each 
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participant’s recording was set up and anonymised according to their study 
identification number. The actigraph was set up to capture one week of baseline data 
and set up again for the laboratory session. The devices were set up to record 
continuously 30-second epochs of activity. Table 2 provides the actigraphy definitions 
for sleep variables as computed by the software.  
 
Table 2 Actigraphy variables and definition 
Actigraphy variables  Definition 
Time in bed Period from bedtime – waketime, 
determined by markers/sleep diary 
Sleep onset latency The latency before sleep onset following 
bedtime 
Total sleep time The amount of sleep as determined by 
software algorithm and is equivalent to 
assumed sleep minus wake time 
Wake time The amount of time spent awake after sleep 
onset as determined by software algorithm 
Sleep efficiency The percentage of time spent asleep relative 
to time in bed 
Fragmentation index Indicator of restless as determined by 
software algorithm, percentage of time 
spent moving during assumed sleep period 
relative to percentage of immobility phases 
in 1 minute 
  
2.1.3 Structured clinical interview, self-reported measure, and sleep diary 
 
Structured clinical interviews can also be used to gain an insight into an 
individual’s sleep patterns, and especially as a baseline screening measure before the 
start of a research study. One such interview is the Duke Structured Interview for Sleep 
Disorders Schedule for Insomnia Screening [DSM-IV and ICSD-2] (Edinger et al., 2009). 
Since there is not currently an updated or another interview schedule for the current 
DSM-V and ICSD-3 classifications, an adapted version of the Duke Structured Interview 
was used in this thesis to reflect the most recent DSM-V and ICSD-3 classification for 
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sleep disorders. This interview usually lasts for an hour. It can form part of a 
participants’ social, physical and mental health history, medication and alcohol use. It 
also has specific questions regarding the timing and onset of sleep and can even delve 
deeper to assess that individuals have no other medical illnesses, psychiatric 
conditions, sleep disorders (e.g., sleep apnoea, narcolepsy, restless leg 
syndrome/periodic limb movement syndrome), or dependency on and abuse of 
medication and substances that could be contributing to any reported or unknown 
sleep disturbance (Buysse, Ancoli-Israel, Edinger, Lichstein, & Morin, 2006). It is worth 
noting that use of clinical interviews such as this is open to lack of standardisation and 
requires other concurrent measures of sleep to be meaningful and interpretable 
within the context of the study.  
 
There are also many standardised and validated self-report questionnaires 
through which participants can report sleep-related cognitions, beliefs, behaviours, 
attitudes, perceived mental and physical health, and quality of life. These are 
presented as used in subsequent chapters. The sleep diary is also a credible standard 
for self-reported assessment of sleep (Carney et al., 2012). Sleep diaries are key to 
understanding an individual’s self-reported sleep patterns and disturbances. Self-
monitoring of sleep using a sleep diary enables the participants to estimate and report 
their overnight sleep quality, the time it takes to fall asleep (sleep onset latency), how 
many times and for how long they wake up overnight (wake after sleep onset times 
and duration), the time spent in bed and total sleep time and from this, their sleep 
efficiency can be calculated which is the percentage of time spent asleep relative to 
the amount of time spent in bed.  The diary is usually completed upon waking and 
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refers back to sleep the prior night and can be completed over a period of one to two 
weeks to get a reliable estimate of sleep pattern. It is recommended and proposed by 
the AASM that the Consensus Sleep Diary developed by Carney et al. (2012) be used 
as a template for a standard sleep diary across research studies. The sleep diary is 
fairly easy to use, however, to ensure the accuracy and completeness of the data, 
participants need to be trained on how to complete the diary properly.  Although 
there is often good correlation between the objective and self-reported sleep 
measures, self-reported sleep from the sleep diary may also differ from PSG measures 
(Lockley, Skene, & Arendt, 1999; Westerlund, Lagerros, Kecklund, Axelsson, & 
Akerstedt, 2016). Recent studies have also suggested that derived PSG sleep measure 
may be less predictive of an individual’s perception of the quality of their overnight 
sleep (Kaplan et al., 2017).  
 
2.2 Assessment of pain  
 
2.2.1 Pain pathways in the brain  
 
Pain is a personal and private experience. The awareness of pain is a 
multidimensional process in that it commands a wide range of different sensory, 
physiological and cognitive processes. This thesis utilises methods to quantitatively 
assess pain perception. To appreciate how the experience of pain can be assessed 
quantitatively beyond self-report, it is important to understand the physiological, 
sensory, and evaluative nature of pain. Specifically, how the central nervous system 
engages several actions to reduce, and sometimes increase perception of pain. The 
awareness of a painful event first starts with contact with a noxious stimuli, a signal is 
then sent to the central nervous system and relayed to be processed by the brain’s 
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pain related cortices, including the primary (S1) and secondary (S2) somatosensory 
cortex, primary motor cortex (M1), anterior cingulate cortex (ACC), insula, prefrontal 
cortex (PFC), hippocampus (HIPP), basal ganglia (BG), hypothalamus (HYP) and 
amygdala (AMYG) (Brooks & Tracey, 2005; Bushnell et al., 2013; Bushnell et al., 1999).  
Structures within the midbrain, brainstem, and spinal cord consequently modulate 
and construe the actual physical perception of pain. Ascending pathways comprised 
of spinothalamic tract, dorsal column medial leminscal pathway (DCML), and 
spinocerebellar tract work together for the detection of noxious stimuli and the 
transformation of these stimuli into pain signals (Apkarian et al., 2005; Brooks & 
Tracey, 2005). 
 
The midbrain periaqueductal grey (PAG), brainstem rostral ventromedial 
medulla (RVM) and dorsal reticular nucleus (DRt) are key structures of the 
endogenous descending pain modulation system. The PAG is the source of the 
descending opioid-mediated inhibition of pain. The RVM and DRt alter inhibition and 
facilitation of pain and enable the PAG to project directly to the spinal dorsal horn for 
regulating nociceptive input at the spinal level (Ossipov, Morimura, & Porreca, 2014). 
Since these structures send and receive projections to and from different cortical sites 
within the central nervous system, this allows the potential for varying cognitive (e.g., 
attention, distraction, beliefs, appraisal, catastrophising), affective (mood), 
behavioural (activity), physiological (inflammation) influences to regulate activity 
within this pain inhibition system and contribute to the overall experience of pain 
(Bushnell et al., 2013; Ossipov, Dussor, & Porreca, 2010).  See Figure 3 for an overview 
of brain structures and pathways involved in the perception of pain.  
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Spinal dorsal horn 
M1 S1 
S2   PPC 
PFC           ACC   
                Insula 
     HIPP   HYP   BG 
            AMYG 
Thalamus 
Endogenous 
Descending Pain 
Modulation 
System 
Midbrain (PAG) 
Brainstem 
(RVM,DRt) 
Primary and secondary somatosensory cortex (S1 & 
S2), primary motor cortex (M1) – pain transmission, 
modality, duration, intensity, and location of pain  
 
Anterior cingulate cortex (ACC), insula, prefrontal 
cortex (PFC) – pain perception, unpleasantness, and 
cognitive evaluation  
 
Hippocampus (HIPP) – pain-related spatial memory 
and mood  
 
Basal ganglia (BG) – integration of motor, emotional, 
autonomic, cognitive pain responses  
 
Hypothalamus (HYP) – regulation of visceromotor and 
motivation pain responses 
 
Amygdala (AMYG) – pain-related fear, anxiety and pain 
modulation  
 
 
C fibres 
A    fibres 
Thalamus – pain recognition, processes and relays 
transmission of nociceptive information to the cerebral 
cortices 
Notes: Schematic diagram of pain pathways within the central nervous system. Black arrows represent 
transmission of pain signals from the periphery; nociceptive information enters the brain from the spinal cord 
through C and A nociceptive fibres, the information is recognised by the thalamus and projected to the cerebral 
cortices involved in the different experience of pain – primary (S1) and secondary (S2) somatosensory cortex, 
primary motor cortex (M1), anterior cingulate cortex (ACC), insula, prefrontal cortex (PFC), hippocampus 
(HIPP), basal ganglia (BG), hypothalamus (HYP) and amygdala (AMYG). Black arrows represent direction of 
ascending pain pathway; spinothalamic tract, dorsal column medial leminscal pathway (DCML), and 
spinocerebellar tract. Dashed arrows represent the direction of descending pain modulation pathways; the 
midbrain periaqueductal grey (PAG), brainstem rostral ventromedial medulla (RVM) and dorsal reticular 
nucleus (DRt) are key structures of the endogenous descending pain modulation system. They receive input 
from spinal cord and cerebral cortices and alter inhibition but also facilitation of pain at the spinal level.  
Adapted from: (Apkarian, Bushnell, Treede, & Zubieta, 2005; Brooks & Tracey, 2005; Bushnell, Čeko, & Low, 
2013; Zhuo, 2008) 
Input from peripheral to CNS 
through C and A nociceptive 
fibres. Local gating control of pain 
and modulation through different 
neurotransmitters and synaptic 
mechanisms.  
Periaqueductal gray (PAG) – descending opioid-
mediated pain inhibition 
 
Rostral ventromedial medulla (RVM) – receives input 
from PAG, bidirectional descending pain modulation  
 
Dorsal reticular nucleus (DRt) – interacts with PAG and 
RVM and projects pain modulatory signals to spinal 
cord 
 
Dorsal column medial leminscal pathway (DCML) – 
ascending pain pathway through spinothalamic and 
spinocerebellar tract  
 
Ascending 
Pain Pathways 
DCML 
Spinothalamic 
& 
Spinocerebellar 
tract 
 Figure 3 Pain pathways in the brain 
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This effect of the central nervous system to modulate pain perception is 
reflected in theories of pain control. One such theory is the gate control theory of pain 
proposed by Melzack and Wall (1965) to describe the process of pain modulation at 
the spinal cord level. The theory also provides the physiological basis to allow such 
explanations how cognitive and affective influences could control sensory outputs and 
regulate pain perception.  They explained that small ‘C’ (nociceptive) and ‘A’ large 
(non-painful) nerve fibres transmit unto ‘inhibitory’ or ‘transmission’ cells within the 
spinal cord. The interplay between these fibres and cells control when pain signals are 
sent to the brain; when there’s no input, the inhibitory cells prevent sending of signals 
to the brain (gate closed), normal somatosensory input means large ‘A’ fibres 
activations and both inhibition and transmission cells are facilitated but inhibitory cells 
prevent sending of signals to the brain (gate still closed).  
 
Pain perception occurs with small fibres activation, this inactivates the 
inhibitory cells and enables the transmission cells to send nociceptive pain signals to 
the brain (Melzack & Wall, 1965). The concept of pain threshold reflects how open the 
gates must become to enable a greater number of small nociceptive fibre signals to 
pass through. Descending pathways from the brain can either help close or keep the 
gate open by sending signals to pain control centres within the midbrain and 
brainstem, from which descending messages are then sent to the spinal cord (Coons 
& Steglitz, 2013). These messages either facilitate pain by amplifying incoming 
nociceptive signals from the body or diminish pain perception by reducing or inhibiting 
the nociceptive signals. 
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2.2.2 Quantitative sensory testing and Conditioned pain modulation  
 
Quantitative sensory testing (QST) is a psychophysical testing method to 
measure these responses to sensory stimuli and can thus be used as an indicator of 
neural function or altered pain processing. Dysfunction of the peripheral nerves or 
ascending and descending pain pathways within central nervous system may give rise 
to abnormalities in QST. A QST protocol can be used to assess minimum sensory 
threshold perceived, localisation of pain, threshold perceived as painful, pain 
tolerance, or differentiation between sensory inputs. It can reflect relevant aspects of 
the somatosensory system, including large and small fibre functions, and signs of 
central sensitisation (Uddin & MacDermid, 2016). Stimulus modality for QST can 
include electrical, thermal (heat or cold), mechanical (pressure, touch, vibration), and 
chemical (capsaicin) (Arendt-Nielsen & Yarnitsky, 2009). QST assesses the subjective 
responses (within a psychophysical parameter) by measuring perception magnitude 
to a controlled quantitative stimulus intensity (Uddin & MacDermid, 2016). 
 
Conditioned pain modulation (CPM) is a quantitative sensory testing paradigm 
and one of the most studied mechanisms of descending endogenous pain control in 
humans (Yarnitsky et al., 2015). The descending pain inhibition that underlies CPM is 
integrated within the DRt, which interacts with the PAG and RVM, projects to the 
spinal cord and involves opioid, serotonergic and noradrenergic neurotransmission 
systems to enhance or attenuate pain input at the spinal level (Ossipov et al., 2010; 
Piché, Arsenault, & Rainville, 2009; Tracey & Dunckley, 2004). It engages pain signals 
arriving at the brainstem, activates the descending pain inhibitory pathways, projects 
pain modulatory signals to the spinal cord and exerts an inhibitory effect on incoming 
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concurrent pain signals (Staud, 2013). This modulation prevents excessive pain by 
attenuating successive and simultaneous painful stimuli, and limits processing of 
nociceptive signals not concerned in processing of the strongest pain stimulus (Le 
Bars, 2002). In other words, it is based on the “pain inhibits pain” phenomenon, where 
a painful stimulus inhibits or subdues the perception of pain produced by a second co-
occurring painful stimulus at a distant body site. CPM was originally studied 
extensively in animals as the diffuse noxious inhibitory control (DNIC) paradigm (Le 
Bars, Dickenson, & Besson, 1979a, 1979b; Le Bars, Villanueva, Bouhassira, & Willer, 
1992) but can also be measured psychophysically in the laboratory in human subjects 
(Figure 4), whereby Stimulus A (a test pain such as pressure pain) given together with 
Stimulus B (a conditioning pain such as cold pain) is perceived as less painful than 
when Stimulus A was given alone (Nir & Yarnitsky, 2015).  
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Figure 2 Conditioned pain modulation  
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Notes: Schematic diagram of conditioned pain modulation using an example of pressure pain 
threshold as test stimulus and cold pain as conditioning stimulus. Stimulus A (test-pain; pressure 
pain) when applied together with Stimulus B (conditioning pain; cold pain) on contralateral body 
sites is perceived as less painful (increased pressure pain threshold) than when it was applied 
alone.  
Stimulus ‘A’ (pressure 
pain) applied to right 
body site 
Conditioned pain modulation (CPM) =  
Reduction in pain perception (i.e.  pressure pain threshold)  
Figure 4 Conditioned pain modulation 
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2.2.3 Questionnaires 
 
 
Questionnaires may also be used to provide necessary details about 
participants’ self-reported experience of pain. The pain-related questionnaires used 
in this thesis are introduced and presented in the methods section of relevant 
chapters. 
 
2.3  Assessment of inflammatory biomarkers implicated in sleep and pain 
 
Protein or protein-like molecules that signal inflammatory pathways are termed 
cytokines. They serve as chemical messengers between cells and are involved in 
processes such as cell growth, tissue repair, and shaping inflammatory immune 
responses from blood cells (Wallace, 2006). Several inflammatory cytokines have been 
extensively studied in relation to sleep and pain. These cytokines play a role in both 
maintenance of pain and regulation of sleep homeostasis. Imbalance in activation and 
levels of these cytokines is implicated in transition from acute to chronic pain, and 
they often also play a pivotal role in central nervous system’s sleep activation 
pathways (Imeri & Opp, 2009). Pain and inflammatory processes often co-occur, and 
inflammatory cytokines have been found not only to be present during the experience 
of acute pain but also inducing and facilitating the continued experience of chronic 
pain. Cytokines such as C-reactive protein, Interleukin 6, Interleukin-1 beta, and 
tumour necrosis factor-alpha are also known to be proinflammatory somnogenic 
cytokines implicated in the experience of pain, fatigue and sleep and are examined in 
this thesis.   
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2.3.1 Interleukin-6 (IL-6) 
 
Interleukin-6 is often used as a marker for systemic activation of 
proinflammatory cytokines. Studies have also revealed that levels of IL-6 are elevated 
in normal populations as part of the normal aging process (Ershler & Keller, 2000; Klein 
& Flanagan, 2016; Wener, Daum, & McQuillan, 2000). IL-6 has both proinflammatory 
and anti-inflammatory properties, is consistently referred to in the pain and sleep 
literature and is linked with a host of sickness manifestations observed in chronic pain 
and sleep disturbances. In healthy adults, lack of sleep and poor sleep have been 
linked to elevation in the levels of IL-6. Increased circulation of IL-6 is often 
accompanied by daytime sleepiness and fatigue, whereas restorative sleep is related 
to decrease in IL-6 secretion and protection of bodily tissues from its proinflammatory 
damaging effect (Irwin, Wang, Campomayor, Collado-Hidalgo, & Cole, 2006; Vgontzas 
et al., 2003). For example, following sleep deprivation, an increase in circulating IL-6 
was linked with increased pain ratings in response to sleep restriction not explained 
by tiredness and fatigue (Haack, Sanchez, & Mullington, 2007). 
 
2.3.2 Interleukin-1beta (IL-1ß) and Tumour necrosis factor-alpha (TNF-α) 
 
Interleukin-1ß directly affects the function of neurons in the hypothalamic and 
brainstem circuits responsible for the regulation of pain, sleep, and wakefulness. 
When activated, IL-1ß triggers many inflammatory cellular pathways involved in pain 
processing (Ren & Torres, 2009). In addition, IL-1ß enhances NREM sleep and EEG 
delta power during slow wave sleep and pharmacologically inhibiting IL-1b reduces 
the depth of NREM sleep and EEG delta power (Opp, 2005; Zielinski & Krueger, 2011). 
TNF-α is also a known marker of inflammation implicated in the regulation of sleep. 
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TNF-α levels and expression in the brain are enhanced during wakefulness and 
following sleep deprivation (Opp, 2005). In humans, TNF-α levels are also increased in 
certain medical conditions associated with altered sleep including sleep apnoea, 
fibromyalgia, and insomnia but it is not necessarily specific to these conditions 
(Zielinski & Krueger, 2011). 
 
2.3.3 C-reactive protein (CRP)  
 
CRP is a protein found in blood plasma, whose levels rise in response to 
inflammation. It is a key indicator of acute response and the formation of plasma 
proteins in response to an inflammatory stimulus (Pepys, 1981; Pepys & Hirschfield, 
2003). In response to infection or tissue inflammation, CRP production is triggered by 
cytokines, particularly IL-6, IL-1ß, and TNF-alpha, hence the production of CRP is 
thought to reflect the activity of these cytokines, especially IL-6. Recent high sensitivity 
technology now permits detection of CRP levels as low as 0.007 mg/dl from the 
previous detectable limits of 3 to 5 mg/dl (Pepys & Hirschfield, 2003). High sensitivity 
C-reactive protein (hsCRP) has since been the extensively studied as a validated 
measure of vascular inflammation and predictor of risk of diseases such as arthritis, 
stroke, and cardiovascular diseases (Otterness, 1994; Pepys & Hirschfield, 2003). CRP 
can also serve as a marker of inflammatory processes activated by inadequate sleep. 
Elevated CRP has been associated with poor sleep quality in the general population 
(Liu et al., 2014), short sleep duration especially in women (Miller et al., 2009) and 
following short-term sleep deprivation in healthy individuals (Meier-Ewert et al., 
2004).   
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2.4 Conclusion 
 
 This chapter explained the techniques that are used to assess sleep, pain and 
inflammation including: polysomnography, actigraphy, structured clinical interviews, 
sleep diaries, quantitative sensory testing, and inflammatory cytokines. This chapter 
aimed to set the scene for the methodological approach of this thesis, which is to use 
the range of sleep assessment options (PSG, actigraphy, sleep diaries etc.) to give an 
insight into both objective and self-reported sleep and associations with pain 
responses and related mechanisms. QST methodologies such as conditioned pain 
modulation provides a way to assess and quantify pain processing and central pain 
inhibitory mechanisms that have been implicated in poor sleep and perpetuating the 
progression of chronic pain. This also provides an opportunity to further examine the 
utility, reliability, and relevance of the CPM paradigm as a pain assessment tool. 
Finally, as another step to clarify both the physiological and psychological factors 
quantifying the association between sleep and pain processes, the thesis also 
considers the relevance of inflammation processes. Specifically, the focus was on the 
range of inflammatory markers heavily implicated in physiological sleep homeostasis, 
pain perception, and chronic pain maintenance. 
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3 Literature overview  
 
3.1 Introduction  
 
Researchers and clinicians have long been aware of the close link between pain 
and sleeplessness, with physical pain often regarded as one of the main causes of 
sleeplessness (Jones, 1913). Despite the large amount of research and literature 
investigating these phenomena separately, recent surge of interest in the interrelation 
between the two processes has stemmed from a lack of understanding of the 
fundamentals of the interaction between pain and sleep disturbances and how to 
tackle the problem when the two issues co-occur. Sleep and pain are known to have 
a reciprocal association, although a comprehensive review of literature has also 
suggested that sleep disturbances may have strong causal effects on the experience, 
maintenance and perception of chronic pain (Finan et al., 2013). Hence, possible 
mechanisms through which sleep disturbances impact on pain, functioning, and 
wellbeing are worth examining.  
 
This chapter considers the interrelationship between sleep and pain and 
presents a brief overview of the body of evidence from experimental and 
observational longitudinal studies. Some of these studies have touched on the 
directionality of the sleep-pain relationship and suggested that the influence of sleep 
on pain may be stronger than the influence of pain on sleep. Furthermore, the chapter 
also visits some investigations into clinical correlates of the relationship. Specifically, 
the contributions of endogenous pain inhibition and inflammation in the regulation of 
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the relationship between sleep and pain and the implications of this on psychological 
functioning, overall pain experience, and clinical management.  
 
3.2 Does pain disturb sleep? 
 
Multiple nocturnal awakenings due to pain are commonly reported by 
individuals with chronic pain conditions. Lavigne et al. (2011) showed that females 
with chronic widespread pain reported significantly shorter sleep duration, lower 
sleep efficiency, twice the number of overnight awakenings, and had significantly less 
power in the EEG delta band in the first and second non-REM sleep cycle compared 
with pain-free controls. Drewes and Arendt-Nielsen (2001) argued that the level of 
pain is related to the severity of sleep disturbances, as reflected in disturbances in 
sleep at a microstructural level influencing arousability, disrupting sleep maintaining 
processes, and interrupting sleep depth and continuity. In spite of this, the CNS usually 
works to protect and preserve sleep continuity, and continues to filter nociceptive 
stimuli, facilitate descending inhibitory pathways, and regulate arousing ascending 
sensory information especially in the deeper stages of sleep (Doufas, 2017). However, 
it is also possible that this is very much dependent on individual’s sensitivity to pain 
stimuli and differences in the capacity of the CNS to regulate the pain sensory 
information during sleep. In addition, the chronic engagement and dysregulation of 
this sensory filter during sleep may be perpetuated by the chronic presence of pain 
and this could alter the protective function of sleep.  
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3.3 Characteristics of sleep in chronic pain – evidence from observational 
and experimental studies  
 
Chronic pain patients often report trouble initiating sleep, frequent awakenings 
overnight, decreased sleep duration, poor sleep quality, non-restorative sleep, 
daytime sleepiness, and fatigue which contributes to patients’ experience of greater 
pain intensity and pain related disability and mood disturbances (Lunde, Pallesen, 
Krangnes, & Nordhus, 2010; Smith & Haythornthwaite, 2004). Observational PSG 
studies in mixed clinical pain populations have also corroborated that patients present 
with longer sleep latencies, reduced total sleep time, increased awakenings, and 
reduced sleep efficiency compared with healthy controls (Bjurstrom & Irwin, 2016; 
Diaz-Piedra, Di-Stasi, Baldwin, Buela-Casal, & Catena, 2015). Specifically, disturbances 
are observed in sleep architecture; sleep in chronic pain patients is often characterised 
by higher proportion of time spent in lighter stages of sleep and lower proportion of 
deep sleep and numerous sleep shift changes from deep to light sleep, respiratory 
disturbances, and movement disturbances (Bjurstrom & Irwin, 2016; Wu, Chang, Lee, 
Fang, & Tsai, 2017). Sleep in chronic pain patients is also characterised by 
microstructural disturbances and fragmentation of sleep continuity in form of 
microarousals and awakenings (Blägestad, Pallesen, Gronli, Tang, & Nordhus, 2016; 
Drewes & Arendt-Nielsen, 2001). Increased alpha EEG power and reduction in delta 
power in deep sleep and cyclic alternating patterns (CAP) are some measures assessed 
as markers of arousal instability and poor sleep quality in patients with chronic pain 
(Parrino, Ferri, Bruni, & Terzano, 2012; Rizzi et al., 2004). In addition, these 
microstructure abnormalities tend to be related to poorer self-reported sleep quality 
and severity of clinical pain symptoms (Blägestad et al., 2016).  
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While these markers are observable measures of sleep instability, it may be that 
they are not only a marker of fragmentation of sleep in chronic pain disorder but 
perhaps also a marker of a biological predisposition to emergence and maintenance 
of chronic pain. These sleep disturbances convey the brain’s difficulty in maintaining 
and preserving sleep and it is thus reflective of sleep instability and internal and 
external sources of disturbances during sleep (Drewes et al., 1995; Roizenblatt, 
Moldofsky, Benedito-Silva, & Tufik, 2001). However, the phenomenon of 
microstructural disturbances requires further exploratory investigations to determine 
if this is indeed a defining quality of sleep disturbance in chronic pain and its relation 
to other physiological markers of pain. Studies have also not been consistent in 
reporting these manners of alterations in sleep and how it maps to pain experience 
across different pain conditions.  Comparisons are needed to highlight the specific 
characteristics of sleep disturbance, pain, and functioning in different chronic pain 
conditions compared to healthy controls. Hence why this thesis will observe if there 
are possible differences between those with widespread pain (i.e. fibromyalgia) and 
individuals with a relatively focal regional pain condition such as chronic back pain. In 
addition, there will also be an initial exploration of how this may be related to pain 
perception and other aspects of the pain experience such as inflammation.  
 
3.4 Prospective associations between sleep and experience of pain  
 
Micro-longitudinal studies examining day-to-day sleep variations in individuals 
with chronic pain have shown that night-time sleep parameters more consistently 
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predict next-day pain compared to pain predicting subsequent sleep. Edwards et al. 
(2009) carried out two overnight polysomnography assessments in patients with 
temporomandibular disorder. The findings revealed that reductions in sleep efficiency 
and total sleep time were significantly associated with impaired conditioned pain 
modulation assessed the next day. Tang, Goodchild, Sanborn, et al. (2012) and 
Lewandowski, Palermo, De la Motte, and Fu (2010) have also shown that sleep quality 
is a significant and consistent predictor of next day pain. These micro-longitudinal 
studies have primarily examined the day-to-day within-person association between 
sleep and pain within homogeneous patient groups, but the balance of outcomes 
provide support for a temporal sequential relationship from sleep to pain among 
patients to whom pain is chronic and require specialist treatment.  
 
The generalisability of these findings to the general population has been 
reinforced by macro-longitudinal (prospective) studies examining epidemiological 
prevalence and incidence of sleep disturbances and pain at the population level. These 
studies have found evidence that sleep tends to emerge as a primary factor 
determining longer-term risks of developing a pain condition and aggravation of pain 
responses (Drewes et al., 2000; Mork & Nilsen, 2012; Nitter et al., 2012). Even in those 
with no sleep problems, the presence of a chronic pain condition increases risk and 
predisposition to developing sleep disturbances (Jansson-Frojmark & Boersma, 2012; 
Tang, McBeth, et al., 2015). 
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Whilst sleep has been established as predictor of subsequent pain, next step 
forward for these investigations would be a thorough assessment of how the 
relationships between sleep and pain may evolve over time dependent on change in 
sleep status. Whilst it is understood that sleep patterns and quality fluctuate naturally 
over time, little is known about the association of these spontaneous sleep changes 
with pain and health outcomes over time in the general population. Studies evaluating 
changes in sleep can also examine the processes underpinning the interrelationship; 
sleep may render individuals more susceptible to the development and aggravation 
of pain over time by altering the physiological and psychological mechanisms 
underlying the interaction between sleep and pain. These studies could further 
highlight the role of sleep in the maintenance of chronic pain and perhaps illustrate 
that improving aspects of sleep may subsequently alleviate some of the short and 
long-term negative health outcomes associated with these conditions.  Consequently, 
this thesis adopts an epidemiological perspective to explore the sleep and pain 
relationship over time in the general population. This incorporates a systematic review 
and analysis of the associations of changes in sleep problems over time with pain-
related health outcomes.  
 
3.5 Mechanisms underlying the interaction between sleep and pain  
 
3.5.1 Endogenous pain inhibition  
 
The literature has revealed that sleep quality seems to have a physiologically 
important role in the regulation of pain processing. Several experimental paradigms 
have been used to show the consequences of sleep disturbance on pain; these include 
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overnight total sleep deprivation, reducing total sleep duration (partial sleep 
restriction) or selectively interrupting sleep stages through the night (sleep 
fragmentation). Healthy populations that undergo these manipulations of sleep tend 
to report increased generalised pain sensitivity and decreased pain thresholds 
(Lautenbacher, Kundermann, & Krieg, 2006; Moldofsky, Scarisbrick, England, & 
Smythe, 1975). Even though these studies only simulate sleep disruption for a couple 
of nights and cannot accurately reflect the chronicity of the sleep disturbance in 
chronic pain populations, it is interesting that after sleep deprivation, healthy 
individuals are also seen to exhibit pain experience and behaviour similar to chronic 
pain conditions like fibromyalgia (Lautenbacher et al., 2006; Schuh-Hofer et al., 2013; 
Smith et al., 2007).   
  
It is possible that sleep affects optimal endogenous inhibition of pain and this 
impairment in the body’s ability to regulate its central pain inhibitory mechanism is 
then implicated in perpetuating the progression of chronic pain conditions. 
Conditioned pain modulation is a measure of pain inhibition in which a painful 
stimulus (conditioning stimulus) inhibits and subdues perception of pain produced by 
a second co-occurring painful stimulus (test stimulus) (van Wijk & Veldhuijzen, 2010). 
A systematic review of the evidence has also further suggested that CPM may be 
impaired in chronic pain conditions, as the application of a second noxious stimulus 
does not always show the expected decreased sensitivity or inhibitory response 
(Lewis, Rice, & McNair, 2012). Impairment in this central pain modulation and 
inhibitory system has been associated with maintaining the maladaptive persistent 
pain in chronic pain. Studies with healthy populations undergoing a partial sleep 
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restriction paradigm and insomniacs have also revealed greater pain sensitivity and 
impaired CPM response the next day (Haack et al., 2007; Haack et al., 2012; Smith et 
al., 2007). Another study showing the relationship between sleep disturbances and 
CPM responses in clinical pain population found that PSG measured higher sleep 
efficiency and longer total sleep time were positively correlated with better 
functioning CPM responses in their sample with temporomandibular joint disorder 
(Edwards et al., 2009). 
 
 Further studies are, however, needed to substantiate the associations 
between altered CPM and sleep disturbances across the range of chronic pain 
conditions. Considering that CPM reflects an interaction between physiological and 
psychological pain pathways, and is a phenomenon of growing interest, it may be an 
indicator of how poor sleep impacts the pain experience.  Hence, it is also of 
consequence to consider its validity and applicability as a sensitive marker of 
endogenous pain inhibition.  This thesis attempts to address this by exploring the 
validity and reliability of the pain stimuli and quantitative sensory testing protocols 
used to assess CPM response. As well as validating and refining the CPM testing 
paradigm, the thesis also delves into what distinguishes healthy individuals with 
normal CPM responses with those presenting with no CPM response, across pain and 
sleep parameters. This could be used to inform therapeutic pathways and to provide 
important phenotypic information to characterise pain perception in individuals 
susceptible to persistent pain conditions. 
 
 62 
3.5.2 Inflammation  
 
Sleep loss impairs inflammatory function and several inflammatory cytokines 
(IL-6, IL-1ß, and TNF-) form part of the brain’s neurobiological and neurochemical 
network regulating normal physiological sleep. How sleep alters inflammatory 
function is difficult to disentangle given the complexity and multiplicity of the actions 
and mechanisms of the immune system, but it is suggested that sleep disruption at 
least induces low- grade inflammation (Imeri & Opp, 2009; Opp & Krueger, 2017). It 
has also been suggested that boosting of immune system occurs during sleep 
(Moldofsky, 1995). Although most chronic pain conditions are not explicitly 
inflammatory diseases, the range of symptoms associated with them such as 
hyperalgesia, fatigue, sleep, pain sensitivity, anxiety, cognitive dysfunction are also 
stress and arousal-related and potentially influenced by cytokines (Wallace, 2006).  
Hence, we can acknowledge the potential role of physiological stress and 
inflammation as having an indirect influence on sleep and pain processes. It is possible 
that under the continual physiological and psychological stress resulting from chronic 
pain and sleep disturbances, cells of the immune system induce levels of chronic 
inflammation that foster chronic pain disorders and associated sleep disturbances 
(Bote, Garcia, Hinchado, & Ortega, 2012). Nevertheless, the co-occurrence of and 
interrelationship between sleep disturbances, pain, and inflammatory processes has 
not been extensively investigated in the context of chronic pain. The links between 
sleep disturbance and chronic pain, and inflammation remains puzzling, although 
several aspects underlying the puzzle have been considered.  
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Increased presence of proinflammatory cytokines and proteins (e.g. TNF-α, IL-
1ß, IL-6 and CRP) has been linked to the molecular processes enhancing hyperalgesia 
in pain disorders and sleep disruption has also been associated with elevations of 
these inflammatory markers both in normal populations and in idiopathic chronic pain 
disorders (Drewes & Arendt-Nielsen, 2001; Haack et al., 2007; Vgontzas et al., 2003). 
A systematic review and meta-analysis by Irwin, Olmstead, and Carroll (2016) of 72 
cohort and experimental studies assessed CRP and IL-6 levels in relation to sleep 
disturbances. Poor sleep quality especially in the long-term and more persistent sleep 
problems were associated with raised CRP, and to a lesser extent with raised IL-6. 
Shorter sleep duration was also associated with raised CRP and extreme long sleep 
duration with raised IL-6 and CRP. No associations were found for TNF-α and IL-1ß as 
not enough studies were found which investigated TNF-α and IL-1ß levels in relation 
to sleep. Associations between inflammatory makers and sleep were also not 
significant when pooled for experimental studies, which begs the question of whether 
sleep interacts with inflammatory process more cumulatively in the long-term rather 
than acutely. Research thus far has suggested that increase in inflammatory responses 
in the body may be linked with persistent sleep and pain disturbances, but this is yet 
to be assessed at length across both healthy and clinical population. Inflammation 
may play a role in the immediate and long-term association between pain and sleep, 
but further studies are needed to investigate the concurrent association of the triad 
of sleep, pain and inflammation. This thesis presents a quasi-experimental study 
considering the interrelationship between sleep, pain, and inflammation in the short 
term within the context of chronic pain. In addition, the thesis also considers within a 
systematic review the current evidence of how sleep problems may be associated with 
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pain-related physiological status and inflammation in the general population in the 
long-term. 
 
3.5.3 Cognition and behaviour 
 
Sleep and pain are processes relying on biological and physiological regulation. 
Yet, the perception, experience, and control of both sleep and pain is also heavily 
influenced by emotional and psychological characteristics. Chronic pain and sleep 
disturbances influence daily mental and physical functioning. Sleep may lead to 
greater daily pain and disability through sleep’s influence on negative mood, 
subsequently affecting pain experience and perceived ability to cope with  pain (Busch 
et al., 2012; Harrison, Wilson, Heron, Stannard, & Munafo, 2016; O'Brien et al., 2010, 
2011). There are diverse ways in which sleep may be associated with pain and mood 
processing, increase emotional symptomology, and enhance the affective dimension 
of pain perception.  People with chronic pain may develop depression due to the 
consequences of pain on their functioning and a lost sense of who they are (Tang, 
Goodchild, Hester, & Salkovskis, 2010). For example, when sleep is manipulated in 
those with rheumatoid arthritis compared with healthy controls, partial sleep 
deprivation led to increased self-reported fatigue, depression and anxiety symptoms 
and these were consequently associated with disease activity (Irwin et al., 2012). 
Furthermore, the neurological interrelation of emotional regulation, sleep, and pain 
in cortical areas such as the limbic area, anterior cingulate cortex, and amygdala also 
shed some light on the interrelationship (Boakye et al., 2016).  
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In addition, poor sleep has been consistently linked to the cognitive behavioural 
factors that perpetuate the unpleasantness of chronic pain condition and the 
maladaptive cognitive coping style found in this population (Smith & 
Haythornthwaite, 2004). For example, pain catastrophising is an exaggerated 
response to chronic pain, and hypervigilance to pain sensations and has been shown 
to impact individual perception of pain and daily functioning abilities (Crombez, Van 
Damme, & Eccleston, 2005; Sullivan, Bishop, & Pivik, 1995; Vlaeyen, Kole-Snijders, 
Boeren, & van Eek, 1995). Studies have addressed the role of sleep disturbance in 
mediating the effect of pain catastrophising in chronic pain and found that pain 
catastrophising is associated with greater sleep disturbance. A significant portion of 
variance in clinical pain severity and pain-related interference attributable to pain 
catastrophising was mediated by sleep disturbance in individuals with osteoarthritis 
(Campbell et al., 2015) and temporomandibular disorder (Buenaver et al., 2012). 
Psychological concepts such as pain catastrophising are generally of therapeutic 
importance in the non-pharmacological clinical management of chronic pain 
conditions in a clinical setting. Hence, this thesis aims to consider the influence of this 
psychological correlate of pain catastrophising when exploring the association 
between sleep and pain perception both in healthy and clinical chronic pain 
populations.  
 
3.6 Clinical management of co-occurring sleep disturbance and chronic 
pain  
 
Treating comorbid sleep and pain problems is a challenging task. The comorbid 
relationship between the two is a vicious cycle and forward-feeding interaction. 
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Getting rid of pain only may not necessarily lead to better sleep and address the 
cognitive-behavioural factors maintaining chronic sleeplessness. The current 
approach to clinical pain management is mostly focused on pharmacological 
treatments for pain – ranging from acetaminophen, nonsteroidal anti-inflammatory 
drugs (NSAIDs) to opioids, and sometimes incorporating antidepressants, hypnotics 
and benzodiazepines, and anticonvulsants for widespread and neuropathic pain 
(Makris, Abrams, Gurland, & Reid, 2014). Notably, a lot of these medications also alter 
sleep; they may or may not bring about better self-reported sleep, but could also 
disrupt sleep continuity, suppress REM and slow wave sleep, as well as altering pain 
perception and improving functional outcomes. Goforth, Preud'homme, and Krystal 
(2014) and Park and Moon (2010) present more detailed overviews of influence of 
pharmacological treatment of sleep in chronic pain.  
 
Despite the common co-occurrence, sleep is usually not routinely considered 
and highlighted as a therapeutic target for pain management (Tang, Goodchild, 
Hester, & Salkovskis, 2012). However, a growing body of evidence supports non-
pharmacological treatments for sleep problems such as cognitive behavioural therapy 
for insomnia (CBT-I) for clinical pain management. Currently, there is already strong 
evidence for cognitive behavioural therapy for insomnia (CBT-I) as a pragmatic, and 
effective non-pharmacological intervention that provides clinically significant 
improvements in sleep for those with chronic insomnia. Trauer, Qian, Doyle, 
Rajaratnam, and Cunnington (2015) carried out a systematic review and meta-analysis 
analysing the effectiveness of CBT-I across 20 randomised controlled trials (RCTs) with 
total of 1162 participants with insomnia. Their findings reported that the treatment 
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led to significant improvements in time taken to fall asleep, overnight awakening, total 
sleep time and sleep efficiency in those with insomnia. Their analysis was however 
limited to studies on primary chronic insomnia and did not consider those with 
comorbid insomnia. More specifically for those with comorbid insomnia and chronic 
pain, RCTs have shown effectiveness of using CBT-I to treat insomnia associated with 
chronic pain across conditions such as musculoskeletal pain, fibromyalgia, chronic 
neck and back pain (Currie, Wilson, Pontefract, & deLaplante, 2000; Edinger, 
Wohlgemuth, Krystal, & Rice, 2005; Jungquist et al., 2010; Vitiello et al., 2009). Tang, 
Lereya, et al. (2015) also reported in their systematic review and meta-analysis of 11 
RCTs with 1066 participants with malignant and non-malignant chronic pain that non-
pharmacological treatment of insomnia in this population leads to better patient 
outcomes, not only in sleep quality but also in pain, fatigue, and depression up to a 
year after treatment.  
 
Recent development is also underway to establish the efficacy of a hybrid 
cognitive behavioural therapy that aims to tackle pain and sleep problems 
simultaneously. Beyond just addressing sleep and pain problems alone or separately, 
the therapy places special attention to addressing patients' unhelpful beliefs about 
pain, sleep, and the interaction of the two. By addressing worries and anxiety 
concerning sleep and pain, tackling and altering sleep habits that impair sleep 
propensity and regulation, and reducing maladaptive pain coping cognitions such as 
pain catastrophising (Pigeon et al., 2012; Tang, 2009; Tang, Goodchild, & Salkovskis, 
2012; Vitiello et al., 2014). The hybrid intervention is a worthwhile pursuit but for it to 
fulfil its efficacy potential, there is still a need to identify specific targets for 
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interventions and predictors of poor sleep and pain interference and individual 
differences in the physiological and psychological manifestation of pain and 
sleeplessness. An overarching aim of this thesis is to add to this body of evidence by 
considering the development of a clearer conceptualisation of the sleep and pain 
relationship and relevant bio-psychological mechanisms at play.  
 
3.7 Conclusion  
 
Sleep disturbance and chronic pain are complex intertwined biological and 
psychological processes. It can be argued that chronic pain provides the physiological 
and psychological stressor that invades sleep physiology and consequently sleep 
disturbances also works through several somatic mechanisms and psychological 
processes to foster the chronic pain process and the physiological and psychological 
pain experience. This chapter sought to present an overview of existing evidence on 
the biopsychosocial conceptualisations of the association between sleep and pain and 
potential directions for further experimental and epidemiological investigations. 
Consequently, the studies described in the subsequent chapters of this thesis 
considers the associations of objective and self-reported sleep with different aspect 
of the pain experience in healthy population and chronic pain conditions. The studies 
also explore physiological and psychological mechanisms underlying the sleep and 
pain relationship. The thesis further adopts a multi-methodological approach to allow 
for the investigations of these parameters within both an immediate experimental 
setting in healthy and clinical populations and the long-term consequences of the 
sleep and pain interrelationship within the general population.   
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4 Validity of the cold-pressor task and bag-holding task 
conditioning stimuli for eliciting conditioned pain 
modulation in healthy young adults: The influence of 
distraction, pain catastrophising, and self-reported sleep  
 
4.1 Introduction  
 
Conditioned pain modulation (CPM), as introduced in Chapter 2 (2.2.2) plays an 
important role in our understanding of not only how the brain perceives and inhibits 
acute pain but also the pathogenesis of chronic pain conditions. CPM is a normal, 
healthy response to a barrage of painful stimuli and is indicative of central pain 
inhibitory processes. Yet, dysfunction in this central modulation of nociceptive input 
may be indicative and predictive of development and aggravation of future chronic 
pain (Lewis et al., 2012; van Wijk & Veldhuijzen, 2010; Yarnitsky, 2015). Whilst CPM 
has been found to be impaired in a range of idiopathic chronic pain conditions such as 
fibromyalgia (FM) (Lautenbacher, Prager, & Rollman, 2007), irritable bowel syndrome 
(IBS) (Wilder-Smith, Schindler, Lovblad, Redmond, & Nirkko, 2004), migraine (Sandrini 
et al., 2006), temporomandibular joint disorder (TMD) (King et al., 2009). It is not as 
prominent in osteoarthritis (OA) (Kosek & Ordeberg, 2000), and chronic back pain 
(CBP) (Julien, Goffaux, Arsenault, & Marchand, 2005; Mlekusch et al., 2016). 
Impairment in CPM may be a wider characteristic of individual’s pain profile and pain 
researchers have thus called for research into the utility of CPM for constructing 
profiles of pain modulation that can subsequently be used to predict important 
features of clinical pain and responses to treatment (Granovsky & Yarnitsky, 2013). 
However, before CPM can be used as a dependable biomarker of individual 
differences in pain perception and treatment response, the testing procedure 
involved and the mechanisms underlying the phenomenon still need standardisation 
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and clarification. As highlighted in a recent review, the reliability of the CPM response 
is often dependent on stimulation parameters and varying study methodology 
(Kennedy, Kemp, Ridout, Yarnitsky, & Rice, 2016). There is a clear need to establish 
practical, suitable and clinically relevant CPM protocols, the validity of CPM effect as 
a robust physiological phenomenon, and how CPM is being shaped by psychosocial 
aspects of pain experience such as pain catastrophising and sleep.   
 
4.1.1 Validity and practicality of protocols assessing conditioned pain modulation  
 
Theoretically, the CPM effect refers to the ability of a noxious conditioning 
stimulus to decrease the pain intensity of a noxious testing stimulus, and a dysfunction 
in this mechanism is taken to indicate a potential impairment in the body’s 
endogenous pain modulatory ability. However, there is currently no defining 
characteristics to discern the intensity of noxiousness a conditioning stimulus must 
possess to elicit the CPM response. Based on current studies and protocols, it seems 
that the type, location, and intensity of a conditioning stimulus could affect the validity 
of the CPM response. 
 
Oono, Nie, Matos, Wang, and Arendt-Nielsen (2011) assessed CPM effects 
using three different pain-inducing conditioning stimulus modalities (2-40C cold pain, 
ischemic tourniquet pain at 36kPa, tonic mechanical pressure pain) on pressure pain 
threshold and pressure pain tolerance test stimuli at different assessment body sites 
(masseter, forearm, leg). They found that a cold pain conditioning stimulus induced 
the greatest subjective pain intensity and the most powerful CPM effect on a pressure 
pain threshold test stimulus (i.e. resulted in the greatest increase in pressure pain 
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threshold) with the leg as the assessment site. This combination also had the greatest 
test-retest reliability and smallest intra and inter-individual variation compared with 
other body sites (masseter region and the forearm) and conditioning stimulus 
(tourniquet pain and mechanical pressure pain). They argued that CPM effect is 
usually greater with higher pain intensity of the conditioning stimulus. However, other 
studies have found that once the intensity of the conditioning stimuli reaches a certain 
level of moderate pain, any more increase in pain intensity is not related to the 
magnitude of the CPM effect (Granot et al., 2008; Nir, Granovsky, Yarnitsky, Sprecher, 
& Granot, 2011).  
 
These variations in CPM response by conditioning stimuli could mean that 
different pain stimuli evoke endogenous inhibition through slightly different 
mechanisms. CPM effect could be more related to the type and intensity of the 
conditioning stimuli and the type of nociceptive or somatic nerve fibres it activates 
rather than the pain it induces (Lautenbacher, Roscher, & Strian, 2002; Le Bars et al., 
1992). Consequently, it is worth exploring what underpins the different modalities of 
conditioning stimuli used to assess pain modulation capabilities. For example, a 
conditioning stimulus eliciting muscle pain originating from somatic tissue nociceptors 
may better represent certain clinical pain states such as in chronic back pain, where 
limited studies of CPM have been done (Weissman-Fogel, Sprecher, & Pud, 2008). 
Such a conditioning stimulus may optimise sensitivity and specificity of CPM to 
describe the clinical pain experience by activating pain of a nature that is relevant to 
the daily physical challenges faced by those with chronic back pain.  
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In addition, there has been an increased interest in individual variability in 
endogenous pain-inhibitory processes (Edwards, Dworkin, et al., 2016). However, 
research studies have not fully classified individual differences in response to CPM 
paradigms and the characteristics of ‘normal’ and ‘abnormal’ CPM response in healthy 
individuals. Few CPM studies have reported when healthy participants do not 
demonstrate the expected inhibitory response and instead show a facilitation of pain 
(Locke et al., 2014; Oono et al., 2011). Furthermore, the studies do not fully describe 
the characteristics of these non-responders compared with responders. Further 
evaluation of  the proportion of participants that do not show the expected CPM effect 
would not only improve interpretation of the meaningfulness of CPM in healthy 
populations but also further contribute to understanding of the mechanisms 
underpinning and factors influencing impaired pain inhibition (Kennedy et al., 2016).   
 
4.1.2 Conditioned pain modulation and cognitive distraction 
 
Investigating the factors influencing CPM is also necessary to provide greater 
understanding of the physiological and psychological processes underlying the 
phenomenon. Cognitive processes such as attention and distraction have the 
potential to modify the way pain is perceived (Melzack & Wall, 1965). From a cognitive 
psychology view, the experience of pain is often reliant on attentional mechanisms 
dependent on the threat value of the stimuli and accompanying emotional arousal 
and expectations (Eccleston, 1995; Eccleston & Crombez, 1999; Wiech, 2016). The 
processing of both acute and chronic pain has been consistently shown to demand the 
central attentional resources. This is because multiple pain-related brain pathways 
send and receive projections from several cortical areas and thus can potentially 
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modulate pain through several cognitive and psychological mechanisms (Ossipov et 
al., 2010). As described in Chapter 2 (2.2.1) descending pain control pathways 
underlying CPM involve the PAG, RVM and DRt which are all connected to the 
forebrain and activates projections from areas such as the primary somatosensory 
cortex and insula to direct cognitive attention to painful stimuli (Bushnell et al., 2013; 
Tracey & Mantyh, 2007; Tracey et al., 2002). These pathways are receptive to 
cognitive manipulation as they can interact concurrently with both cognitive and 
affective pain processing regions in the brain.  
 
These interactions explain why it has been suggested that the CPM 
phenomenon may in part be due to distraction. With the test and conditioning pain 
stimuli competing for limited cognitive resources for pain processing, a drawing of 
attention away from the perceived pain of the test stimulus to the greater pain of the 
conditioning stimulus may subsequently lead to lower pain being perceived from the 
test stimulus (Birnie, Chambers, & Spellman, 2017). However, the extent to which the 
CPM effect can be explained by distraction has not been fully quantified. Staud, 
Robinson, Vierck, and Price (2003) explored the effect of distraction during a CPM 
paradigm by prompting 11 fibromyalgia female patients, 22 healthy female controls, 
and 11 healthy male controls to focus their attention on either the conditioning 
stimulus of immersion of left hand in a hot water bath (distraction condition) or test 
stimulus which was repeated heat taps on the right hand (control condition 1), or 
given no prompts or explicit instructions as to where to focus their attention (control 
condition 2) whilst CPM was measured. Then, the participants were asked to rate the 
sensation felt at the non-attended site or the conditioning stimulus site (for the 
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control groups).  Across both healthy and clinical groups, they found that the CPM 
effect was generally stronger in the distraction condition than the control conditions. 
This shows CPM as a physiological mechanism with some potential overlap with 
distraction and attentional processes. However, the researchers assessed distraction 
using attention manipulation and relied on whether or not the participants managed 
to shift their attention to or away from the pain stimuli based on self-report. Attention 
is often defined as selective intrinsic reaction to the presence of pain; pain interrupts 
attention and forces a new action and/or priority to escape (Eccleston & Crombez, 
1999). A distraction from a painful stimuli requires the shifting of attention away from 
the pain sensation specifically via engagement in another affectively neutral 
competing task (Eccleston, 1995). Compared to this, the operationalisation of 
distraction in studies like Staud et al. (2003)  deviates from the definition of distraction 
which ideally involves active engagement in a competing cognitive task.  
 
Moont, Pud, Sprecher, Sharvit, and Yarnitsky (2010) presented a study that 
directly assessed the effect of cognitive distraction on CPM by including a non-painful 
distraction task that actively increased cognitive load. Their CPM paradigm consisted 
of intermittent heat pain pulse stimulation as test stimulus and tonic heat pain as a 
conditioning stimulus. They used a visual task with three levels of difficulties, which 
involved counting shapes appearing on a screen as a cognitive distracter task. Their 
testing conditions involved assessment of CPM using the conditioning stimuli, the 
distracter task, and a combination of the conditioning stimuli and distracter task. The 
results showed that CPM was most pronounced under the combined condition. This 
is expected and in line with theories of distraction and attention; under the combined 
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condition, the distraction task must have engaged extra cognitive processes that 
directed attention away from the test stimulus, thus enhancing CPM effect.  
 
Moreover, their protocol also quantified CPM effect based on the self-
reported pain ratings felt when the test stimulus was applied alone compared to when 
it was applied with the conditioning stimulus. From this rating, they did not provide a 
quantitative estimation of the effect of distraction. Psychophysical measures such as 
computerised pressure pain threshold assessments would be more reliable as a test 
stimulus as they would provide a clearer way to quantify the effect of distraction on 
pain inhibition (Kennedy et al., 2016; Oono et al., 2011). Noticeably, the similarity of 
their test and conditioning stimuli (both heat pain) could also have enhanced the 
distraction effect that they observed (Lautenbacher et al., 2007). Using a distracter 
stimulus that considers and mirrors the physical and sensory processes evoked by the 
conditioning stimuli may provide a better platform for comparing and quantifying the 
influence of distraction across the conditioning and distraction stimuli. For example, a 
distracter stimulus with perceptual similarity with a cold pressor task conditioning 
stimulus would incorporate a non-painful version of the task with an additional 
demanding cognitive task component.  There is currently no study that has assessed 
the influence of distraction on CPM using these parameters.  
 
4.1.3 Conditioned pain modulation and pain catastrophising  
 
Pain catastrophising is described as a maladaptive heightened reaction to and 
interpretation of a painful stimulus (Quartana, Campbell, & Edwards, 2009). This could 
be an individual’s tendency to engage and invoke certain affective and behavioural 
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responses towards pain, or a cognitive process that an individual engages in during a 
painful procedure (Sullivan et al., 1995). Studies have assessed situational pain 
catastrophising related to experimental pain procedures and general pain 
catastrophising which is a tendency to catastrophise about general daily pain 
experiences. The process of pain catastrophising may impact on pain experience via 
activation of cortical areas related to affective pain processing (Quartana et al., 2009). 
This may subsequently influence spinal gate control mechanisms, priming the  
descending pain modulation pathways towards facilitation of pain processing and, 
leading to a disrupted CPM response (Sullivan et al., 2001). Goodin et al. (2009) 
reported that situational pain catastrophising during the experimental CPM procedure 
was related to increased pain ratings and impaired CPM response.  
 
On the other hand, studies assessing general pain catastrophising tendencies 
using the Pain Catastrophising Scale (PCS) by Sullivan et al. (1995) have found mixed 
results.  Some studies have found that a greater tendency towards general pain 
catastrophising was related to impaired CPM response (Weissman-Fogel et al., 2008). 
Other studies have only found this association when eliciting CPM response using a 
specific conditioning stimuli such as the cold pressor task (Granot et al., 2008). A 
recent meta-analysis of 17 studies assessing pain catastrophising in relation to CPM 
response across a range of different protocols and modalities in healthy populations 
also revealed no significant correlation between pain catastrophising and CPM 
response (Nahman-Averbuch, Nir, Sprecher, & Yarnitsky, 2016). While the evidence 
supports situational catastrophising as a potential cognitive process of pain 
sensitisation during experimental procedures, less is known about trait 
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catastrophising and if a tendency and predisposition to engage in the pain 
catastrophising amplifies pain signals and distorts endogenous pain inhibitory 
mechanisms. Studies on the associations between catastrophising and CPM 
magnitude are needed to clarify if trait catastrophising is a psychological construct 
only present in those presenting with impaired CPM response or if CPM phenomenon 
is independent of this individual variability.  
 
4.1.4 Conditioned pain modulation and sleep  
 
The full clinical relevance of the interaction of sleep and physiological pain 
experience in managing and characterising clinical pain states is not fully understood. 
Assessment of sleep related factors may provide further predictive and defining 
information about individual pain processing profiles. Experimental manipulation of 
sleep, notably sleep restriction in healthy participants has been shown to alter 
sensitivity to different types of noxious stimuli. Increase in perception of muscle pain 
following sleep restrictions for example reflects greater pressure pain sensitivity and 
influence of sleep on descending pain inhibitory control systems (Lautenbacher et al., 
2006). Smith et al. (2007) altered the sleep of 32 healthy adult females over 7 nights 
by randomising participants into either forced overnight awakenings, partial sleep 
restriction or control conditions where participants slept continuously for 8 hours. 
Polysomnographic measures of sleep revealed that the forced awakening paradigm 
that simulates overnight sleep continuity disturbance experienced by people with 
chronic pain led to impaired endogenous pain inhibition. Their CPM protocol involved 
using a pressure pain threshold test stimulus and cold pressor task conditioning 
stimuli. Using the same CPM protocol, a cross-sectional study by Edwards et al. (2009) 
 78 
also reported that PSG measures of higher sleep efficiency and longer total sleep time 
were associated with better CPM response in those with temporomandibular joint 
disorder.  
 
In other chronic pain patients, self-reported sleep efficiency was negatively 
associated with reduced CPM response in fibromyalgia patients (Paul-Savoie et al., 
2012). In addition, CPM response was also poorer in those with rheumatoid arthritis 
compared to healthy controls and this interaction was mediated by greater self-
reported sleep problems in those with arthritis (Lee et al., 2013). However, research 
in healthy population has yet to comprehensively explore associations between 
subjective sleep reports derived from standardised assessment methods such as daily 
sleep diaries and association of these with measures of pain inhibition derived from 
CPM. In addition, studies have yet to look specifically at the self-reported sleep 
profiles of healthy individuals presenting with impaired CPM response. Investigations 
of those in the general population with impaired CPM and any associated sleep 
problems would help isolate factors linked to the worsening or alleviation of pain 
experience.  
 
4.1.5 Aim of the current studies  
 
Two experiments are presented to assess the validity of the CPM paradigm 
elicited using two different conditioning stimuli and to evaluate if efficiency and 
magnitude of CPM response vary as a function of cognitive distraction, pain 
catastrophising, and self-reported sleep in a healthy population. The first experiment 
acts as a proof of concept study of a novel CPM testing paradigm using a conditioning 
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stimulus with potential clinical ecological validity (a bag-holding task to induce muscle 
pain) and comparing it in validity and reliability to the established cold pressor task 
conditioning stimuli. This experiment also aimed to explore the influence of pain 
catastrophising and sleep quality on CPM response. The second experiment serves to 
address some limitations of the first; a replication using a larger sample size and 
further test of the validity of the bag-holding task as a conditioning stimulus. In 
addition, the second experiment aimed to examine and quantify the role of distraction 
in CPM response. 
 
4.2 Experiment 1 – Methods  
 
4.2.1 Participants  
 
The study sample included 57 healthy young adults (9 males and 48 females; 
mean age 19 years) recruited from within the university. Inclusion criteria were: aged 
between 18 and 65 years, healthy English-speakers and with the ability to understand 
and sign the consent form and complete all study procedures. Exclusion criteria were: 
i) acute pain due to injury, surgery etc., ii) malignant or non-malignant pain 
condition(s) present for at least 6 months or more, iii) any known organic sleep 
disorder(s) (e.g., sleep apnoea, restless leg syndrome/periodic limb movement 
disorder, narcolepsy) and iv) presence of Raynaud’s disease, history of epilepsy, 
frostbite, cardiovascular disease, and any other medical problem(s) affecting 
participation in the cold pressor task.  The cold pressor procedure closely followed a 
conservative guideline to ensure safety and comfort of the participants (von Baeyer, 
Piira, Chambers, Trapanotto, & Zeltzer, 2005). Of 57 participants, three participants 
did not complete the sleep diary data and full procedure at both visits and were 
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therefore excluded due to this non-compliance with study procedure and missing 
data. The final sample for analysis involved 54 participants. Those excluded from the 
final analysis did not differ from the final sample across the demographics, sleep, and 
pain variables.  
 
4.2.2 Design and Procedure 
 
The study protocol was approved by the Department of Psychology Research 
Ethics Committee. After screening (Appendix 7) and reading the Participant 
Information Sheet (Appendix 2), participants gave signed informed consent (Appendix 
1). The study used a repeated measures design; all participants completed 2 sessions 
of quantitative sensory test (QST) (2.2.2) – one week apart – to assess conditioned 
pain modulation response (CPM) and were also required to complete a daily sleep 
dairy for a week in between (see Figure 5 for study design). The two QST sessions were 
administered by the same experimenter who followed the same standardised 
experimental protocol. QST was done at the same time of the day for both visits to 
minimise any diurnal or circadian effects. 
 
During Visit 1, the study was explained in detail to the participants, they 
provided demographic information, and were asked to complete self-report 
questionnaires (Appendix 8) to assess pain status, sleep quality, and pain 
catastrophising. After this, they were given a training and a practice trial opportunity 
to familiarise with the experimental procedure. This was essentially a short training 
session before beginning the experiment to familiarise participants with the sensation 
of the experimental stimuli, namely the pressure pain from algometer and cold-water 
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bath. Consequently, they underwent the actual test procedure as illustrated in Figure 
5. Participants were also given detailed instructions and overview of a sleep diary to 
complete for the week. The sleep diary was used to tap into the participant’s self-
reported between the testing visits. Visit 2 took place exactly a week later, with the 
exception of one participant who completed Visit 2 a day later than planned. 
Participants returned their completed sleep diaries, and again at this session, 
completed a questionnaire to assess pain and underwent the same series of QST to 
assess CPM response. At the end of Visit 2, participants were debriefed (Appendix 3) 
about their participation, reimbursed with course credits, and given the opportunity 
to express concerns about the study and their participation.  
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Visit 1 – Screening + Consent form + Questionnaire + QST Procedure 
CPT (4°C) 
10 seconds 
+ 
PPTh 
(2 trials) 
 
PPTh 
(2 trials) + 
PPTh 
(2 trials) 
BHT (5-6kgs) 
1 minute 
+ 
PPTh 
(2 trials) 
 
Sleep Diary – 1 week  
 
2mins 
rest + 
Visit 2 – Questionnaire and QST Procedure 
Experiment 1 
Notes: Figure 5 presents the procedure for Experiment 1. At Visit 1 participants underwent screening 
and informed consent, completed questionnaires to assess pain status, sleep quality, and pain 
catastrophising. They also completed the QST procedure which involved a baseline assessment of 
pressure pain threshold the right upper shoulder (trapezius posterior) or right forearm (anterior 
brachoradialis) and then reassessment of pressure pain threshold after the application of the 
conditioning stimuli on the left side of the body (cold pressor task or bag holding task). The testing 
order of conditioning stimuli was randomly assigned for the first visit. The participants were given a 
sleep diary to complete during the week between the testing visits. Visit 2 took place exactly a week 
later at the same time of the day. At this visit, participants completed a questionnaire to assess pain 
status and completed the QST procedure in the same sequence as Visit 1.  
 
QST (Quantitative sensory testing) PPTh (Pressure pain threshold) CPT (Cold pressor task) BHT (Bag 
holding task) 
 
Figure 5 CPM Experiment 1 Study design and QST protocol 
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4.2.3 Measures 
 
4.2.3.1 Pain measures 
 
4.2.3.1.1 Conditioned Pain Modulation (CPM) 
 
The QST protocol for assessing CPM was adapted from previous studies 
(Edwards et al., 2009; Martel, 2013; Smith et al., 2007). The CPM methodology 
assesses pain inhibition and involves the application of a test pain stimulus and a 
conditioning pain stimulus to two distant body sites.  
 
Test stimulus 
 
Pressure pain threshold (PPTh) was used as the test pain stimulus and was 
assessed using an Algomed Computerised Pressure Algometer by Medoc Ltd. It was 
recorded by pushing the tip of the algometer with gradually increasing pressure at 
approximately 30 KiloPascals on the right upper shoulder (trapezius posterior) or right 
forearm (anterior brachoradialis). Participants were instructed to press the response 
button when the ‘pain threshold’ is reached, which was defined in the current study 
as ‘when the pressure stimulus had become just noticeably painful’. PPTh was 
assessed twice (once at each site) with a 5-second interval between trials and average 
of the two PPTh was taken and used for analysis. PPTh is reported in KPa (Kilopascals).  
 
To measure CPM response, the test stimulus was combined with two 
conditioning stimuli [Cold pressor task (CPT) and Bag holding task (BHT)] that were 
applied to the contralateral (left) side of the body. This was done as per guidelines for 
assessing CPM recommending that conditioning stimuli are administered at a distant 
body site away from the test stimulus (Yarnitsky et al., 2015).  
 84 
Conditioning stimuli 
 
Cold pressor task  
 
Pressure pain threshold was combined with the cold pressor task (CPT) as a 
conditioning stimulus in the current QST protocol. This combination is a consistently 
reliable way of eliciting CPM response (Kennedy et al., 2016; Oono et al., 2011). For 
this task, participants were asked to keep their left hand up to the wrist in a circulating 
water bath maintained at 4oC whilst pressure pain threshold is reassessed at the 
baseline site (right upper shoulder) 10 seconds following hand immersion. 10-seconds 
was used in this experiment since prolonged immersion in other studies (e.g., 20 
seconds or longer) is often deemed by participants as too painful and this often means 
they are unable to comply further and complete the full CPM procedure (Oono et al., 
2011; Smith et al., 2007).  
 
Bag-Holding Task  
 
To measure CPM, the test stimulus was also combined with a bag holding task 
(BHT). This task was used as a novel conditioning stimuli to assess CPM response, in 
an attempt to generate musculoskeletal back pain to compare to the cold pressor task 
(Tang, Salkovskis, et al., 2007; Vlaeyen et al., 1995). Participants were asked to hold 
a weighted shopping bag (5kgs females/ 6kgs males) with their left hand, whilst 
pressure pain threshold is reassessed at the baseline site (right forearm) after 1 
minute of bag-holding. The bag weight did not account for individual differences in 
physical strength, but all participants held it for the same standard time. One minute 
of bag-holding was trialled in this experiment to assess feasibility of the bag-task as a 
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conditioning stimulus to elicit to engage a CPM response, whilst minimising 
participant burden or boredom from holding the bag.  
 
The order of applying the conditioning stimuli to assess CPM response was 
randomly assigned to each participant for the first testing visit and remained the same 
for the follow-up visit. During the CPM assessment, participants were standing, 
instructed to fixate their gaze on a spot on the wall to minimise distraction. They were 
especially reminded to focus on and pay attention to the pressure pain from the 
algometer and press the stop button immediately when “the pressure stimulus had 
become just noticeably painful and not the conditioning stimulus”. 
 
4.2.3.2 Sleep Measures and Questionnaires 
 
 
Consensus Sleep Diary (CSD) (2.1.3) (Carney et al., 2012) 
 
Participants were asked to fill in a daily sleep diary with the purpose of 
gathering information about participants’ daily sleep pattern between testing visits. 
The CSD has items asking the participants to report bedtime (“What time did you get 
into bed?”; “What time did you try to go to sleep?”) and risetime (“What time was 
your final awakening?”; “What time did you get out of bed for the day?”), to estimate 
sleep onset latency (SOL), (“How long did it take you to fall asleep?”), wake up after 
sleep onset (WASO) and WASO duration (“How many times did you wake up, not 
counting your final awakening?”; “In total, how long did these awakenings last?”).  
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Demographic questionnaire 
 
The demographic questionnaire provided details on participants’ age, sex, 
ethnicity, and body mass index. Validated questionnaires described below were used 
to characterise participants based on sleep quality, pain rating, and pain 
catastrophising tendency. 
 
Pittsburgh Sleep Quality Index (PSQI) (Buysse, Reynolds, Monk, Berman, & Kupfer, 
1989)  
 
The PSQI assesses the overall sleep quality in the past month. It consists of 19 
individual items computed into sub-components of subjective sleep quality, sleep 
latency, sleep duration, sleep efficiency, sleep disturbances, use of sleeping 
medication, and daytime dysfunction. The score for each subscale ranges from 0 (no 
difficulty) to 3 (severe difficulty). A global PSQI score is then derived from the total of 
the seven component scores. The global PSQI score ranges from 0 to 21 and lower 
scores are indicative of better sleep quality; with a suggested a cut-off score of > 5 to 
indicate poor sleepers. The PSQI has shown good internal consistency in non-clinical 
groups, Cronbach’s alpha 0.83 (Buysse et al., 1989). The scale also correlates with 
other objective and self-reported sleep measures and has shown strong reliability and 
stability as a subjective measure of sleep dissatisfaction across studies in non-clinical 
samples (Grandner, Kripke, Yoon, & Youngstedt, 2006; Mollayeva et al., 2016).  
 
Pain Catastrophising Scale (PCS) (Sullivan, 2009; Sullivan et al., 1995) 
 
The PCS is a 13-item scale to measure the tendency of pain catastrophising. 
The scale assesses thoughts and feelings that individuals may have experienced during 
past painful episodes. The scale requires the participants to think about these past 
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painful experiences and to rate the extent to which they experience the items on a 5-
point scale of 0 (not at all) to 4 (all the time). The PCS has shown reliability and validity 
as a measure of catastrophic thoughts about pain, with high internal consistency 
(Cronbach alpha = 0.87) and test–retest reliability (r = 0.70–0.75) (Sullivan et al., 2001). 
The PCS total score ranges from 0 – 52 with higher scores indicating greater tendency 
to engage in catastrophic thinking about pain, with a suggested cut-off score of >30 to 
indicate clinically relevant levels of catastrophising (Sullivan, 2009). 
 
Brief Pain Inventory (BPI) (Cleeland & Ryan, 1994) 
 
The BPI is a measure that assesses pain severity and pain-related interference. 
For this study, only the 4 items assessing pain severity were used to confirm 
participants were not currently experiencing acute pain before starting the 
experimental procedure.  These are numerical rating scales [0 (no pain at all) to 10 
(pain as bad as you can imagine)] for assessing worst pain in the past week, least pain 
in the past week, pain on average, and pain right now.  
 
4.2.4 Data Analysis 
 
PPTh and CPM index were calculated separately for both visits and were also 
averaged across both testing visits. Consistent with previous studies and research 
recommendations (Edwards et al., 2009; Smith et al., 2007; Yarnitsky et al., 2010; 
Yarnitsky et al., 2015), CPM index was derived by calculating the percent change of 
PPTh during the conditioning stimulus to PPTh prior to conditioning stimulus 
(
𝑀𝑒𝑎𝑛 𝑃𝑃𝑇ℎ 𝑑𝑢𝑟𝑖𝑛𝑔 𝐶𝑆
𝑀𝑒𝑎𝑛 𝑃𝑃𝑇ℎ 𝑝𝑟𝑖𝑜𝑟 𝐶𝑆
 ×  100). CPT-CPM represents the index for the cold pressor task 
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conditioning stimulus and BHT-CPM represents the index for the bag holding stimulus. 
A CPM index greater than 100% indicates a positive CPM effect and an increased pain 
threshold during the CPM compared to baseline PPTh. A CPM index less than 100% 
reflects the reverse. The percent difference reflects the magnitude of the CPM effect 
(CPM) which is the observed CPM index subtracted from a CPM index of 100% (no 
CPM effect).  
 
As per previous studies (Biurrun Manresa et al., 2014; Lewis et al., 2012; 
Martel, 2013), intraclass correlation coefficients (ICCs) were calculated to examine the 
relative stability of CPM responses. This indicates the stability of interindividual 
differences in CPM responses across both testing visits. ICCs are established measures 
of relative stability. Coefficients ranging between 0.00 – 0.40, 0.41 – 0.60, 0.61 – 0.80, 
and 0.81 – 1.0 are interpreted as poor, moderate, good, and excellent reliability 
respectively (Shrout & Fleiss, 1979; Weir, 2005). ICC was calculated between visits 1 
and 2, for PPTh and CPM index and for both conditioning stimuli (cold pressor and bag 
holding task). ICC analysis was carried out using a two-way mixed effect model with 
terms of absolute agreement and ICCs of average measurements are reported. 
 
The sleep diary data was scored to extract and calculate a week average of 
subjective sleep parameters – sleep onset latency (SOL), wake after sleep onset 
(WASO) duration, sleep efficiency (SE), time in bed (TIB), and total sleep time (TST). SE 
was calculated using the formula: TST/TIB * 100. TST was estimated and derived based 
on the formula: TIB-(SOL+WASO duration) (Morin & Espie, 2004).  
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To examine the influence of sleep and pain catastrophising on CPM response, 
Pearson correlations were computed to examine simple bivariate relationships of 
sleep variables derived from the PSQI and sleep diary and pain catastrophising scores 
with PPTh and CPM index. Given the multiplicity of the correlations, a post-hoc 
Bonferroni correction was applied and all correlations were Bonferroni corrected to a 
p < 0.001.  
 
Finally, participants were also split by CPM responders and non-responders. 
CPM responders and non-responders were defined as participants with a positive CPM 
effect (> 100%) and negative CPM effect (< 100%) respectively. To account for unequal 
sample sizes between the two groups, a non-parametric t-test was used to compare 
the two groups by pain catastrophising (PCS scores), sleep quality (PSQI scores), and 
sleep diary averages.   
 
All statistical analyses were conducted using SPSS version 23 (IBM Corporation, 
2013). Means are presented with standard deviations in parentheses, unless 
otherwise stated. The level of significance was set at p < 0.05 unless otherwise stated. 
 
4.2.5 Results 
 
4.2.5.1 Descriptive Statistics 
 
Descriptive statistics for the participants’ demographics, questionnaire 
variables, and sleep diary averages are presented in Table 1. The sample included 
50.9% Caucasians, 35.2% Asians and 13.9% Black, other and mixed ethnicities.  
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Table 3 CPM Experiment 1 Participant Characteristics 
N = 54 M (SD) 
Age 19.4 (3.86) 
BMI (n = 48; due to missing data) 22.01 (3.31) 
Sex (Female %) 84.21% 
Ethnic origins (Caucasian %) 50.9% 
 
Pain catastrophising (PCS total score) 
 
15.93 (10.52) 
 
Sleep variables  
 
Sleep disturbance (PSQI total score) 5.91 (2.60) 
 
Sleep diary – week average  
 
Sleep onset latency (mins) 19.30 (16.85) 
WASO duration (mins) 10.99 (22.46) 
Total sleep time (mins)  503.19 (73.91) 
Sleep efficiency (%)  94.22 (5.52) 
Notes: Means are presented with standard deviations in parentheses, unless 
otherwise stated. PCS (Pain Catastrophising Scale), PSQI (Pittsburgh Sleep Quality 
Index), Sleep onset latency (take taken to fall asleep), Wake after sleep onset 
(overnight awakenings), total sleep time (sleep duration), sleep efficiency 
(percentage of total time in bed spent asleep).  
 
 
4.2.5.2 Reliability of CPM response across conditioning stimuli. 
 
Table 4 shows the Mean PPTh (KPa) and CPM index measurement at Visit 1 
and Visit 2, averages across both visits, and the ICC of scores between Visits 1 and 2. 
Pressure pain thresholds for both cold pressor and bag-holding stimuli conditioning 
stimuli showed good ICC scores across both sessions. CPM responses for cold pressor 
and bag-holding stimuli respectively showed poor and moderate ICC scores across 
both sessions.  
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Table 4 CPM Experiment 1 – PPTh (KPa), CPM index (%) and magnitude 
( CPM) and interclass correlations 
 Visit 1 Visit 2 
 
Average  
 
CPM ICC 
CPT - 
PPTh  
202.54 
(29.34) 
 
203.10 
(35.54) 
 
202.82 
(28.41) 
 0.69[0.46 – 0.82] *** 
p = 0.000 
CPT- 
CPM   
107.10 
(13.66) 
108.28 
(14.48) 
 
107.69 
(10.88) 
7.69% 0.33[-0.16 –  0.61]  
p = 0.077 
 
BHT - 
PPTh 
203.06 
(30.95) 
208.06 
(37.24) 
 
205.56 
(31.01) 
 0.78[0.62 – 0.87] *** 
p = 0.000 
BHT- 
CPM  
96.84  
(8.97) 
99.02 
(13.27) 
 
97.93  
(9.60) 
 
-2.07% 0.60[0.31 – 0.77] *** 
p = 0.000 
 
Notes: *p < 0.05 ** p < 0.01 *** p < 0.001. ICC correlations are presented with 95% 
confidence intervals in square brackets. PPTh (Pressure pain threshold) CPT (Cold 
pressor task) BHT (Bag holding task) CPM (Conditioned pain modulation) ICC 
(Intraclass correlation) CPM (percent magnitude of CPM effect) 
 
 
 
4.2.5.3 Magnitude of CPM response across conditioning stimuli 
 
To evaluate the magnitude of CPM index between the cold pressor and bag 
holding conditioning stimulus, the CPM effect and magnitude was calculated for both 
stimuli (Table 4). CPT stimulus elicited the strongest CPM response (7.69%) compared 
to the BHT stimulus (-2.07%) which on average produced a negative CPM response.  
 
4.2.5.4 Associations between CPM response, pain catastrophising, and sleep  
 
To explore the influence of sleep and pain catastrophising on the magnitude 
of CPM index, Pearson correlations were computed between PSQI scores, PCS scores, 
sleep diary variables, average PPTh, and CPM index (Table 5). These measures were 
not significantly associated with CPM scores after Bonferroni correction. Although, 
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sleep onset latency showed a small negative association with average pressure pain 
threshold (r = -0.3, [95%CI -0.539; -0.054] p < 0.05).  
 
Table 5 CPM Experiment 1 – Associations between CPM response, pain 
catastrophising, and sleep 
N = 54 PSQI SOL WASO TST SE PCS CPM PPTh 
PSQI 1 .237 .006 -.189 -.200 .259 .146 -.068 
SOL  1 .027 .172 -.481 .079 .012 -.317 
WASO   1 -.210 -.849 -.010 .102 .154 
TST    1 .240 .131 -.071 -.175 
SE     1 -.046 -.119 -.005 
PCS      1 -.054 .109 
CPM       1 -.203 
PPTh        1 
 
4.2.5.5 CPM responders and non-responders across pain catastrophising and 
sleep 
 
Lastly, differences in pain catastrophising and sleep variables were examined 
for both CPM responders versus non-responders (Table 6). Only CPM response from 
the cold pressor task was used for this analysis as this was the conditioning stimulus 
that is already established and validated in other CPM protocols, whereas the validity 
and reliability of the bag-holding task was under evaluation in this experiment. There 
were a small number of CPM non-responders (n = 10) compared to responders (n = 
44) and they reported higher PCS scores (M = 22.30, SD = 12.13) than responders (M 
= 14.60, SD = 9.73), U = 137.00, z = −1.85, p < .05. There were no other significant 
differences between the two groups.  
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Table 6 CPM Experiment 1 – CPM responders and non-responders 
 CPM Non- 
responders  
N = 10 
CPM  
Responders 
N = 44 
Mann-Whitney U test 
PSQI (Sleep quality) 6.20 (1.99) 5.79 (2.71) U = 190.50, z = -0.663, p = 0.259 
PCS (Pain catastrophising) 22.30 (12.13) 14.60 (9.73) U = 137.00, z = -1.850, p = 0.032* 
Sleep onset latency (SOL) (mins) 22.39 (16.34) 18.60 (17.06) U = 176.50, z = -0.969, p = 0.170 
WASO duration (mins) 9.29(15.72) 11.38 (23.87) U = 186.00, z = -0.758, p = 0.229 
Total sleep time (TST) (mins) 510.85(114.49) 501.44(63.03) U = 175.50, z = -0.991, p = 0.164 
Sleep efficiency (SE) (%) 94.24(4.12) 94.22(5.95) U = 200.00, z = -0.445, p = 0.334 
 
Notes: Means are presented with standard deviations in parentheses  
***p < 0.001 **p < 0.01 *p < 0.05 
 
4.3 Summary of Experiment 1 findings and justification for Experiment 2  
 
Experiment 1 aimed to evaluate the utility of using a novel conditioning stimulus 
to evoke the CPM response, however, there was no evidence that the bag holding task 
could reliably be used to elicit CPM. The CPM index was less than 100% suggesting 
that the task tend to show a reverse CPM effect, which is puzzling. Research has shown 
that the effect of CPM may be correlated with the intensity of the conditioning stimuli 
(Nir et al., 2011; Nir & Yarnitsky, 2015), hence perhaps having participants holding the 
weighted bag for just a minute was insufficient to elicit the pain necessary to evoke 
CPM. To clarify this, in Experiment 2, the length of bag-holding was increased to 2 
minutes as an attempt to up the intensity of the pain. In addition, a pain rating was 
added to gauge how participants perceive the pain intensity from both conditioning 
stimuli. A body manikin (pain drawing tool) was also used to assess pain distribution 
after the application of the conditioning stimulus, to confirm the stimuli are perceived 
as painful and in the expected contralateral side of the body.  
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In Experiment 1, apart from CPM non-responders reporting greater pain 
catastrophising than responders, there was no other significant differences between 
the two groups across sleep variables. Given the small sample of non-responders in 
this experiment, we aimed to replicate the findings using a larger sample to 
characterise CPM responders and non-responders and to evaluate potential 
associations (or the lack thereof) with pain catastrophising and self-reported sleep. In 
addition, Experiment 2 aimed to further explore the validity of the CPM methodology 
as a measure of the body’s endogenous pain-modulation system. Cognitive factors are 
known to play a part in affecting pain inhibition mechanisms, however, previous 
studies on the effect of distraction on CPM have only assessed the extent to which 
distraction affects participants’ pain rating during the application of conditioning 
stimuli (Moont et al., 2010). Applying Experimental 1’s CPM protocol of 
psychophysical pressure pain threshold as test stimulus and cold pressor task and hag 
holding task as conditioning stimulus, the aim of Experiment 2 was to quantify and 
compare the effect of modality-matching cognitive distraction tasks (as conditioning 
stimuli) on the magnitude of CPM index).  
 
4.4 Experiment 2 – Methods 
 
4.4.1 Participants  
 
A separate sample of 124 healthy young adults from the university were 
recruited for this experiment and inclusion and exclusion criteria were the same as 
Experiment 1 (Appendix 7). Subjects gave signed informed consent (Appendix 4 – 6) 
and all procedures were approved by the Department of Psychology Research Ethics 
Committee. Of 124 participants, four participants were excluded due to the presence 
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of a non-malignant chronic pain condition (chronic back pain and migraines). In 
addition, two participants did not complete the sleep diary data and were excluded 
due to non-compliance with study procedure and missing data. The final sample for 
analysis was 118 participants; however, only 103 (87.29%) participants completed the 
full quantitative sensory testing protocol at both sessions. The overall study sample 
was consisted of 24 males and 94 females and included 61% Caucasians, 34% Asians 
and 5% Blacks, other, and mixed ethnicities. Those excluded from the final analysis did 
not differ from the final sample across most variables, although the four with chronic 
pain reported greater pain intensity.  
 
4.4.2 Design and Procedure 
 
The study used the same repeated measure design and order of procedure as 
described in Experiment 1 (4.2.2). Figure 6 details the different QST protocol used for 
Experiment 2. The order of conditioning stimuli and additional distracter tasks were 
randomly assigned for Visit 1 and remained the same for Visit 2.  
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Figure 6 CPM Experiment 2 – QST Protocol 
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Notes: Figure 6 presents the QST protocol for Experiment 2. QST procedure involved a baseline 
assessment of pressure pain threshold on the right upper shoulder (trapezius posterior) or right 
forearm (anterior brachoradialis) and then reassessment of pressure pain threshold after the 
application of the conditioning and distraction stimuli on the left side of the body.  
 
QST (Quantitative Sensory Testing) PPTh (Pressure pain threshold) CPT (Cold pressor task) BHT 
(Bag holding task) CPTd (Cold pressor task distractor) BHTd (Bag holding task distractor) BM (Body 
Manikin) MC (Manipulation Check)  
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4.4.3 Measures 
 
4.4.3.1 Pain measures  
 
4.4.3.1.1 Conditioned pain modulation 
  
The QST protocol to measure CPM response was similar to Experiment 1 
(4.2.3). Pressure Pain Threshold was used as test stimulus and was combined with two 
conditioning stimuli – Cold Pressor Task and Bag Holding Task (with duration of bag 
holding increased to two minutes). Two additional distractor conditioning stimuli with 
perceptual similarity to the cold pressor and bag holding task were used to examine 
distraction effects.  
 
Cold pressor task distraction stimulus 
 
The cold pressor distraction stimuli (CPTd) aimed to be a pain-free task which 
mirrored the physical sensation of the standard cold pressor task (hand in water minus 
the cold pain sensation) whilst the participants were engaged in a distracting and 
attention demanding cognitive task adapted from Moont et al. (2010). Participants 
were asked to place their left hand in a water bath maintained at normal body 
temperature (35±1oC) whilst identifying and remembering the figure of a set of 20 (26 
during Visit 2) beads placed at the bottom of the water bath. The shape was 
standardised for every participant and they asked to describe the shape and recall the 
number of beads afterwards to ensure they had been counting. To avoid learning 
effects between the two visits, the shape was arranged differently for Visit 2 
(trapezoid) than for Visit 1 (rhomboid).  
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Bag holding task distraction stimulus 
 
The bag holding distraction stimuli (BHTd) was designed again as a pain-free 
version of the physical act of the bag holding task whilst the participants were engaged 
in a cognitively demanding distracting task. Participants were asked to hold up an 
empty shopping bag using the left hand and vocalise a mental arithmetic exercise 
adapted from Nilsen, Christiansen, Holmen, and Sand (2012). Participants were asked 
to subtract 3 (and 7 during visit 2) from 1000 successively. Evidently, subtracting 7 
constitute a harder task than subtracting 3 but this was to avoid learning effect 
between the two visits and to ensure the task at Visit 2 was nevertheless still quite 
distracting.  
 
4.4.3.2 Sleep measures and questionnaires 
 
The same set of questionnaires was used as in Experiment 1 (4.2.3.2) (CSD, 
demographics questionnaire, PSQI, PCS, and BPI) (Appendix 8). Additional measures 
and questionnaires used in Experiment 2 are described below.  
  
Pain rating 
  
A VAS numerical rating scale [0 (no pain at all) to 10 (pain as bad as you can 
imagine)] was used to index pain intensity after application of the conditioning 
stimulus, immediately prior to PPTh reassessment. Participants were given additional 
training before the beginning of the experiments in the use of the pain rating scale.  
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Body Manikin (Lacey, Lewis, Jordan, Jinks, & Sim, 2005; Lacey, Lewis, & Sim, 2003; 
Margolis, Chibnall, & Tait, 1988) 
 
A body manikin/ pain drawing was used to assess location and prevalence of 
pain after application of the conditioning stimulus. Participants were asked to shade 
their pain within the outlines of front and back views of a blank body manikin. This 
was visually inspected for the spread of the pain and the number of areas shaded was 
noted.  
 
Manipulation check questionnaire 
 
A manipulation check questionnaire was used at the end of the distraction task 
to assess participant’s distraction levels and the extent to which the tasks were 
successful in drawing the participants’ attention away from the test pain stimuli 
(Verhoeven et al., 2010). This was assessed using a numerical scale from 0 to 10 (0 = 
not at all; 10 = very much) to rate the perceived effect of the distraction task (“how 
much did this task distract you from the pressure pain”).  
 
4.4.4 Data analysis 
 
Data analysis plan is the same as that reported for Experiment 1 (4.2.4) with 
some additional analyses. PPTh, CPM index, CPM magnitude and intraclass correlation 
coefficients (ICCs) were also calculated for the additional distraction stimuli and 
magnitude of the CPM effect was also compared across both conditioning and 
distraction stimuli. The pain ratings and drawings on the body manikin were examined 
visually to confirm that perception of pain after the application of the conditioning 
stimulus is present at the intended body areas. A t-test was used to compare the 
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perceived pain ratings during the cold pressor and bag holding stimuli and the 
perceived distraction effect during both distraction tasks.  
 
4.4.5 Results 
 
4.4.5.1 Descriptive statistics  
 
Descriptive statistics for participants’ demographics, questionnaire variables, 
and sleep diary averages are presented in Table 7.  
 
Table 7 CPM Experiment 2 – Participant Characteristics 
N = 118  M (SD) 
Age 19.5 (2.09) 
BMI (n = 113; due to missing data) 21.13 (3.84) 
Sex (Female %) 79.66 
Ethnic origins (Caucasian %) 61.01 
 
Pain catastrophising (PCS total score) 
 
17.83 (10.34) 
 
Sleep variables  
 
Sleep disturbance (PSQI total score) 6.64 (1.28) 
 
Sleep diary – week averages 
 
Sleep onset latency (mins) 21.64 (18.73) 
WASO duration (mins) 9.75 (13.59) 
Total sleep time (mins)  444.69 (72.23) 
Sleep efficiency (%)  93.17 (6.28) 
 
Notes: Means are presented with standard deviations in parentheses, unless otherwise stated.  
 
 
 
4.4.5.2 Reliability of CPM response 
 
Table 8 shows the Mean PPTh (KPa) and CPM index measurement at Visit 1 
and Visit 2, the averages across both visits, CMP magnitude, and the ICC between Visit 
1 and 2. In both experiments, the ICCs were mostly statistically significant. Pressure 
pain thresholds for all conditioning and distraction stimuli showed excellent ICC scores 
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across both sessions. CPM responses for cold pressor and bag holding stimuli 
respectively showed moderate and poor ICC scores across both sessions. CPM 
response for the bag holding and cold pressor distraction stimuli respectively showed 
moderate and poor ICC across both sessions.  
 
 
4.4.5.3 Magnitude of CPM response across conditioning and distraction stimuli 
 
The magnitude of CPM effect was calculated across all conditioning stimuli 
used to elicit CPM response (Figure 7). All protocol showed CPM response; CPT 
stimulus elicited the strongest CPM response (29.16%) and the BHT showed a weak 
CPM response (4.34%). The distraction tasks also engaged the pain inhibition 
responses and elicited CPM response – cold pressor distraction tasks (10.40%) and bag 
holding distraction tasks (11.95%). The cold pressor task elicited stronger pain 
intensity than the bag holding tasks. Perceived pain rating during CPT (M = 5.8 SD = 
1.95) was significantly higher than during BHT (M = 3.93, SD = 1.88), t (105) = 9.28, p 
< .001. The cold pressor distraction task (CPTd) had a lesser distraction effect than the 
bag holding distraction task (BHTd). Perceived distraction effect during CPTd (M = 3.46 
SD 2.49) was significantly lower than during BHTd (M = 5.16 SD = 2.69) t (105) = -6.31, 
p < .0001.  
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Table 8 CPM Experiment 2 – PPTh (KPa), CPM index (%) and magnitude 
(CPM), intraclass correlations, pain and distraction (0-10) ratings 
 Visit 1 Visit 2 Average CPM ICC 
CPT – 
PPTh  
178.74 
(64.02) 
166.77 
(58.60) 
172.76 
(56.84) 
 
 0.83[0.74 – 0.86]***  
p = 0.000 
 
CPT – CPM 
index  
129.88 
(33.14) 
128.44 
(27.47) 
129.16 
(24.49) 
 
29.16% 0.53[0.31 – 0.68]***  
p = 0.000 
 
CPT – pain 
rating 
5.62  
(2.17) 
5.97  
(2.05) 
5.80 
(1.93) 
  
 
 
BHT – 
PPTh 
186.05 
(52.67) 
169.71 
(56.52) 
177.88 
(50.39) 
 0.83[0.74 – 0.89]*** 
p = 0.000 
  
BHT – 
CPM index  
100.44 
(19.71) 
108.24 
(23.25) 
104.34 
(16.96) 
 
4.34% 0.29[-0.02 – 0.51] 
p = 0.033 
BHT – pain 
rating  
3.57  
(1.97) 
4.30  
(2.17) 
3.94  
(1.85) 
 
 
 
 
CPTd – 
PPTh 
185.37 
(69.23) 
 
164.83 
(55.76) 
175.10 
(57.13) 
 0.77[0.62 – 0.85]***  
p = 0.000 
 
CPTd – 
CPM index  
109.03 
(22.57) 
 
111.77 
(23.94) 
110.40 
(15.95) 
10.40% -0.14[-0.67 – 0.23] 
p = 0.739 
 
CPTd – 
distraction 
3.40  
(3.14) 
3.53  
(2.82) 
3.47  
(2.51) 
  
 
 
BHTd – 
PPTh 
189.92 
(60.66) 
 
174.40 
(55.88) 
182.16 
(53.67) 
 0.84[0.75 – 0.89]*** 
p = 0.000 
 
  
BHTd – 
CPM index  
111.44 
(27.46) 
 
112.45 
(22.45) 
111.95 
(20.64) 
11.95% 0.47[0.22 – 0.63]**   
p = 0.001 
  
BHTd – 
distraction 
4.63  
(3.37) 
5.71  
(2.77) 
5.17  
(2.70) 
  
 
 
Notes: *p < 0.05 ** p < 0.01 *** p < 0.001. Number in [] are 95% confidence intervals. PPTh 
(Pressure pain threshold) CPT (Cold pressor task) BHT (Bag holding task) CPTd (Cold pressor 
task distractor) BHTd (Bag holding task distractor) CPM (Conditioned Pain Modulation) 
CPM (percent magnitude of CPM effect), ICC (Intraclass correlation)  
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Figure 7 CPM Experiment 1 & 2 – CPM response across all conditioning 
and distraction stimuli 
 
 
 
4.4.5.4 Association between CPM response, pain catastrophising, and sleep 
 
To examine the association of sleep and pain catastrophising with the 
magnitude of CPM index, Pearson correlations were computed between PSQI scores, 
sleep diary variables, PCS scores, average PPTh, and CPM index (Table 9). These 
measures were not associated with CPM scores after Bonferroni correction. Although 
total sleep time showed a small positive correlation with CPM response (r = 0.2 [95%CI 
0.023; 0.393], p < 0.05) and PPTh (r = 0.2 [95%CI 0.053; 0.418], p < 0.05).  
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Notes: Average CPM index for cold pressor (CPT) and bag-holding (BHT) task 
conditioning stimuli and for the cold pressor (CPTd) and bag-holding distraction (BHTd) 
tasks across both Experiment 1 (exp 1) and Experiment 2 (exp2).  
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Table 9 CPM Experiment 2 – Associations between pain 
catastrophising, sleep, and CPM response 
 
N = 103 PSQI SOL WASO TST SE PCS CPM PPTh 
PSQI 1 .335 .127 -.187 -.329 .337 -.084 .032 
SOL  1 .353 -.244 -.853 .075 .014 .027 
WASO   1 -.269 -.644 .108 .106 -.080 
TST    1 .470 .055 .216 .244 
SE     1 -.110 .042 -.039 
PCS      1 -.025 -.012 
CPM       1 -.427 
PPTh        1 
 
4.4.5.5 CPM responders and non-responders across pain catastrophising and 
sleep 
 
Table 10 reports sleep variables and pain catastrophising scores in CPM 
responders (n=91) compared with CPM non-responders (n = 12). CPM non-responders 
reported significantly less total sleep time. They also reported longer sleep onset 
latency and poorer sleep efficiency, but these were not statistically significantly after 
adjusting for the unequal sample sizes.  
 
Table 10 CPM Experiment 2 – CPM non-responders and responders 
 CPM Non-
responders  
(n = 12) 
CPM  
Responders 
(n = 91) 
Mann-Whitney U test  
  
PSQI (Sleep quality) 6.33 (2.77) 5.97(2.86) U = 508.50, z = -0.389, p = 0.351 
PCS (Pain catastrophising) 17.41(7.90) 17.78 (10.40) U = 516.50, z = -0.303, p = 0.383 
Sleep onset latency (SOL) (mins) 30.43 (28.86) 19.59 (16.41) U = 422.50, z = -1.270, p = 0.104 
WASO duration (mins) 9.11 (12.00) 6.56 (9.13) U = 489.50, z = -0.581, p = 0.284 
Total sleep time (TST) (mins) 404.28 (68.06) 453.39 (69.18) U = 331.00, z = -2.210, p = 0.013** 
Sleep efficiency (SE) (%) 90.64 (8.61) 94.03 (4.76) U = 457.99, z = -0.915, p = 0.184 
Notes: Means are presented with standard deviations in parentheses ***p < 0.001 **p < 0.01 *p < 0.05 
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4.5 Discussion 
 
4.5.1 Summary of findings 
 
In the present study, pressure pain threshold test stimulus with cold pressor 
task conditioning stimulus showed the strongest and most reliable CPM response, 
with bag holding stimulus showing a weak CPM response in this sample of healthy 
participants. CPM magnitude from this study (average 29%) is comparable to other 
studies using the same test and conditioning stimuli protocol in healthy participants; 
Oono et al. (2011) reported a CPM magnitude of 16.7% +/- 2.8 and Smith et al. (2007) 
reported 17% - 28%. Cognitive distraction had some effect on pain inhibition; the 
distraction tasks elicited CPM response, but the magnitude was only half as powerful 
compared to the cold pressor task conditioning stimulus. Compared to CPM 
responders, the few CPM non-responders showing impaired pain inhibitory responses 
reported greater pain catastrophising scores in Experiment 1. They also self-reported 
shorter sleep duration in Experiment 2. 
 
4.5.2 Defining the characteristics of a conditioning stimulus to elicit CPM 
 
Whilst it is generally thought that the test and conditioning stimuli to elicit 
CPM must be ‘noxious’, there is currently no standard approach and specification for 
determining this (Kennedy et al., 2016). Across these experiments, the findings show 
that the bag holding task either tended to show a reverse CPM response or a weak 
CPM response compared to the other conditioning stimulus used in the experiment. 
This could be because the pain elicited by the bag task was not enough to engage the 
descending pain inhibitory pathway. However, previous studies have found no 
relationship between self-reported pain rating of the conditioning stimulus and 
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magnitude of CPM effect (Granot et al., 2008; Nir et al., 2011). There was similarly no 
correlation here between participants’ pain ratings for either cold pressor or bag 
holding task and extent of CPM response, although, pain ratings did show that the bag 
task was perceived as less painful than the cold pressor task.  
 
Nir et al. (2011) had shown that increasing the intensity or perceived 
painfulness of the conditioning stimuli does not affect CPM response so long as the 
stimuli was initially perceived as painful. In their experiment, they used three different 
levels of exposure to the conditioning stimulus, hot water hand immersion at different 
temperature intensities (44.5oC, 45.5 oC, and 46.5 oC) to induce mild, moderate, and 
intense pain levels. The findings showed that CPM was induced by the moderate and 
intense pain levels but there was no difference between the magnitudes of response 
between these two levels. This could also be due to the fact that the range of 
temperature assessed was not that wide. Furthermore, CPM was independent of 
perceived painfulness of the conditioning pain levels. In developing the bag holding 
task as a conditioning stimulus, it was important to bear in mind that the task was 
specifically developed as a behavioural task for chronic back pain patients and if the 
stimulus was too painful, it would not be tolerated by all participants. Moreover, if a 
conditioning stimulus is perceived as too painful by healthy participants, it will not 
have applicability within a chronic pain population. Indeed, other studies have used 
different modalities of conditioning stimuli to elicit CPM and these stimuli have often 
varied in intensity, exposure levels and in tolerability. The bag holding task may also 
have a different effect in a chronic pain population and thus should be tested within 
this population. The bag holding task was hoped to be a simple and accessible stimulus 
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to measure CPM and could still have utility to be used in a clinical setting to reduce 
participants burden associated with elaborate quantitative sensory testing 
procedures. 
 
To ensure that both conditioning stimuli were tolerated and applied 
consistently for all participants and to ensure interpretability of the findings, the 
current experiment adopted a standard protocol and application of conditioning 
stimuli before reassessing the test pain, rather than until a specific numerical pain 
rating had been reached. Pain ratings were also assessed at both sessions to ensure 
that participants were pain free at both times. The application of both conditioning 
stimuli was also kept standard for all the participants, i.e. hand immersion in cold 
water for 10 seconds and bag holding for 2 minutes before reassessment of pressure 
pain threshold.  Increasing time of bag-holding from 1 minute to 2 minutes in the 
Experiment 2 led to an increase CPM magnitude. Some participants may not have 
perceived the bag holding task as painful perhaps because of differences in muscle 
tone and physical strength which was not controlled for in the current study. Further 
amendment of the present experimental protocol may produce different results. For 
example, having a heavier bag to increase pain intensity and increasing the bag 
holding time could lead to an increase in the magnitude of CPM response. As a further 
consideration, the protocol could also be amended to involve continuous pain ratings 
whereby the duration of the bag-holding task for a participant would be determined 
by the level of pain achieved.  
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It is also possible that the musculoskeletal pain elicited by the bag-holding task 
is not a suitable conditioning stimulus to activate the necessary nerve fibres to engage 
the pain inhibitory pathway. Lautenbacher et al. (2002) explained that activation of 
the CPM response could be more dependent on the type and effect of nociceptive 
input produced by the conditioning stimulus, than the subjective painful sensation it 
elicits. Lewis et al. (2012) compared cold pressor task as a conditioning stimulus to 
ischemic pain (induced by tightening an inflatable cuff on the arm) and found that the 
cold pressor task was a more consistently reliable method of inducing CPM. They 
argued that compared to the direct focal pain from the cold pressor task, the diffuse 
effect of the ischemic pain may be the reason underlying why it did not consistently 
and reliably activate the descending inhibitory pathway. The same issue could be 
relevant here for the type of muscle pain evoked by the bag-holding task. Upon visual 
inspection of the body manikins, the spread of the pain induced by the bag holding 
task was generally more widespread (hand, wrist, forearm, shoulders, back, thighs, 
and legs). Whereas, spread of the cold pressor task pain was limited to the hand. 
Future studies can perhaps investigate and in a more quantitative manner how the 
spread of the pain produced by a conditioning stimulus could affect CPM response. 
Most of the conditioning stimuli used to assess CPM are usually quite direct and focal 
(cold, heat, or electrical pain). It may be interesting for future research to investigate 
the endogenous inhibitory pathways underlying cutaneous pain compared to more 
diffuse ischemic and muscle pain.  
 
Physiological factors such as heart rate and blood pressure could also mediate 
the effect of a conditioning stimulus on CPM response. Shared brain structure 
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underlying pain modulation and cardiovascular regulatory systems include the 
anterior cingulate cortex, the amygdala and the functional connections between these 
cortical areas and descending pain pathways centres such as the periaqueductal grey 
are also implicated in autonomic cardiovascular activity (Bruehl & Chung, 2004). 
Chalaye, Devoize, Lafrenaye, Dallel, and Marchand (2013) found that increase in blood 
pressure induced by application of cold pressor task conditioning pain was positively 
correlated with magnitude of CPM response in a healthy population. Importantly, it 
could also be that conditioning stimuli inducing ischemic or muscular pain such as the 
bag holding task may not be engaging the cardiovascular reactivity necessary to drive 
a stronger pain inhibitory CPM response. It may be a worthwhile consideration for 
future studies to explore the mediating role of cardiovascular activity in CPM 
dysfunction and whether changes in blood pressure responses to different modalities 
of conditioning stimuli could be a cause or effect of CPM efficiency. Although, there 
are also additional challenges in getting reliable measure of blood pressure and heart 
rate; during the tasks, blood pressure and heart rate could also be affected by and 
interact with cognitive and psychological factors (e.g., attention, anxiety, and 
catastrophising). 
 
4.5.3 The role of cognitive distraction in endogenous pain inhibition 
 
Findings from this study revealed that a non-painful cognitively distracting 
conditioning stimulus can also induce CPM response. The magnitude of CPM effect 
across the distraction stimuli (10 – 11%) attests to the potency of the effect of 
cognitive distraction in driving a pain inhibitory effect however, the CPM magnitude 
was still lower than the cold pressor task conditioning stimulus (29%). The distraction 
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stimuli used in this experiment aimed to be comparable and easily interpreted 
alongside the conditioning stimuli. They were attention demanding, cognitively 
engaging, and involved the same perceptual modality as the cold pressor and bag 
holding task conditioning stimuli. Furthermore, in contrast to other studies evaluating 
effect of distraction on CPM (Moont et al., 2010), this study did not rely only on 
changes in pain ratings of the test stimuli to derive CPM response. Rather, a 
psychophysical criterion was used to determine difference in test stimulus (pressure 
pain threshold) prior to and after application of the conditioning stimulus.  The 
distraction tasks were also consistently reliable across both testing visits, hence, 
expectation that the distraction tasks were not painful did not affect the pattern of 
results.  
 
This study showed that the conditioned pain modulation phenomenon 
involves an act of directing attention towards the conditioning stimuli and thus the 
inhibitory effect elicited on the test stimuli. The findings show that the impact of a 
non-painful but cognitively distracting conditioning stimuli does not engage as much 
of an intensity to override and extend beyond the inhibitory effect expected from 
nociceptive sensations. These findings attest to the validity of the CPM as a measure 
of the central pain modulation but highlight that the process also comprises different 
functional physiological and psychological mechanisms. Distraction as a cognitive 
process is hypothesised to produce hypoalgesic effects by introducing stimuli to 
compete with noxious stimuli for attentional resources. The neural origin for this is 
perhaps from the decreased activation of pain-related activity in multiple cortical 
regions such as primary and secondary somatosensory cortices, anterior cingulate 
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cortex, insular cortex, regions of the frontal cortex, midbrain PAG (Bushnell et al., 
1999; Frankenstein, Richter, McIntyre, & Remy, 2001; Petrovic, Petersson, Ghatan, 
Stone-Elander, & Ingvar, 2000; Tracey et al., 2002). In addition, the inhibition of 
incoming pain signals and behavioural pain reduction at the spinal cord level as 
proposed in the gate control theory of pain is perhaps also relevant  (Sprenger et al., 
2012). In relation to the CPM paradigm, distraction possibly causes hypoalgesia to the 
test stimuli, which in this case increases pressure pain threshold and drives a pain 
inhibitory response. Further work is needed to disentangle where the effects of 
distraction differs and separate from physiological CPM response. Studies should 
explore and specify the pain inhibitory mechanisms evoked by distraction hypoalgesia, 
how the sensory and affective components of pain perception and modulation work 
together and if this can be manipulated to control conditioned pain modulation 
response.  
 
4.5.4 Associations between pain catastrophising and endogenous pain inhibition 
 
In the present study, PCS scores was seen to be higher in CPM non-responders 
in Experiment 1 but not Experiment 2. This study assessed trait catastrophising 
whereas previous studies investigated the influence of pain catastrophising on CPM 
have asserted that situational catastrophising during the actual painful experimental 
procedure may be more related to increased pain ratings and impaired endogenous 
pain modulation (Goodin et al., 2009). In this study, PCS as a measure of trait pain 
catastrophising was not able to consistently discriminate between CPM responders 
and non-responders. Inconsistencies in the current finding may be explained by the 
relatively low level of pain catastrophising in this non-clinical healthy population. 
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There are perhaps more to consider about different aspects of cognitive, affective and 
behavioural factors underpinning pain catastrophising. Factors such as negative 
cognitive ruminations, misinterpretations of bodily sensations, exaggerated and 
inaccurate worries about pain, hypervigilance to pain stimuli may all have varying 
impact on different modalities and components of the quantitative sensory testing 
procedures to elicit CPM (Campbell et al., 2010; Quartana et al., 2009).   
 
In an overview of studies that have assessed PCS score across different CPM 
protocols, only studies using electrical pain as test stimulus and cold pain as 
conditioning stimulus seem to show an effect for the influence of trait pain 
catastrophising (Nahman-Averbuch et al., 2016). However, the association was not in 
the expected direction, with higher pain catastrophising indicative of greater CPM 
response. Weissman-Fogel et al. (2008) on the other hand, demonstrated that higher 
trait PCS was related to diminished CPM response elicited by heat pain test stimulus 
and deep muscle pain conditioning stimuli. Inconsistencies across studies could be 
resulting from the fact that it is not clear which of the stimuli to elicit CPM is most 
affected by pain catastrophising. These authors further found that PCS scores were 
correlated with both the heat pain test stimulus and muscle pain conditioning stimulus 
but had no discriminative effect between test pain and conditioning pain. It could be 
that increased level of pain catastrophising in general leads to increased perception 
of the conditioning stimuli pain, away from the test stimuli and consequently resulting 
in a heightened CPM effect. Or it could be vice-versa, that pain catastrophising 
thoughts heighten perception of the test stimuli relative to the conditioning stimulus 
and attenuates CPM response. This again emphasises the need and importance of 
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standardising task instructions when telling participants where to focus their attention 
(on the test stimulus) during the procedure. In the current study, findings of higher 
PCS scores in non-responders may be related to increase perception of the pressure 
pain test stimulus but there was no means of determining this. Influence of pain 
catastrophising on CPM may be modality specific and have different effects on the 
test and conditioning stimulus. This underlines the need for future research to assess 
and consider the varying impact of different testing paradigms on specific underlying 
psychological factors.  
 
4.5.5 Associations between self-reported sleep and endogenous pain inhibition 
 
The current study provides some initial findings for disrupted self-reported 
sleep in those with impaired CPM response. Total sleep time seems to be correlated 
with CPM magnitude and lower in CPM non-responders than non-responders in 
Experiment 2. Other markers of sleep disturbance, namely sleep onset latency and 
wake after sleep onset duration were also higher in CPM non-responders in 
Experiment 2 but were not statistically significantly after adjusting for unequal sample 
sizes. These findings extend those other studies exploring the associations between 
sleep deprivation/restriction and pain perception and pain modulation. Schuh-Hofer 
et al. (2013) revealed the effect of one night of total sleep deprivation on objective 
pain measures in their 14 healthy participants in a cross-over design. They found lower 
cold, heat, and pressure pain threshold and mechanical pain sensitivity after the sleep 
deprivation condition compared to habitual sleep. Campbell et al. (2011) split healthy 
participants by self-reported sleep duration in past month and found that those 
reporting 6.5 hours or less reported subjective pain sensitivity and when subjected to 
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a 70-min application of heat and capsaicin nociceptive stimuli, they also showed 
physical signs of secondary hyperalgesia (higher pain sensitivity outside of the area 
the stimulus was applied to).  
 
The mechanism underlying secondary hyperalgesia reflects descending pain 
inhibitory capability such as CPM and general disturbance of nociceptive modulation 
at the spinal cord level. Matre, Andersen, Knardahl, and Nilsen (2016) found similar 
results for hyperalgesia to heat pain used as a test stimulus in a CPM protocol. They 
used a cross-over design in which 22 healthy adults were assessed over 2 nights of 
habitual sleep, followed by 2 nights of 50% sleep restriction, based on the participant’s 
reported habitual sleep length. The assessment was self-administered in the 
participant’s home and involved an ambulatory EEG sleep assessment. A stronger 
CPM response was observed after the sleep restriction condition compared to 
habitual sleep. Notably, the test pain stimuli of heat pain threshold used in their study 
was perceived as significantly more painful after the sleep restriction condition 
compared to the habitual sleep condition. This finding suggests that it could be 
response to test pain that is dependent on the sleep duration effect, and indirectly 
influencing the overall CPM response. 
 
Different types of sleep disturbance may also be implicated in central pain 
processing. Smith et al. (2007) found that it was an overnight forced-awakening sleep 
fragmentation protocol that led to attenuation of CPM response in their sample of 
healthy female participants. In their sleep restriction condition, similar to Matre et al. 
(2016) participants showed a tendency towards elevation of baseline test pain 
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pressure pain threshold and greater CPM response although this was not statistically 
significant. They explained that complex pain modulation processes such as CPM may 
be reflective of slow wave sleep loss as observed in the sleep fragmentation condition 
compared to the sleep restriction condition where there was no significant loss of slow 
wave sleep. Slow wave sleep usually responds weakly to sleep restriction protocols 
possibly due to increased sleep pressure (Akerstedt, Kecklund, Ingre, Lekander, & 
Axelsson, 2009). These preliminary findings reveal that those with pain regulation 
dysfunction also seem to show mild sleep disturbance and provide some support for 
the idea that sleep disturbance and disrupted sleep processes may be risk factors for 
greater pain disability.  
 
 
4.5.6 Limitations of the experiments 
  
The two experiments presented have some limitations that should be 
considered. First, participants were young healthy individuals undergoing laboratory 
based QST procedures and this may limit generalisability to general and clinical 
population. CPM procedures have been shown to be relevant across clinical chronic 
pain populations (Edwards, Dolman, et al., 2016; Valencia, Kindler, Fillingim, & 
George, 2013) and it would be important to further investigate the relevance of the 
bag-holding task in eliciting pain of certain focus and threshold that would trigger CPM 
responses. Second, gender differences and ethnicity were not examined due to the 
fairly homogenous sample. Males are thought to have more pronounced CPM effect 
and although this predominantly female sample still showed significant CPM 
response, the skewness in gender may affect findings. Furthermore, other potential 
confounding factors in females such as menstrual cycle was not controlled for 
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(Popescu, LeResche, Truelove, & Drangsholt, 2010; Wilson, Carvalho, Granot, & 
Landau, 2013).   
 
Third, the experiments relied on self-reported natural sleep patterns and sleep 
disturbances and so causal interpretations cannot be drawn from these findings. 
However, there was the advantage of ecological validity from getting an aggregate of 
sleep report across the week using a standardised sleep diary to yield information 
about relevant sleep measures (SOL, WASO, TST and SE). Sleep parameters from 
standard self-reported sleep measures such sleep diaries remain an accurate 
assessment of sleep quality, even comparable to objective assessments (Carney et al., 
2012; Lockley et al., 1999). Nevertheless, future experiments should endeavour to 
investigate and replicate findings of associations of sleep in CPM non-responders with 
a combination of both self-reported and objective measures of sleep using PSG and 
actigraphy. This would offer deeper insights into the multi-dimensionality of the sleep 
experience. 
 
Lastly, there was a risk of inflated Type 1 errors given the large number of 
comparisons involved in both studies reported in this chapter. To correct for this, a 
Bonferroni correction (Bland & Altman, 1995) was applied and all correlations were 
adjusted to a p < 0.001. Correlations were observed between sleep onset latency and 
pressure pain threshold in Experiment 1 and between total sleep time and pressure 
pain threshold and conditioned pain modulation in Experiment 2. However these were 
non-significant once a blanket Bonferroni correction was applied to all analyses.  It has 
been argued that the Bonferroni itself is quite a conservative test and with greater 
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number of tests and corrections, alpha levels may become set so small that sets up an 
eventuality for Type 2 errors and this may mean that important findings may be 
deemed as non-significant (Fiedler, Kutzner, & Krueger, 2012; Savitz & Olshan, 1995). 
Calculating confidence intervals for correlations provide another way to interpret 
effects based on magnitude of the correlation and likely size of the population effect. 
These recommendations were followed when reporting the results in this chapter, 
however, ideally, to keep the risk of Type 1 and 2 errors minimal, an increase in sample 
size would be needed to combat multiplicity corrections (Bender & Lange, 2001; Savitz 
& Olshan, 1995).   
 
4.6 Conclusion 
 
Conditioned pain modulation (CPM) has been found to be impaired in a range 
of chronic pain conditions and is commonly thought to be a key clinical marker of 
central pain inhibitory processes. Importantly, CPM reflects an interaction between 
physiological pathways and psychological cognitive processes. This study aimed to 
assess the validity of the CPM paradigm elicited using two different conditioning 
stimuli and to evaluate if efficiency and magnitude of CPM response vary as a function 
of cognitive distraction, pain catastrophising, and self-reported sleep in a healthy 
population. Findings reveal that different modalities of conditioning stimulus could be 
a key factor underlying CPM efficiency. Cognitive distraction also had some effect on 
pain inhibition; the distraction tasks elicited CPM response, but less magnitude 
compared to the cold pressor task. This provides further support for CPM as a robust 
physiological marker of central pain processing and inhibition. Evidence on the 
influence of pain catastrophising on CPM remains inconclusive but has highlighted the 
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possible varying impact of different CPM testing paradigms on specific underlying 
psychological factors.  
 
The findings also provide insight that less efficient CPM response may be 
associated with self-reported daily sleep disruptions. This association is further tested 
in the next chapter and could have implications for understanding of sleep disturbance 
and pain processing in healthy individuals and clinical populations with chronic pain. 
In all, these experiments extend our understandings of the descending pain 
modulatory pathway and the neurobiological and cognitive influences on CPM 
response. Consequently, this enhances CPM’s value as a predictive clinical marker of 
pain perception in both healthy and chronic pain conditions.  
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5 Objective and self-reported sleep, psychological 
functioning, pain responses, and inflammation in 
fibromyalgia and chronic back pain compared with healthy 
controls 
 
5.1 Introduction  
 
As explained in Chapter 1 (1.1), sleep is a dynamic form of restfulness that serves 
as a restorative process permitting the reorganisation of cortical neural activities and 
maintenance of various homeostatic processes. Complaints of sleep being “non-
restorative” is common among people with chronic pain disorders, particularly in 
those with fibromyalgia. However, it is unclear why this is the case and what the 
underpinning mechanisms of non-restorative sleep are. This chapter presents a study 
that attempted to examine polysomnographic and self-reported sleep, physiological, 
and psychological characteristics of patients with fibromyalgia and chronic back pain, 
compared with pain-free controls.  
 
5.1.1 Sleep architecture and spectral analysis in chronic pain conditions 
 
As described in Chapter 2 (2.1), sleep electroencephalography (EEG) provides 
an electrophysiological analogue of the brain processes and neuronal activity during 
sleep and gives insight into features of the sleep process (Bjurstrom & Irwin, 2016). 
This understanding has helped to improve the knowledge of disrupted objective sleep 
in response to pain and in the pathophysiology of chronic pain conditions. PSG studies 
in those with chronic pain (notably fibromyalgia and arthritis) compared with healthy 
controls usually report disruption of sleep continuity as the most common alteration 
of sleep architecture. A comprehensive review of observational PSG studies in chronic 
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pain patients by Bjurstrom and Irwin (2016), revealed that individuals with a range of 
long term pain conditions (including fibromyalgia, chronic widespread pain, 
rheumatoid and osteoarthritis, ankylosing spondylitis, migraines, temporomandibular 
disorders, and other mixed chronic pain conditions) tend to report poor sleep. This 
included decreased sleep efficiency (SE), increased sleep onset latency (SOL), 
increased wake after sleep onset (WASO) and decreased total sleep time (TST) 
(Drewes et al., 1995; Lavigne et al., 2011; Rizzi et al., 2004; Roehrs et al., 2013; Sergi 
et al., 1999). Some alterations have also been noted in sleep architecture such as an 
increase of N1, some equivocal results for both an increase and decrease in 
percentage of N2 and reduction in deep sleep and REM sleep but this evidence was 
limited and not consistent across studies (Landis, Lentz, Tsuji, Buchwald, & Shaver, 
2004; Rizzi et al., 2004; Sergi et al., 1999).  
 
The emergence of new analytic techniques in sleep assessment further allows 
the use of spectral analysis to provide a quantitative measurement of the frequency 
analysis of different power bands of sleep EEG (2.1.1.2). For example, high frequency 
beta and alpha waves reflect arousal processes and are associated with higher 
cognitive activities during sleep and low frequency delta bands reflect deep slow wave 
sleep and the normal homeostatic processes maintaining sleep (Achermann, 2009; 
Campbell, 2009). Sigma waves reflect the sleep spindles observed in stage 2 sleep 
represent regulatory activities of the thalamic neurons for information relay from the 
arousal centres to the cortex. They are sometimes associated with unresponsiveness 
during sleep and perception of greater sleep depth by the sleeper (Feige et al., 2013; 
Halasz, Terzano, Parrino, & Bodizs, 2004). Moldofsky et al. (1975) were one of the first 
 121 
to assess sleep microarchitecture in patients with fibromyalgia symptoms by visually 
inspecting and noticing increased alpha EEG in all NREM stages even in slow wave 
sleep, a stage that normally would be dominated by delta waves. This increase in alpha 
waves was consequently associated with greater reports of pain and fatigue. They also 
found that selective disruption of slow wave sleep in healthy subjects produced the 
same effect of increased alpha activities during the sleep period and subsequent 
reports of pain and fatigue the next day. Other studies reporting manually scored EEG 
alpha and delta waves in fibromyalgia patients have also reported increased alpha 
power in stages N2 and N3 and reduced delta power in these sleep stages (Drewes et 
al., 1995; Roizenblatt et al., 2001). 
 
It is thought that this alpha-EEG anomaly is a marker for non-restorative sleep 
as it indicates central internal arousal mechanisms interfering with normal restful 
sleep and subsequently leading to subjective complaints of unrefreshed sleep 
(Drewes, 1999). In healthy individuals, when muscle and joint pain was experimentally 
invoked during sleep, this led to increased power in beta and alpha bands and reduced 
power in delta and sigma bands (Drewes et al., 1997). In insomniacs and those 
undergoing SWS deprivation, increased power for beta and sigma bands during sleep 
have also been noted (Spiegelhalder et al., 2012). Perlis, Giles, Bootzin, et al. (1997)  
also noted that in those with fibromyalgia, this alpha-EEG dysfunction reflects 
increased vigilance and arousability during sleep. This translates into a heightened 
state of perceptual sensitivity and increased awareness of environment and self, 
rather than the usual unconsciousness associated with sleep. However, the 
phenomenon is not distinct to fibromyalgia and it may not play a direct etiological role 
 122 
in producing pain responses (Rains & Penzien, 2003). It has also been observed in 
other pain disorders such as rheumatic diseases (Drewes & Arendt-Nielsen, 2001) and 
by one study in chronic back pain patients (Staedt et al., 1993).   
 
In spite of this accumulating evidence, alterations in sleep microstructure still 
need to be characterised to determine their clinical significance in chronic pain 
conditions. The majority of older studies have focused on manually scored analysis of 
alpha waves in sleep EEG and not utilised the recent technologies that allows for 
analysis of the other power bands. Furthermore, the focus of analyses has been 
specifically in alpha and delta bands. This has limited further comprehensive insights 
into the relevance of other power bands as markers of disruptions in sleep-
maintaining processes. A study by Blägestad et al. (2012) assessed polysomnography 
sleep variables in 24 older adults with mixed chronic pain conditions (chronic back 
pain, rheumatoid arthritis, osteoarthritis, and fibromyalgia), compared with age- and 
sex- matched 19 healthy controls. They found differences in sleep variables 
investigated in this study, namely poorer sleep in the chronic pain group compared to 
the control group. Specifically, longer sleep onset latency and longer latency to N2, 
poorer sleep efficiency, longer wake time after sleep onset, and increased number of 
awakenings. Furthermore, spectral analysis revealed that the chronic pain groups 
showed lower delta power throughout the whole night, especially in the initial hours 
of sleep, indicating lower intensity of deep restorative sleep.  
 
A doctoral thesis (Yeung, 2015) also compared polysomnography sleep 
characteristics in patients with fibromyalgia and osteoarthritis with healthy controls. 
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This was carried out with the aim to assess and evaluate the role of sleep 
microstructure especially the alpha-delta sleep anomaly as either a possible 
contributor to or consequence of pain experience.  The study did not find differences 
in power bands except across sigma bands. The patterns of sleep microstructure were 
statistically similar in both chronic pain groups. Only psychological measures (trait 
anxiety and depression) better discriminated the chronic pain group from the healthy 
controls rather than sleep variables. Nevertheless, the study gives some insights into 
the association of the levels of cortical arousal reflected by these spectral power bands 
and sleep microstructure with dysregulation of sleep processes. However, the study 
only compared those with fibromyalgia and osteoarthritis and did not include other 
musculoskeletal conditions such as chronic back pain. Other similar studies with a 
focus on sleep microstructure abnormalities in pain conditions have mostly either 
been in mixed pain groups or exclusively in those with fibromyalgia.  
 
Fibromyalgia is often readily investigated in relation to sleep especially since 
sleep problems accompany the somatic symptoms that characterises a diagnosis of 
fibromyalgia (1.3.1) (Clauw, 2014). However, to fully understand the nature of sleep 
across the full extent of pain conditions and a reliable view of the sleep-pain dynamic, 
it remains to be determined if association of sleep and pain varies across conditions 
and the extent to which sleep disturbances differentially affects pain experiences 
across different pain diagnosis. The pain that accompanies conditions like fibromyalgia 
and other rheumatic conditions are usually multi-factorial involving varying levels of 
central pain modulations processes. The interaction between sleep and pain may then 
differ with respect to the sensory, physiological, and behavioural aspects of a 
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condition such as chronic back pain (Drewes, 1999). Hence, further comparative 
investigations across different types of pain conditions would further corroborate 
extant findings and elucidate if there are differential occurrences of these sleep 
processes across different pain conditions and associations with pain experience.  
 
5.1.2 Sleep and conditioned pain modulation in chronic pain conditions  
 
Chapter 4 (4.5.1) of this thesis reported initial findings to suggest a relationship 
between disruptions in self-reported sleep (notably reduced sleep quantity) and 
impaired conditioned pain modulation (CPM) response. The current study aimed to 
combine self-reported sleep assessment with objective PSG sleep parameters to 
explore the extent of the association of patterns of sleep disturbances with measures 
of pain threshold and pain inhibition, specifically in those with chronic pain. 
Disinhibition of descending inhibitory pain pathways represents a significant 
pathophysiological alteration prominent in pain conditions and is implicated as a 
mechanism of hyperalgesia and central sensitisation in chronic pain conditions (Lewis 
et al., 2012). This impairment in pain inhibition may also be one of the key mechanisms 
linking the co-occurrence and interrelationship between sleep and pain. A study in 
patients with chronic temporomandibular joint disorder showed that impaired CPM 
may be associated with disrupted PSG measured sleep (Edwards et al., 2009). In these 
patients, a positive correlation was observed between polysomnography-verified 
total sleep time, sleep efficiency, and pain inhibitory CPM, assessed with pressure pain 
threshold as the test stimuli and with 4 °C cold water as conditioning stimuli. However, 
the study did not involve the use of a comparative healthy pain-free control group, 
hence the associations may be different for healthy controls and even those with a 
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different pain condition. Good sleep may be key to maintaining the function of 
endogenous pain modulatory systems and disruptions in optimal sleep processes may 
be a marker for an impaired pain inhibition response, but the differential effects of 
these associations across different pain conditions and compared to healthy controls 
require further examination.  
 
5.1.3 Sleep and inflammatory processes in chronic pain conditions 
 
Upregulation of peripheral proinflammatory cytokines (2.3) has been 
suggested as one of the most important factors linked to pain processing and 
subsequently also contributing to the development of chronic pain (Marchand, 
Perretti, & McMahon, 2005). Raised levels of inflammatory cytokines interleukin-6 (IL-
6) and tumour necrosis factor alpha (TNF-α) are also typically elevated in sleep 
disorders that result in daytime fatigue and sleepiness, such as chronic insomnia, sleep 
apnoea and narcolepsy (Vgontzas et al., 1999; Vgontzas et al., 2002). In healthy adults, 
these cytokines are usually elevated after acute sleep deprivation and may mediate 
sleep propensity and fatigue the next day (Vgontzas et al., 1999; Vgontzas et al., 2004; 
Vgontzas et al., 2003). Haack et al. (2007) have also found that small peripheral 
changes of IL-6 levels even as little as 1pg/ml may be involved in the onset and 
facilitation of pain experienced following a prolonged phase of insufficient sleep. Their 
study used a sleep restriction protocol of 8 hours to 4 hours per night for 10 days in 
healthy participants sleeping from 23:00 to 03:00, compared to people in the control 
group who were not subjected to sleep restriction. Levels of C-reactive protein (CRP) 
serum levels were also elevated but not significantly different. Levels of other 
markers; plasma soluble tumour necrosis factor receptor p55 (sTNF-R p55), urinary 
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levels of prostaglandin (PG) metabolites D2 and E2, remained the same. Importantly, 
the study reported that self-reported bodily discomfort, tiredness, and fatigue also 
increased in the sleep restriction group and that the increased IL-6 levels were 
associated with these increased self-reported ratings. Meier-Ewert et al. (2004) also 
reported a similar pattern of findings with increased concentrations of CRP following 
total (88 hours) and partial sleep deprivation condition where sleep was decreased 
from 8.2 to 4.2 hours for 10 consecutive days and compared to normal sleeping 
control groups. These inflammatory markers were also correlated with self-reported 
levels of pain and discomfort.  
 
In those with chronic pain, Heffner, France, Trost, Mei-Ng, and Pigeon (2011) 
assessed 25 patients with chronic back pain present for 6 months or longer compared 
with 25 age-matched and sex-matched healthy controls without chronic pain. Sleep 
was assessed using the PSQI and they found the pain group reported more sleep 
disturbances, greater daytime dysfunction, and lower habitual sleep efficiency 
compared with controls. In this group as well, lower sleep quality was associated with 
raised IL-6 levels. IL-6 was further related to affective ratings of pain as ‘tiring’ and 
‘exhausting’, and this association was mediated by sleep quality. Poor sleep quality 
(PSQI global scores) has also been shown to be associated with greater pro-
inflammatory cytokine levels: IL-1β, IL-6, and TNF-α in a study of 60 women with 
chronic fatigue syndrome and/or myalgic encephalomyelitis (Milrad et al., 2017).   
 
Regarding the other inflammatory cytokines linked with sleep, a systematic 
review and meta-analysis by Irwin et al. (2016) did not find a relationship between 
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sleep disturbances or sleep duration with TNF-alpha. The review also did not consider 
the cytokine IL-1 since not enough studies were done to confirm its associations with 
sleep disturbances. Overall, the consistency of which cytokines are most implicated in 
sleep disturbances reported in chronic pain is still debated. Few studies have 
specifically explored the concurrent associations between sleep, pain, and 
inflammation levels by simultaneously assessing a range of relevant inflammatory 
cytokines, pain inhibition impairment, and sleep disturbances in pain conditions 
compared with healthy controls. A first step would be observing how levels of these 
markers of inflammation differ across chronic pain groups. This could be another step 
clarifying if there are indeed associations between chronic pain, elevated 
inflammatory markers, sleep disruptions, and the pain experience.  
 
5.1.4 Aims of the current study  
 
This current study therefore intended to use a range of self-reported and 
quantitative measures to observe and assess the associations between sleep and pain 
parameters across two different chronic pain populations (fibromyalgia and chronic 
back pain) compared with healthy controls. As an attempt at unravelling the 
mechanisms underlying the interrelationship between sleep and pain, the study also 
considered the association between sleep and pain inhibition pathways, and 
compared levels of inflammatory cytokines across the groups. 
 
It was hypothesised that the chronic pain group (fibromyalgia and chronic back 
pain) would show greater sleep and functioning disturbances compared with healthy 
controls. However, the specific direction of the associations between sleep, pain, and 
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inflammation level were exploratory since studies have not considered the 
associations between all these variables in these specific chronic pain groups 
compared with healthy controls.   
 
5.2 Methods 
 
5.2.1 Design 
 
The current study is quasi-experimental comparative study comparing three 
groups – fibromyalgia patients, chronic back pain patients and age-matched healthy 
controls free of chronic pain. Ethical approval for the study was granted by the 
University of Warwick Biomedical & Scientific Research Ethics Committee (BSREC) 
and NHS Research Ethics Service Committee East Midlands – Leicester (REC 
reference: 14/EM/1138) (Appendix 9).  
 
5.2.2 Participants and recruitment  
 
Participants in the study included 26 adults and aimed to be age and sex-
matched. This included nine fibromyalgia patients (M = 45.44, SD = 8.17, females = 7), 
eight chronic back pain patients (M = 49.50, SD = 12.35, females = 7) and nine 
participants in the healthy control group (M = 49.75 SD = 10.07, females = 3). The 
groups were age-matched (within 5 years) at the group level rather than individual 
level based on mean and counts observed during the recruitment process. The chronic 
pain group were recruited first and consequently the healthy controls were recruited 
to reflect a similar age distribution observed in the chronic pain group. The inclusion 
and exclusion criteria are presented below.  
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Inclusion criteria for chronic pain patients (fibromyalgia and chronic back pain) were 
as follows: 
• Adults 18 – 65 years of age 
• English-speaker with ability to understand and sign the consent form and 
complete the study.  
• Medical diagnosis of fibromyalgia OR chronic back pain present for more than 6 
months.  
• No other malignant (e.g., cancer pain) or non-malignant co-morbid chronic pain 
condition (e.g., arthritis, migraines etc.) 
• Non – smoker 
An additional inclusion criterion for pain-free healthy controls was the: 
• Absence of diagnosis of any malignant (e.g., cancer pain) or non-malignant chronic 
pain condition present for more than 6 months (e.g., arthritis, chronic back pain, 
fibromyalgia etc.) 
Exclusion criteria for all groups were as follows: 
• Presence of acute pain due to injury, surgery etc.  
• Presence of any debilitating or life threatening medical condition (e.g., cancer, HIV, 
dementia etc.) or diagnosis of learning disability or recurrent history of psychiatric 
disorder that would impede the ability to give consent and full participation in the 
study  
• Pregnant or breastfeeding females 
• Shift worker with irregular sleep pattern 
• Diagnosed with an organic sleep disorder (e.g., sleep apnoea, periodic limb 
movement disorder, narcolepsy) or periodic leg movements during sleep (PLMS) 
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arousal index per total sleep time outside of the “mild” range (5-25 per hour) or a 
sleep apnoea hypopnea (AHI) index per total sleep time of greater than the “mild” 
range (5-14) per hour as per AASM criteria and as determined on adaptation and 
screening PSG on Night 1 of the lab session (Berry et al., 2017). 
• Currently receiving psychological treatments for pain/insomnia or enrolled in drug 
trials 
Exclusion criteria specifically for the quantitative sensory testing and CPM procedure 
as additional precaution for participants’ safety and wellbeing and based on von 
Baeyer et al. (2005) guideline as used in the study described in Chapter 4 (4.2.1): 
• History of cardiovascular disorder/heart disease 
• History of fainting or seizure 
• History of frostbite 
• History of Reynaud’s phenomenon (hands gets white then blue on exposure to 
cold, then red on warming) 
• Open cut, sore or fracture on arm or hand 
 
5.2.3 Procedure 
 
Figure 8 details the recruitment procedures for the study. As an avenue for 
recruitment for the chronic pain groups, patients were approached and recruited from 
the pain management and rheumatology clinic of the local hospital (UHCW). 
Recruitment posters were distributed in the waiting rooms of the clinic and the 
researcher was also present at the clinic with permission to approach interested 
patients after their outpatient appointment. Eligible participants screened using 
inclusion and exclusion criteria checklist were provided with further information for 
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participating and enrolling in the study. The researcher also collaborated with 
consultants from both clinics to accept referrals of potentially suitable patients with 
fibromyalgia or chronic back pain.   
 
The healthy controls and some of the chronic pain participants were drawn 
and recruited from the local community through distribution of recruitment posters, 
the local chronic pain support groups and word of mouth. The laboratory also had an 
online database where individuals with or without chronic pain interested in 
participating in a study can submit interest by providing their contact details. 
Individuals from this database were contacted with an invitation email and sent 
further information about the study if they were eligible.  For individuals with chronic 
pain recruited through the database and from the community, with their consent their 
GP was contacted to confirm their diagnosis of fibromyalgia or chronic back pain.  
 
If a participant responded and met the inclusion and exclusion criteria for the 
study as confirmed either face to face or telephone screening using the screening 
checklist (Appendix 13), they were provided with further information about the study 
and sent a copy of the Participant Information Sheet (Appendix 11) by email. The 
researcher was contactable to answer any questions and address any concerns and 
each participant was given at least a 24-hour period after being given study 
information to consider taking part in the research. Once they were happy to take 
part, they were invited for the baseline and assessment visit. At this visit, the 
experimental procedures involved in the study was explained again in detail to the 
participant and written informed consent (Appendix 10) was taken. 
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Recruitment route I 
Lab database email invite 
Recruitment posters in community   
Local chronic pain support groups 
Word of mouth  
Recruitment route II 
Local hospital pain management 
and rheumatology clinic 
 
115 patients approached and  
8 patients referred by clinical team   
 
34 responded and invited for 
screening and assessment  
5 responded and invited for 
screening and assessment  
 
22 screened and eligible 
 
5 did not meet all inclusion criteria 
4 unable to commit to study 
3 did not turn up for screening 
 
 
 
4 screened and eligible  
 
1 did not turn up for screening  
26 eligible participants assessed and 
enrolled in study   
25 completed the study  
9 Fibromyalgia 
8 Chronic Back Pain 
8 Healthy Controls 
1 excluded  
Could not complete 
Night 2 of the study  
 Figure 8 Sleep and chronic pain – Recruitment flowchart 
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Assessment Visit  
 
and 
 
Informed 
Consent  
 
Screening – Duke Structured Interview for Sleep Disorders  
 
Questionnaires – Demographics, pain history, BPI, PCS, 
PVAQ, PSWQ, BDI, STAI, POMS, SSS, PSQI, PSAS, DBAS-16, 
APSQ, MQS 
 
Overview and practice of lab session procedures 
Instruction for actigraphy and diaries 
Baseline Week 
 
Complete Consensus Sleep Diary (CSD), pain and mood rating  
Actigraphy monitoring   
Lab Session 
Night 1 
Arrives at lab 
 
Actigraphy check  
 
Pain rating 
Adaptation and screening PSG 
 
Actigraphy monitoring 
Lab Session  
Day 1 
Morning 
questionnaire  
CSD 
 
30 mins after wake 
• QST – CPM   
Cognitive Tasks  
PVT  
Day Leave 
No strenuous 
exercise 
No naps  
No caffeine 
No alcohol 
Lab Session  
Night 2 
 
Return to lab 
 
Actigraphy check  
 
Pain rating  
PSG assessment 
 
Actigraphy monitoring 
 
Lab Session  
Day 2 
Morning questionnaire 
CSD 
 
30 mins after wake 
• Blood Sampling  
• QST – CPM   
Cognitive Tasks  
PVT  
 
End of 
study and 
debrief 
Notes: Figure 9 presents screening, assessment, and lab session schedule. CSD – Consensus Sleep Diary, PSQI – 
Pittsburgh Sleep Quality Index, DBAS-16 – Dysfunctional Beliefs & Attitudes about Sleep, APSQ – Anxiety & 
Preoccupation about Sleep Questionnaire, PSAS – Pre-Sleep Arousal Scale, SSS – Stanford Sleepiness Scale. MQS– 
Medication Quantification Scale, BPI – Brief Pain Inventory, PCS – Pain Catastrophising Scale, PVAQ – Pain Vigilance & 
Awareness Questionnaire. PSWQ – Penn State Worry Questionnaire, STAI – State Trait Anxiety Inventory, BDI – Beck 
Depression Index, POMS – Profile of Mood States. PVT – Psychomotor Vigilance Task, QST – Quantitative Sensory 
Testing, CPM – Conditioned Pain Modulation, PSG – Polysomnography.  
 
Figure 9 Sleep and chronic pain – Study schedule 
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5.2.4 Study schedule  
 
5.2.4.1 Baseline assessment  
 
At the assessment visit, a further screening interview was carried out using a 
version of the Duke Structured Interview for Sleep Disorders Schedule (Edinger et al., 
2009) adapted by the lab team for Diagnosis and Statistical Manual of Mental 
Disorders 5th Edition (DSM-V) and International Classification of Sleep Disorders 2nd 
Edition (ICSD-3) (2.1.3). This was used to establish that individuals have no other 
medical illnesses, psychiatric conditions, organic sleep disorders (e.g., sleep apnoea, 
narcolepsy, restless leg syndrome/periodic limb movement syndrome), or strong 
dependency on medication and substances that could be contributing to any reported 
or unknown sleep disturbance asides from insomnia. After this interview, eligible 
participants were also asked to complete a questionnaire pack (Appendix 14).  
 
The schedule of the laboratory session was then explained to participants and 
they were given instructions and overview of the procedures that they will be 
performing during the study. Specifically, for the quantitative sensory testing (QST), 
they were given a practice trial opportunity to adjust to the experimental procedure. 
This was essentially a short training session to minimise noise due to unfamiliarity and 
other confounding as it would familiarise participants with the sensation of the 
experimental stimuli, namely the pressure pain from algometer and cold-water bath, 
and to explain the concept of QST and terms such as ‘pain threshold’ as described in 
Chapter 4 (4.2.3.1). 
 
 135 
 
At this visit, participants were also trained in how to complete a week of sleep 
diary and pain diary prior to the laboratory session and given instructions for the 
actigraphy monitoring. They were to complete the sleep diary upon waking and the 
pain diary in the evening before sleeping. They were also to wear the actigraphy 
device on the wrist of their non-dominant arm continually, only to be taken off in 
instances such as bathing or swimming as the device was not water-proof. They were 
instructed to press the device marker upon light out (start of the sleep period) and 
getting up (end of the sleep period). The sleep and pain diary were used to gain a 
record of an individual's baseline sleeping and waking times and related information 
about their sleep, daily mood, pain and medication use. The actigraphy also provided 
objective sleep data and served as a further screening measure and to rule out any 
unreported irregular sleep patterns (caused by shift-work, jetlag or any other cause of 
unusually early/late bedtime and wake time). In order to observe a true reflection of 
the participants’ habitual sleep, participants were asked not to change their usual 
medication or sleep-wake pattern prior to the laboratory session. The use of 
stimulants and substances that may influence sleep were not directly restricted during 
the baseline week as again the aim was to capture an unfiltered and unadulterated 
typical week for the participants, but there were more specific restrictions given 
during the lab sessions.  
 
5.2.4.2 Laboratory session  
 
The laboratory session was carried out in the sleep and pain laboratory within 
the university. Participants stayed in the laboratory for two consecutive nights and 
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mornings and underwent two overnight polysomnography procedures, quantitative 
sensory pain testing and other physiological, cognitive and psychological assessments 
as detailed in the study schedule (Figure 9). The first night of the laboratory session 
consisted of a PSG screening to detect the presence of sleep disorder such as 
parasomnias, sleep apnoea, and periodic limb movement syndrome. During the 
second day (Lab Session Day 1), after the quantitative sensory testing session, 
participants could leave the lab for the day and were advised to refrain from strenuous 
exercise, naps and consumption of caffeine and alcohol that could affect their sleep. 
They returned to complete the second night of PSG monitoring and subsequent 
procedures the next morning. After the end of study (Lab Session Day 2), participants 
were reimbursed with gift vouchers and travel expenses directly incurred by 
participation in the study. Participants were provided with an oral and written debrief 
(Appendix 12) of the rationale, purpose, design, and implications of the study. After 
data analysis, participants were also sent a brief description and summary of their 
sleep pattern overnight and a result summary of the study in lay terminology.  
 
5.2.5 Measures 
 
5.2.5.1 Pain measures  
 
Conditioned pain modulation (CPM) 
 
The QST protocol for assessing CPM was exactly as described in Experiment 1 
in Chapter 4 (4.2.3.1).  CPM methodology assesses pain inhibition and involves the 
application of the test pain stimulus (pressure pain threshold) gradually increasing 
pressure (approx. 30 KPa/s) on right forearm (anterior brachoradialis) and combined 
with two conditioning pain stimuli applied to the contralateral (left) side of the body: 
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Cold pressor task (CPT) and Bag holding task (BHT). The order of applying the 
conditioning stimuli to assess CPM response was randomly assigned for the Lab 
Session Day 1 and remained the same for Lab Session Day 2.  
 
Pain and mood diary 
 
Record of daily level of average and current pain intensity and mood on a 0 
(not at all) to 10 (pain as bad as you can imagine) rating and filled in the evening 
before sleep.   
 
Demographics and Pain Characteristics  
 
This included general questions to capture demographics and pain history 
(pain location, pain duration, history of any pain-relieving interventions). 
 
Pain Catastrophising Scale (PCS) (Sullivan, 2009; Sullivan et al., 1995) – as in Chapter 
4 (4.2.3.2) 
 
Medication Quantification Scale version 3 (MQS-III) (Harden et al., 2005) 
This is a record of the name and dosage of all the medications the participant 
is currently using. It is used to quantify and monitor the variety of medications used 
to treat a variety of chronic pain conditions. In this study, it was used to quantify and 
compare the current medication regimen of the chronic pain participants. It provides 
a score based on three aspects of medication regimen; the drug class, dosage level 
and detriment weighting. Detriment weight refers to the potential risk of the drug 
class to produce acute or chronic adverse effects in those with chronic pain (e.g., 
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system toxicity, abuse potential, tolerance and dependence, sleep problems).  A 
detriment weight is given for each drug class and these were determined by a survey 
of physician members of the American Pain Society. The measure consists of 22 drug 
classes used in the chronic pain management (e.g., nonsteroidal anti-inflammatory 
drugs [NSAIDs], antidepressants, benzodiazepines, opiates). An MQS score is 
calculated for each medication by multiplying value for the detrimental weight by 
score given for dosage scores based on current prescribing recommendation obtained 
from the British National Formulary (Joint Formulary Committee, 2017). Scores for 
each medication are then summed to give a total overall score and a single numeric 
value to describe a participant’s medication profile. Higher values reflect increased 
medication use and the ‘relevant risk’ of their current medication regime.  
 
Brief Pain Inventory (BPI) (Cleeland & Ryan, 1994) 
The BPI is a self-report questionnaire administered to assess the severity of 
pain and a measure of pain-related interference. Of the 4 items assessing pain 
severity, the numerical rating scale of current pain rating [0 (no pain at all) and 10 
(pain as bad as you can imagine)] was utilised to index present pain intensity in the 
current study. The interference sub-scale assesses the extent to which pain interferes 
with 1) general activity; 2) mood; 3) walking ability; 4) work both inside and outside 
the home; 5) relations with people; 6) sleep; and 7) enjoyment of life. Participants 
were asked to rate the 7 items between 0 (does not interfere) and 10 (interferes 
completely) during the past week. A total pain interference score is calculated as the 
average of the 7 items. The interference subscale for sleep was also examined 
separately for the current study. A higher average interference subscale score 
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indicates greater interference in daily life due to pain. The BPI has been shown to have 
good internal consistency (Cronbach’s α = .88), and high sensitivity to the effect of 
treatment  
 
Pain Vigilance and Awareness Questionnaire (PVAQ) (McCracken, 1997) 
The PVAQ is a 16-item measure of pain-related awareness and vigilance and 
assesses preoccupation with or attention to pain. Participants are asked to rate on a 
scale of 0 (never) to 5 (always) how items such as “I focus on sensations of pain” is 
reflective of them and their behaviours. Total score for the PVAQ ranges from 0 – 80, 
with a higher score indicating a greater preoccupation to attention to pain sensations. 
The scale has shown reliability and validity in chronic pain populations with high 
internal consistency (Cronbach alpha = 0.83 – 0.86) and test–retest reliability over two 
weeks (r = 0.80) and correlations with similar constructs such as the pain 
catastrophising scale , pain anxiety symptoms scale, and Tampa scale of kinesiophobia 
(Roelofs, Peters, McCracken, & Vlaeyen, 2003).  
 
5.2.5.2 Sleep measures 
 
Actigraphy as described in Chapter 2 (2.1.2) 
Polysomnography as described in Chapter 2 (2.1.1) 
During the recording, participants were monitored continuously for duration of time 
similar to their normal sleep schedule. This was determined based on the average of 
habitual bedtime and wake time recorded using the actigraphy and sleep diary data 
collected during the baseline screening week. 
Sleep Scoring as described in Chapter 2 (2.1.1.1) 
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Spectral Analysis as described in Chapter 2 (2.1.1.2) 
Consensus Sleep Diary (CSD) (Carney et al., 2012) – as in Chapter 4 (4.2.3.2) 
Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989) – as in Chapter 4 (4.2.3.2) 
 
Dysfunctional Beliefs and Attitudes about Sleep (DBAS-16) (Morin, Vallières, & Ivers, 
2007) 
The brief version of the DBAS contains 16 items for the assessment of general 
negative beliefs and attitudes about sleeplessness, perceived consequences of 
insomnia, and control of sleep habits such as (e.g., “I need 8 hours of sleep to feel 
refreshed and function well during the day”). DBAS-16 was used because it has proven 
to be as reliable and valid as the original 30-item version, but shorter and briefer thus 
less burdensome to complete. Participants were asked to rate their level of agreement 
with each statement between 0 ‘strongly disagree’ and 10 ‘strongly agree’. Scores are 
summed and averaged across the 16-items to reflect possible score of between 0 - 10 
and a higher average score is indicative of more strongly held negative beliefs about 
sleep. The DBAS-16 has demonstrated acceptable internal consistency (Cronbach’s α 
> .77), temporal stability (r = .83) over a 2-week interval and concurrent validity 
(correlation with Insomnia Severity Index: r = .45). 
 
Anxiety & Preoccupation about Sleep Questionnaire (APSQ) (Tang & Harvey, 2004)  
Sleep-related anxiety was assessed using the 10-item APSQ which includes 
scale items such as “I worry about my loss of control over sleep”.  Participants were 
asked to reference the previous month and rate their agreement to each item 
between 1 (not true) and 10 (very true). The total calculated score is between 10 and 
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100; higher total scores indicate greater sleep related anxiety. The APSQ has shown 
good internal consistency (Cronbach’s α = .92) and concurrent validity with both 
measure of sleep disturbances (Pittsburgh Sleep Quality Index: r = .44) and anxiety 
(Beck Anxiety Inventory: r = .37). 
 
Pre-Sleep Arousal Scale (PSAS) (Nicassio, Mendlowitz, Fussell, & Petras, 1985)  
This is a 16-item self-report questionnaire to measure the state of cognitive 
(e.g. worrying and racing mind) and somatic (e.g., heart racing and muscle tension) 
manifestations of arousal prior to falling asleep. The scale is scored on a 5-point scale 
(1 = not at all – 5 = extremely) to reflect how strongly an individual experience each 
symptom as they try to fall sleep. The scale is computed to provide a total and 
summary score for each subscale (cognitive and somatic). Scores for each subscale 
range from 8 – 40, higher score reflecting increased presleep arousal. The scale has 
shown good internal consistency in normal sleepers and insomniacs for both cognitive 
and somatic subscales (Cronbach’s α ranging from 0.67 – 0.76 and 0.81 – 0.84). Test-
retest reliability over three weeks were also r = 0.72 for cognitive and r = 0.76 for 
somatic subscales. It has shown good correlation with sleep indices of sleep onset 
latency, overnight awakenings, and self-reported measures of sleep disturbances.  
 
Stanford Sleepiness Scale (SSS) (Hoddes, Zarcone, Smythe, Phillips, & Dement, 1973)  
The SSS is 8-point Likert scale to quantify self-reported changes sleepiness for 
any time period. It consists of 7 statements denoting increasing degrees of sleepiness 
ranging from “feeling active, vital alert, or wide awake” (score = 1) to “no longer 
fighting sleep, sleep onset soon and having dream-like thoughts” (score = 7). The 
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measure has shown test-retest reliability over the period of day (r = 0.88) and 
correlation with vigilance tests and other standard measures of performance and is 
indicative of the effect of acute sleep loss.  
 
5.2.5.3 Blood sampling  
 
Blood samples were taken from 18 participants, the remaining participants 
either had poor veins (n = 3), felt faint during the blood sampling procedure (n =2) or 
did not consent to have blood samples taken (n = 3).  Blood samples were taken during 
the second morning of the lab session.  The samples were all taken in the morning 
between 06:00am – 09:00am to minimise the influence of circadian and diurnal 
variations in circulating levels of inflammatory markers (Keller et al., 2009; Meier-
Ewert et al., 2001; Zhou, Fragala, McElhaney, & Kuchel, 2010). Participants were in a 
sitting position with arms elevated and blood samples were obtained through 
venepuncture using a Vacutainer (plastic hub, a hypodermic needle and a vacuum 
tube) into two 5mls blood collection tube. The researcher completed training in 
venepuncture and the procedure was carried out according to the relevant 
University’s Health and Safety and Human Tissue Authority guidelines and NHS ethical 
approvals and clinical practice guidelines (Appendix 9). The collected blood samples 
were transferred by fast courier within 1-2 hours to the biochemistry laboratory at 
University Hospital Coventry & Warwickshire (UHCW).  
 
At the lab, the samples were allowed to clot at room temperature for up to 2 
hours until centrifuged and plasma was extracted into aliquots and frozen and stored 
at −80 °C until assayed for expression of intracellular inflammatory cytokines (IL-6, 
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hsCRP, TNF, IL-1) at the end of the study. Analysis of hsCRP was carried out on the 
main automated Roche/Hitachi cobas c system used in the UHCW biochemistry lab 
according to manufacturer’s instructions. The levels of cytokines were assessed in the 
University of Warwick CSRI Medical School unit within UHCW, with high sensitivity 
ELISA MSD technology Proinflammatroy Panel 1 (humans) assay kit. Samples were 
assayed in duplicate and according to the manufacturer’s (Meso Scale Discovery) 
instructions. Appendix 15 further details the inter- and intra assay coefficients of 
variability to test the precision and sensitivity of the immunoassay test results.  
 
5.2.5.4 Cognitive task   
 
Psychomotor Vigilance Task (PVT) (Dinges & Powell, 1985)  
This is a sustained-attention reaction timed task used to assess vigilance levels. 
It is widely used, methodologically reliable and versatile assessment of vigilance as it 
is brief and devoid of practice and learning effects (Loh, Lamond, Dorrian, Roach, & 
Dawson, 2004). For the task, participants were asked to sit in front of a Lenovo 
ThinkVision LT2934z 29-inch display computer monitor with a 2560 x 1080 resolution 
and the PVT task was administered from The Psychology Experiment Building 
Language (PEBL) test battery computer software (Mueller, 2014; Mueller & Piper, 
2014). Duration of the task was set to 5 minutes and the participants were asked to 
press the spacebar button when the stimulus (a red dot) appears. The circle stimulus 
appeared for each trial randomly at delays between 2 and 12 seconds, and 
participants were told to press the spacebar as quickly as possible. Derived variables 
from the task were reaction time (RT) (in milliseconds) and lapses of attention (% 
number of times relative to number of trials where reaction time was > 500 ms).  
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5.2.5.5 Psychological characteristics  
 
Penn State Worry Questionnaire (PSWQ) (Meyer, Miller, Metzger, & Borkovec, 1990)  
The PSWQ is a trait measure of worry. Its 16-items rate how typical sentences 
such as “Once I start worrying I cannot stop” on a scale of 1 (not typical of me) to 5 
(very typical of me) and gives a total score ranging from 16 – 80. Higher scores reflect 
a greater tendency to worry. The scale has shown reliability and validity with high 
internal consistency (Cronbach’s α >0 .9) and test–retest reliability over 8-10 weeks (r 
= 0.92) and is correlated with other psychological measures on heightened anxiety 
levels and depression. 
 
Profile of Mood States - Short (POMS – Short) (Curran, Andrykowski, & Studts, 1995; 
McNair, Lorr, & Droppleman, 1971)  
The POMS-Short is a 36-items rating scale to assess transient and fluctuating 
affective mood states. The POMS assesses both positive and negative affective states. 
The POMS items can be computed into subscales – Anger-Hostility, Confusion-
Bewilderment, Depression-Dejection, Fatigue-Inertia, Tension-Anxiety, and Vigour-
Activity. The scale has shown excellent internal consistency of subscales (Cronbach’s 
α 0.76 – 0.95) in both healthy and clinical populations and has shown correlations with 
other measures of mood and affective states. In the present study, the global indices 
of negative affect (NA) (Anger-Hostility + Confusion-Bewilderment + Depression-
Dejection + Fatigue-Inertia + Tension-Anxiety) and sub-index of Fatigue-Inertia were 
calculated for analysis.  
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State-Trait Anxiety Inventory (STAI-Form Y) (Spielberger, Gorsuch, Lushene, Vagg, & 
Jacobs, 1983) 
The STAI is a self-report measure of anxiety, with twenty items assessing trait 
anxiety (e.g., I am tense) and 20 items assessing state anxiety (e.g., I worry too much 
over something that really doesn’t matter. These items are assessed on a four-point 
scale from 1(not at all/almost never) – 4 (very much so/almost always). Score for each 
trait and state subscales ranges from 20 – 80 with higher scores suggesting greater 
levels of anxiety. The scale has shown reliability and validity with high internal 
consistency (Cronbach’s α 0.86 – 0.95) and test–retest reliability over 2 months (r = 
0.65 – 0.75).  
 
Beck Depression Inventory (BDI-II) (Beck, Steer, & Brown, 1996) 
The BDI-II is a widely used 21-item self-report inventory used for measuring 
the severity of depression and assessment of symptoms. It contains items related to 
depressive symptoms such hopelessness, feelings and thoughts of guilt and physical 
symptoms such as weight loss and fatigue. Response for each item ranges from 0 – 3 
to reflect increasing intensity of symptoms. Total score ranges from 0 – 63, higher 
scores indicative of more severe depressive symptoms. The following cut-offs have 
been suggested for the BDI-II: 0–13: minimal depression; 14–19: mild depression; 20–
28: moderate depression; and 29–63: severe depression. The scale has shown 
reliability and validity with high internal consistency (Cronbach’s α = 0.91) and test–
retest reliability over one week (r = 0.93).  
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5.2.6 Data analysis  
 
5.2.6.1 Power calculation  
 
A sample size calculation was performed using G Power – a statistical software 
specifically designed for doing power and sample size calculations (Faul, Erdfelder, 
Lang, & Buchner, 2007). No other study has specifically considered differences across 
sleep in the three specific groups proposed for this study using all the objective PSG 
sleep parameters. Hence, the theoretical rationale for sample size calculation was 
based on the sleep parameter of sleep efficiency. This is a consistently reliable 
indicator of sleep quality, has been assessed routinely in PSG studies comparing sleep 
in chronic pain groups with healthy controls (Bjurstrom & Irwin, 2016) and has shown 
significant differences when chronic pain populations are compared with healthy 
controls. Therefore, it was considered a good parameter to use as a basis to distinguish 
group differences in sleep disturbance. Sleep efficiency scores range from 0% to 100%. 
As per previous studies (Blägestad et al., 2012; Wu et al., 2017), a mean difference of 
at least 9-10% was hypothesised between the chronic pain groups and healthy 
controls. This would be sufficiently large enough to indicate a clinically significant 
change. Specifically, Blägestad et al. (2012) ‘s difference of 8.03 (p < 0.01) between a 
chronic pain group and healthy control formed the basis of the rationale of an 
expected effect size of f = 0.4 (d = 1.0).  Furthermore, since an ANOVA can only indicate 
if at least one group is different from the others, post hoc testing with t-tests would 
have to be done to determine which groups differ, hence the sample size calculation 
was based on a comparison of 2 group means (a chronic pain group vs. healthy 
controls) so that the t-tests during post-hoc testing will not be underpowered. The 
sample required based on this calculation then informed the size of each of the three 
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equally sized groups to be tested.  Subsequently, with alpha set to 0.05 level, results 
expected to have 80% power and an effect size f = 0.4 (d=1.0), a sample size of 17 per 
group (51 in total) was deduced from G Power calculations (Figure 10). However, the 
sample size was not achieved due to difficulties with recruitment.  
 
Figure 10 Sleep and chronic pain power calculation 
 
5.2.6.2 Analysis  
 
A series of one-way ANOVAs were carried out to determine group differences 
(fibromyalgia x chronic back pain x healthy control) on all sleep, pain, inflammation, 
and psychological measures. χ2 for chi square tests are reported for between-samples 
differences for categorical data. F values for one-way ANOVAs are reported for 
between sample-differences for continuous data categories. Bonferroni post-hoc 
tests were reported for significant results of the ANOVA, except when the assumption 
[10] -- Monday, June 30, 2014 -- 19:11:29 
t tests - Means: Difference between two independent means (two 
groups) 
 
Analysis: A priori: Compute required sample size  
Input:  Tail(s)                        = Two 
   Effect size d                  = 1 
   α err prob                     = 0.05 
   Power (1-β err prob)           = 0.8 
   Allocation ratio N2/N1         = 1 
Output:  Noncentrality parameter δ      = 2.9154759 
   Critical t                     = 2.0369333 
   Df                             = 32 
   Sample size group 1            = 17 
   Sample size group 2            = 17 
   Total sample size              = 34 
   Actual power                   = 0.8070367 
 
Notes: 1-β refers to the required power/ the population effect size to be detected with probability 
(Cohen’s d), α err prob refers to the pre-specified level of significance.  In ‘output’, Noncentrality 
parameter δ refers to the noncentral distribution of the t statistics results if the alternative 
hypothesis is true, critical t refers to the number of standard deviations from the null mean where 
an observation becomes statistically significant, and df refers to number of degrees of freedom.  
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of homogeneity was not assumed, Dunnett T3 post hoc tests are reported (Field, 
2013). As a post-hoc consideration since the chronic pain groups differed significantly 
from the healthy controls in terms of MQS scores, these results were further adjusted 
for MQS scores as a co-variate and these adjusted ANCOVAs are also reported. Non-
parametric Kruskal-Wallis H test was used to explore inferential differences between 
the groups across EEG spectral powerbands. The adjustment for MQS scores was only 
feasible and appropriate for linear outcomes and hence this was not reported for the 
non-parametric Kruskal-Wallis H test analysis.  
 
PPTh and CPM index were calculated for both lab days and also averaged 
across both days CPM index calculations are as described in Chapter 4 (4.2.4), derived 
by calculating the percent change of PPTh during the conditioning stimulus to PPTh 
prior to conditioning stimulus (
𝑀𝑒𝑎𝑛 𝑃𝑃𝑇ℎ 𝑑𝑢𝑟𝑖𝑛𝑔 𝐶𝑆
𝑀𝑒𝑎𝑛 𝑃𝑃𝑇ℎ 𝑝𝑟𝑖𝑜𝑟 𝐶𝑆
 ×  100).  
 
Pearson correlations were computed to examine simple bivariate relationships 
between sleep variables derived from PSG and self-reported sleep parameters with 
pain catastrophising scores, PPTh, CPM index on Lab day 2 and separately for each 
group.  Given the multiplicity of the correlations, a post-hoc Bonferroni correction was 
applied and all correlations were Bonferroni corrected to a p < 0.001. Means are 
presented with standard deviations in parentheses, unless otherwise stated. Different 
sample sizes are due to cases with missing data excluded from the analysis on a test-
by-test basis.  For all results (unless otherwise stated): *p < 0.05, **p < 0.01, ***p < 
0.001 
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5.3 Results  
 
5.3.1 Descriptive statistics 
 
Table 11 presents a general overview of the three participants groups by 
demographic characteristics. The groups were age-matched to within 5 years and 
there were no significant differences between the groups in terms of age, BMI, 
ethnicity, relationship status, employment status, and highest education level 
attained. The groups were not sex-matched due to difficulties with recruitment, and 
thus resulted in a larger percentage of females in the patient group compared to the 
healthy controls. The majority of the participants were of Caucasian ethnicity. In 
addition, the majority of those in the fibromyalgia group had degree level education 
or above as opposed to the chronic back pain group.  
Table 11 Sleep and chronic pain – Demographics and lifestyle 
 
Demographics Fibromyalgia 
 
N = 9 
Chronic 
Back 
Pain 
N = 8 
Healthy 
Controls 
N = 8 
Test 
Statistics  
 p 
value  
Between-
Samples 
Differences 
Age  45.44  
(8.17) 
49.50 
(12.35) 
49.75 
(10.07) 
Unadjusted 
F (2,24) = 
0.480 
 
Adjusted 
F (2,20) = 
0.334 
 
p = 
0.625 
 
 
p = 
0.720 
n/a 
Gender 
(Female %) 
77.8% 87.5% 37.5% χ2 (2, n = 
25) = 5.213 
 
p = 
0.074 
n/a 
BMI 27.37  
(5.30) 
26.31 
(2.03) 
25.16 
(2.43) 
Unadjusted 
F (2,24) = 
0.776 
 
Adjusted  
F (2,20) =  
0.206 
 
p = 
0.472 
 
 
p = 
0.816 
n/a 
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Ethnicity 
(Caucasian %) 
88.9% 87.5% 100% χ2 (2, n = 
25) = 3.986 
 
p = 
0.408 
n/a 
Relationship  
(Marriage %) 
 
55.6% 75.0% 37.5% χ2 (2, n = 
25) = 4.380 
 
p = 
0.821 
n/a 
Employment  
(Paid work %) 
 
55.6% 50.0% 62.5% χ2 (2, n = 
25) = 6.878 
 
p = 
0.866 
n/a 
Education  
(Degree or 
above %) 
66.7% 37.5% 50.0% χ2 (2, n = 
25) = 6.546 
p = 
0.365 
n/a  
   
 
 
5.3.2 Pain characteristics  
 
Table 12 presents pain characteristics of the fibromyalgia, chronic back pain, 
and healthy control participants. Overall, the pain measures suggest that the chronic 
pain groups were similar in terms of pain intensity, pain interference, pain duration, 
and medication use. They were both significantly different to the pain-free healthy 
control group who reported negligible medication use. After adjustment for 
medication use scores, the three groups did not show significant differences in most 
pain characteristics.  
Table 12 Sleep and chronic pain – Pain characteristics 
Baseline 
Subjective 
Pain  
Fibromyalgia 
 
N = 9 
Chronic 
Back Pain 
N = 8 
Healthy 
Controls 
N = 8 
Test 
Statistics  
p 
value 
Between-
Samples 
Differences 
Baseline – BPI 
average pain  
 
4.55  
(2.19) 
4.00  
(2.00) 
0.88  
(1.81) 
Unadjusted 
F (2,24) = 
8.013** 
 
Adjusted  
F (2, 20) =  
2.672 
 
p = 
0.002 
 
 
p = 
0.092 
 
FM – HC 
CBP – HC 
 
 
n/a 
 
Week – 
average pain 
 
5.27  
(1.82) 
5.32  
(2.36) 
1.72  
(2.32) 
Unadjusted 
F (2,24) = 
7.401** 
 
p = 
0.003 
 
 
FM – HC 
CBP – HC 
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Adjusted  
F (2, 20) =  
3.457 
 
p = 
0.05 
 
n/a 
 
Lab session – 
average pain  
4.22  
(3.15) 
4.75  
(3.15) 
0.50  
(1.07) 
Unadjusted 
F (2,24) = 
8.934*** 
 
Adjusted  
F (2, 20) =  
3.462 
p = 
0.001 
 
 
p = 
0.05 
FM – HC 
CBP – HC 
 
 
n/a  
 
Baseline – BPI 
sleep 
interference  
 
 
7.22  
(2.77) 
 
 
6.50  
(2.67) 
 
- 
 
Unadjusted 
F (2,24) = 
25.626*** 
 
Adjusted  
F (2, 20) =  
14.370*** 
 
 
p = 
0.000 
 
 
p = 
0.000 
 
FM – HC 
CBP – HC 
 
 
FM – HC  
CBP – HC  
Baseline – BPI 
average 
interference 
  
5.02  
(2.21) 
4.99  
(1.90) 
1.30  
(2.18) 
Unadjusted 
F (2,24) = 
8.403** 
 
Adjusted  
F (2,20) = 
3.428 
 
p = 
0.002 
 
 
p = 
0.051 
FM – HC 
CBP – HC 
 
 
n/a  
PCS  
 
 
16.00  
(11.68) 
19.36  
(12.97) 
14.86 
(9.57) 
Unadjusted  
F (2,24) = 
0.334 
 
Adjusted  
F (2,20) = 
0.204 
 
p = 
0.720 
 
 
p = 
0.817 
n/a 
 
 
 
 
n/a 
PVAQ  
 
35.78  
(16.83) 
52.50  
(9.90) 
29.75 
(7.07) 
Unadjusted  
F (2,24) = 
4.278* 
 
Adjusted  
F (2,20) = 
2.744 
p = 
0.027 
 
 
p = 
0.087 
CBP – HC 
 
 
 
 
n/a 
 
Pain duration 
(months) 
 
110.22  
(79.77) 
 
114.00 
(92.90) 
 
- 
 
 
Unadjusted  
F (2,24) = 
6.748** 
 
Adjusted  
F (2,20) = 
2.419 
 
p = 
0.005 
 
 
p = 
0.113 
 
FM – HC 
CBP – HC 
 
 
 
n/a 
 
MQS score  
 
10.90  
(7.88) 
 
11.04  
(10.04) 
 
0.75  
(2.12) 
 
Unadjusted  
F (2,24) = 
5.062* 
 
 
 
p = 
0.016 
 
 
 
 
FM – HC 
CBP – HC 
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5.3.3 Quantitative sensory testing 
 
Table 13 presents pressure pain threshold and conditioned pain modulation 
measures for all three groups. After adjustments for MQS scores, there were no 
significant differences noted for pressure pain threshold measurements and CPM 
response. In addition, across the three groups, CPT stimulus elicited the strongest CPM 
response compared to the BHT stimulus which on average did not produce a CPM 
response. In this study, CPM index for the cold pressor task ranged from 15% - 19% 
compared to 7% - 29% in Chapter 4. For the bag task, a pattern of negative CPM index 
emerges -12% to -8% compared to -2% - 4% in Chapter 4 (4.4.5.3).  
Table 13 Sleep and chronic pain – Quantitative sensory testing 
QST  
Average 
across lab 
session and 
Day 2  
Fibromyalgia 
 
 
N = 8 
Chronic 
Back Pain 
 
N = 7 
Healthy 
Controls 
 
N = 8 
Test 
Statistics  
p 
value 
Between-
Samples 
Differences 
PPTh (KPas) – 
lab average  
177.47  
(52.07) 
203.54 
(32.91) 
232.25 
(43.03) 
Unadjusted  
F (2,22) = 
3.125* 
 
Adjusted  
F (2,20) = 
1.584 
 
p = 
0.056 
 
 
p = 
0.231 
FM – HC 
 
 
 
n/a 
PPTh (KPas) – 
day 2 
average  
 
172.44  
(53.11) 
195.50 
(38.27) 
236.86 
(52.80) 
Unadjusted 
F (2,22) = 
3.539* 
 
Adjusted 
F (2,20) = 
1.656  
 
p = 
0.048 
 
 
p = 
0.217 
FM – HC 
 
 
 
n/a 
CPM % (CPT) 
– lab average  
 
115.74  
(24.60) 
113.33 
(10.82) 
119.75 
(16.35) 
Unadjusted 
F (2,22) = 
0.234 
 
Adjusted  
F (2,20) = 
0.747 
 
p = 
0.794 
 
 
p = 
0.487 
 
n/a 
 
 
 
 
n/a 
 153 
CPM % (CPT) 
– day 2 
average  
 
111.32  
(11.76) 
113.64 
(13.92) 
118.73  
(22.77) 
Unadjusted 
F (2,22) = 
0.397 
 
Adjusted  
F (2,20) = 
0.711 
 
p = 
0.678 
 
 
p = 
0.504 
n/a 
 
 
 
n/a 
CPM % (BHT) 
– lab average  
88.20  
(19.94) 
92.11 
(12.37) 
92.80  
(15.84) 
Unadjusted 
F (2,22) = 
0.757 
 
Adjusted  
F (2,20) = 
1.283 
 
p = 
0.482 
 
 
p = 
0.300 
n/a 
 
 
 
n/a 
CPM % (BHT) 
– day 2 
average 
94.31 
(20.71) 
 
94.57 
(10.06) 
94.56  
(15.54) 
Unadjusted 
F (2,22) = 
0.001 
 
Adjusted  
F (2,20) = 
0.311 
p = 
0.999 
 
 
p = 
0.736 
n/a 
 
 
 
n/a 
 
 
5.3.4 Psychological characteristics 
 
Table 14 presents baseline psychological characteristics to compare 
psychosocial status between the fibromyalgia, back pain, and healthy controls groups. 
After adjustment for MQS scores, there were mostly no significant differences for 
measures of mood, worry, depression and anxiety traits. Based on the BDI-II cut-off 
scores, the fibromyalgia group reported levels of mild depression symptoms, chronic 
back pain group reported levels of moderate symptoms, and healthy controls 
reported minimal depression symptoms.  
 
Table 14 Sleep and chronic pain – Psychological characteristics 
Baseline 
psychological 
characteristics 
Fibromyalgia 
 
N = 9 
Chronic 
Back 
Pain 
N = 8 
Healthy 
Controls 
N = 8 
Test 
Statistics  
p 
value 
Between-
Samples 
Differences 
PSWQ  
 
 
49.78  
(16.05) 
53.88 
(14.07) 
47.13 
(10.52) 
Unadjusted 
F (2,24) = 
0.483 
p = 
0.623 
 
n/a 
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Adjusted  
F (2,20) = 
0.571 
 
 
p = 
0.573 
BDI  
 
 
18.00  
(14.76) 
20.00 
(10.09) 
11.13 
(11.80) 
Unadjusted 
F (2,24) = 
1.121 
 
Adjusted  
F (2,20) = 
0.184 
 
p = 
0.344 
 
 
p = 
0.833 
n/a 
STAI-state 
 
 
38.44  
(14.57) 
41.38 
(16.22) 
33.00 
(14.02) 
Unadjusted 
F (2,24) = 
0.648 
 
Adjusted  
F (2,20) = 
0.560 
 
p = 
0.533 
 
 
p = 
0.579 
n/a 
STAI-trait 
 
 
43.89  
(12.92) 
43.63 
(12.81) 
39.13 
(12.47) 
Unadjusted 
F (2,24) = 
0.362 
 
Adjusted  
F (2,20) = 
0.070 
 
p =  
0.701 
 
 
p = 
0.932 
n/a 
POMS-fatigue 
 
 
13.22  
(5.21) 
10.25  
(7.70) 
5.00  
(6.23) 
Unadjusted 
F (2,24) = 
3.533* 
 
Adjusted  
F (2,20) = 
1.148 
 
p = 
0.047 
 
 
p = 
0.337 
FM – HC 
 
 
 
n/a 
POMS-negative 
 
 
26.44  
(12.08) 
26.75 
(21.92) 
14.13 
(22.15) 
Unadjusted 
F (2,24) = 
1.168 
 
Adjusted 
F (2,20) = 
0.460 
 
p = 
0.330 
 
 
p = 
0.637 
n/a 
 
 
 
n/a 
Mood –  
week average  
6.19  
(1.39) 
7.55  
(1.11) 
7.84  
(1.30) 
Unadjusted 
F (2,24) = 
4.101* 
 
Adjusted  
F (2,20) = 
2.969 
p = 
0.031 
 
 
p = 
0.073 
FM – HC 
 
 
 
n/a 
 
 
 155 
5.3.5 Cognitive task 
 
Table 15 presents PVT scores during the lab sessions. The fibromyalgia and 
chronic back pain groups showed the slowest reaction time (RT) and greater 
percentage of lapses but there were no significant group differences noted after 
adjustments for MQS scores. 
Table 15 Sleep and chronic pain – Cognitive task 
PVT 
functioning 
(lab day 2) 
Fibromyalgia 
 
N = 9 
Chronic 
Back Pain 
N = 8 
Healthy 
Controls 
N = 8 
Test 
Statistics  
p 
value 
Between-
Samples 
Differences 
PVT – lapse % 
 
 
23.75  
(22.65) 
34.09 
(27.67) 
6.44  
(3.38) 
Unadjusted 
F (2,24) = 
3.605* 
 
Adjusted  
F (2,20) = 
1.549 
 
p = 
0.044 
 
 
p = 
0.236 
CBP – HC 
 
 
 
n/a 
PVT – RT  432.83  
(62.96) 
450.06 
(62.20) 
386.69 
(25.62) 
Unadjusted 
F (2,24) = 
2.997 
 
Adjusted  
F (2,20) = 
1.206 
p = 
0.071 
 
 
p = 
0.319 
n/a 
 
5.3.6 Sleep characteristics during the baseline week 
 
Table 16 compares self-reported sleep variables across all three participant 
groups including fibromyalgia, chronic back pain, and healthy control groups. After 
adjustments for MQS scores, the chronic pain groups did not differ from one another 
but show significantly worse PSQI scores than healthy controls. Their PSQI scores were 
12.48 and 14.00 respectively and greater than the suggested clinical cut-off for poor 
sleep quality (> 5). The chronic pain groups also reported greater somatic arousal and 
anxiety about sleep than healthy controls. There were no group differences noted for 
sleepiness, cognitive arousal, and maladaptive beliefs about sleep as measured by 
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DBAS-16. For self-reported sleep diary parameters, fibromyalgia and chronic back pain 
groups had longer sleep onset latency and worse sleep efficiency (respectively) than 
healthy controls. The chronic pain groups reported sleep efficiency lower than the 
85% cut-off for good sleep efficiency. However, there were no significant group 
differences noted for overnight awakenings and total sleep time. There was also no 
group difference noted for week baseline actigraphy derived sleep variables.  
 
Table 16 Sleep and chronic pain – Baseline sleep assessment 
Baseline  
Sleep   
Fibromyalgia 
 
N = 9 
Chronic 
Back Pain 
N = 8 
Healthy 
Controls 
N = 8 
Test 
Statistics  
p 
value  
Between-
Samples 
Differences 
SSS 
 
 
2.89  
(1.27) 
2.75  
(1.58) 
2.00  
(0.93) 
Unadjusted 
F (2,24) = 
1.140 
 
Adjusted  
F (2,20) = 
0.053 
 
p = 
0.338 
 
 
p = 
0.948 
n/a 
 
 
 
n/a 
PSQI  
 
 
12.78  
(3.40) 
14.00  
(3.29) 
3.25  
(1.58) 
Unadjusted 
F (2,24) = 
28.725*** 
 
Adjusted  
F (2,20) = 
15.799*** 
p = 
0.000 
 
 
p = 
0.000 
FM – HC  
CBP – HC 
 
 
FM – HC  
CBP – HC 
PSAS  
 
 
38.44  
(14.93) 
41.88 
(13.35) 
21.50 
(4.50) 
Unadjusted 
F (2,24) = 
6.668** 
 
Adjusted  
F (2,20) = 
6.163**  
 
p = 
0.005 
 
 
p = 
0.008 
FM – HC  
CBP – HC 
 
 
FM – HC  
CBP – HC 
PSAS 
somatic 
 
 
17.56  
(6.56) 
16.63  
(6.21) 
8.75  
(0.71) 
Unadjusted 
F (2,24) = 
6.849** 
 
Adjusted  
F (2,20) = 
6.216** 
 
p = 
0.005 
 
 
p = 
0.008 
FM – HC  
CBP – HC 
 
 
FM – HC 
CBP– HC  
 
 
PSAS 
cognitive 
 
20.89  
(9.97) 
25.25  
(8.61) 
12.75 
(4.50) 
Unadjusted 
F (2,24) = 
4.870* 
p = 
0.018 
 
CBP – HC 
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Adjusted  
F (2,20) = 
4.541* 
 
 
p = 
0.023 
 
n/a 
DBAS-16  
 
 
5.53  
(1.95) 
5.83  
(2.06) 
4.31  
(2.09) 
Unadjusted 
F (2,24) = 
1.172 
 
Adjusted  
F (2,20) = 
0.295  
 
p = 
0.328 
 
 
p = 
0.748 
n/a 
 
 
 
n/a 
APSQ  56.78  
(24.44) 
70.25 
(24.88) 
28.25 
(16.66) 
Unadjusted 
F (2,24) = 
7.347** 
 
Adjusted  
F (2,20) = 
4.516* 
p = 
0.004 
 
 
p = 
0.023 
FM – HC  
CBP – HC 
 
 
CBP – HC 
 
Sleep diary  
(week 
average) 
Fibromyalgia 
 
N = 9 
Chronic 
Back Pain 
N = 8 
Healthy 
Controls 
N = 8 
Test 
Statistics  
p 
value 
Between-
Samples 
Differences 
SOL 
 
 
35.16  
(21.71) 
32.68 
(11.81) 
9.29  
(3.54) 
Unadjusted 
F (2,24) = 
7.615** 
 
Adjusted  
F (2,20) = 
3.836* 
 
p = 
0.003 
 
 
p = 
0.038 
FM – HC  
CBP – HC 
 
 
FM – HC  
WASO 
duration 
 
 
41.13  
(39.21) 
48.98 
(22.97) 
4.22  
(5.51) 
Unadjusted 
F (2,24) = 
6.265** 
 
Adjusted  
F (2,20) = 
2.847 
 
p = 
0.007 
 
 
p = 
0.081 
FM – HC  
CBP – HC 
 
 
n/a 
TST 
 
 
402.71  
(62.09) 
376.81 
(78.31) 
430.18 
(56.22) 
Unadjusted 
F (2,24) = 
1.303 
 
Adjusted  
F (2,20) = 
0.889 
 
p = 
0.292 
 
 
p = 
0.426 
n/a 
 
 
 
n/a 
 
Sleep 
efficiency % 
84.33  
(9.55) 
81.53  
(7.43) 
96.91  
(1.24) 
Unadjusted 
F (2,24) = 
10.568*** 
 
Adjusted 
F (2,20) = 
5.069* 
p = 
0.001 
 
 
p = 
0.016 
 
 
FM – HC  
CBP – HC 
 
 
CBP – HC 
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Actigraphy  
(week 
average) 
 
Fibromyalgia 
 
N = 9 
Chronic 
Back Pain 
N = 7 
Healthy 
Controls 
N = 8 
Test 
Statistics  
p 
value 
Between-
Samples 
Differences 
Actigraphy 
SOL 
 
 
12.77  
(7.59) 
11.79 
(10.68) 
4.85  
(4.19) 
Unadjusted 
F (2,23) = 
2.501 
 
Adjusted  
F (2,19) = 
0.569 
 
p = 
0.106 
 
 
p = 
0.575 
n/a 
 
 
 
n/a 
Actigraphy 
‘wake times’ 
 
71.29  
(50.10) 
56.94 
(27.40) 
48.45 
(15.79) 
Unadjusted 
F (2,23) = 
0.907 
 
Adjusted  
F (2,19) = 
0.431 
p = 
0.419 
 
 
p = 
0.656 
 
 
 
n/a 
 
 
 
n/a 
Actigraphy 
TST 
 
 
424.05  
(44.34) 
448.98 
(55.68) 
403.91 
(35.32) 
Unadjusted 
F (2,23) = 
1.850 
 
Adjusted  
F (2,19) = 
0.915 
 
p = 
0.182 
 
 
p = 
0.417 
n/a 
 
 
 
n/a 
Actigraphy SE 83.41  
(6.65) 
86.79  
(3.94) 
87.91  
(3.96) 
Unadjusted 
F (2,23) = 
1.765 
 
Adjusted  
F (2,19) = 
1.135 
p = 
0.196 
 
 
p = 
0.341 
 
n/a 
 
5.3.7 Sleep during the lab session   
 
Table 17 presents self-reported sleep from sleep diary, actigraphy and 
polysomnography during the lab sessions, only data from the second night of sleep 
monitoring were analysed for comparison. Night 1 sleep was used for screening sleep 
disorders only and no participant was excluded because of PSG abnormalities. There 
was no significant group difference noted across all sleep variables.  During the lab 
session, compared to the baseline week, self-reported sleep efficiency remained poor 
for chronic pain group (less than 85%) compared to healthy controls. However, for 
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objective sleep efficiency derived from actigraphy and PSG, all groups had fairly similar 
patterns of poor sleep efficiency (85% or lower). 
 
Table 17 Sleep and chronic pain – Lab session sleep assessment  
Sleep diary 
(Lab night 2) 
Fibromyalgia 
 
N = 9 
Chronic 
Back 
Pain 
N = 8 
Healthy 
Controls 
N = 8 
Test 
Statistics  
p 
value  
Between-
Samples 
Differences 
Night 2 SOL 
 
 
31.67  
(17.68) 
25.00 
(19.09) 
31.88 
(16.24) 
Unadjusted 
F (2,24) = 
0.397 
 
Adjusted  
F (2,20) = 
0.817 
 
p = 
0.677 
 
 
p = 
0.455 
n/a 
 
 
 
n/a 
Night 2 WASO 
duration 
 
55.00  
(44.44) 
53.75 
(47.87) 
15.00 
(20.87) 
Unadjusted 
F (2,24) = 
2.666 
 
Adjusted  
F (2, 20) = 
0.893 
 
p = 
0.092 
 
 
p = 
0.424 
n/a 
 
 
 
n/a 
Night 2 TST 
 
 
385.00  
(90.59) 
404.13 
(69.43) 
450.25 
969.43) 
Unadjusted 
F (2,24) = 
1.190 
 
Adjusted  
F (2,20) = 
0.448 
 
p = 
0.323 
 
 
p = 
0.645 
n/a 
 
 
 
n/a 
Night 2 SE  80.81  
(14.26) 
82.88 
(16.64) 
90.85  
(5.55) 
Unadjusted 
F (2,24) = 
1.355 
 
Adjusted  
F (2,20) = 
0.333 
 
p = 
0.279 
 
 
p = 
0.721 
n/a 
 
 
 
n/a 
 
Actigraphy  
(Lab night 2) 
 
      
Night 2 Actigraphy 
SOL 
 
16.11  
(9.18) 
28.86 
(39.92) 
22.63 
(21.69) 
Unadjusted 
F (2,24) = 
0.503 
 
Adjusted  
F (2,20) = 
1.264 
 
p = 
0.612 
 
 
p = 
0.303  
n/a 
 
 
 
n/a 
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Night 2 Actigraphy 
‘wake times’ 
 
71.00  
(28.30) 
52.37 
(18.94) 
51.25 
(35.23) 
Unadjusted  
F (2,24) = 
1.328 
 
Adjusted 
F (2,20) = 
1.317 
 
p = 
0.285 
 
 
p = 
0.289 
 
 
n/a 
 
 
 
n/a 
Night 2 Actigraphy 
TST 
 
410.89  
(60.93) 
439.37 
(67.88) 
435.75 
(64.19) 
Unadjusted 
F (2,24) = 
0.456 
 
Adjusted  
F (2,20) = 
0.579 
 
p = 
0.640 
 
 
p = 
0.569 
n/a 
 
 
 
n/a 
Night 2 Actigraphy 
SE 
80.98  
(8.35) 
84.79 
(6.61) 
85.75  
(9.07) 
Unadjusted  
F (2,24) = 
0.839 
 
Adjusted  
F (2,20) = 
0.524 
p = 
0.445 
 
 
p = 
0.600 
n/a 
 
 
 
n/a 
       
Polysomnography 
(Lab night 2) 
 
      
Night 2 PSG SOL 22.78  
(18.06) 
10.84 
(10.25) 
19.85 
(19.53) 
Unadjusted 
F (2,24) = 
1.177 
 
Adjusted  
F (2,20) = 
1.171  
p = 
0.327 
 
 
p = 
0.330 
n/a 
 
 
 
n/a 
Night 2 PSG WASO 
duration  
 
91.19  
(39.53) 
89.83 
(58.33) 
96.63 
(72.87) 
Unadjusted 
F (2,24) = 
0.031 
 
Adjusted  
F (2,20) = 
0.017 
 
p = 
0.969 
 
 
p = 
0.983 
n/a 
 
 
 
n/a 
Night 2 PSG TST 
 
377.83  
(67.64) 
405.81 
(82.28) 
388.44 
(80.46) 
 
Unadjusted 
F (2,24) = 
0.278 
 
Adjusted  
F (2,20) = 
0.261 
 
p = 
0.760 
 
 
p = 
0.772 
 
n/a 
 
 
 
n/a 
Night 2 PSG SE  
 
76.43  
(9.54) 
79.94 
(13.41) 
78.71 
(14.01) 
 
Unadjusted 
F (2,24) = 
0.177 
 
Adjusted  
p = 
0.839 
 
 
p = 
0.849 
n/a 
 
 
 
n/a 
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F (2,20) = 
0.164 
 
Night 2 PSG  
awakening index 
7.02  
(3.62) 
4.34  
(1.41) 
5.90  
(2.76) 
 
Unadjusted 
F (2,24) = 
1.963 
 
Adjusted 
F (2,20) = 
1.867 
 
p = 
0.164 
 
 
p = 
0.179 
n/a 
 
 
 
n/a 
Night 2 PSG arousal 
index 
8.75  
(10.72) 
11.88  
(9.49) 
6.21  
(4.83) 
 
Unadjusted 
F (2,24) = 
0.831 
 
Adjusted  
F (2,20) = 
0.698 
 
p = 
0.422 
 
 
p = 
0.509 
n/a 
 
 
 
n/a 
Stage N1 % 
 
26.27  
(12.71) 
23.20 
(9.38) 
24.74  
(13.91) 
 
Unadjusted 
F (2,24) =  
0.134 
 
Adjusted  
F (2,20) = 
0.172 
 
p = 
0.875 
 
 
p = 
0.843 
n/a 
 
 
 
n/a 
Stage N2% 
 
42.40  
(15.05) 
37.10  
(12.22) 
38.56  
(11.86) 
 
Unadjusted 
F (2,24) = 
0.369 
 
Adjusted  
F (2,20) = 
0.599 
p = 
0.696 
 
 
p = 
0.558 
n/a 
 
 
 
n/a 
Stage N3% 
 
16.79 
(8.67) 
19.74  
(7.73) 
18.85  
(7.25) 
 
Unadjusted 
F (2,24) = 
0.354 
 
Adjusted 
F (2,20) = 
0.826 
 
p = 
0.706 
 
 
p = 
0.452 
n/a 
 
 
 
n/a 
Stage REM% 
 
14.54 
(6.78) 
19.96  
(7.43) 
17.89  
(5.44) 
Unadjusted 
F (2,24) = 
1.462 
 
Adjusted  
F (2,20) = 
1.410 
 
p = 
0.253 
 
 
p = 
0.266 
n/a 
 
 
 
n/a 
 
 
 162 
5.3.8 Spectral analysis 
 
The aim of spectral analysis of the EEG data from the three groups was to 
investigate the microstructure of sleep for the whole night. Across all the power 
bands, there were no significant group differences observed across all NREM, Stage 2, 
Stage 3, and REM sleep stages.
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Table 18 Sleep and chronic pain – Spectral analysis 
Logarithmic Log (10) transformed means and standard deviation of power of EEG frequency (Hz) in all frequency bands [Delta-1 (0.1-
1Hz), Delta-2 (1-3.5Hz), Theta (3.5-8Hz), Alpha (8-12Hz), Sigma-1 (12- 16Hz), Beta-1 (16-24Hz), Beta-2 (24-32Hz) and Gamma (32-48Hz)] 
in the sleep EEG for sleep stages NREM merged, N2, N3 and REM. Group differences assessed with Kruskal-Wallis test.  
 
Sleep stage Group (n) Delta-1 Delta-2 Theta Alpha Sigma Beta-1 Beta-2 Gamma 
NREM  
(1 – 3) 
 
 
 
FM (9) 
CBP (8) 
HC (8) 
 
X2 (p value) 
7.34 (0.45) 
7.16 (1.03) 
7.46 (0.50) 
 
0.375 (0.829) 
7.79 (0.19) 
7.60 (0.79) 
7.83 (0.25) 
 
0.339 (0.844) 
8.39 (0.15) 
8.18 (0.74) 
8.38 (0.17) 
 
0.352 (0.839) 
8.74 (0.22) 
8.54 (0.76) 
8.74 (0.25) 
 
0.088 (0.957) 
9.03 (0.18) 
8.75 (0.78) 
9.03 (0.33) 
 
0.572 (0.751) 
9.19 (0.16) 
8.95 (0.87) 
9.23 (0.45) 
 
1.242 (0.538) 
9.37 (0.26) 
9.21 (0.92) 
9.48 (0.56) 
 
2.098 (0.350) 
9.19 (0.31) 
9.11 (0.98) 
9.33(0.68) 
 
1.656 (0.437) 
 
N2 
 
 
  
 
FM (9) 
CBP (8) 
HC (8) 
 
X2 (p value) 
7.50 (0.58) 
7.47 (0.48) 
7.58 (0.58) 
 
0.534 (0.766) 
7.87 (0.20) 
7.90 (0.17) 
7.91 (0.26) 
 
0.616 (0.735) 
8.41 (0.13) 
8.43 (0.11) 
8.41 (0.13) 
 
0.538 (0.764) 
8.74 (0.21) 
8.79 (0.17) 
8.76 (0.18) 
 
0.180 (0.914) 
9.02 (0.18) 
8.99 (0.22) 
9.07 (0.28) 
 
0.489 (0.783) 
9.18 (0.17) 
9.22 (0.19) 
9.39 (0.17) 
 
4.210 (0.122) 
9.42 (0.31) 
9.49 (0.29) 
9.70 (0.21) 
 
3.424 (0.180) 
9.25 (0.40) 
9.39 (0.38) 
9.64 (0.24) 
 
4.635 (0.099) 
 
N3 
 
FM (9) 
CBP (8) 
HC (8) 
 
X2 (p value) 
7.23 (0.34) 
7.52 (0.12) 
7.27 (0.39) 
 
3.750 (0.153) 
7.54 (0.24) 
7.66 (0.19) 
7.58 (0.22) 
 
0.958 (0.619) 
8.27 (0.22) 
8.34 (0.14) 
8.32 (0.10) 
 
0.583 (0.747) 
8.66 (0.39) 
8.82 (0.17) 
8.86 (0.12) 
 
1.848 (0.397) 
9.12 (0.22) 
9.11 (0.16) 
9.21 (0.21) 
 
0.512 (0.774) 
9.33 (0.23) 
9.38 (0.19) 
9.52 (0.22) 
 
4.920 (0.085) 
9.58 (0.31) 
9.64 (0.36) 
9.80 (0.24) 
 
2.035 (0.361) 
9.48 (0.38) 
9.59 (0.48) 
9.71 (0.32) 
 
1.500 (0.472) 
 
REM 
 
 
 
  
  
FM (9) 
CBP (8) 
HC (8) 
 
X2 (p value) 
7.74 (0.74) 
7.84 (0.41) 
7.65 (0.61) 
 
0.897 (0.639) 
8.19 (0.60) 
8.39 (0.21) 
8.28 (0.46) 
 
0.093 (0.955) 
8.58 (0.36) 
8.75 (0.81) 
8.68 (0.18) 
 
1.308 (0.520) 
8.89 (0.27) 
9.05 (0.13) 
8.99 (0.16) 
 
2.394 (0.302) 
9.19 (0.21) 
9.29 (0.19) 
9.34 (0.21) 
 
1.925 (0.382) 
9.11 (0.21) 
9.20 (0.24) 
9.26 (0.24) 
 
2.263 (0.323) 
9.36 (0.40) 
9.51 (0.33) 
9.49 (0.30) 
 
0.825 (0.662) 
9.32 (0.62) 
9.42 (0.41) 
9.44 (0.45) 
 
0.371 (0.831) 
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5.3.9 Inflammatory biomarkers 
 
Across groups there were no significant differences noted across levels of 
inflammatory biomarkers. The chronic pain groups often had slightly elevated levels 
of hsCRP and TNF-alpha that are out of normative reference range (Table 19) 
compared with healthy controls and healthy controls with slightly lower levels of Il-
1beta and within range levels of other cytokines (Figure 11).  
 
 
Figure 11 Sleep and chronic pain – Inflammatory marker levels 
 
 
 
 
 
 
 
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
hsCRP [mg/L]
TNF-alpha
[pg/ml]
IL-6 [pg/ml]
IL-1beta [pg/ml]
INFLAMMATORY MARKERS
Healthy Controls (n=6) Fibromyalgia (n=6) Chronic Back Pain (n=6)
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Table 19 Sleep and chronic pain – Inflammatory marker levels 
(Out of range values are shown in red)  
 
hsCRP (mg/L) Fibromyalgia 
 
N = 6 
Chronic 
Back Pain 
N = 6 
Healthy  
Controls 
N = 6 
Test  
Statistics  
Between-
Samples 
Differences 
Reference  
for disease risk 
<1 = No/low risk 
1-3 = Average risk 
>3 = High risk 
0.43 2.73 0.63  
1.08 0.73 0.31 
0.43 2.42 0.62 
2.66 0.75 0.97 
0.53 1.51 1.32 
2.77 1.36 0.48 
Mean value  1.32 1.58 0.72 Unadjusted  
F (2, 17) = 1.697 
p = 0.217  
 
Adjusted  
F (2,13) = 0.250 
p = 0.782 
n/a 
 
 
 
n/a 
 
 
TNF-alpha (pg/ml) Fibromyalgia 
 
N = 6 
Chronic 
Back 
Pain 
N = 6 
Healthy  
Controls 
N = 6 
Test  
Statistics  
Between-
Samples 
Differences 
Reference range  
0.10 - 1.75  
1.70 1.64 1.08  
1.20 1.89 1.42 
1.46 2.71 1.34 
1.20 1.16 1.7 
2.23 2.45 1.53 
2.26 1.56 1.44 
Mean value   1.68  1.90 1.42 Unadjusted  
F (2, 17) = 1.725 
p = 0.212 
 
Adjusted  
F (2,13) = 0.573  
p = 0.576 
n/a 
 
 
 
n/a 
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Sleep and chronic pain – Inflammatory marker levels 
(Out of range values are shown in red)  
 
IL-1beta (pg/ml) Fibromyalgia 
 
N = 6 
Chronic 
Back Pain 
N = 6 
Healthy  
Controls 
N = 6 
Test  
Statistics  
Between- 
Samples 
Differences 
Reference range  
0.11 - 24.3 
0.09 0.10 0.07  
0.19 0.18 0.12 
0.08 0.11 0.03 
0.05 0.11 0.06 
0.15 0.17 0.06 
0.06 0.12 0.19 
Mean value  0.10 0.13  0.09 Unadjusted  
F (2, 17) = 1.156 
p = 0.341  
 
Adjusted  
F (2,13) = 1.685  
p = 0.221 
n/a 
 
 
 
n/a 
 
 
IL-6 (pg/ml) Fibromyalgia 
 
N = 6 
Chronic 
Back Pain 
N = 6 
Healthy 
Controls 
N = 6 
Test  
Statistics  
Between-
Samples 
Differences 
Reference range  
0.16 - 27.2 
0.10 0.89 0.28  
0.22 0.18 0.51 
0.23 0.87 0.15 
0.79 0.31 2.43 
1.13 0.86 0.59 
0.77 0.75 0.05 
Mean value 0.54 0.64 0.67 Unadjusted  
F (2, 17) = 0.079 
p = 0.925  
 
Adjusted  
F (2,13) = 0.090  
p = 0.914 
n/a 
 
 
 
n/a 
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5.3.10 Associations between PSG sleep, pain catastrophising, and pain response  
 
To examine the association of objective PSG sleep in the lab with pain 
responses, Pearson correlations were computed between Night 2 PSG sleep variables, 
PCS scores, average day 2 PPTh and CPM indices (Table 20).  For the healthy controls, 
a correlation was not observed between the PSG sleep measures, pain 
catastrophising, and PPTh and CPM indices, unlike Chapter 4 (4.2.5.4) where 
correlations between total sleep time and sleep onset latency with PPTh and CPM 
were observed in the healthy population sample.  
 
For the chronic pain groups, after Bonferroni corrections was applied, there 
were no significant correlations observed between the PSG sleep measures, pain 
catastrophising, and PPTh and CPM indices. Prior to adjustment, for the fibromyalgia 
group, arousal index showed a negative correlation with pressure pain threshold (r = 
-0.7 [95% CI -0.941; -0.009], p < 0.05) and CPM response (r = -0.8, [95% CI -0.962; -
0.218] p < 0.01). In addition, sleep onset latency showed a negative correlation with 
CPM response (r = -0.8, [95% CI -0.962; -0.218] p < 0.01). For the chronic back pain 
groups, total sleep time showed a positive correlation with CPM response (r = 0.8 [95% 
CI -0.969; -0.118], p < 0.05) and arousal index showed a negative correlation 
(unadjusted) with pressure pain threshold (r = -0.8, [95% CI -0.969; -0.118] p < 0.01).  
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Table 20 Sleep and chronic pain – Associations between pain 
catastrophising, sleep, and CPM response 
Correlations between PSG sleep parameters, pain catastrophising, PPTh, and CPM 
Fibromyalgia (N=8)  
PSQI PSG 
SOL 
PSG 
WASO 
PSG TST PSG SE Arousal PCS CPM PPTh 
PSQI 1 -.193 .444 -.263 -.337 -.020 .410 .401 -.383 
PSG SOL 
 
1 -.298 -.031 -.144 .859 .169 -.849 -.595 
PSG WASO   1 -.752 -.863 -.377 -.286 .594 .074 
PSG TST    1 .927 .256 .564 -.265 -.101 
PSG SE     1 .096 .379 -.226 .078 
Arousal      1 .492 -.835 -.740 
PCS       1 -.223 -.551 
CPM        1 .298 
PPTh        
 
1 
 
Correlations between PSG sleep parameters, pain catastrophising, PPTh, and CPM 
Chronic Back Pain (N=7)  
PSQI PSG 
SOL 
PSG 
WASO 
PSG TST PSG SE Arousal PCS CPM PPTh 
PSQI 1 .508 .309 -.007 -.360 -.032 .549 .032 -.031 
PSG SOL  1 .075 .492 -.077 .573 .066 .218 -.727 
PSG WASO   1 -.776 -.994 .101 .788 -.577 .081 
PSG TST    1 .799 .309 -.607 .777 -.612 
PSG SE     1 -.043 -.813 .619 -.149 
Arousal      1 -.010 -.037 -.884 
PCS       1 -.559 .194 
CPM        1 -.393 
PPTh         1 
 
Correlations between PSG sleep parameters, pain catastrophising, PPTh, and CPM 
Healthy Controls (N= 8)  
PSQI PSG 
SOL 
PSG 
WASO 
PSG TST PSG SE Arousal PCS CPM PPTh 
PSQI 1 .074 .516 -.032 -.462 -.575 .474 .662 -.240 
PSG SOL  1 .785 -.757 -.788 .136 .235 .074 .566 
PSG WASO   1 -.752 -.995 -.299 .546 .557 .154 
PSG TST    1 .805 .300 -.135 -.395 -.389 
PSG SE     1 .304 -.472 -.556 -.191 
Arousal      1 -.145 -.334 .038 
PCS       1 .260 -.119 
CPM        1 -.216 
PPTh         1 
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5.4 Discussion 
 
5.4.1 Summary of findings 
 
This study aimed to gain insight into what characterises and differentiates those 
with fibromyalgia, chronic back pain, and pain-free healthy controls. As hypothesised, 
the chronic pain groups mostly showed greater self-reported sleep disturbances 
compared with healthy controls and also showed signs of slightly elevated 
inflammatory marker levels, but this was not significantly different from healthy 
controls. In addition, objective sleep in the chronic pain groups was not significantly 
correlated with physiological pain response and pain inhibition.  
5.4.2 Sleep characteristics  
 
When the three groups were compared across sleep characteristics, it was 
observed that only on self-reported sleep characteristics did the chronic pain groups 
significantly differ from the healthy controls. On baseline sleep questionnaires and 
from the sleep diary over the week, both the chronic back pain and fibromyalgia 
reported poorer sleep quality, longer sleep onset latency, more overnight sleep 
awakenings, and lower sleep efficiency. Unlike the present study, a few studies and 
systematic reviews have been able to show that there are objective differences in 
actigraphy sleep parameters, sleep microarchitecture and macro architecture in 
polysomnography measured sleep between those with chronic pain, especially 
between fibromyalgia and healthy controls (Bjurstrom & Irwin, 2016; Diaz-Piedra et 
al., 2015; Lunde et al., 2010; O'Donoghue, Fox, Heneghan, & Hurley, 2009; Roth, 
Bhadra-Brown, Pitman, Roehrs, & Resnick, 2016).   
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Nevertheless, the observation in the current study was in the right direction 
towards greater physiological abnormalities of sleep in chronic pain groups and 
stronger self-reported sleep disturbance. Moreover, a meta-analysis of case-control 
studies found that sleep difficulties in fibromyalgia were of greater severity when self-
reported than when assessed objectively.  The pooled effect sizes across studies of 
the differences in sleep disturbance measured using the PSQI was larger than that 
measured using PSG (Wu et al., 2017). This is consistent with the idea that insomnia is 
still inherently a subjective experience, and this is apparent in the current findings in 
these groups of pain patients. Furthermore, thinking about the interaction between 
pain and sleep is said to be an integral part of chronic pain patients’ insomnia 
experience (Afolalu, Moore, Ramlee, Goodchild, & Tang, 2016; Ramlee, Afolalu, & 
Tang, 2016; Smith, Perlis, Smith, Giles, & Carmody, 2000; Tang, Wright, et al., 2007) 
and excessive cognitive arousal has been highlighted as a key feature of both primary 
and pain-related insomnia (Byers, Lichstein, & Thorn, 2016; Dillon, Thomas, & 
Lichstein, 2011).  
 
It has further been suggested and demonstrated in a pilot intervention of 
hybrid cognitive behavioural therapy that aims to tackle pain and sleep simultaneously 
and is focused on helping patients understand the pain-sleep interaction and 
addressing the cognitive-behavioural factors perpetuating their insomnia may be a 
fruitful intervention (Tang, Goodchild, & Salkovskis, 2012). Further studies are still 
needed to determine the efficacy of these treatments and elaborate the cognitive and 
behavioural concepts underlying and perpetuating sleep disturbances within the 
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context of chronic pain so as to improve the efficacy of such interventions in sustaining 
better quality of life in spite of ever-present chronic pain 
 
5.4.3 PSG sleep parameters, pain response and inflammation  
 
As a further extension of Chapter 4 (4.5.5), this study also aimed to explore the 
association between objective pain measures and sleep but this time using 
polysomnography sleep measures and within a chronic pain population. The groups 
did not differ on conditioned pain modulation (CPM) response, a marker of pain 
inhibitory processes. The chronic pain group did show slightly lower pressure pain 
threshold and CPM response and inflammatory markers that were slightly out of range 
but this was not significantly different from healthy controls.  
 
Furthermore, there was no association between the pain measures and sleep 
in healthy controls. Prior to Bonferroni corrections, for the group with chronic back 
pain, less total sleep time was associated with lower CPM response and greater 
arousal index associated with lower pressure pain threshold assessed the next 
morning. Similar pattern was observed in the fibromyalgia group where a greater 
arousal index was related to lower pressure pain thresholds and CPM, and longer 
sleep onset latency with lower CPM. It is important to emphasise that these were the 
unadjusted simple correlations and associations within very small sample sizes, which 
limits any causal interpretations and generalisability. The actual study sample was 
below the recruitment target derived from the power calculation, and this 
compromised study power. Furthermore, this limited sample did not permit for a 
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meaningful comparison and discrimination of the characteristics of CPM responders 
and non-responders within these groups as was done in Chapter 4 (4.4.5.5). This 
would have provided additional benefit of deciphering the significance of the 
associations between overnight sleep parameters and next day pain, CPM, and 
inflammatory responses. 
 
Chapter 4 (4.5.5) discussed the relevance of an association between disrupted 
sleep, especially in those with impaired CPM response. Previous studies have 
emphasised that chronic pain patients with self-reported sleep quality, poor sleep 
efficiency and reports of non-restorative sleep were associated with attenuated CPM 
response (Edwards et al., 2009; Lee et al., 2013; Paul-Savoie et al., 2012). There is also 
the possibility of an association between CPM response and increased disruption in 
objective markers of sleep quantity and arousal index, reflecting both greater sleep 
insufficiency and sleep instability overnight. Conditioned pain modulation is generally 
impaired in populations with chronic pain (Lewis et al., 2012), but studies have also 
found impaired endogenous pain inhibitory systems exclusively in fibromyalgia but 
not chronic back pain when the two patient groups were compared (Julien et al., 
2005). Other findings have demonstrated that perhaps CPM response may have low 
sensitivity and specificity within chronic pain groups. Potvin and Marchand (2016) 
proposed that deficient endogenous pain inhibition may not be a definitive feature of 
FM but rather a contributing mechanism, a cause or consequence of prolonged pain 
in a subgroup of patients with FM. This needs to be better characterised to sufficiently 
characterise pain patients and their sleep disturbances based on their pain inhibition 
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profiles. Further studies are required to expand these findings in larger chronic pain 
groups. Knowledge of influences of sleep on a patients’ pain perception may 
subsequently open up further areas for possible interventions and treatments within 
pain management.  
 
5.4.4 Pain and psychological characteristics  
 
Surprisingly, the three groups did not show differences in their scores on the 
questionnaires measuring cognitive pain processes (e.g., pain catastrophising). The 
chronic back pain group seemed to report greater scores on pain vigilance and 
attention and those with fibromyalgia reported greater fatigue levels compared to 
healthy pain-free controls. Pain vigilance and attention to pain have been shown to 
be positively associated with reports of pain, distress, disability, and health care 
utilisation in those with chronic musculoskeletal problems (McCracken, 1997). The 
fear-avoidance model is a behavioural and cognitive model of pain-related fear which 
posits those that are fearful of their pain will tend to attend to possible signs of pain 
and threats (Leeuw et al., 2007; Vlaeyen et al., 1995; Vlaeyen & Linton, 2000). This 
hypervigilance restricts ability to shift attention away from pain-related information 
or potentially pain-inducing problems and consequently impacts negatively on active 
coping with daily lives, mood, greater distress and disability and disuse resulting from 
limited engagement in activities (Crombez, Eccleston, Baeyens, van Houdenhove, & 
van den Broeck, 1999; Crombez et al., 2005). In the current study, this was more 
pronounced in those with chronic back pain, although the fear-avoidance model does 
not suggest that pain related fear of movement is only exclusive in sustaining chronic 
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pain disability in chronic back pain. Fibromyalgia patients in this study still reported 
heightened pain related vigilance relative to healthy controls, as already shown in 
previous studies (Crombez et al., 2005; Peters, Vlaeyen, & van Drunen, 2000).   
  
Although fibromyalgia is marked by chronic widespread pain, fatigue remains 
one of the condition’s most troublesome and common problems. This was also 
observed in the current findings. Fatigue in those with fibromyalgia is often more 
widely reported than with other rheumatic or chronic pain conditions. Daily clinical 
fatigue levels with as high prevalence as 76% have been reported in fibromyalgia 
patients and it prevents ability to effectively carry out daily tasks and activities 
(Overman, Kool, Da Silva, & Geenen, 2016; Wolfe, Hawley, & Wilson, 1996). However, 
there remains a general lack of understanding concerning the aetiology of fatigue, its 
relationship with sleep problems in those with long-term pain, and the most effective 
management approach for tackling the issue. Nicassio, Moxham, Schuman, and 
Gevirtz (2002) investigated the role of depression, sleep and pain status in 
determining fatigue levels in fibromyalgia patients. In the cross-sectional phase of 
their study, in a sample of 105 fibromyalgia patients, greater depression scores and 
lower sleep quality were concurrently associated with higher fatigue. When a subset 
of 63 patients were monitored for over a week to assess the daily relationship 
between their pain, sleep quality, and fatigue, average daily scores revealed that 
previous day’s pain and sleep quality predicted next day’s fatigue. Importantly, daily 
poor sleep quality mediated the positive relationship between pain and fatigue. This 
is suggestive that non-restorative sleep may be a key factor contributing to fatigue in 
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this population. Self-reported sleep may have more of a contributing factor in the 
resulting pain-related psychological, behavioural, and fatigue problems. Further 
empirical assessments of the dynamic daily patterns between sleep, mood, pain, and 
fatigue in FM and other chronic pain condition are needed to carefully discriminate 
the potential temporal role of both objective and subjective sleep in precipitating 
fatigue episodes and shaping psychological and behavioural pain responses.  
 
5.4.5 Limitations 
 
It is important to note that the study is limited by an overall small sample size 
and the sample was also not sex-matched. The final sample size differed from the kind 
of sample size needed to detect a sizeable and significant difference between groups 
(n = 17 in each group as per the power calculation). Recruitment was complicated by 
low participant uptake from the pain clinic recruitment avenue and also due to 
practical difficulties of recruitment within the time frame of the doctoral project. 
Subtle differences between the groups could have been undetected due to statistical 
power limitations and increased risk of Type 2 errors. Extant PSG studies do not often 
have large sample sizes and a lot of studies in this field are underpowered. Larger 
sample sizes and further systematic reviews and meta-analyses are required for PSG 
studies in chronic pain patient to drive optimal statistical power, especially to detect 
differences in sleep microstructure using spectral analysis.  On the other hand, the 
study reported in this chapter also contained a large number of multiple and 
simultaneous testing. This could also pave way for Type 1 errors and greater chance 
of observing at least some significant results even if all of the tests are not actually 
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significant. The study is also subject to the same limitations concerning adjustments 
for Type 1 errors as discussed in Chapter 4 (4.5.6).  
 
Notably, even though the healthy controls reported good sleep patterns 
during screening and from self-reported sleep assessments, their objective actigraphy 
and PSG derived sleep was relatively poor and not markedly different from the chronic 
pain groups. It is possible that these group of participants may have not been as good 
a sleeper as they characterised themselves to be. This could also contribute to lack of 
observable differences in microstructure and power spectral analysis where 
differences have been observed between groups with chronic pain and those without 
in other studies (Blägestad et al., 2012; Drewes et al., 1995). Participants also 
underwent only 2 nights of polysomnography assessment and this may have limited 
the specificity and sensitivity of the sleep assessment. While there is a possible first 
night effect that could affect sleep in the lab, reverse first night effect may also come 
into play cancelling the first night differences out. This phenomenon has been 
observed in insomniac participants who usually sleep better than normal for the first 
night, but even more poorly than normal on the second night (Hauri & Olmstead, 
1989; Riedel, Winfield, & Lichstein, 2001). Hence, it is now recommended that more 
than two nights of PSG recording be obtained in order to reflect more realistic 
variability of sleep in participants (Bjurstrom & Irwin, 2016).   
 
This study deliberately did not exclude patients based on medication use. 
Some of the medications used by participants in this study included ibuprofen (NSAID), 
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paracetamol (acetaminophen), tramadol, amitriptyline (tricyclic anti-depressant), 
opioids such as fentanyl patch, codeine, and morphine and less rarely 
benzodiazepines such as diazepam.  These analgesics, hypnotics, antidepressants, and 
other pharmacotherapy measures in pain management are known to disturb sleep 
(Onen, Onen, Courpron, & Dubray, 2005). Yet despite patients being on these 
medications for a long time, they continue to report problems with sleep. For ethical 
reasons and to gain a naturalistic observation of the sleep characteristics within these 
groups of patients and a wider perspective of the pain and sleep experience, it was 
necessary to allow the use of these medications as commonly prescribed. 
Nevertheless, the study did quantify medication use with the Medication 
Quantification Scale (Harden et al., 2005) and the two chronic pain groups were on 
average fairly matched and similar concerning the relevant clinical risk weighting of 
their current medication regime. The analysis was also adjusted for differences in MQS 
scores between the chronic pain groups and healthy controls, although given the small 
sample size, the effect of the adjustment was fairly negligible. Nevertheless, future 
case-controlled experimental studies may want to eliminate the confounding effect of 
medications and gain a clearer picture of sleep processes in pain conditions and to 
establish further causal inferences from the interrelationship between sleep and pain 
problems. To maintain ecological validity, it may also be useful to match or stratify 
pain groups appropriately and draw comparisons between chronic pain patients who 
do not use such medications or who do not experience sleep problems. Whilst at the 
same time, statistically controlling for other confounding variables (such as age, 
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gender, ethnic group, educational level, marital status, body mass index, physical 
activity, health status etc.).  
 
5.5 Conclusion 
 
This study aimed to observe and characterise sleep and pain characteristics in two 
chronic pain groups compared with healthy controls. Notably, findings revealed that 
those with fibromyalgia did not greatly differ from patients with chronic back pain 
across a range of sleep, pain, physiological and psychological characteristics. Although 
limited by a small sample size, this study suggests further need for comparative 
knowledge regarding the sleep disturbances in individuals with chronic pain. For those 
with chronic pain conditions such as fibromyalgia and chronic back pain, it may still be 
worthwhile in clinical settings to consider how their sleep infers on aspects of their 
pain experience. This can range from self-reported mood, fatigue, pain catastrophising 
to other physiological markers such as pain inhibitory processes and inflammation. 
There is potential benefit to investigate how the interaction between sleep and these 
factors can inform and affect chronic pain management. 
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6 Sleep changes and pain-related health outcomes in the 
general population: A systematic review of longitudinal 
studies with exploratory meta-analysis 
 
6.1 Introduction 
 
There is increasing epidemiological evidence highlighting sleep deficits and 
disturbances as risk factors of poor physical health (Cappuccio et al., 2011; Leng et al., 
2015) and mental well-being (Bernert et al., 2014; Riemann & Voderholzer, 2003). 
Sleep problems have been specifically linked to the development of chronic pain, 
which refers to pain that persists beyond the expected time of healing from injury, 
illness or tissue damage (3-6 months) (Merskey & Bogduk, 1994; Treede et al., 2015). 
Unlike acute pain that serves the important function of signalling harm to the body’s 
integrity, chronic pain is in itself a disease with poor prognosis, featuring peripheral 
and central sensitisation to pain signals in the absence of clear underlying pathology 
(Siddall & Cousins, 2004; Tracey & Bushnell, 2009). Despite its invisible nature, chronic 
pain - like insomnia - can considerably limit one’s day-to-day functioning; from 
concentrating on a task, to walking, sleeping, maintaining social relationships, and 
holding down a job for independent living (Breivik et al., 2006). In primary care, 
chronic pain is ranked the top cause of quality-adjusted life-year loss, surpassing 
cardiovascular disease, high blood pressure, mood and anxiety disorders, diabetes, 
and common respiratory conditions (Fernandez et al., 2010). Considering the high 
prevalence of both insomnia symptoms (10 – 30%; (LeBlanc et al., 2009; Ohayon, 
2002; Roth, 2007)) and chronic pain (10 – 20%; (Breivik et al., 2006; Goldberg & 
McGee, 2011)) in the general population and their potency to impair well-being, the 
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frequent co-occurrence of sleep and pain presents a serious public health challenge 
to our aging society (Gureje, Von Korff, Simon, & Gater, 1998; Simon & Von Korff, 
1997; Tang, Afolalu, & Ramlee, in press). 
 
6.1.1 Evidence for the effect of sleep problems on pain from micro-longitudinal 
studies  
 
Conventionally, sleep disturbance is thought to be a symptom secondary to 
pain and the two conditions are assumed to be broadly bi-directionally linked. 
However, recent research has been able to show that sleep problems may have a 
stronger contributory effect on pain than the effect of pain on sleep, shifting the 
research emphasis onto the temporal association from sleep to pain (Finan et al., 
2013; Smith & Haythornthwaite, 2004). Much of the evidence on the temporal impact 
of sleep on subsequent pain has come from longitudinal studies. Micro-longitudinal 
studies as described by Affleck, Zautra, Tennen, and Armeli (1999) use ‘time-series’ 
designs to examine day-to-day sleep and pain variations in individuals over a period 
of one to two weeks. These studies have shown that night-time sleep parameters 
more consistently predict next-day pain compared to pain predicting subsequent 
sleep. Edwards, Almeida, Klick, Haythornthwaite, and Smith (2008) found evidence to 
support a close link between sleep and pain on a day-to-day basis. In their sample of 
971 healthy adults assessed over the telephone for a week, self-reported sleep 
duration the previous night was a significant predictor of pain symptoms frequency 
the next day. Whilst pain symptoms did in turn predict subsequent sleep duration, the 
magnitude of the effect was only half as strong as the influence of sleep duration 
predicting pain.  
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Tang, Goodchild, Sanborn, et al. (2012) monitored sleep and pain reports over 
a week in a sample of 119 mixed chronic pain patients in their natural living and 
sleeping environments, using actigraphy and electronic daily diaries to assess sleep, 
pain, and mood reports at three time points over the course of the day. Results from 
multilevel modelling indicated that sleep quality was a significant and consistent 
predictor of next day pain at all assessment points. In contrast, whilst presleep pain 
was a predictor of poorer sleep efficiency calculated based on sleep diary entries, it 
was not a significant predictor of subsequent sleep efficiency as estimated by 
actigraphy. Compared to pain, presleep cognitive arousal and mood were better 
predictors of subsequent sleep. 
 
6.1.2 Evidence for the effect of sleep problems on pain from macro-longitudinal 
studies 
 
There are some macro-longitudinal (prospective) studies with less frequent 
assessments but longer timeframes that have examined the incidence of insomnia and 
chronic pain at the population level. These studies have found evidence that poor 
sleep is a primary factor predicting aggravation of pain responses and determining 
longer-term risks of developing a pain condition. Mork and Nilsen (2012) 
demonstrated in a sample of 12,350 healthy women that incidence of self-reported 
sleep problems tripled the risk of reporting physician-diagnosed fibromyalgia 11 years 
later. The analyses were adjusted for age, general physical health status, and 
psychological wellbeing, with the resultant risk increasing depending on the frequency 
and severity of sleep problems. Gupta et al. (2007) and McBeth et al. (2014) also 
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reported that poor self-reported sleep quality strongly predicted the onset of 
widespread pain symptoms up to 3 years later, even when other psychological, 
lifestyle, and health factors were all controlled for. Similarly, Nitter et al. (2012) found 
that self-reported disrupted and non-restorative sleep were significant predictors of 
chronic pain onset in pain-free individuals over the course of 17 years. The same sleep 
predictors also increased the risk of pain persistence and worsening among those who 
already had chronic pain at baseline.  Despite not having intensive repeated 
assessments of sleep, findings from these prospective studies have shed light on the 
potential long-term impact of sleep on pain. 
 
6.1.3 Focusing on the long-term impact of changes in sleep on pain outcomes  
 
That said, the causality of the relationship between sleep and pain needs finer 
characterisation. Whilst it is understood that sleep patterns and sleep quality fluctuate 
over time, little is known about the effect of these sleep changes on pain and other 
health variables in the long run. This is in part due to the fact that many macro-
longitudinal studies examined sleep statically at a certain time point rather than 
studying the dynamic changes in sleep across multiple assessment points. Further 
research using repeated measurements of sleep disturbances would help establish 
whether greater or lesser exposure to sleep problems over time leads to remission of 
pain and related symptoms (Bradford-Hill, 1965; Ferrie, Kumari, Salo, Singh-Manoux, 
& Kivimaki, 2011).   
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Macro-longitudinal studies also often do not have suitable designs and 
assessment technologies to explore the processes underpinning sleep changes. In 
experimental studies, acute sleep restriction in healthy pain-free participants in the 
form of 88-hour total sleep deprivation (Haack, Lee, Cohen, & Mullington, 2009) and 
partial sleep deprivation of 6 hours a night over a week (Vgontzas et al., 2004) or 4 
hours a night over 10 days (Haack et al., 2007) were associated with impaired 
immunity, elevated inflammatory response and raised cytokines levels, namely, 
interleukin-6(IL-6), C-Reactive Protein (CRP), cortisol, prostaglandin E2 (PGE2), and 
tumour necrosis factor alpha (TNF-). These biomarkers are also believed to be 
related to greater self-reported pain, exaggerated pain sensitivity, fatigue, and 
consequent decline in self-reported health status (Irwin, 2011). However, the use of 
measures that assess these biomarkers is sporadic in longitudinal studies and as such 
their roles in influencing the impact of sleep changes on long-term pain outcomes 
require confirmation. Finally, it should be mentioned that, of the few studies that 
examined change in sleep, the focus of analysis is primarily on the effects of negative 
rather than positive changes. It would be important to verify whether improvement 
in sleep – outside of clinical trials – is also associated with improvement in pain-related 
health outcomes. 
 
6.1.4 Aim of the current systematic review 
 
Given the above considerations, the present review examined prospective 
(macro-longitudinal) studies that have assessed improvement and deterioration in 
sleep over time and the association of these changes with pain-related outcomes. The 
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aims of this review were thus to: (i) systematically summarise the state of the 
research, (ii) critically assess the methodological quality of and consistency in findings 
across existing studies, and (iii) carry out an exploratory meta-analysis to quantify the 
effect of changes in sleep on self-reported health outcome over time.  
 
The predicting/exposure variable was defined as changes in sleep parameters 
(e.g., insomnia symptoms, sleep quantity, and sleep quality). To gain a clearer idea of 
how different sleep measures influence pain, findings were separated by different 
pain-related health outcomes. These outcomes were not only limited to diagnosis of 
the pain condition itself, but also included pain-related physiological status such as 
inflammation/immune functions and self-reported health status (Refer to Figure 12 
for a schematic figure summarising this approach, and the methodologies of included 
studies). Factors such as anxiety and depression may play an important role in changes 
in sleep and subsequent health outcomes. However, since they were not the focus of 
this review, the reader is referred to Alvaro, Roberts, and Harris (2013) and Lustberg 
and Reynolds (2000) for comprehensive reviews on these topics and the long-term 
effect on sleep status. 
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Baseline  
Assessment of 
Sleep 
 
Follow-up  
Assessment of 
Sleep  
 
Pain-Related Health Outcomes# 
Diagnosis of a pain condition, 
inflammatory processes and self-
reported health status 
 (assessed at follow-up or any time after) 
Change in Sleep*  
(sleep status at follow-up compared to baseline) 
Notes: Summary of the framework underlying this systematic review and 
methodological design on the included studies. Based on the experimental and 
epidemiological evidence, the figure illustrates the potential prospective relationship 
between changes in sleep and chronic pain experience. Changes in sleep from 
baseline to follow-up represents the variable associated with subsequent chronic 
pain experience. Change in sleep* refers to change in (i) sleep duration, (ii) sleep 
quality, and/ or (iii) insomnia symptoms. Pain-related health outcomes# represents 
the factors that make up overall pain experience, namely, the risk of developing a 
pain condition, changes in physiological inflammatory and immune processes and 
changes in subjective reports of pain-related health and functioning status. 
 Figure 12 Systematic review – Summary of framework and 
methodology of included studies 
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6.2 Methods  
 
6.2.1 Data source and search strategy  
 
The data source for this systematic review was studies that have evaluated the 
associations of prospective changes in sleep with pain-related health outcomes. 
Relevant articles were identified through electronic searches performed using 
PubMed MEDLINE, Ovid EMBASE, and Proquest PsycINFO. Reference lists of included 
studies and relevant reviews were also hand-searched to ensure comprehensive 
coverage. The protocol of this systematic review was reviewed and registered with 
PROSPERO, an international prospective register of systematic reviews. The Prospero 
Registration Number is 2015:CRD42015023943.  
 
The initial search was carried out by the researcher (EA) in June 2015 and 
repeated just before the final analysis (April 2017) to provide an update. Searches 
were carried out on each database using both study subject (sleep* OR insomnia) AND 
study methodology (longitudinal OR prospective) search terms in the Title and 
Abstract fields. There was no restriction on publication year, but filters were set 
limiting the search to human studies and in the English language. Given that a broad 
array of measures can be used to index pain-related health outcomes, no restriction 
was set to limit the search by outcomes reported. This approach returned a large 
volume of potentially eligible articles. Whilst the screening process was laborious, it 
was considered a more comprehensive and inclusive method to capture all relevant 
studies.  
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6.2.2 Screening  
 
Due to the large volume of hits returned, the first round of screening was a 
“title” screen carried out by the author to screen for unrelated articles, animal studies, 
studies in children populations and in critically ill/hospitalised patients. This resulted 
in a number of irrelevant articles being eliminated. The next step was an eligibility 
assessment of both titles and abstracts and involved four researchers (FR, SA, NK, and 
PC - a doctoral student and three undergraduate students), all of whom had been 
given training and detailed guidance on the screening procedure. They did the 
screening collaboratively using an eligibility checklist to identify relevant studies. The 
screening checklist included six questions requiring a ‘yes’ or ‘no’ response. Each 
question reflects each of the inclusion criteria (see Table 21). Only studies with a ‘yes’ 
response to questions 1, 2, 4, 5, and 6 and a ‘no’ response to question 3 were included 
for full-text screening.  The title and abstract screen was cross-checked by the author, 
and differences in opinion among the reviewers were resolved through team 
discussion. The discussion erred on the side of caution to include studies for further 
full-text screening even if there were doubts on study eligibility based on response to 
the six questions. A total of 14 studies required further extensive discussion on 
eligibility. Interrater agreement rate (Cohen’s Kappa) between reviewers and the 
author was 0.77, a value considered ‘good’ (Altman, 1991). 
                                             
 188 
 
 
6.2.3 Study selection  
 
Figure 13 (flow diagram) depicts the search and screening process. After the 
initial title and abstract screen, 44 articles were selected for full-text screening. The 
full texts of these studies were then assessed for eligibility by the author as per the 
inclusion criteria, using the same aforementioned screening checklist, but with further  
emphasis on the following qualities: (i) the study had to have a follow-up design, (ii) 
that reported a change in sleep parameters using a measure of sleep, (iii) on at least 
two occasions (baseline and follow-ups) and (iv) that the association of change in sleep 
with a subsequent pain-related outcome was reported (See Figure 12). 
 
1. Is the study an original article in the English language? (i.e., not a secondary analysis or 
a review paper) “Yes” to include 
2. Is the study population in human/adults (over 18 years)? “Yes” to include 
3. Is the study of sleep conducted within the context of sleep disorders, drug trials, 
psychological therapy, medical illness/hospitalised patients*, circadian rhythm disorders 
or shift work? “No” to include 
4. Does the study report a change in sleep or a measure of sleep on at least two 
occasions? “Yes” to include 
5. Is the study design longitudinal? # “Yes” to include 
6. Does the study include an outcome measure of health? “Yes” to include 
Note: *This excluded studies carried out on acutely ill and hospitalised medically ill or 
psychiatric patients but did not exclude populations within the general community with 
other pain or medical conditions. #This included studies where outcome is assessed 
prospectively OR where there is a sustained measure of the exposure and/or outcome 
over several assessment points in the same cohort of individuals. 
Table 21 Systematic review – Screening criteria questions 
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Citations identified through database 
(PubMed MEDLINE, EMBASE, + 
PsycINFO) 
(as of April 2017): 
Total – 13,669 
  
Duplicates removed        
(n = 6,460) 
Records screened after 
duplicates removed                      
(n = 7,209) 
Records excluded from initial title 
screen – unrelated topic, animal 
studies, not adults, critically 
ill/hospitalised patients  
(n = 6,632) 
Records excluded (n=542) 
Not longitudinal study (n = 321) 
No relevant outcomes (n = 153) 
Not full-text paper (n = 68) 
Abstracts screened 
(n = 577) 
 
Records excluded (n= 28) 
Cross-sectional design (n = 1) 
Sleep assessed only at baseline (n = 12) 
No analysis of change in sleep (n= 8) 
Sleep not exposure variable (n = 6) 
No pain-related outcomes (n = 1) 
 
Full-text articles from screening  
(n = 35) 
+ 
Full texts hand searched and 
from reference lists (n=9) 
 
Narrative review (n = 16)  
Meta-analysis (n = 3) 
 
 
Included in review (n = 16) 
 
Figure 13 Systematic review – Flowchart of study selection 
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Following the full-text screening, 28 studies were excluded because they did 
not meet all the inclusion criteria. Most were excluded as they only assessed sleep at 
baseline, did not report an analysis of change in sleep or sleep was not the main 
exposure or predicting variable. Sixteen studies met the full inclusion criteria and were 
selected for data extraction and data synthesis. All screened full-text articles and 
included studies were cross-checked for eligibility by a senior member of the review 
team (NT).  
 
6.2.4 Predicting and outcome variables 
 
The predicting/exposure variable was ‘change in sleep’ and outcome variable 
was ‘pain-related health outcomes’. ‘Change in sleep’ was defined as change in any 
sleep parameters assessed in the study between two time points, e.g., change in sleep 
quantity, sleep quality, and/or insomnia symptoms. Change in sleep was derived from 
the difference in sleep at follow-up compared to sleep at baseline. ‘Pain-related health 
outcomes’ was operationalised as measures indicative of any pain conditions and/or 
pain symptoms. This included incidence or presence of pain-related health conditions 
(back pain, fibromyalgia, arthritis, hip fractures etc.), inflammatory and immune 
system biomarkers, pain intensity, pain interference, fatigue, pain-related 
psychosocial functioning, and quality of life. This diverse definition of pain-related 
health outcome covered different dimensions of the chronic pain experience and can 
be grouped into those representing (i) the diagnosis (given by health care 
professionals), (ii) the physiological underlying factors (indicated by relevant 
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biomarkers) and (iii) individuals’ self-reported health-related perceptions and 
judgements (reflected by responses to questionnaires).   
 
6.2.5 Data extraction  
 
Characteristics of the included studies are presented in Table 2 which 
summarises the extracted details on study methodology (i.e. final sample size at 
follow-up, participants’ characteristics, sleep assessment measure, outcome 
assessment measure, number of follow-up assessment and duration of follow-up, 
adjusted variables, and main results on the association of changes in sleep with 
outcome measure). For studies with multiple outcome measures, the main results 
included in this review were those related specifically to the association of change in 
sleep with a pain-related health outcome. When the relevant information was missing 
or not reported in the preferred formats in the original paper, the corresponding 
author of the article was contacted by email, with another follow-up email sent after 
three weeks if no response. Requests were sent out requesting additional information 
for seven (Ferrie et al., 2013; Irish, Dougall, Delahanty, & Hall, 2013; Rueggeberg, 
Wrosch, & Miller, 2012; Shakhar, Valdimarsdottir, Guevarra, & Bovbjerg, 2007; Silva 
et al., 2009; Suh et al., 2014; Zhang, Lam, Li, Li, & Wing, 2012) of the included articles. 
Five authors responded and three (Ferrie et al., 2013; Silva et al., 2009; Zhang et al., 
2012) were able to provide the requested information.  
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6.2.6 Risk of bias assessment 
 
Risk of bias was assessed qualitatively using a checklist adapted from: The 
Strengthening the Reporting of Observational studies in Epidemiology (STROBE) 
guidelines for reporting observational epidemiological studies (Sanderson, Tatt, & 
Higgins, 2007) and the modified Agency for Healthcare Research and Quality (AHRQ) 
quality assessment criteria for observational studies (Manchikanti, Singh, Smith, & 
Hirsch, 2009). All included studies were assessed for risk of bias using four categories: 
(i) methods of selecting and assessing study participants, (ii) measurement methods, 
(iii) design-specific issues (attrition and confounders), and (iv) statistical analysis 
methods (see Figure 14 for description of each category and the corresponding 
studies). This descriptive approach to risk of bias assessment provides details on the 
direction and magnitude of bias across the different methodological domains relevant 
to the study design and conduct. This approach has been used in other systematic 
reviews (Bernstein et al., 2016; Hertenstein et al., 2016) and follows the 
recommendation of the Cochrane collaboration (Higgins & Green, 2011), which 
advises against the use of summary scores and quality scales. 
 
6.2.7 Data synthesis and analysis 
 
All included studies were synthesised in a narrative form, organised by 
outcome and presented under three subsections: (i) change in sleep and risk of 
developing pain condition, (ii) change in sleep and inflammatory or immune function 
biomarkers, and (iii) change in sleep and self-reported pain-related health status. The 
primary aim of the systematic review was a narrative review, but we were able to pool 
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together a subset of the studies reporting the Physical Component Summary (PCS) 
score from the Short Form Health Survey-36 (SF-36) as a measure of pain-related 
health status for an exploratory meta-analysis. The SF-36 (Ware, 1993) is a validated 
measure of health-related quality of life and gives two summary scores: Mental 
Component Summary (MCS) and Physical Component Summary (PCS). For this review, 
we were interested in the PCS score which provided a composite score that is a 
combination of four of the SF-36 subscales (physical functioning, physical role 
functioning, bodily pain, and general health).  Data were available from the three 
studies which assessed PCS as an outcome measure (Komada et al., 2012; Silva et al., 
2009; Suh et al., 2014) and these were included as part of the exploratory meta-
analysis to compare differences between associations of sleep change over time with 
self-reported physical health status.  
 
For the meta-analysis, means and standard deviation of relevant outcome (PCS 
scores) were extracted for the individuals with no change or with change in sleep over 
the follow-up period. Change in sleep was a change in the reporting of sleep status at 
follow-up compared to the reported sleep status at baseline. Standardised mean 
differences (SMD) between those with change and those with no change in sleep were 
estimated using a random effect model. A similar method was used for an additional 
analysis comparing the PCS scores between persistent poor sleepers (i.e. no change in 
poor sleep between two time points) and persistent good sleepers (i.e. no change in 
good sleep between two time points). Statistical heterogeneity among the studies was 
assessed using the I2 statistic along with visual inspection of the forest plot. Sensitivity 
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analysis was carried out when a meta-analysis showed significant heterogeneity (I2 
>50%) and involved omitting one study at a time to reveal the potential source of 
heterogeneity. All statistical analysis was performed using RevMan 5 (The Cochrane 
Collaboration).  
 
6.3 Results  
 
6.3.1 Characteristics of included studies  
 
The 16 cohort studies included involved a total of 61,100 participants (female 
%:  50 - 100%; mean age: 30 – 80+ years) from 10 different countries (USA = 6, UK = 2, 
Israel, Sweden, Japan, Canada, Hong Kong, Finland, Korea and Singapore) and 
recruited from the community. The length across these studies ranged from 1 month 
to 23 years, with a median follow-up period of 4.5 years. See Table 22 for all study 
characteristics. 
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Table 22 Systematic review – Study characteristics 
 
 
Citation  
Country 
Final sample  
Gender 
Mean age  
(final sample) 
Ethnicity 
Predicting 
variable 
Pain-
related 
health 
outcome 
Follow-
up 
duration 
Timing of 
assessments 
Adjusted 
variables 
Results: sleep 
deterioration 
Results: sleep 
improvement 
Agmon & 
Armon 
(2014)1 
Israel  
N = 2131  
66% male 
46.20 years 
Not stated 
Change in self-
reported 
insomnia 
symptoms from 
Athens Insomnia 
Scale. 
Diagnosis of 
back pain 
(confirmed 
through 
medical 
records and 
medical 
interview 
with 
physician) 
3.7 years  Predicting 
variable and 
pain-related 
health outcome 
assessed at three 
time points 
spread over a 
period of 3.7 
years. 
Age, gender, 
education, 
physical 
activity, self-
rated health, 
smoking, BMI, 
levels of high-
sensitivity C-
reactive 
protein.  
Increase in 
insomnia 
symptoms from 
Time 1 to Time 2 
was associated 
with increased 
risk of diagnosis 
of back pain at 
Time 3 (OR = 1.40 
94% CI 1.10-
1.71). 
None reported. 
Campbell et 
al. (2013)2 
UK 
N = 2622  
42.1% male 
Not stated 
(range 50 – 
80+ years) 
Not stated 
Change in self-
reported sleep 
quality (Jenkins 
Sleep 
Questionnaire). 
Self-
reported 
pain 
presence, 
persistence, 
interference 
and 
depressive 
symptoms. 
6 years Predicting 
variable and 
pain-related 
health outcome 
assessed at three 
time points 
(Baseline, 3 years 
and 6 years). 
Age, gender, 
alcohol 
consumption, 
smoking, 
marital status, 
employment 
status, and 
BMI. 
New onset of 
sleep problems 
associated with 
increased pain 
interference and 
increased risk of 
depression at 
follow-up. 
None reported. 
                                             
 196 
Ferrie et al. 
(2013)2 
UK 
N = 5,003 
71.8% male 
49.3 years 
Not stated 
Change in self-
reported sleep 
quantity. 
Immune 
marker – 
CRP and IL-6 
levels. 
5 years Predicting 
variable and 
pain-related 
health outcome 
assessed at two 
time points 
(baseline and 
follow-up). 
Age, gender, 
occupation, 
systolic blood 
pressure, BMI, 
total 
cholesterol, 
and diabetes. 
Decrease in sleep 
quantity 
significantly 
associated with 
higher IL-6 levels 
but not CRP at 
follow-up. 
Increase in sleep 
quantity not 
significantly 
associated with 
CRP and Il-6 levels 
at follow-up. 
Foley et al. 
(1999)4 
USA 
N = 6899 
62% male 
Not stated 
(aged 65+ 
years) 
Not stated 
Change in self-
reported 
insomnia 
symptoms 
(difficulty falling 
asleep or early 
morning arousal). 
Diagnosis of 
hip fracture 
by 
physician. 
3 years Predicting 
variable and 
pain-related 
health outcome 
assessed at two 
time points 
(baseline and 
follow-up). 
Age, gender, 
community 
(state of 
residence), 
income, and 
education. 
New incidence 
and persistence 
of insomnia 
symptoms 
significantly 
associated with 
newly reported 
presence of hip 
fracture at 
follow-up (OR = 
2.08 95% CI 1.18, 
3.65). 
None reported.  
 
Irish et al. 
(2013)5 
USA 
N = 128  
63% male 
36.45 years 
92% White 
Change in self-
reported sleep 
quality 
(Pittsburgh Sleep 
Quality Index 
[PSQI]). 
Self-report 
physical 
symptoms. 
Immune 
marker – 
natural 
killer (NK) 
cell number 
and 
cytotoxicity 
(n=51). 
12 
months 
Two time points. 
Predicting 
variable assessed 
at baseline and 
follow-up. Pain-
related health 
outcome 
assessed only at 
follow-up. 
None stated. Deterioration of 
sleep quality not 
significantly 
correlated with 
pain-related 
health outcomes 
at follow-up. 
Improvement in 
sleep quality not 
significantly 
correlated with 
pain-related 
health outcomes 
at follow-up. 
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Janson et al. 
(2001)6 
Sweden 
N = 2602 
100% male  
Not stated 
(range 30 – 
69 years) 
Not stated 
Change in self-
reported 
insomnia 
symptoms 
(difficulty falling 
asleep and 
difficulty 
maintaining 
sleep). 
Diagnosis of 
a medical 
disorder, 
including 
joint or low 
back 
disorders by 
physician. 
10 years Predicting 
variable and 
pain-related 
health outcome 
assessed at two 
time points 
(baseline and 
follow-up). 
Age, BMI 
smoking, 
physical 
inactivity, 
alcohol 
dependence, 
and medical 
disorders. 
Increase in 
insomnia 
symptoms 
associated with 
newly reported 
medical disorder 
at follow-up. 
None reported.  
 
Komada et al. 
(2012)7 
Japan 
N = 1577 
43% male 
58.6 years 
Not stated 
Change in self-
reported sleep 
quality (Japanese 
version of PSQI – 
cut-off score of 
5.5 indicating 
insomnia). 
SF36 – PCS 2 years Predicting 
variable and 
pain-related 
health outcome 
assessed at two 
time points 
(baseline and 
follow-up). 
Age, gender, 
disease status, 
alcohol 
consumption, 
smoking habits, 
living status, 
sleep 
medication use, 
depression, 
MCS, PCS, and 
PSQI scores at 
baseline. 
New incidence of 
insomnia 
symptom 
associated with a 
decline in PCS 
scores at follow-
up.  
 
Remission of 
insomnia 
symptoms not 
significantly 
associated with 
increase in PCS 
scores at follow-
up. 
Parthasarathy 
et al. (2015)8 
USA 
N = 1409 
45% male 
47 years  
Not stated 
Change in self-
reported 
insomnia 
symptoms 
derived from ICSD 
insomnia 
diagnosis criteria.  
Immune 
marker – 
CRP levels 
assessed in 
722 
participants.  
6 years Two time points. 
Predicting 
variable assessed 
at baseline and 
follow-up. Pain-
related health 
outcome 
assessed only at 
6-year follow-up. 
Age, gender, 
BMI, smoking, 
physical 
activity, use of 
alcohol and 
medications to 
get to sleep, 
marital status, 
habitual 
snoring, 
diabetes 
mellitus and 
hypertension.  
Persistence of 
insomnia 
symptoms 
associated with 
an increase in 
and higher CRP 
levels at follow-
up compared to 
those with 
intermittent or 
no insomnia.  
None reported.  
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Quan et al. 
(2005)9 
USA 
N = 4667 
40.9% male 
72.3 years 
Not stated 
Change in self-
reported 
insomnia 
symptoms 
(trouble falling 
asleep, frequent 
awakenings and 
excessive daytime 
sleepiness). 
Diagnosis of 
arthritis by 
physician. 
1 – 4 
years 
(mean 
3.55) 
Predicting 
variable and 
pain-related 
health outcome 
assessed at two 
time points 
(baseline and 
follow-up). 
Age, gender, 
race, time 
interval 
between 
baseline and 
follow-up 
examinations. 
New incidence of 
insomnia 
symptoms 
associated with 
baseline report of 
arthritis in 
women.  
None reported.  
 
Rueggeberg 
et al. (2012)10 
Canada 
N = 157  
48.40% male 
71.71 years 
Not stated 
Change in self-
reported sleep 
quantity using 
items from Brief 
Pittsburgh Sleep 
Quality Index 
[PSQI]. 
Immune 
marker – 
diurnal 
cortisol 
secretion. 
4 years Predicting 
variable and 
pain-related 
health outcome 
assessed at three 
time points 
(Baseline, 2 years 
and 4 years). 
Age, gender, 
partnership 
status, 
education, 
chronic illness, 
cortisol-related 
medication 
usage, BMI and 
smoking. 
Decrease in sleep 
quantity 
associated with 
significant 
increases in 
cortisol secretion 
level at follow-
up. 
 
Increase in sleep 
quantity not 
significantly 
associated with 
changes in cortisol 
level at follow-up. 
Ropponen et 
al. (2013)11 
Finland 
N = 18979  
47% male 
45 years 
Not stated 
Change in self-
reported sleep 
quality and sleep 
quantity.   
Diagnosis of 
back pain by 
physician 
and 
included in 
national 
register 
database on 
disability 
pension due 
to low back 
pain 
diagnosis.  
23 years Two time points. 
Predicting 
variable assessed 
at baseline and 
follow-up. Pain-
related health 
outcome 
assessed only at 
follow-up. 
Age, education, 
socioeconomic 
status, marital 
status, BMI, 
physical 
activity, 
musculoskeletal 
pain locations, 
smoking, 
alcohol, life 
satisfaction, 
use of hypnotic 
agents, diurnal 
type, and type 
of work. 
Deterioration and 
persistent of 
poor sleep 
quality 
associated with 
higher risk of low 
back pain 
diagnosis at 
follow-up (HR = 
1.84 95% CI 1.01-
3.37). No 
association with 
decrease in sleep 
quantity. 
Improvement in 
sleep quantity and 
quality not 
associated with 
risk of low back 
pain diagnosis at 
follow-up. 
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Shakhar et al. 
(2007)12 
USA 
N = 45  
0% male 
39.7 years 
47% White 
40% Black 
Change in self-
reported sleep 
quantity. 
Immune 
marker – 
Natural 
Killer Cell 
Activity 
(NKCA) 
levels. 
1 month Two time points. 
Predicting 
variable and 
pain-related 
health outcome 
assessed at both 
baseline and 
follow-up. 
Self-reported 
POMS 
Depression and 
Tension 
subscales 
levels. 
Decrease in sleep 
quantity not 
associated with 
NKCA levels at 
follow-up.  
 
Increase in sleep 
quantity was 
significantly 
related to an 
increase in NKCA 
levels at follow-
up.  
Silva et al. 
(2009)13 
USA 
N = 3078  
45% male 
67.3 years 
75% White 
Change in self-
reported 
insomnia 
symptoms 
(difficulty 
initiating and 
maintaining 
sleep, daytime 
sleepiness. 
SF36 – PCS 5 years Predicting 
variable and 
pain-related 
health outcome 
assessed at two 
time points 
(baseline and 
follow-up). 
Age, gender, 
BMI, smoking, 
sleeping pill 
use, PSG total 
sleep time, 
baseline 
coronary heart 
disease and 
respiratory 
disease. 
Deterioration of 
insomnia 
symptoms was 
not associated 
with PCS scores. 
Increase in 
daytime 
sleepiness was 
associated with 
decline in PCS 
scores at follow-
up.  
Improvement of 
insomnia 
symptoms not 
significantly 
associated with 
PCS scores at 
follow-up.  
 
Smagula et al. 
(2016)14 
Singapore 
N = 8265 
41.05% male 
64.59 years 
98.6% Asian 
Change in self-
reported sleep 
quantity. 
Diagnosis of 
arthritis by 
physician 
and 
diagnosis of 
hip fracture 
recorded on 
hospital 
database. 
12.7 
years 
Predicting 
variable and 
pain-related 
health outcome 
assessed at two 
time points 
(baseline and 
follow-up). 
Age, gender, 
baseline sleep 
duration. 
No association 
between change 
in sleep and 
arthritis. Increase 
in sleep quantity 
from 6-8 to 
>8hours linked 
with greater risk 
of hip fracture at 
follow-up (OR = 
None reported.  
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1.52 95% CI 1.16 
– 2.00). 
Suh et al. 
(2014)15 
Korea 
N = 1247  
40.1% male  
54.3 years 
Not stated 
Change in self-
reported 
insomnia 
symptoms 
(difficulty 
initiating and 
maintaining 
sleep, early 
morning 
awakenings and 
unrefreshed in 
the morning). 
SF36 – PCS 2 years Predicting 
variable and 
pain-related 
health outcome 
assessed at three 
time points 
spread over 2 
years. 
Age, gender, 
marital status, 
employment, 
smoking, 
alcohol, 
hypertension, 
diabetes, 
depression, 
PSQI and BMI 
score. 
Deterioration and 
persistence of 
insomnia 
symptoms 
associated with 
significantly 
lower PCS scores 
at follow-up. 
None reported. 
Zhang et al. 
(2012)16 
Hong Kong 
N = 2291 
50% male  
46.3 years 
Not stated 
Change in self-
reported 
insomnia 
symptoms (non-
restorative sleep). 
Subjective 
physical 
health 
status. 
Diagnosis of 
arthritis and 
other 
chronic pain 
condition by 
physician. 
5 years Predicting 
variable and 
pain-related 
health outcome 
assessed at two 
time points 
(baseline and 
follow-up). 
Age, gender, 
education, 
family income, 
medication, 
and comorbid 
sleep problems 
(insomnia 
subtypes, 
habitual 
snoring, short 
sleep duration). 
New incidence of 
insomnia 
symptoms 
significantly 
associated with 
higher risk of 
reporting a 
chronic pain 
condition at 
follow-up (OR = 
2.47 95% CI 1.30-
4.69) 
Remission of 
insomnia 
symptoms 
associated with a 
relatively lowered 
risk of developing 
a chronic pain 
condition at 
follow-up (OR = 
1.23, 95% CI 0.57-
2.59). 
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6.3.2 Measures of sleep changes 
 
Most studies assessed sleep twice, once at baseline and once at follow-up, 
except for four studies (Agmon & Armon, 2014; Campbell et al., 2013; Rueggeberg et 
al., 2012; Suh et al., 2014) that assessed sleep at three time points. Sleep was primarily 
assessed using self-report. Five of the studies (Foley, Monjan, Simonsick, Wallace, & 
Blazer, 1999; Janson, Lindberg, Gislason, Elmasry, & Borman, 2001; Quan et al., 2005; 
Suh et al., 2014; Zhang et al., 2012) assessed self-reported insomnia symptoms 
(difficulty falling asleep, difficulty maintaining sleep, early morning awakenings, 
symptoms of impaired daytime functioning, concern about not getting enough sleep 
and daytime sleepiness) and other similar general indicators of non-restorative sleep. 
Parthasarathy et al. (Parthasarathy et al., 2015) assessed these insomnia symptoms 
based on definitions derived from the International Classification of Sleep Disorders 
insomnia diagnostic criteria. Agmon and Armon (Agmon & Armon, 2014) used a 
validated questionnaire (Athens Insomnia Scale) to assess insomnia symptoms. Three 
studies used validated questionnaires, e.g., the Pittsburgh Sleep Quality Index (PSQI) 
(Irish et al., 2013; Komada et al., 2012) and the Jenkins Sleep Questionnaire (Campbell 
et al., 2013), to index sleep quality. Four studies (Ferrie et al., 2013; Rueggeberg et al., 
2012; Shakhar et al., 2007; Smagula, Koh, Wang, & Yuan, 2016) assessed changes in 
sleep quantity by asking self-reported sleep duration at baseline and follow-up. One 
study (Ropponen et al., 2013) assessed sleep using both self-reported sleep quality 
and sleep quantity. Only one study (Silva et al., 2009) used both self-report and 
overnight polysomnography (PSG) to assess sleep. However, in this study, PSG was 
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only used to index overnight respiratory disturbance and no other objective sleep 
parameters were reported.  
 
6.3.3 Measures of pain-related health outcomes  
 
Seven studies (Agmon & Armon, 2014; Foley et al., 1999; Janson et al., 2001; 
Quan et al., 2005; Ropponen et al., 2013; Smagula et al., 2016; Zhang et al., 2012) 
focused on looking at change in sleep and risk of developing a pain-related health 
condition (namely; arthritis, back pain, general chronic pain, hip fractures) by means 
of self-report or using information from physician medical interviews, medical 
records, and linked national databases. Four studies (Ferrie et al., 2013; Parthasarathy 
et al., 2015; Rueggeberg et al., 2012; Shakhar et al., 2007) assessed changes in sleep 
in relation to physiological health status. This included assessments of inflammatory 
and immune system biomarkers. There was no restriction placed on the diversity of 
biomarkers, as long as they were immune or inflammatory biomarkers with 
established connection to pain conditions (Marchand et al., 2005). Three studies 
(Komada et al., 2012; Silva et al., 2009; Suh et al., 2014) assessed the effect of changes 
in sleep on self-reported pain-related health status, mostly using the Physical 
Component Summary and Bodily Pain scores derived from the SF-36. One study 
(Campbell et al., 2013) used a general health assessment questionnaire to determine 
pain presence and pain interference. Only one study (Irish et al., 2013) assessed 
changes in both self-reported physical pain symptoms and immune biomarkers.  
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6.3.4 Risk of bias assessment results 
 
The results of the risk of bias assessment are graphically presented in Figure 
14. Most of the reviewed studies were “low/medium risk” except for one (Foley et al., 
1999), which was categorised as “high risk” in three out of the four risk categories.  
The main issues affecting the quality of the included studies were a heavy reliance on 
self-report and a lack of objective sleep/pain-related health outcome measures (i.e., 
polysomnography-determined sleep and quantitative sensory testing). In addition, 
some studies provided insufficient details on attrition, resulting in a lack of 
comparison with non-responding participants, which could affect the generalisability 
of association between variables and bias the interpretation of the results. Finally, 
other methodological issues included studies with small sample sizes (e.g., less than 
50 in one study) and short follow-up period (i.e. 1 month). Small sample size in itself 
may not be an issue when combined with greater numbers of follow-up assessments 
as this would increase statistical power. However, statistical power to detect 
significant association will be limited in the case of both a small sample size and limited 
follow-up assessments. 
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0 2 4 6 8 10 12 14 16
Statistical methods
Design-specific issues
Measurement methods
Selection of participants
Number of studies
High risk Moderate risk Low risk
Figure 14 Systematic review – Risk of bias checklist and rating 
 
 
 
 
 
 
 
 
Figure Key: High risk  Moderate risk Low risk   
Selection and 
assessment of 
participants 
Minimal description of 
participants and inclusion 
characteristics.  
 
Sample size n < 100 with 
no justification given and 
two follow-up 
assessments. 
 
Ref: 4, 12 
Some but insufficient 
description of participants 
and inclusion 
characteristics. 
 
Sample size n = 100 – 1000 
and no justification given 
but at least two follow-up 
assessments.  
Ref: 6,7,10,16,5,8,14 
Clear detailed description 
of participants and 
inclusion characteristics.  
 
Sample size n > 1000 or 
justification of sample 
size, and more than two 
follow-up assessments 
 
Ref: 9,13,2,3,11,1,15 
Measurement 
methods  
Uses only non-validated 
subjective measure of 
exposure or outcome. 
 
Ref: 4,6,9,16 
Uses only validated 
subjective measure of 
exposure or outcome. 
 
Ref: 12,7,10,2,3,5,11, 
1,15,8,14 
Uses a standard objective 
and a validated 
subjective measure of 
exposure and outcome. 
Ref: 13 
Design – specific 
issues  
Attrition rate > 80%. 
Minimal description of 
attrition levels and 
comparison of non-
responders with 
participating individuals. 
 
Very little/no 
confounding variables 
stated and controlled for.  
 
Ref: 4,14 
Attrition rate 60 – 80%. 
Insufficient description of 
attrition levels and 
comparison of non-
responders with 
participating individuals. 
 
Limited range of 
confounding variables 
stated and controlled for.  
 
Ref: 9,12,13,10,16,3, 
5,11,1,15,8 
Attrition rate < 60%. 
Clear description and 
comparison of non-
responders with 
participating individuals. 
 
Describes and controls 
for a range of relevant 
confounding variables. 
 
 
Ref: 6,7,2 
Statistical 
methods 
Poorly described 
statistical analysis. 
 
Lack of appropriate 
significance testing and 
minimal justification for 
lack of further sensitivity 
analysis.  
Ref: N/A 
Statistical analysis methods 
not sufficiently described.  
 
Insufficient details to justify 
lack of further sensitivity 
analysis.  
 
 
Ref: 6,12,5,15 
Well-described and 
appropriate statistical 
analysis. 
Reports adjusted 
estimates, missing data, 
subgroups and other 
sensitivity analysis.  
 
Ref: 4,9,13,7,10,16 
2,3,11,1,8,14 
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6.3.5 Association of change in sleep with the risk of developing a pain condition 
 
Increase in insomnia symptoms  
The reviewed studies conveyed the relationship between a negative change in 
insomnia symptoms and risk of developing a pain condition in those with no pain 
condition at baseline. Foley et al. (1999) reported that newly developed insomnia 
symptoms over a three-year period doubled the risk of the presence of self-reported 
hip fracture problems at follow-up (OR = 2.08 95% CI 1.18, 3.65). Zhang et al. (2012) 
also reported that incidence of insomnia symptoms and non-restorative sleep was 
associated with over a two-fold increase in risk of reporting a chronic pain disorder at 
five-year follow-up (OR = 2.47 95% CI 1.30-4.69). Agmon and Armon (2014) showed 
that increase in insomnia symptoms was associated with a 40% increased risk of new 
back pain diagnosis over a period of over 3 years (OR = 1.40 95% CI 1.10-1.71). With a 
much longer follow-up period of 23 years, Ropponen et al. (2013) reported an 
association of persistent poor sleep (HR = 1.84 95% CI 1.01-3.37) with an 84% 
increased risk of being included on the national register for disability pension due to 
low back pain diagnosis at follow-up. However, reduction in sleep quality (HR = 1.17, 
95% CI 0.77-1.77) was not significantly associated with an increased risk. Janson et al. 
(2001) also found that an increase in insomnia symptoms over a ten-year period was 
associated with newly reported medical conditions including joint and low back pain 
disorder at follow-up, although the risk ratios were not specified in this report. In 
contrast to the other studies, Quan et al. (2005) did not find a link between the 
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development of insomnia symptoms over a four-year period and the presence of pain 
conditions at follow-up.  
 
Decrease in insomnia symptoms  
Notably, only Zhang et al. (2012) reported the effect of a positive change in 
insomnia symptoms. They reported an association of remission of insomnia symptoms 
with a 23% lowered risk of developing a chronic pain condition at follow-up, but this 
association was not significant (OR = 1.23, 95% CI 0.57-2.59).  
 
Increase in sleep quantity  
Ropponen et al. (2013) did not find an association between increased sleep 
quantity and risk of low back pain diagnosis over a 23-year follow-up period. Smagula 
et al. (2016) similarly, did not find a link between an increase in sleep quantity and 
developing arthritis at ten-year follow-up. However, these authors did report that an 
increase in nightly sleep quantity to > 8hrs was associated with a 52% greater risk of 
hip fracture problems as registered on a national hospital database (OR = 1.52 95% CI 
1.16 – 2.00). The causal order of the relationship was unclear; the authors suggested 
that recent hip fractures and consequent low physical activity might be key 
determinants of the lengthened sleep duration.  
 
Summary – change in sleep and risk of developing a pain condition  
In the studies reviewed, reporting a negative change in insomnia symptoms 
was associated with a greater risk of developing and reporting a pain-related medical 
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condition. On the other hand, a remission or a positive change in insomnia symptoms 
did not necessarily neutralise or fully avert the risk of developing chronic pain. 
Moreover, an increase in sleep quantity might not be associated with a positive pain-
related health outcome.   
 
6.3.6 Association of change in sleep with inflammatory or immune biomarkers 
 
Increase in sleep quantity and natural killer cells activities (NKCA) 
Shakhar et al. (2007) and Irish et al. (2013) looked at the association between 
changes in sleep quantity and natural killer cells activities (NKCA). Natural killer cells 
play a physiologically protective role in activating immune responses to contain and 
clear viral infections. Low levels are linked to certain pain conditions such as 
fibromyalgia, and possibly contribute to exaggerated pain response in some 
individuals with chronic pain (Landis et al., 2004; Marchand et al., 2005). Shakhar et 
al. (2007) using a small sample (n = 45) with a short (1 month) follow-up found that an 
increase in sleep quantity was associated with an increase in NKCA levels. On the other 
hand, Irish et al. (2013) did not find a relationship between either an increase or 
decrease in sleep quantity and quality over 1-year with changes in natural killer cell 
levels. The analysis was carried out in a small subset (n = 51) of their sample and the 
standard deviation for mean NK cell number was quite large (Mean = 285.21, SD = 
204.53).  
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Decrease in sleep quantity and cortisol levels 
Cortisol is the body’s primary stress hormone needed to activate the 
physiological ‘flight or fight’ response; however, high cortisol levels interfere with 
immune functions and are a risk factor for many illnesses (McEwen, 1998; McEwen & 
Kalia, 2010). Chronic pain states have been linked to sustained stress response and 
consequently higher cortisol levels (Vachon-Presseau et al., 2013). Rueggeberg et al. 
(2012) found that a decrease in sleep quantity (by 1 standard deviation) over the first 
two years of their study was associated with an increase in diurnal cortisol secretion 
over the total four-year follow-up period. By contrast, an increase in sleep quantity 
was not significantly associated with cortisol levels.  
 
Decrease in sleep quantity and Interleukin-6(IL-6) and C-reactive protein (CRP) levels 
IL-6 and CRP are markers of systemic inflammation, activated to combat 
infections (Watkins & Maier, 2000). They also possess a pain facilitatory effect and can 
alter pain modulation and pain processing (De Jongh et al., 2003; Irwin, 2011; Irwin et 
al., 2016). Persistent elevated presence of these markers has been observed in several 
chronic illnesses and implicated in the generation, maintenance and severity of 
chronic pain conditions (Lund Haheim, Nafstad, Olsen, Schwarze, & Ronningen, 2009; 
Marchand et al., 2005). Ferrie et al. (2013) analysing data from the UK Whitehall study, 
did not find an association between increases in sleep quantity and changes in levels 
of IL-6 and CRP. However, they revealed that a five-year decrease in sleep quantity 
was associated with higher levels of inflammatory markers. In the fully-adjusted 
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analysis controlling for age, sex, occupation, blood pressure, BMI, cholesterol level 
and presence of diabetes, each 1-hour decrease in sleep quantity was associated with 
a 2.7% higher level of IL-6. The reduction in sleep quantity was also associated with a 
4.2% higher level of CRP, but this association was not statistically significant.  
 
Summary – change in sleep and inflammatory or immune biomarkers 
 It appeared that a reduction in sleep quantity is temporally linked to elevated 
levels of inflammatory and immunological markers. However, a reverse association 
was not noted for an increase in sleep quantity. Only one study examined the effect 
of changes in insomnia symptoms and sleep quality on inflammatory and 
immunological markers indicative of pain. Parthasarathy et al. (2015) found that CRP 
levels were higher and increased at a greater rate in those with persistent insomnia 
compared with those with intermittent or no insomnia. It is important to note that 
the assessment of the biomarkers reviewed were not pain-specific. We cannot rule 
out other disease processes involving inflammation that might have affected the 
relationship of sleep changes with deterioration in health status. 
 
6.3.7 Association of change in sleep with pain-related health status  
 
Three of the reviewed studies (Komada et al., 2012; Silva et al., 2009; Suh et 
al., 2014) assessed perceived physical health status using the Physical Component 
Summary (PCS) from the SF-36. PCS is a summary of the SF-36 subscales that assess 
physical functioning, physical role functioning, bodily pain, and general physical health 
(Ware, 1993). Lower scores on the PCS and the bodily pain subscale indicates greater 
                                             
 210 
physical health limitations and pain-related interference and disability. All three 
studies reviewed reported the PCS scores, but only the Silva et al. (2009) study 
provided the subcomponent bodily pain score separately.   
 
Increase in insomnia symptoms 
All three studies revealed an association of lowered PCS scores over time with 
an increase in or maintenance of insomnia symptoms. Silva et al. (2009) found that 
those who developed insomnia symptoms or whose insomnia symptoms persisted 
over a five-year follow-up period reported a decline in PCS scores and lower PCS scores 
at follow-up, compared with persistent good sleepers with no change in insomnia 
symptoms. Komada et al. (2012) used PSQI scores to assess those with newly 
developed insomnia symptoms over a two-year follow-up period. These individuals 
who reported increased insomnia symptoms over time reported a decline in PCS 
scores from baseline to follow-up and worse PCS scores at follow-up compared with 
persistent good sleepers. Suh et al. (2014) also reported a similar decrease in PCS 
score over a 2-year follow-up period for those with worsening and persistent insomnia 
symptoms.  
 
Two studies used other forms of pain health assessment such as self-reported 
pain symptoms. Irish et al. (2013) did not find a one-year increase or decrease in PSQI 
to be related to physical pain symptoms. In their sample of rescue workers who 
performed rescue and clean-up operations at the site of a major airplane crash, the 
findings might have been affected by life stressors and other symptoms of 
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psychological distress following the crash. However, over 80% of the sample reported 
‘good’ or ‘excellent’ physical health and had stable PSQI scores over the year. 
Campbell et al. (2013) on the other hand, found that new onset of sleep problems and 
insomnia symptoms in a chronic pain sample over three years significantly increased 
the risk of depression (relative risk 3.47) at six-year follow-up. Importantly, this risk 
was mediated by increased pain interference measured at three-year follow-up and 
the findings revealed a significant association between increased insomnia symptoms 
and increased pain interference.  
 
Summary – change in sleep and pain-related health status 
Compared to no change in good sleep, an increase in insomnia symptoms was 
associated with worse pain outcomes and physical functioning status over time.  
 
6.3.8 Sleep change trajectories and PCS scores 
 
To further explore the observed trend of changes in sleep and physical 
functioning, the next step was to quantitatively and visually compare change in PCS 
from baseline to follow-up by sleep change trajectories (Figure 15). Namely, the four 
trajectories are (i) persistent good sleepers (no sleep disturbance at baseline and 
follow-up), (ii) new incident poor sleepers (developed sleep disturbance from baseline 
to follow-up), (iii) remitted poor sleeper (sleep disturbance resolved from baseline to 
follow-up), and (iv) persistent poor sleepers (sleep disturbance at baseline and follow-
up).  
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Across the three studies with this kind of data (Komada et al., 2012; Silva et al., 
2009; Suh et al., 2014), persistent good sleepers fared the best and reported the 
highest PCS scores at both baseline and follow-up compared with the other 
trajectories. They also showed the greatest stability in PCS scores across both time 
points. New incident poor sleepers showed a decline in PCS scores. Whilst the PCS 
scores for remitted poor sleepers also showed fluctuations, the effect was not 
consistent across studies and the direction of the effect was unclear. Persistent poor 
sleepers fared the worst; they presented with the lowest PCS scores at both baseline 
and follow-up.  
 
Subcomponent scores for bodily pain could not be extracted for all three 
studies, but using the data available from Silva et al. (2009), comparison of  the 
different sleep change trajectories using the bodily pain subscale of the PCS was 
possible for this particular study. Remitted poor sleepers had the highest bodily pain 
score at baseline and this worsened at follow-up. However, the other patterns 
observed for the bodily pain subscale were similar to overall PCS scores; persistent 
good sleepers fared the best whereas new incident poor sleepers showed an increase 
in pain scores over time.  
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Figure 15 Systematic review – Sleep change trajectories and PCS scores 
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Figure 16 Systematic review – Exploratory meta-analyses 
Figure 16a Forest plot of PCS scores at follow-up, comparing individuals who were ‘persistent poor sleepers’ with those who were ‘persistent good sleepers’.  
Lower PCS scores represent worse physical functioning and health limitations.   
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Favours persistent 
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 215 
Figure 16b Forest plot of PCS scores at follow-up, comparing individuals who developed sleep disturbances over time (‘new poor sleepers’) with those who were 
‘persistent good sleepers’ (i.e., evaluating the effect of negative sleep deterioration). Lower PCS scores represent worse physical functioning and health 
limitations.   
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Figure 16c Forest plot of PCS scores at follow-up, comparing individuals whose sleep disturbances remitted over time (‘remitted poor sleepers’) with those who 
were ‘persistent poor sleepers’ (i.e., evaluating the effect of positive sleep improvement). Lower PCS scores represent worse physical functioning and health 
limitations.   
 
 
  
  
                                          
 
 
 
Favours remitted 
poor sleepers to 
have lower PCS 
scores at follow-up 
Favours remitted 
poor sleepers to 
have higher PCS 
scores at follow-up 
    
 217 
6.3.9 Exploratory meta-analysis 
 
Three exploratory meta-analyses were conducted to compare PCS score at 
follow-up to examine how different trajectories of sleep changes affected physical 
health. This was done using available data from the three studies (Komada et al., 2012; 
Silva et al., 2009; Suh et al., 2014) using PCS as an outcome measure. The total number 
of participants across the three studies was 5902 (female: 57.1%, mean age: 60 years) 
and the follow-up periods were 5 years and 2 years. An analytic approach was used 
that allowed comparison of the PCS scores at follow-up between persistence of poor 
sleep and good sleep, and then examine the separate association of sleep 
deterioration and sleep improvement with PCS scores. Statistics of these analyses are 
summarised with forest plots in Figures 16a-c. 
Meta-analysis 1: Persistence of poor sleep and PCS scores 
 In comparing persistent poor sleep with persistent good sleep (Figure 16a), 
persistent poor sleep was significantly associated with lower PCS scores at follow-up. 
This analysis showed significant heterogeneity (I2 = 67%). Sensitivity analysis identified 
Komada et al. (2012) as the potential source, possibly due to the use of a Japanese 
version of the PSQI compared to individual questions for assessing insomnia symptom 
as used in the other studies. Omitting this study reduced I2 from 67% to 39% and 
decreased the effect from -0.47 to -0.41 (95% CI -0.54, -0.25) Z = 6.23, p < 0.00001. 
This standardised mean difference indicates a medium effect size and that 
approximately 66% of those with persistent poor sleep had worse PCS scores at 
follow-up than those with persistent good sleep.  
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Meta-analysis 2: Sleep deterioration and PCS scores 
New poor sleepers were compared with persistent good sleepers to assess the 
associations with sleep deterioration over time (Figure 16b). Developing insomnia 
symptoms was associated with significantly lower PCS scores at follow-up compared 
with persistent good sleep. There was no significant heterogeneity across the studies. 
A standardised mean difference of -0.33 (95% CI -0.41, -0.24) Z = 7.68, p < 0.00001 is 
a medium effect size indicating that approximately 62% of those who developed sleep 
problems from baseline to follow-up had worse PCS score at follow-up than those with 
persistent good sleep.   
Meta-analysis 3: Sleep improvement and PCS scores 
Finally, remitted poor sleepers were compared with persistent poor sleepers 
to assess the association with sleep improvement over time (Figure 16c). Remission 
of insomnia symptoms was significantly associated with higher PCS scores at follow-
up compared with persistent poor sleepers whose sleep problems showed no 
improvement. However, the analysis did show heterogeneity across the two studies 
(I2 = 60%). Given that only two studies were included in the analysis, we were unable 
to conduct a sensitivity analysis to identify the source of heterogeneity. The 
standardised mean difference effect of 0.23 (95% CI 0.05, 0.41) Z = 2.51, p < 0.01, 
which if heterogeneity was not an issue, suggests that approximately 58% of those 
with improvement in sleep from baseline to follow-up had better PCS scores at follow-
up than those with persistent sleep problems. 
Summary – exploratory meta-analyses 
Findings from the exploratory meta-analyses suggest that incidence and 
persistence of sleep problems may be associated with worse physical health over 
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time. Remission of sleep disturbances was associated with better outcome, but the 
effect was weak. PCS scores usually have high test-retest reliability in the general 
population, yet, a drop in PCS scores was seen in those with persistent sleep problems 
and those who newly developed sleep problems. Such drop in PCS scores could be 
interpreted as signifying “some more” physical limitation among these individuals 
(Ware, 1993). Moreover, the PCS scores of these individuals at follow-up were 
comparable to levels of PCS scores observed in population groups with minor medical 
conditions or serious physical illnesses (Ware, 1993; Ware, Kosinski, & Keller, 1996). 
Together, these findings suggest a detrimental influence of deterioration in sleep 
quality and maintenance of sleep problems in contrast to persistent good sleep. 
 
6.4 Discussion  
 
6.4.1 Summary of findings  
 
Findings from this systematic review and meta-analysis indicate that sleep 
deterioration is associated with pain-related health outcomes over time. There was, 
however, insufficient evidence to suggest a clear positive effect of sleep improvement 
on pain. Overall, the findings extend previous evidence highlighting poor sleep at 
baseline as a risk factor for developing a future pain condition (Gupta et al., 2007; 
McBeth et al., 2014; Mundal, Gräwe, Bjørngaard, LInaker, & Fors, 2014). A decline in 
sleep quality and sleep quantity was associated with a two- to three-fold increase in 
risk of developing a pain condition, small elevations in levels of inflammatory markers, 
and a decline in self-reported physical health status. An exploratory meta-analysis 
further revealed that deterioration in sleep was associated with worse self-reported 
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physical functioning (medium effect size), whilst improvement in sleep was associated 
with better physical functioning (small effect size). The review consolidates evidence 
that changes in sleep are prospectively associated with pain-related outcomes, adding 
weight to the argument for a causal association and highlighting the need for further 
longitudinal investigations on the long-term impact of sleep improvements.  
 
6.4.2 Disentangling the effect of different sleep parameters 
 
Sleep is a multidimensional construct and research has suggested that sleep 
quality and other aspects of sleep behaviours (e.g., use of sleep medications) may be 
more strongly associated with future health and well-being and should be considered 
alongside sleep quantity (Pilcher, Ginter, & Sadowsky, 1997; Tang, Fiecas, Afolalu, & 
Wolke, 2017). Notably, it emerged from this review that changes in sleep quality but 
not sleep quantity were associated with the risk of developing a pain condition and 
worse self-reported health outcomes. Whereas, changes in sleep quantity were 
mostly reported to be contributing to altered levels of pain-related biomarkers. These 
differing patterns of association reflect potential specificity in the roles of sleep quality 
and quantity on pain. 
 
That said, there were considerable variations across studies in the way changes 
in insomnia symptoms, sleep quality and quantity were measured. Some studies 
reported changes in insomnia symptoms such as difficulty in initiating and maintaining 
sleep, some assessed only reports of non-restorative sleep, and others used 
questionnaires to assess sleep quality. For sleep quantity, some used predetermined 
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sleep duration categories, e.g., short (< 7 hours), average (7-8 hours), and long (> 8 
hours), whilst others gathered single-item responses on average nightly sleep 
duration. In addition, these measures also vary in assessment of severity and 
chronicity of sleep problems, with studies assessing different sleep problems (e.g., 
mild vs. severe symptoms) across different time frames (e.g., currently, past month, 
past year, or in a lifetime). This further limit generalisation and meaningful 
comparisons.  
 
Distinctions should also be made between insomnia symptoms and general 
dissatisfaction with sleep quality and quantity, as changes in insomnia symptoms and 
other sleep disturbance parameters may have differential effects on different health 
outcomes (Ohayon, 2002). Cross-sectional studies have provided some evidence to 
support this; Yokoyama et al. (2010) compared three sub-symptoms of insomnia – 
difficulty initiating sleep, early morning awakenings and difficulty maintaining sleep, 
and they found that difficulty initiating sleep was most strongly associated with 
depression than the other insomnia symptoms. Consequently, future studies 
exploring the association of sleep changes should consider not only assessing different 
parameters of sleep disturbances but also using standardised measures. Similar 
recommendations for assessing core outcome measures have been made for trials of 
chronic pain treatment efficacy and effectiveness. The Initiative on Methods, 
Measurement, and Pain Assessment in Clinical Trials (IMMPACT) proposed and 
encouraged the use of key standardised measures for assessing and reporting changes 
in pain intensity, physical functioning, emotional functioning and improvement and 
satisfaction with treatment (Dworkin et al., 2005).  Whilst it is appreciated that aspects 
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of such proposal may be more applicable to clinical trials than longitudinal studies, the 
IMMPACT recommendations can be useful as an illustrative guideline on how core 
sleep outcomes could be measured, defined, and reported for improving 
comparability and interpretability across studies.  
 
6.4.3 Mechanisms underlying the interaction between sleep and pain-related 
biomarkers  
 
The current review shows that a negative change in sleep quantity may be a 
key predictor of elevated pro-inflammatory markers and deterioration of pain-related 
physical health over time. There is also some evidence suggesting that a negative 
change in insomnia symptoms is associated with raised inflammatory levels. These 
findings are consistent with longitudinal studies that have reported baseline sleep 
quality as a predictor for pathogenic levels of inflammatory markers at follow-up 
(Nakamura et al., 2014; Prather, Epel, Cohen, Neylan, & Whooley, 2013). That said, 
the observed association with these biomarkers may not be pain-specific but 
reflecting a decline in physiological health status in general. Future development of a 
more comprehensive biopsychosocial model linking sleep quality, pain, and 
inflammation would enable more rigorous examination of the underpinning 
physiological mechanisms (Smith, Quartana, Okonkwo, & Nasir, 2009). It is thought 
that the effects of sleep problems on pain responses are mediated by impaired 
immunity, elevated inflammatory responses, and raised cytokines levels such as those 
assessed by studies considered in this review, namely interleukin-6(IL-6), C-Reactive 
Protein (CRP), and cortisol (Haack et al., 2007; Vgontzas et al., 2004). However, their 
meditational roles are yet to be verified in the general population whereby sleep 
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disruptions and pain symptoms are assessed in a more naturalist way with ecological 
validity. 
 
6.4.4 Clarifying the effect of sleep improvement on pain outcomes   
 
Findings from this review suggest that deterioration in sleep and persistent 
poor sleep are key risk factors of poor health. However, the findings do not provide 
sufficient evidence that an improvement in sleep quality or an increase in sleep 
quantity has a protective function of mitigating disease risk, as many clinicians and 
researchers would assume. The meta-analysis revealed that the development of sleep 
problems over time has a negative association with self-reported physical health 
(Ware, 1993; Ware et al., 1996). The meta-analysis also showed that remission of 
sleep problems over time was associated with higher PCS scores at follow-up, but the 
effect size was small and was only significant when compared with those who 
reported persistent poor sleep. However, the amount of evidence available for the 
current review was limited due to the small number of studies examining positive 
sleep changes over time outside of the context of a clinical trial.  
 
There is some evidence emerging to suggest that naturally occurring good 
sleep is a potential predictor of chronic pain remission in the general population. Aili, 
Nyman, Svartengren, and Hillert (2015) reported in their prospective analysis that out 
of 883 participants from the general population, for the 53 individuals who reported 
multi-site pain at baseline but not at follow-up, a lack of or minimal report of sleep 
disturbance at baseline was a significant predictor of the ‘resolution’ of their multi-
site pain (adjusted OR 3.96 95% CI 1.69-9.31), after controlling for age, gender, 
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smoking, BMI, physical occupational risks, and psychosocial activities. However, the 
small size of the group limits the statistical power, risk estimation, and generalisability 
of these findings. Davies et al. (2008) similarly showed that self-reported restorative 
sleep at baseline was a predictive factor for the ‘resolution’ of chronic widespread 
pain (adjusted OR 2.0 95% CI 1.02-3.8) in 300 of the 679 participants presenting with 
pain at baseline but not at follow-up. However, the participants in this study who 
reported resolved widespread pain at follow-up still reported some regional pain. As 
such, the impact of restorative sleep on pain experience may have been overstated.  
What these studies are not able to say is whether resolution in pain are preceded by 
positive changes in sleep and to what extent improvement in pain is sustained. The 
current review has highlighted that there is room for further longitudinal studies with 
longer follow-up, to strengthen the evidence for the impact of sleep improvement on 
long-term pain outcomes. 
 
6.4.5 Methodological considerations and recommendations  
 
Although the included studies were mostly of low and medium risk of bias, 
there were some recurrent methodological issues that could affect the rigour and 
generalisability of the findings and conclusions drawn. Based on the findings of the 
risk of bias assessment in the current review, future studies could improve 
methodological rigour by clarifying the rate of participation and attrition and by 
ensuring sufficient statistical power for detecting significant (and meaningful) results 
over a sufficiently long follow-up period. Two further specific recommendations are 
offered below:  
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I. Improving research designs to substantiate the impact of changes in sleep on 
pain outcomes 
One of the main methodological drawbacks noted in the included studies was 
a reliance on self-report and a lack of objective sleep and quantitative pain outcome 
measures. Objective sleep assessments beyond self-report are less vulnerable to 
reporting biases. It is important for future prospective studies to strive to include 
assessment of both objective and self-reported changes in sleep using 
polysomnography or actigraphy. This can then be used in combination with 
quantitative sensory testing that assesses normal and abnormal psychophysical pain 
responses and physiological pain sensitivity. Whilst these methods would increase 
research costs, they are often utilised in experimental studies and could have an 
equally important role to play in sleep epidemiology research that combines 
experimental laboratory studies with longitudinal follow-up assessments.  This would 
provide clarity in our understanding of the physiological factors underlying sleep and 
pain disturbances.    
In addition, the evidence from the meta-analysis was also restricted to a broad 
evaluation of general physical health and well-being scores derived from the SF-36. 
For example, only one of the included studies (Silva et al., 2009) provided data 
specifically on PCS bodily pain subcomponent scores over time, whereas none of the 
other studies with PCS scores as an outcome measure allowed for this level of detail 
for comparison.  Future studies should consider incorporating direct pain measures to 
better demonstrate the long-term temporal relationship between sleep and pain 
intensity. Additional repeated ratings of pain (Jensen & Karoly, 2011) can mark the 
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trajectory of pain intensity over time and to clarify the influence of pain intensity, 
rather than pain interference, on health outcomes.  
II. Improving longitudinal assessments of sleep and pain 
A lot of the studies did not have an outcome that was measured only 
prospectively. Strictly speaking, to qualify as longitudinal studies, future studies 
should ensure that instead of having multiple assessments of the outcomes at 
different time points, their outcome should be assessed prospectively. Most of the 
reviewed studies also have just two assessment points. Two observations are the bare 
minimum needed to provide information about change over time, but this 
information is usually insufficient for a thorough understanding of the processes 
responsible for these changes. If the screening criteria only allowed for the inclusion 
of studies with more than two assessment time-points, only four studies would have 
met this requirement. This highlights the need for additional waves of assessment for 
investigating the temporal relationship between changes in sleep and pain outcomes 
and for revealing the trajectories of health status over time within groups of 
individuals with different patterns of sleep. Cross-lagged and cluster analysis could be 
applied to these multi-wave data to establish directions of causality (Kenny, 1975).  
Finally, the findings from these longitudinal studies were mostly drawn from 
analyses at the general population level to maximise generalisability. Future studies 
may benefit from incorporating subgroup analyses to dissect the sleep and pain 
relationship, for example, through stratification by age, by gender, by those with 
malignant and non-malignant chronic pain conditions, and by those with chronic pain 
but no sleep problems. This would help reveal the context in which a change in sleep 
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is a contributing factor to the development, perpetuation, or alleviation of these 
conditions. It would also provide new insights into the potential of sleep as an 
amenable treatment target in the management of these conditions across different 
spectra of the population. 
 
6.4.6 Limitations of the review   
 
Some limitations in the present review and meta-analysis should be 
acknowledged. First, the number of studies included in the review and the meta-
analysis was limited due to a lack of access to required data and the stringent inclusion 
criteria. The results of the meta-analysis should thus be considered as exploratory. 
That said, the stringent inclusion criteria were necessary to capture only studies with 
an appropriate longitudinal design that addresses and analyses the association of 
change in sleep with pain-related outcomes. Second, the high level of heterogeneity 
observed in the analysis was possibly due to variations in research methodologies, but 
the small number of studies eligible for meta-analysis has made it impossible to pin 
down the source of heterogeneity at this stage. Also, not all studies assessed sleep in 
the same way despite having similar outcome measures and there was consequently 
no consistent definition of what denotes sleep stability, sleep deterioration and sleep 
improvements. 
 
Finally, as inherent in most systematic reviews, there is a risk of publication 
bias although there was no obvious evidence of publication bias. Funnel plots were 
visually inspected to detect the presence of bias, including publication bias in the 
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meta-analysis, however, formal statistical tests which exist for detecting asymmetry 
in a funnel plot (e.g. Egger’s test) were not conducted (Egger, Davey Smith, Schneider, 
& Minder, 1997). Given the few studies available for meta-analysis (three studies), 
these tests would have had very low power for funnel plot asymmetry detection and 
are generally not recommended in such a case (Sterne et al., 2011). The studies 
reviewed were limited to texts in English even though studies included in the review 
involved cities/countries that are not English-speaking. There appeared to be no 
indication that cultural differences in pain reports distort the sleep-pain association 
being examined. Nevertheless, future studies should consider the possible influence 
of culture on the perception of sleep and pain.   
 
6.5 Conclusion 
 
The current evidence provides moderate support that negative changes in 
sleep may be associated with detrimental health effects and that consistently good 
sleep may favour better pain-related health outcomes. Although there is emerging 
preliminary evidence for the relationship between changes in sleep status and pain-
related health outcomes, full understanding of the mechanisms underlying the causal 
relationship between sleep and pain remains incomplete. In this review, 
improvements in sleep quantity and sleep quality were not consistently associated 
with better health outcomes. The jury is out regarding whether positive changes in 
sleep could lead to a reduction of, or even full recovery from, pain symptoms. 
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7 Changes in insomnia symptoms and their association with 
physical and mental health outcomes within the general 
population and among individuals with arthritis  
 
7.1 Introduction  
 
Chapter 6 (6.4.1) of this thesis presented a systematic review of studies 
highlighting the negative association of sleep deterioration over time on both 
objective and self-reported pain-related outcomes and the potential benefits of sleep 
improvements. Specifically, the review uncovered the need to conduct further studies 
to examine the association of both negative and positive changes in sleep with pain-
related health outcomes. The sleep-pain associations demonstrated in the studies 
reviewed in Chapter 6 were based primarily on data from a general pain-free 
population. The study presented in this chapter aimed to incorporate a more focused 
analysis by respondents’ characteristics and evaluate if such associations also applies 
to individuals who are already affected by chronic pain. Finally, studies from the 
review in Chapter 6 adopted a wide range of operationalisation of sleep quality, sleep 
quantity and insomnia symptoms, which makes it difficult to compare findings and 
draw generalisable conclusions across studies. The study reported in this chapter 
aimed to address these issues by detangling the differential association of changes in 
insomnia symptoms with health outcomes. 
 
7.1.1 Insomnia symptoms in arthritis  
 
It is essential to describe the sleep characteristics and associated health 
outcomes not just in the healthy populations but for those with chronic pain 
conditions for whom sleep disturbance is often a co-occurring problem impacting on 
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functioning and quality of life.  It is possible that compared with pain-free individuals, 
those with persistent chronic pain may show differences in trajectory of sleep and self-
reported health status over time.  Separate explorations of patterns by pain status of 
sleep changes would clarify if insomnia onset and aggravation of insomnia symptoms 
are associated with health and functioning status in this population.  
 
This present analysis sought to extract data from a panel study of the UK 
population consisting of individuals reporting a diagnosis of arthritis. Arthritis is a 
common chronic pain condition and leading cause of health-related disability (1.3.3). 
In spite of this, not a lot of studies focus on changes in sleep over time and in those 
with arthritis as evidence is still limited to cross-sectional overviews from a single 
time-point. Wolfe, Michaud, and Li (2006) reported an increased prevalence of 
general sleep disturbance in 8,676 rheumatoid arthritis participants living in the 
community, explaining that 25% - 42% of their sleep disturbance can be uniquely 
attributed to the condition. In addition, these sleep problems were linked to pain, 
mood, and disease activity. Westhovens, Van der Elst, Matthys, Tran, and Gilloteau 
(2014) also found an association between increased RA disease activity and poor sleep 
quality determined from PSQI scores and decreased daytime sleepiness. However, the 
study was another cross-sectional study with 305 patients presently seeking 
treatment from and attending a rheumatology clinic. It has also been suggested that 
emotional disturbance such as depression may be mediating the associations between 
sleep disturbance and symptoms in this population. Nicassio et al. (2012) reported 
that poor physical and mental functioning derived from the SF-36, predicted sleep 
disturbance and higher PSQI scores in 106 RA patients from a pain clinic. Furthermore, 
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this association was mediated by increased report of depressive symptoms. These 
findings pave the way for further studies to consider the associations of long-term 
changes in insomnia symptoms with mental and physical health-related outcomes in 
those with arthritis.   
 
7.1.2 Differentiating the effect of insomnia symptoms on health outcomes  
 
Poor sleep has been shown to have a direct effect on emotional appraisal and 
is a persistent predictor of life dissatisfaction (Paunio et al., 2009). Sivertsen et al. 
(2009) presented one of the largest cross-sectional investigations into the patterns of 
insomnia symptoms and association with physical and mental health in the general 
population. The study comprised data from 47,700 Norwegian individuals from the 
HUNT-2 survey and the researchers reported a 13.5% prevalence of insomnia within 
the study sample. They found the strongest association of insomnia with mental 
health conditions (anxiety and depression), followed by pain conditions with uncertain 
organic aetiology (e.g., fibromyalgia), general chronic pain conditions (e.g., arthritis) 
and the weakest association with somatic conditions (e.g., asthma). The study 
assessed individual symptoms of insomnia; frequency of sleep onset problems, waking 
up too early, and experiencing non-restorative sleep. However, it was not a full 
insomnia diagnostic measure and they had no information to verify middle of the night 
awakenings and sleep-related daytime impairments. Nevertheless, they showed that 
reports of insomnia symptoms were generally strongly associated with psychological 
and psychosomatic health problems in the general population. These findings provide 
a preliminary understanding of the association of deterioration in sleep with physical 
and emotional functioning within the general population.  
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However, as the review in Chapter 6 highlighted, there are often 
inconsistencies in observational and epidemiological studies in how poor sleep and 
change in sleep is defined and operationalised. The diagnosis of insomnia incorporates 
several symptoms and components that may have differential associations and it is 
important to clarify the differences in both stability and changes in these symptoms 
over time. Insomnia is defined as long-term and continuous difficulty falling and 
staying asleep, dissatisfaction with sleep and resultant daytime impairments (DSM-5, 
2013; ICSD-3, 2014). Hence, Ohayon (2002) suggested distinguishing symptomatic 
aspects of insomnia and breaking down elements of insomnia diagnosis in order to 
better understand how they may affect health outcomes in the general population. 
One of the studies from the systematic review (Silva et al., 2009) extensively studied 
patterns of poor sleep and daytime sleepiness over 5 years in 3078 participants and 
the association of these changes with SF-36 scores. Worsening of difficulty initiating 
and maintaining sleep (a key part of insomnia diagnosis) was related to poorer MCS 
scores, while worsening daytime sleepiness was related to both poorer MCS and PCS 
scores. Their analysis consisted of a sample of just over 3000 individuals but was 
restricted to a specific cardiovascular and respiratory disease cohort (Sleep and Heart 
Health Study) of those over 40 years of age. The current study aimed to present an 
extension of the findings with a larger general population sample. Previous work by 
Tang et al. (2017) has also examined changes in sleep quantity, sleep quality and use 
of sleep medication in the UK general population and associations with health and 
well-being outcomes (SF-12 and GHQ). Not only was sleep deterioration associated 
with poorer health outcomes but positive changes were also associated with better 
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perceived health and well-being. Importantly, associations of changes in sleep quality 
with health outcomes had the greatest effect size when assessing the associations 
between perceived physical and mental health. 
 
7.1.3 Aims 
 
Tang et al. (2017) explored individual factors such as sleep duration, sleep 
quality, and use of sleep medication but not symptoms that match with insomnia 
diagnostic presentation. This current study aimed to extend their findings by 
examining changes in insomnia symptoms (prolonged sleep onset latency, frequency 
of overnight and early morning awakenings and daytime sleepiness) over 4 years 
(Waves 1-4) using the same dataset, for their associations with Wave 4 physical and 
mental health outcomes. In addition, the current analysis also explored changes in 
these insomnia symptoms in a subset of the cohort reporting a chronic pain condition 
(arthritis). 
 
7.2 Methods 
 
7.2.1 Study Design – UK Household Longitudinal Survey (UKHLS) background 
 
This analysis used data from the Understanding Society UK Household 
Longitudinal Survey (UKHLS). UKHLS is a household panel study commenced in 2009, 
building up from and incorporating the existing British Household Panel Survey 
(BHPS). The BHPS was commenced in 1991, with boosted Scottish and Welsh sample 
added in 1999 and boosted Northern Irish sample added in 2001 (Buck & McFall, 
2012). Ethical approval for the panel study was granted by the University of Essex and 
data use for this study was granted under an end user licence from UK Data Service 
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(University of Essex Institute for Social and Economic Research, NatCen Social 
Research, & Kantar Public, 2016). 
 
The UKHLS provides an understanding of the trajectories of individuals’ health, 
wellbeing, social, environmental and economic behaviours, and psychological 
attributes. UKHLS is a large survey, with a rough target of 40,000 households across 
the country. It has the advantage of being a household panel design in that it 
represents a sample of the entire population of all ages across the country. In addition, 
the UKHLS also has a unique consideration for the multi-ethnic nature of current UK 
society and aimed for a greater coverage of ethnic minority populations through 
oversampling of a booster ethnic sample and having additional ethnicity related 
measures. A total of 18 waves of data collection are planned for the UKHLS. Data is 
collected with annual measurements and each wave of data is collected over two 
years due to the large sample size. Presently, the first six waves of data have been 
released, however, only Wave 1 and Wave 4 are used for this analysis. At the time of 
planning for the analysis, Wave 4 was the first and only available wave repeating the 
same rotating sleep and well-being module first administered in Wave 1.  
 
Wave 1 and Wave 4 samples included the general population (GP) sample and 
the ethnic minority booster (EMB) sample. The GP sample were drawn using a 
stratified, clustered, equal probability approach from residential addresses across the 
UK, however, the Northern Ireland sample were selected systematically from property 
agency lists. The ethnic booster sample was identified by over-sampling geographic 
areas with at least 5% density of the targeted five largest ethnic minority groups 
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(Indian, Pakistani, Bangladeshi, Caribbean, and African). Data collection for the UKHLS 
was carried out through Computer Assisted Personal Interviewing (CAPI). The initial 
four waves of data collection were done face-to-face to boost initial compliance and 
response rates. The interview schedule and questions were made available across a 
range of languages including Bengali, Punjabi, Welsh, Arabic, Somali, Cantonese, Urdu, 
and Gujarati. One person from an eligible household completed the household list and 
household interview. Everyone over the age of 16 then completed an individual adult 
interview and self-completion questionnaire. The self-completed questionnaire 
contained the questions on health, well-being, sleep habits and health conditions that 
were used for the current analysis. Further details and discussion on the design, 
conduct and sample of the UKHLS can be found in the design overview (Buck & McFall, 
2012). For the current analysis, the focus was on using the UKHLS panel data to explore 
the association of change in reported insomnia symptoms in the same cohort of 
individuals from Wave 1 to Wave 4 with perceived health outcomes assessed at Wave 
4. Figure 17 shows the design methodology for the analysis. 
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Figure 18 summarises the response and participation rates respectively at the 
household and individual levels at Wave 1 and Wave 4 and resulting sample size for 
the current analysis derived from the survey technical reports (Boreham, 
Boldysevaite, & Killpack, 2012; Jessop & Oskala, 2014). At Wave 1, 45,431 GP and 
10,253 EMB sample households were identified as eligible at Wave 1. Response rate 
for the household interview was 57% for the GP sample and 40% for the EMB sample. 
Of the total eligible adults of 59,333, there was 82% response rate in the GP sample 
and 73% for the EMB sample. From these, 87% of adults from the GP sample and 70% 
from the EMB subsequently also completed the self-completion questionnaire, giving 
Wave 1   
Assessment of 
insomnia 
symptoms 
 
Wave 4  
Assessment of 
insomnia  
symptoms  
Wave 4 
Assessment of 
mental and 
physical health 
outcomes#  
 
Change in insomnia symptoms*  
(report of frequency of symptom at follow-up compared to baseline) 
Note: *Change in insomnia symptoms refers to change in frequency of (i) sleep onset 
latency (ii) overnight awakenings and (iii) daytime sleepiness symptoms. 
#Mental and physical health outcome refers to measures and scores of General Health 
Questionnaire (GHQ) and Short Form Health Survey-12 [Mental Health 
Component(MCS) and Physical Health Component (PCS)] at Wave 4. 
Figure 17 UKHLS analysis – Design methodology 
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a total of 42,393 individuals at Wave 1. At Wave 4, 31,447 households were eligible 
for the recurring repeat assessment, these also included a sample of 6,840 household 
from the BHPS sample who were introduced into UKHLS in Wave 2. Total response 
rates the household level was 82% and 92% at the individual level. From this, the 
response rate for the self-completing questionnaire was 93%, 83%, and 94% 
respectively for the GP, EMB, and BHPS sample, leaving a total of 43,745 eligible 
individuals at Wave 4. Taking away the BHPS sample and other individuals that do not 
have matching self-completion questionnaire data at both Wave 1 and Wave 4 leaves 
a total of 30,594 participants considered for this current analysis. Of these, 4,300 
individuals had reported having a chronic pain health condition (arthritis) at Wave 1 
and were used for the subgroup analysis.  
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Eligible Individual Interview 
GP sample n = 50138 EMB sample = 9195 
Total = 59333 
Response GP sample (82%) 41046 + EMB sample (73%) 6683  
Total = 47729 
 W
av
e 
1 
 
(2
00
9 
– 
20
1
1)
 
Eligible Individual Interview  
GP sample n = 34445 EMB sample n = 5625 BHPS sample n = 
11509  
Total = 51579 
Response GP (92%) 31689 + EMB (88%) 4950 + BHPS (94%) 
10814  
Total (92%) n = 47453  
 
Total participants for current analysis 
n = 30594 
Total participants for subgroup analysis 
n = 4300 
Missing self-
completion 
questionnaire data 
at both Waves 1 
and 4 
(n = 13151)* 
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Self-completion Questionnaire 
Response GP sample (87%) 35710 + EMB Sample (70%) 4678 
Total = 42393 
 
Self-completion Questionnaire 
Response GP (93%) 29471 + EMB (83%) 4109 + BHPS (94%) 
10165  
Total = 43745 
 
Notes: *Includes the former BHPS sample introduced at Wave 2, but these participants’ 
data were not included in the current analysis as their Wave 1 data were missing.  
Figure 18 UKHLS analysis – UKHLS survey flowchart 
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7.2.2 Measures – Exposure, Outcomes, Confounders 
 
Exposure  
 
As shown in Figure 17, the sleep parameters and insomnia symptoms of 
interests were – frequency of sleep onset latency of more than 30 minutes 
(henceforth – ‘sleep onset latency’), frequency of overnight and early morning 
awakenings (henceforth – ‘awakenings’), and frequency of difficulty staying awake 
during the day (henceforth – ‘daytime sleepiness’). These sleep variables were 
considered since they were closest to the (DSM-5, 2013) and (ICSD-3, 2014) diagnostic 
criteria for insomnia disorder; dissatisfaction with sleep quantity or quality due to one 
or more: difficulty initiating sleep, difficulty maintaining sleep and early-morning 
awakenings, and daytime difficulties and impairments including fatigue, poor 
concentration, low mood, or impaired ability to perform social, occupational or 
caregiving responsibilities). However, the information from this dataset cannot 
determine if sleep difficulty occurs on at least three nights per week for at least 3 
months, despite adequate opportunity to sleep, and if symptoms are better explained 
by other co-occurring medical or mental condition (DSM-5, 2013; ICSD-3, 2014)  
 
At Wave 1 and Wave 4, frequency of ‘sleep onset latency’ problem was 
assessed using the question – ‘During the past month, how often have you had trouble 
sleeping because you cannot get to sleep within 30 minutes’. Frequency of problem 
with ‘awakenings’ was assessed using the question – ‘During the past month, how 
often have you had trouble sleeping because you woke up in the middle of the night 
or early in the morning’. Frequency of ‘daytime sleepiness’ symptoms was assessed 
using the question – ‘During the past month, how often have you had trouble staying 
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awake, while driving, eating meals or engaging in social activities’. The response 
formats to these questions were the same – ‘not during the past month’, ‘less than 
once a week’, ‘once or twice a week’ and ‘three or more times a week’. The measure 
of exposure were derived variables reflecting changes in these insomnia symptoms 
between Wave 1 and Wave 4. These derived categories were ‘increase’, ‘no change’ 
and ‘decrease’, denoting a change in the frequency of problems with sleep onset 
latency, awakenings, and daytime sleepiness symptoms. These questions were 
adapted for the UKHLS survey from the Pittsburgh Sleep Quality Index (PSQI); the time 
scale, word choice, and response scale are all similar to the PSQI. The original PSQI is 
a valid and established measure of general sleep quality and insomnia symptoms 
(4.2.3.2) 
 
Outcomes  
 
The outcome variables were health and well-being, measured with total scores 
from the 12-item General Health Questionnaire (GHQ-12) and the 12-item Short-Form 
Health Survey (SF-12) at Wave 4.  
 
General Health Questionnaire (GHQ-12) (Goldberg et al., 1997) 
 
The GHQ-12 is an established measure of psychological and mental well-being. 
It assesses psychological distress and minor psychiatric symptoms within the general 
population, in a community setting, and general non-psychiatric clinical setting. It has 
a range of 12 questions on normal functioning and behavioural patterns associated 
with psychological distress with items such as ‘ability to concentrate’, ‘constantly 
under strain’ and ‘enjoy normal activities’, with responses ranging from ‘less than 
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usual’ to ‘much more than usual’. In the UKHLS, it was scored using a Likert scale with 
score ranging from 0-3 for each item instead of the usual 1-4 for each individual item. 
Items are summed, and total scores range from 0 (least distress) to 36 (most distress). 
The GHQ-12 has shown reliability with alpha coefficients ranging from 0.82 to 0.90 
across studies, and sensitivity (83.4%) and specificity (76.3%) to detect minor 
psychiatric symptoms and is correlated with other measures of psychological distress 
such as the Beck’s Depression Inventory (BDI) and Spielberger’s State Trait Anxiety 
Index (STAI). 
 
Short-Form Health Survey (SF-12) (Ware et al., 1996) 
 
The SF-12 is the shortened version of SF-36, another well-validated scale for 
measuring health-related quality of life, and functional physical and mental health and 
well-being. It was originally developed for a longitudinal study of patients with chronic 
conditions but has since been applied and widely used in large population health 
surveys. The SF-12 provides two component scores: Physical Component Scores (PCS) 
and Mental Component Score (MCS) from eight domains assessing physical and 
mental health. PCS items assess physical functioning, role interference due to physical 
problems, bodily pain, and general health. The MCS items assess vitality, social 
functioning, role interference due to emotional problems and mental health. Scores 
from each component ranges from 0 – 100 with higher scores indicating higher and 
better level of health and functioning (Ware, 1993). The PCS and MCS were used as 
separate outcomes variables for this current analysis. The SF-12 has shown internal 
consistency and reliability with Cronbach’s  of 0.81 for the PCS and 0.84 for the MCS 
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(Lim & Fisher, 1999) and test-retest reliability of 0.86 for the PCS and 0.77 for the MCS 
and validity estimates of 0.67 for the PCS and 0.97 for the MCS (Ware et al., 1996).  
 
Confounders 
 
Several potential confounding variables were adjusted for and were selected 
in accordance to possible associations with sleep and mental and physical health 
functioning and according to previously published studies (Ferrie et al., 2013; Silva et 
al., 2009; Tang et al., 2017). These included baseline demographic information from 
Wave 1: age (determined from date of birth or age at last birthday), sex, ethnicity 
(selected from a list of 14 ethnic origins and for this analysis, ethnicity was pooled into 
five main groups by order of size – White, Asian, Black, mixed and other), education 
(selected from a list of highest qualification achieved, for this analysis, responses were 
pooled into degree level or above, any other qualification below degree level and no 
qualification), and employment status (selected from a list asking about current 
employment situation and for this analysis, responses were pooled into full-time, part-
time and not in employment). Body mass index (BMI) was also assessed as a 
cofounding variable, it was a variable derived by UKHLS from self-reported weight and 
‘height without shoes’.  Lastly, baseline (Wave 1) value of the relevant insomnia 
symptoms variables, and baseline (Wave 1) scores of GHQ-12, PCS, and MCS were also 
considered to adjust for differences in symptom presentation.   
 
7.2.3 Analysis 
 
All analyses were carried out in R (R Core Team, 2016). The main analysis was 
to determine how Wave 4 scores of each outcome (GHQ-12, PCS, and MCS) were 
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associated with changes in each insomnia symptom (sleep onset latency, awakenings, 
daytime sleepiness). Analysis was only carried out for participants who have all the 
sleep variables as well as confounders of interest to match the three outcome 
variables at both Wave 1 and Wave 4. Analysis for each outcome was a multivariate 
linear regression on the outcome score at Wave 4 on each of the change in insomnia 
symptom parameters (increase or decrease), adjusted for baseline outcome score, 
confounders and baseline measure of the insomnia symptom parameter concerned.  
 
Potential confounding factors were adjusted for in the multivariate regression 
analysis. Reference indicator categories were created for the categorical variables. For 
the confounders, this was ‘female’ for sex, ‘white’ for ethnicity, ‘full-time’ for 
employment, and ‘degree level or above’ for education. For the change in insomnia 
symptom parameter, this was ‘no change’. For each of the regression analysis, biases 
in the survey sample were accounted for by applying longitudinal weights computed 
by the UKHLS. These weights are particularly relevant for the adult self-completion 
questionnaire data from Wave 1 to Wave 4. They represent adult population who 
continued to live in the UK at both time points and were computed to account for 
potential sampling biases, participants’ non-response, and unequal selection 
probability (Knies, 2014).  
 
In addition, local effect sizes (Cohen’s f2) were calculated for each change in 
insomnia symptom predictor. This provides an estimate of how much more adding the 
change in insomnia symptom predictor to the regression model with confounders 
alone explained the variance in the outcome measure. This method of effect size 
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calculation quantifies one variable’s effect size within the context of the multivariate 
regression model (Cohen, 1988). Cohen’s f2 is interpreted as small (approx. 0.02 or 2% 
of variance), medium (approx. 0.15 or 13% of variance) and large (approx. 0.35 or 26% 
of variance). Essentially, Cohen’s f2 reflects the proportion of variance uniquely 
accounted for by ‘change in insomnia symptom’ over and above that of all the other 
confounders. Not only does it help interpret the influence of the change in insomnia 
symptoms, it also provides a gauge of which change in insomnia symptom had the 
greatest association with health and well-being outcomes.  
 
Chronic pain subgroup analysis  
 
The subgroup analysis was restricted to those with a chronic pain condition 
namely, arthritis). The presence of a chronic pain condition was assessed at Wave 1 
with the following question – ‘Has the doctor or another health professional ever told 
you that you have any of the conditions listed?’ Arthritis was listed as one of the 
conditions and the response to the question was ‘mentioned’, ‘don’t know’ or not 
mentioned’. A similar process for the multivariate linear regression analysis explained 
above was repeated for the subgroup analysis.  
 
Sensitivity analysis 
 
To account for the number of observations with missing data across the 
dataset, the Multiple Imputation by Chained Equation (MICE) technique was applied 
as an additional sensitivity analysis. This imputed analysis is only reported for the 
subgroup analysis given the considerably smaller number of participants and a higher 
rate of missing observation across all the predicting, confounders and outcome 
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variables. MICE is an established method of dealing with missing data and is based on 
a posterior predictive distribution model, in which the imputed values depend on 
values of the outcome and covariate variables to create a prediction of missing values 
(van Buuren, 2012; van Buuren & Groothuis-Oudshoorn, 2011). The combined 
standard errors produced from multiple imputation methods such as MICE are greater 
and fairly accurate compared to single imputations and account for statistical 
uncertainties created by estimating missing values (Azur, Stuart, Frangakis, & Leaf, 
2011). For this analysis, the procedure included all the variables (predictors, 
confounders and outcomes) used in the subsequent analysis. The regression analysis 
was then performed on each of the imputed data sets for the arthritis subgroup 
analysis. Effect size (Cohen f2) was computed for each imputed dataset and this was 
summarised using the mean effect size, this approach to compute and pool effect size 
of the imputed datasets was informed by Little and Rubin (2002). 
 
The multiple imputation by chained equation (van Buuren & Groothuis-
Oudshoorn, 2011) procedure was also utilised by Tang et al. (2017) and is described 
as follows: 
• All missing value in the dataset are initially temporarily replaced by random 
sampling of mean observed values (predictive mean matching).  
• The values for the first variable (‘a’) that will be imputed are then replaced 
back to missing. The variable (‘a’) is regressed upon the other variables in the 
dataset and the missing values for ‘a’ are then replaced with the imputations 
(posterior predictive distribution) from the regression model.  
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• These steps are then repeated for the next variables (‘a’, ‘b’, ‘c’ and so forth) 
using the previously imputed values. This continual looping through the 
variables stabilises the results.  
• At the end of these cycles, all the missing values have then been replaced with 
the predictions from the regression models, giving a final complete imputed 
dataset that represents the interactions apparent in the data.  
• Given the large data size, the MICE procedure was repeated multiple times (5 
rounds of imputations and 50 iterations) for this analysis to produce the final 
imputed dataset, it has been reported that this number of rounds is enough 
imputations to obtain valid results (Little & Rubin, 2002).  
 
7.3 Results  
 
7.3.1 Full sample  
 
Sample characteristics 
 
Table 23 shows the baseline characteristics of the whole sample and complete 
cases of participants providing data for all combined outcomes, exposure, and 
confounders. The baseline demographic characteristics and reports of insomnia 
symptoms were similar across analyses. Based on the complete cases, just over half 
of the sample was female (53.17%), mean age of 44.65 years, and mean BMI of 25.89. 
Most of the sample were white (87.43%), just over half were in full-time employment 
(50.60%) and less than half were with below degree-level education (48.27%). Mean 
score for GHQ-12 was 10.02, 52.48 for PCS, and 52.42 for MCS and all these values 
were within the normative range for the general population (Ware, 1993).  
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Baseline insomnia symptoms 
 
For the sleep parameters, at baseline, the majority of the sample did not report 
sleep onset difficulties in the previous month (48.89%), 27.01% reported difficulties 
less than once a week, 16.79% reported difficulties once or twice a week, and only 
7.31% reported difficulties three of more times a week. The prevalence of frequency 
of problems with overnight and early morning awakenings were fairly evenly split with 
29.9% reporting no problems in the past month, 24.4% reporting problems less than 
once a week, 26.0% reporting problems once or twice a week, and 20.64% reporting 
problems three or more times a week. A large majority of the sample (86.72%) 
reported no daytime sleepiness symptoms during the past month, 9.35% reported 
symptoms less than once a week, 3.25% reported symptoms once or twice a week, 
and 0.67% reported symptoms three or more times a week.  
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Notes: Summary statistics for the full samples and restricted to complete cases for Wave 1 and Wave 4 measurements for each outcomes and predictors as well as 
confounders. Complete case data in the last column refers to sample characteristics restricted to all combined outcomes, exposures, and confounders.
Table 23 UKHLS analysis – Full sample baseline 
characteristics 
GHQ analysis 
(n = 12,350) 
PCS analysis 
(n = 12,533) 
MCS analysis 
(n= 12,533) 
Complete case 
(n = 12,326) 
Sex, n female (% female) 6569 (53.19%) 6667 (53.19%) 6667 (53.19%) 6554 (53.17%) 
Age, mean (sd) 44.67 (15.98) 44.57 (16.01) 44.57 (16.01) 44.65 (15.97) 
BMI, mean (sd) 25.89 (4.73) 25.88 (4.73) 25.88 (4.73) 25.89 (4.73) 
Ethnicity                                                                             White, n (%) 10797 (87.42%) 10925 (87.17%) 10925 (87.17%) 10777 (87.43%) 
     Asian, n (%) 841 (6.81%) 873 (6.97%) 873 (6.97%) 838 (6.80%) 
    Black, n (%) 385 (3.12%) 396 (3.16%) 396 (3.16%) 384 (3.12%) 
    Mixed, n (%) 174 (1.41%) 181 (1.44%) 181 (1.44%) 174 (1.41%) 
    Other, n (%) 153 (1.24%) 158 (1.26%) 158 (1.26%) 153 (1.24%) 
Employment                                                                Full time, n (%) 6242 (50.54%) 6318 (50.41%) 6318 (50.41%) 6237 (50.60%) 
    Part time, n (%) 2162 (17.51%) 2197 (17.53%) 2197 (17.53%) 2158 (17.51%) 
Not in employment, n (%) 3946 (31.95%) 4018 (32.06%) 4018 (32.06%) 3931 (31.89%) 
Education                                              Degree level or above, n (%) 5329 (43.15%) 5398 (43.07%) 5398 (43.07%) 5317 (43.14%) 
    Any other qualification, n (%) 5957 (48.23%) 6054 (48.30%) 6054 (48.30%) 5950 (48.27%) 
    No qualification, n (%) 1064 (8.62%) 1081 (8.63%) 1081 (8.63%) 1059 (8.59%) 
Sleep latency (> 30 mins)          Not during the past month, n (%) 6040 (48.91%) 6122 (48.84%) 6122 (48.84%) 6026 (48.89%) 
    Less than once a week, n (%) 3336 (27.01%) 3378 (26.95%) 3378 (26.95%) 3330 (27.01%) 
    Once or twice a week, n (%) 2073 (16.76%) 2109 (16.83%) 2109 (16.83%) 2069 (16.79%) 
    Three or more times a week, n (%) 901 (7.30%) 924 (7.37%) 924 (7.37%) 901 (7.31%) 
Awakenings                                 Not during the past month, n (%) 3594 (29.10%) 3649 (29.12%) 3649 (29.12%) 3582 (29.06%) 
    Less than once a week, n (%) 2989 (24.20%) 3037 (24.23%) 3037 (24.23%) 2988 (24.24%) 
    Once or twice a week, n (%) 3219 (26.06%) 3267 (26.07%) 3267 (26.07%) 3212 (26.06%) 
    Three or more times a week, n (%) 2548 (20.63%) 2580 (20.59%) 2580 (20.59%) 2544 (20.64%) 
Daytime sleepiness                    Not during the past month, n (%) 10709 (86.71%) 10861 (86.66%) 10861 (86.66%) 10690 (86.72%) 
Less than once a week, n (%) 1115 (9.35%) 1177 (9.39%) 1177 (9.39%) 1152 (9.35%) 
Once or twice a week, n (%) 403 (3.26%) 408 (3.26%) 408 (3.26%) 401 (3.25%) 
Three or more times a week, n (%) 83 (0.67%) 87 (0.69%) 87 (0.69%) 83 (0.67%) 
GHQ-12, Mean (SD)   10.02 (4.24) - - 10.02 (4.24) 
PCS, Mean (SD) - 52.47 (8.35) - 52.48 (8.33) 
MCS, Mean (SD) - - 52.42 (7.86) 52.42 (7.85) 
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Changes in insomnia symptoms from Wave 1 to Wave 4 
 
Tables 24-26 describe the pattern of changes in the frequency of insomnia 
symptoms for all participants with insomnia symptoms measurements (sleep onset 
latency, awakenings, and daytime sleepiness) at both Wave 1 and Wave 4. The most 
common trajectory was stability in reports of the frequency of insomnia symptoms. 
Of 19,032 general population sample presenting data for sleep onset latency 
problems, 48.03% reported no change from Wave 1 to Wave 4, 23.48% reported an 
increase in the frequency of problems and 28.48% reported a decrease. For the 15,793 
reporting on problems with overnight and early morning awakenings, 37% reported 
no change in presentation of symptoms, while 25.30% reported an increase and 37.7% 
reported a decrease in the frequency of symptoms. Finally, for the 24,316 individuals 
reporting on daytime sleepiness symptoms, a large majority (79.33%) reported no 
change in symptoms, while 8.13% reported an increase in symptoms and 12.53% 
reported a decrease in the frequency of symptoms.  
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Table 24 UKHLS analysis – Full sample: Changes in insomnia symptoms for participants with sleep onset latency 
measurements at both Wave 1 and Wave 4. 
Sleep onset latency 
 
“cannot get to sleep within 30 
minutes” 
 
Wave 4     
Not during the past 
month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
 
Wave 1 Not during the 
past month 
No change 
n=6,305 
Increase 
n=1,442 
Increase 
n=767 
Increase 
n=485 
 
n = 8,999 
 Less than once a 
week 
Decrease 
n=2,209 
No change 
n=1,397 
Increase 
n=850 
Increase 
n= 398 
 
n = 4,854 
 Once or twice a 
week 
Decrease 
n=1,190 
Decrease 
n=767 
No change 
n=893 
Increase 
n=527 
 
 n = 3,377 
 Three or more 
times a week 
Decrease 
n=519 
Decrease 
n=286 
Decrease 
n=450 
No change 
n=547 
 
n = 1,802 
   
n = 10,223 
 
n = 3,892 
 
n = 2,960 
 
n = 1,957 
 
n = 19,032 
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Table 25 UKHLS analysis – Full sample: Changes in insomnia symptoms for all participants with awakenings 
measurements at both Wave 1 and Wave 4. 
Awakenings 
 
“woke up in the middle of the 
night or early in the morning” 
 
Wave 4     
Not during the past 
month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
 
Wave 1 Not during the 
past month 
No change 
n=2,619 
Increase 
n=774 
Increase 
n=617 
Increase 
n=431 
 
n = 4,441 
 Less than once a 
week 
Decrease 
n=1,428 
No change 
n=970 
Increase 
n=755 
Increase 
n=528 
 
n = 3,681 
 Once or twice a 
week 
Decrease 
n=1,275 
Decrease 
n=876 
No change 
n=1,122 
Increase 
n=891 
 
n = 4,164 
 Three or more 
times a week 
Decrease 
n=922 
Decrease 
n=592 
Decrease 
n=861 
No change 
n=1,132 
 
n = 3,507 
   
n = 6,244 
 
n = 3,212 
 
n = 3,355 
 
n = 2,982 
 
n = 15,793 
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Table 26 UKHLS analysis – Full sample: Changes in the sleep parameters of all participants with daytime 
sleepiness measurements at both Wave 1 and Wave 4. 
 
Daytime sleepiness 
 
“trouble staying awake while 
driving, eating meals, or 
engaging in social activities” 
 
Wave 4     
Not during the past 
month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
 
Wave 1 Not during the 
past month 
No change 
n=18,876 
Increase 
n=889 
Increase 
n=508 
Increase 
n=319 
 
n = 20,592 
 Less than once a 
week 
Decrease 
n=1,805 
No change 
n=256 
Increase 
n=133 
Increase 
n=65 
 
n = 2259 
 Once or twice a 
week 
Decrease 
n=758 
Decrease 
n=124 
No change 
n=103 
Increase 
n=63 
 
n = 1048 
 Three or more 
times a week 
Decrease 
n=266 
Decrease 
n=41 
Decrease 
n=54 
No change 
n=56 
 
n = 417 
   
n = 21,705 
 
n = 1,310 
 
n = 798 
 
n = 503 
 
n = 24,316 
 
 
 
    
 253 
Changes in insomnia symptoms and Wave 4 GHQ-12 
 
Table 27 presents a summary of the parameter estimates (β) of all the sleep 
exposure variables included in the multivariable regression models assessing the 
association with Wave 4 GHQ-12 score, controlling for Wave 1 GHQ score and all 
potential confounders. An increase in the frequency of sleep onset problems was 
associated with higher GHQ scores at Wave 4 (β = 1.646 [95% CI 1.456, 1.836]), 
indicative of greater psychiatric symptoms and mental distress. Decrease in the 
frequency of symptoms was associated with lower GHQ scores (β = -1.066 [95% CI -
1.284, -0.849). Increase in the frequency of awakenings was associated with higher 
Wave 4 GHQ scores (β = 1.078 [95% CI 0.864, 1.293]) and a decrease in symptoms with 
lower Wave 4 GHQ scores (β = -0.967 [95% CI -1.177, -0.756]). An increase (β = 1.585 
[95% CI 1.299, 1.869]) in frequency of daytime sleepiness symptoms was significantly 
associated with higher Wave 4 GHQ scores but a decrease in symptoms was not 
significant. Of the three parameters, changes in sleep onset problems had the greatest 
effect and yielded a small effect size of 𝑓2 = 0.04.
    
 254 
Table 27 UKHLS analysis – Full sample: Summary of regression models of associations with Wave 4 GHQ score by potential confounders and 
changes in insomnia symptoms (analysis using complete cases) 
 Model 1 
Wave 1 GHQ  
+ confounders  
+ change in sleep onset latency 
(n = 16,515) 
Parameter estimate (β) 
Model 2 
Wave 1 GHQ  
+ confounders  
+ change in awakenings  
(n = 13,759) 
Parameter estimate (β) 
Model 3 
Wave 1 GHQ  
+ confounders  
+ change in daytime sleepiness 
(n = 20,866) 
Parameter estimate (β) 
Wave 1 GHQ 0.422 (0.404, 0.439) 0.422 (0.402, 0.441) 0.450 (0.435, 0.465) 
Male -0.550 (-0.705, -0.395) -0.672 (-0.843, -0.501) 0.829 (-0.982, -0.675) 
Age -0.012 (-0.017, -0.008) -0.019 (-0.024, -0.013) -0.021 (-0.026, -0.016) 
Asian 0.478 (0.124, 0.832) 0.810 (0.443, 1.178) 0.687 (0.341, 1.034) 
Black -0.150 (-0.743, 0.442) -0.159 (-0.802, 0.484) -0.586 (-1.172, -0.0005) 
Mixed -1.459 (-2.151, -0.766) -0.736 (-1.459, -0.014) -0.975 (-1.663, -0.287) 
Other 0.223 (-0.524, 0.970) 0.249 (0.574, 1.071) 0.365 (-0.394, 1.123) 
BMI 0.024 (0.008, 0.039) 0.026 (0.008, 0.044) 0.045 (0.030, 0.060) 
Any other qualification -0.054 (-0.216, 0.109) 0.098 (-0.079, 0.274) 0.213 (0.047, 0.379) 
No qualification -0.159 (-0.423, 0.104) -0.111 (-0.415, 0.194) 0.241 (-0.012, 0.494) 
Part-time employment -0.167 (-0.389, 0.055) -0.244 (-0.483, -0.004) -0.229 (-0.454, -0.003)  
Not in employment 0.205 (0.022, 0.387) 0.216 (0.016, 0.415) 0.459 (0.277, 0.640) 
Sleep onset latency – Increase 1.646 (1.456, 1.836)   
Sleep onset latency – Decrease -1.066 (-1.284, -0.849)   
Awakenings – Increase  1.078 (0.864, 1.293)  
Awakenings – Decrease  -0.967 (-1.177, -0.756)  
Daytime Sleepiness – Increase    1.585 (1.299, 1.869) 
Daytime Sleepiness – Decrease   -0.471(-0.969, 0.027) 
 Effect size (𝑓2) 0.04 Effect size (𝑓2) 0.03 
 
Effect size (𝑓2) 0.01 
 
Notes: Model parameter estimates (β) and 95% confidence intervals (CI) in parentheses for each of the considered models in the complete case analysis. Significant results in bold. A higher GHQ score 
indicates more psychological distress, hence risk factors = positive estimates and protective factors = negative estimates. Effect size = local effect size (Cohen’s 𝑓2) - proportion of variance explained by 
adding a sleep exposure variable to the model with confounders alone. 
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Changes in insomnia symptoms and Wave 4 PCS 
 
Table 28 presents a summary of the parameter estimates (β) of all the sleep 
exposure variables included in the multivariable regression models assessing the 
association with Wave 4 PCS scores, controlling for Wave 1 PCS score and all potential 
confounders. An increase in the frequency of sleep onset problems was associated 
with lower PCS scores at Wave 4 (β = -0.905 [95% CI -1.230, -0.575]), indicative of 
poorer physical health status and functioning and a decrease in frequency of symptom 
was not significant. An increase in the frequency of awakenings was associated with 
lower PCS scores (β = -0.555 [95% CI -0.908, -0.201]) and a decrease in symptoms with 
higher PCS scores (β = 0.609 [95% CI [0.261, 0.956]). An increase (β = -2.563 [95% CI -
3.034, -2.092]) in frequency of daytime sleepiness was significantly associated with 
lower Wave 4 PCS scores and a decrease was not significant. Of the three parameters, 
changes in daytime sleepiness had the greatest effect and yielded a small effect size 
of 𝑓2 = 0.01.
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Table 28 UKHLS analysis – Full sample: Summary of regression models of associations with Wave 4 PCS score by potential confounders and 
changes in insomnia symptoms (analysis using complete cases) 
 Model 1 
Wave 1 PCS 
+ confounders 
+ change in sleep onset latency 
(n = 16,793) 
Parameter estimate (β) 
Model 2 
Wave 1 PCS 
+ Confounders 
+ change in awakenings 
(n = 13,985) 
Parameter estimate (β) 
Model 3 
Wave 1 PCS 
+ Confounders 
+ change in daytime sleepiness 
(n = 21,250) 
Parameter estimate (β) 
Wave 1 PCS -0.435 (-0.449, -0.420) -0.472 (-0.488, -0.455) -0.410 (-0.423, -0.398) 
Male -0.031 (-0.299, 0.237) -0.084 (-0.365, 0.197) 0.177 (-0.076, 0.430) 
Age -0.102 (-0.111, -0.094) -0.082 (-0.090, -0.072) -0.100 (-0.108, -0.092) 
Asian -2.187 (-2.792, -1.581) -2.129 (-2.730, -1.529) -1.810 (-2.376, -1.243) 
Black -1.290 (-2.316, -0.263) -1.454 (-2.506, -0.402) -1.135 (-2.093, -0.177) 
Mixed -0.620 (-1.816, 0.576) -1.985( -3.171, -0.798) -1.222 (-2.353, -0.092) 
Other 0.312 (-0.982, 1.607) 0.337 (-1.013, 1.687) -0.348 (-1.593, 0.897) 
BMI -0.127 (-0.155, -0.099) -0.115 (-0.144, -0.086) -0.128 (-0.153, -0.103) 
Any other qualification -0.792 ( -1.075, -0.510) -0.833 (-1.125, -0.541) -1.014 (-1.289, -0.739) 
No qualification -1.928 (-2.385, -1.471) -2.194 (-2.698, -1.691) -1.893 (-2.311, -1.474) 
Part-time employment -0.353 (-0.739, 0.032) -0.351 (-0.745, 0.043) -0.459 (-0.832, -0.086) 
Not in employment -1.668 (-1.988, -1.347) -1.577 (-1.910, -1.245) -2.028 (-2.332, -1.724) 
Sleep onset latency –  Increase -0.905 (-1.230, -0.575)   
Sleep onset latency – Decrease -0.093 (-0.470, 0.284)   
Awakenings – Increase    -0.555 (-0.908, -0.201)  
Awakenings – Decrease  0.609 (0.261, 0.956)  
Daytime Sleepiness – Increase   -2.563 (-3.034, -2.092) 
Daytime Sleepiness – Decrease   0.541 (-0.282, 1.364) 
 Effect size (𝑓2) 0.006 
 
Effect size (𝑓2) 0.004 
 
Effect size (𝑓2) 0.01 
 
Notes: Model parameter estimates (β) and 95% confidence intervals (CI) in parentheses for each of the considered models in the complete case analysis. Significant results in bold. A higher PCS score 
indicates better physical health/functioning, hence protective factors = positive estimates and risk factors = negative estimates. Effect size = local effect size (Cohen’s 𝑓2) - proportion of variance explained 
by adding a sleep exposure variable to the model with confounders alone. 
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Changes in insomnia symptoms and Wave 4 MCS 
Table 29 presents a summary of the parameter estimates (β) of all the 
exposure variables included in the multivariable regression models assessing the 
association with Wave 4 MCS scores, controlling for Wave 1 MCS score and all 
potential confounders. An increase in the frequency of sleep onset latency problems 
was associated with lower MCS scores at Wave 4 (β = -2.548 [95% CI -2.894, -2.203]) 
indicative of poorer mental health status and psychological functioning. Decrease in 
the frequency of sleep onset problems was associated with higher Wave 4 MCS scores 
(β = 1.279 [95% CI 0.883, 1.673]). Increase in the frequency of awakening was 
associated with lower MCS scores (β = -1.698 [95% CI -2.085, -1.312]) and a decrease 
with higher MCS scores (β = 1.199 [95% CI [0.819, 1.579]). An increase in frequency of 
daytime sleepiness (β = -2.563 [95% CI (-3.889, -2.882]) was associated with lower 
Wave 4 MCS scores and a decrease (β = 0.959 [95% CI (0.081 – 1.838]) with higher 
MCS score. Of the three parameters, changes in sleep onset problems had the greatest 
effect and yielded a small effect size of 𝑓2 = 0.04
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Table 29 UKHLS analysis – Full sample: Summary of regression models of associations with Wave 4 MCS score by potential confounders and 
changes in insomnia symptoms (analysis using complete cases) 
 Model 1 
Wave 1 MCS 
+ confounders 
+ change in sleep onset latency 
(n = 16,793) 
Parameter estimate (β) 
Model 2 
Wave 1 MCS 
+ confounders 
+ change in awakenings 
(n = 13,985) 
Parameter estimate (β) 
Model 3 
Wave 1 MCS 
+ confounders 
+ change in daytime sleepiness 
(n = 21,250) 
Parameter estimate (β) 
Wave 1 MCS -0.612 (-0.628, -0.595) -0.610 (-0.628, -0.591) -0.591 (-0.605, -0.576) 
Male 0.955 (0.673, 1.236) 1.037 (0.729, 1.346) 1.306 (1.035, 1.577) 
Age 0.073 (0.064, 0.081) 0.088 (0.078, 0.098) 0.089 (0.080, 0.097) 
Asian -0.912 (-1.548, -0.278) -1.712 (-2.368, -1.055) -1.155 (1.760, -0.550) 
Black 0.499 (-0.576, 1.574) 0.085(-1.065, 1.236) 0.878 (-0.145, 1.902) 
Mixed 1.040 (-0.213, 2.294) 0.087(-1.212, 1.386) 0.643 (-0.565, 1.852) 
Other -0.414 (-1.770, 0.942) -0.440 (1.917, 1.036) -0.473 (1.804, 0.857) 
BMI -0.021 (-0.049, 0.007) -0.007 (-0.038, 0.025) -0.045 (-0.072, -0.018) 
Any other qualification 0.479 (0.184, 0.775) 0.239 (0.080, 0.558) -0.060 (-0.354, 0.232) 
No qualification 0.275 (-0.201, 0.751) -0.135 (-0.682, 0.411) -0.688 (-1.132, -0.243) 
Part-time employment  -0.302 (-0.634, 0.031) -0.318 (-0.678, 0.042) -0.843 (-1.163, -0.524) 
Not in employment 0.439 (0.035, 0.843) 0.556 (0.125, 0.987) 0.572 (0.173, 0.970) 
Sleep onset latency – Increase  -2.548 (-2.894, -2.203)   
Sleep onset latency – Decrease 1.279 (0.883, 1.673)   
Awakenings – Increase    -1.698(-2.085, -1.312)  
Awakenings – Decrease  1.199 (0.819, 1.579)  
Daytime Sleepiness – Increase   -3.386 (-3.889, -2.882) 
Daytime Sleepiness – Decrease   0.959 (0.081 – 1.838) 
 Effect size (𝑓2) 0.04 
 
Effect size (𝑓2) 0.02 
 
Effect size (𝑓2) 0.02 
 
Notes: Model parameter estimates (β) and 95% confidence intervals (CI) in parentheses for each of the considered models in the complete case analysis. Significant results in bold. A higher MCS score 
indicates better mental health/functioning, hence protective factors = positive estimates and risk factors = negative estimates. Effect size = local effect size (Cohen’s 𝑓2) - proportion of variance explained 
by adding a sleep exposure variable to the model with confounders alone. 
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Sensitivity analysis 
Each of the analysis described above was also performed with imputed 
datasets computed using the MICE procedure to check the sensitivity of the results. 
Tables 30, 31, and 32 present a summary of the parameter estimates (β) of all the 
sleep exposure variables included in the multivariable regression models assessing the 
associations with Wave 4 GHQ, PCS and MCS scores, controlling for Wave 1 MCS score 
and all potential confounders using the imputed datasets. Overall, the pattern of 
results did not differ from the complete case analysis. The only difference observed 
was that the association of decrease in frequency of sleep onset problems with Wave 
4 MCS score was no longer significant.  
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Table 30 UKHLS analysis – Full sample: Summary of regression models of associations with Wave 4 GHQ score by potential 
confounders and changes in insomnia symptoms (analysis combining results from imputed dataset) 
 Model 1 
Wave 1 GHQ  
+ confounders  
+ change in sleep onset latency 
(n = 30,414) 
Parameter estimate (β) 
Model 2 
Wave 1 GHQ  
+ confounders  
+ change in awakenings  
(n = 30,414) 
Parameter estimate (β) 
Model 3 
Wave 1 GHQ  
+ confounders  
+ change in daytime sleepiness 
(n = 30,414) 
Parameter estimate (β) 
Wave 1 GHQ 0.437 (0.421, 0.454) 0.447 (0.432, 0.462) 0.449 (0.434, 0.464) 
Male -0.655 (-0.803, -0.508) -0.693 (-0.849, -0.537) -0.852 (-1.001, -0.703) 
Age -0.016 (-0.020, -0.011) -0.025 (-0.030, -0.021) -0.020 (-0.024, -0.015) 
Asian 0.458 (0.129, 0.787) 0.547 (0.205, 0.889) 0.468 (0.135, 0.801) 
Black -0.461 (-0.992, 0.071) -0.399 (-0.936, 0.138) -0.543 (-1.077, -0.008) 
Mixed -1.077 (-1.742, -0.412) -0.869 (-1.539, -0.199) -1.048 (-1.718, -0.378) 
Other 0.418 (-0.352, 1.189) 0.582 (-0.164, 1.327)  0.444 (-0.292, 1.179) 
BMI 0.040 (0.025, 0.056) 0.042 (0.027, 0.057) 0.042 (0.026, 0.057) 
Any other qualification 0.100 (-0.063, 0.264) 0.180 (0.019, 0.341) 0.219 (0.056, 0.381) 
No qualification 0.115 (-0.126, 0.355) 0.256 (0.013, 0.499) 0.287 (0.044, 0.530) 
Part-time employment 0.412 (0.235, 0.589) 0.494 (0.319, 0.669) 0.443 (0.267, 0.618) 
Not in employment -0.207 (-0.424, 0.010) -0.221 (-0.442, 0.0003) -0.244 (-0.463, -0.025) 
Sleep onset latency – Increase 1.710 (1.504, 1.916)   
Sleep onset latency – Decrease -0.454 (-0.783, -0.124)   
Awakenings – Increase  1.060 (0.694, 1.427)  
Awakenings – Decrease  -0.7010 (-1.086, -0.333)  
Daytime Sleepiness – Increase    1.529 (1.243, 1.814) 
Daytime Sleepiness – Decrease   -0.517 (1.016, -0.019) 
 Mean effect size (𝑓2) 0.04 Mean effect size (𝑓2) 0.02 
 
Mean effect size (𝑓2) 0.01 
 
Notes: Model parameter estimates (β) and low/high 95% confidence intervals (CI) in parentheses for each of the considered models in the datasets imputed using multivariate imputation by chained 
equation (mice). Significant results in bold. A higher GHQ score indicates more psychological distress, hence risk factors = positive estimates and protective factors = negative estimates. Effect size = mean 
local effect size (Cohen’s 𝑓2) for the imputed datasets - proportion of variance explained by adding a sleep exposure variable to the model with confounders alone.  
 
    
 261 
Table 31 UKHLS analysis – Full sample: Summary of regression models of associations with Wave 4 PCS score by potential 
confounders and changes in insomnia symptoms (analysis combining results from imputed dataset) 
 Model 1 
Wave 1 PCS  
+ confounders  
+ change in sleep latency 
(n = 30,414) 
Parameter estimate (β) 
Model 2  
Wave 1 PCS 
+ confounders  
+ change in awakenings  
(n = 30,414) 
Parameter estimate (β) 
Model 3 
Wave 1 PCS  
+ Confounders  
+ change in daytime sleepiness 
(n = 30,414) 
Parameter estimate (β) 
Wave 1 PCS -0.408 (-0.421, -0.395) -0.405 (-0.418, -0.392) -0.413 (-0.425, -0.401) 
Male  0.098 (-0.150, 0.346) 0.107 (-0.146, 0.360) 0.260 (0.014, 0.507) 
Age -0.101 (-0.109, -0.094) -0.091 (-0.099, -0.083) -0.099 (-0.107, -0.092) 
Asian -1.790 (-2.345, -1.234) -1.881 (-2.436, -1.327) -1.771 (-2.324, -1.218) 
Black -1.233 (-2.118, -0.347) -1.287 (-2.174, -0.400) -1.125 (-2.007, -0.244) 
Mixed -0.844 (-1.954, 0.265) -1.009 (-2.118, 0.099) -0.755 (-1.860, 0.349) 
Other -0.675 (-1.897, 0.546) -0.762 (-1.985, 0.460) -0.599 (-1.813, 0.615) 
BMI -0.130 (-0.155, -0.105) -0.130 (-0.155, -0.106) -0.129 (-0.154, -0.104) 
Any other qualification -0.910 (-1.183, -0.637) -0.963 (-1.236, -0.689) -1.025, (-1.295, -0.755) 
No qualification -1.701 (-2.106, -1.295) -1.809 (-2.223, -1.395) -1.822 (-2.227, -1.417) 
Part-time employment -0.418 (-0.781, -0.056) -0.401 (-0.766, -0.037) -0.392 (-0.754, -0.029) 
Not in employment -2.005 (-2.299, -1.709) -2.104 (-2.401, -1.808) -2.035 (-2.329, -1.740) 
Sleep onset latency – Increase -0.954 (1.377, -0.531)   
Sleep onset latency – Decrease -0.359 (-0.890, 0.173)   
Awakenings –  Increase    -0.808 (1.659, 0.042)  
Awakenings – Decrease   0.548 (0.003, 1.093)  
Daytime Sleepiness – Increase   -2.584 (-3.057, -2.111) 
Daytime Sleepiness – Decrease   0.578 (-0.230, 1.387) 
 Mean effect size (𝑓2) 0.007 
 
Mean effect size (𝑓2) 0.007 
 
Mean effect size (𝑓2) 0.007 
 
Notes: Model parameter estimates (β) and low/high 95% confidence intervals (CI) in parentheses for each of the considered models in the datasets imputed using multivariate imputation by chained 
equation (mice). Significant results in bold.  A higher PCS score indicates better physical health/functioning, hence protective factors = positive estimates and risk factors = negative estimates. Effect size = 
mean local effect size (Cohen’s 𝑓2) for the imputed datasets - proportion of variance explained by adding a sleep exposure variable to the model with confounders alone. 
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Table 32 UKHLS analysis – Full sample: Summary of regression models of associations with Wave 4 MCS score by potential 
confounders and changes in insomnia symptoms (analysis combining results from imputed dataset) 
 Model 1 
Wave 1 MCS 
+ confounders  
+ change in sleep onset latency 
(n = 16,793) 
Parameter estimate (β) 
Model 2  
Wave 1 MCS 
+ confounders  
+ change in awakenings  
(n = 13,985) 
Parameter estimate (β)) 
Model 3 
Wave 1 MCS  
+ confounders  
+ change in daytime sleepiness  
(n = 21,250) 
Parameter estimate (β) 
Wave 1 MCS -0.592 (-0.606, -0.578) -0.583 (-0.597, -0.569) -0.591 (-0.605, -0.577) 
Male 0.914 (0.648, 1.1803) 0.975 (0.707, 1.244) 1.293 (1.029, 1.558)  
Age 0.081 (0.073, 0.090) 0.099 (0.091, 0.108) 0.087 (0.079, 0.095) 
Asian -1.049 (-1.642, -0.456) -1.255 (-1.849, -0.662) -1.033 (-1.622, -0.444) 
Black 0.783 (-0.162, 1.729) 0.607 (-0.336, 1.550) 0.906 (-0.037, 1.850) 
Mixed 0.654 (-0.528, 1.836) 0.247 (-0.939, 1.433) 0.701 (-0.482, 1.884) 
Other -0.511 (-1.814, 0.791) -0.721 ( -2.040, 0.598) -0.439 (-1.741, 0.862) 
BMI -0.045 (-0.072, -0.019) -0.047 (-0.073, -0.021) -0.044 (-0.070, -0.018) 
Any other qualification 0.206 (-0.080, 0.492) 0.078 (-0.210, 0.365) -0.018 (-0.305, 0.269) 
No qualification -0.387 (-0.829, 0.055) -0.626 (-1.060, -0.191) -0.670 (-1.101, -0.240) 
Part-time employment 0.451 (0.065, 0.836) 0.494 (0.102, 0.887) 0.536 (0.147, 0.924) 
Not in employment  -0.787 (-1.108, -0.465) -0.939 (-1.249, -0.628) -0.848 (-1.159, -0.537) 
Sleep onset latency – Decrease 0.306 (-0.151, 0.763)   
Awakenings – Increase    -1.802 (-2.160, -1.445)  
Awakenings – Decrease  0.891 (0.418, 1.364)  
Daytime Sleepiness – Increase   -3.223 (-3.731, -2.716) 
Daytime Sleepiness – Decrease   1.033 (0.166, 1.900) 
 Mean effect size (𝑓2) 0.03 
 
Mean effect size (𝑓2) 0.02 
 
Mean effect size (𝑓2) 0.03 
 
Notes: Model parameter estimates (β) and low/high 95% confidence intervals (CI) in parentheses for each of the considered models in the datasets imputed using multivariate imputation by chained 
equation (mice). Significant results in bold.  A higher MCS score indicates better mental health/functioning, hence protective factors = positive estimates and risk factors = negative estimates. Effect size = 
mean local effect size (Cohen’s 𝑓2) for the imputed datasets - proportion of variance explained by adding a sleep exposure variable to the model with confounders alone.
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7.3.2 Arthritis subgroup  
 
Sample characteristics 
 
Table 33 shows the baseline characteristics of the arthritis subgroup by 
analysis and complete cases of participants providing data for all combined outcomes, 
predictors and confounders. Based on the complete cases, majority of the sample was 
female (53.17%), with mean age of 60.02, and mean BMI of 27.42. Most of the sample 
were white (95.48%), not in employment (56.48%) and just under half had below 
degree level education (47.52%). Mean score for GHQ-12 was 10.45, 43.85 for PCS, 
and 53.22 for MCS, values for GHQ and MCS were within the normative range for the 
general population but PCS values were in the indicative range for those with a ‘minor 
medical condition’ (Ware et al., 1996). This gives further support for the chronic pain 
subgroup classification. Comparing the arthritis subgroup to the full sample, they 
showed no significant differences in baseline insomnia symptoms, GHQ, and MCS 
mean scores. However, the arthritis group were significantly older and showed poorer 
baseline PCS mean scores.  
 
Arthritis subgroup – baseline insomnia symptoms 
For baseline insomnia symptoms, the arthritis subgroup showed a similar 
pattern of symptom prevalence as the full sample. 44.54% of the arthritis sample did 
not report sleep onset difficulties in the previous month, 27.82% reported difficulties 
less than once a week, 18.77% reported difficulties once or twice a week, and 8.87% 
reported difficulties three or more times a week. The frequency of overnight and early 
morning awakenings was evenly distributed among categories, with 20.65% reporting 
no problems in the past month, 22.27% reporting problems less than once a week, 
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28.75% reporting problems once or twice a week, and 28.33% reporting problems 
three or more times a week. The majority (88.23%) reported no daytime sleepiness 
during the past month, 8.28% reported symptoms less than once a week, 2.99% 
reported symptoms once or twice a week and a very small number (0.52%) reported 
symptoms three or more times a week. The frequency of symptoms presentation was 
similar to the full sample, although a higher percentage in the arthritis group reported 
symptoms of sleep onset latency and awakening three or more times a week. This is 
suggestive of greater insomnia symptoms intensity.  
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Notes: Summary statistics for the arthritis subgroup restricted to complete cases for Wave 1 and Wave 4 measurements for each outcomes and predictors as well as confounders. 
Complete case data in the last column refers to arthritis subgroup characteristics restricted to all combined outcomes, exposures, and confounders.  
Table 33 UKHLS analysis – Arthritis subgroup 
baseline sample characteristics 
GHQ analysis  
(n = 1,177) 
PCS analysis  
(n = 1,195) 
MCS analysis  
(n = 1,195) 
Complete case 
(n = 1,172) 
Sex, n Female (% Female) 725 (61.60%) 737 (61.67%) 737 (61.67%) 721 (61.52%) 
Age mean (sd) 60.02 (12.86) 60.02 (12.89) 60.02 (12.89) 60.02 (12.88) 
BMI mean (sd) 27.43 (4.86) 27.45 (4.86) 27.45 (4.86) 27.42 (4.85) 
Ethnicity                                                                        White, n (%) 1123 (95.41%) 1140 (93.40%) 1140 (93.40%) 1119 (95.48%) 
     Asian, n (%) 31 (2.63%) 32 (2.68%) 32 (2.68%) 31 (2.65%) 
    Black, n (%) 12 (1.02%) 11 (0.92%) 11 (0.92%) 11 (0.94%) 
    Mixed, n (%) 7 (0.59%) 8 (0.67%) 8 (0.67%) 7 (0.60%) 
    Other, n (%) 4 (0.34%) 4 (0.33%) 4 (0.33%) 4 (0.34%) 
Employment                                                            Full time, n (%) 348 (29.57%) 351 (29.37%) 351 (29.37%) 347 (29.61%) 
    Part time, n (%) 163 (13.85%) 169 (14.14%) 169 (14.14%) 163 (13.91%) 
Not in employment, n (%) 666 (56.58%) 675 (56.49%) 675 (56.49%) 662 (56.48%) 
Education                                         Degree level or above, n (%) 388 (32.97%) 395 (33.05%) 395 (33.05%) 386 (32.94%) 
    Any other qualification, n (%) 560 (47.58%) 564 (47.20%) 564 (47.20%) 557 (47.52%) 
    No qualification, n (%) 229 (19.46%) 236 (19.75%) 236 (19.75%) 229 (19.53%) 
Sleep latency (>30 mins)            Not during past month,  n (%) 524 (44.52%) 531 (44.44%) 531 (44.44%) 522 (44.54%) 
    Less than once a week, n (%) 327 (27.78%) 329 (27.53%) 329 (27.53%) 326 (27.82%) 
    Once or twice a week, n (%) 222 (18.86%) 229 (19.16%) 229 (19.16%) 220 (18.77%) 
    Three or more times a week, n (%) 104 (8.84%) 106 (8.87%) 106 (8.87%) 104 (8.87%) 
Awakenings                             Not during the past month, n (%) 244 (20.73%) 248 (20.75%) 248 (20.75%) 242 (20.65%) 
    Less than once a week, n (%) 261 (22.18%) 264 (22.09%) 264 (22.09%) 261 (22.27%) 
    Once or twice a week, n (%) 338 (28.72%) 342 (28.62%) 342 (28.62%) 337 (28.75%) 
    Three or more times a week, n (%) 334 (28.34%) 341 (28.54%) 341 (28.54%) 332 (28.33%) 
 Daytime sleepiness               Not during the past month, n (%) 1037 (88.11%) 1053 (88.12%) 1053 (88.12%) 1034 (88.23%) 
Less than once a week, n (%) 99 (8.41%) 99 (8.28%) 99 (8.28%) 97 (8.28%) 
Once or twice a week, n (%) 35 (2.97%) 35 (2.93%) 35 (2.93%) 35 (2.99%) 
Three or more times a week, n (%) 6 (0.51%) 8 (0.67%) 8 (0.67%) 6 (0.52%) 
GHQ-12, Mean (SD) 10.44(4.43) - - 10.45 (4.44) 
PCS, Mean (SD) - 43.69 (12.41) - 43.85 (12.37) 
MCS, Mean (SD) - - 53.20 (8.70) 53.22 (8.69) 
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Arthritis subgroup – changes in insomnia symptoms from Wave 1 to Wave 4 
 
Tables 34-36 describe the pattern of changes in the frequency of insomnia 
symptoms for participants within the arthritis subgroup with insomnia symptoms 
measurements (sleep onset latency, awakenings, and daytime sleepiness) at both 
Wave 1 and Wave 4. As also observed in the full sample, stability in reports of the 
frequency of insomnia symptoms was still the most common trajectory. However, in 
this group, there was more reports of improvement rather than deterioration of 
symptoms. Of 2,324 presenting data for sleep onset problems, 43.89% reported no 
change from Wave 1 to Wave 4, 24.66% reported an increase in the frequency of 
problems, and 31.45% reported a decrease. For the 1,647 reporting problems with 
overnight and early morning awakenings, 34.55% reported no change in presentation 
of symptoms, while 27.32% reported an increase, and 38.13% reported a decrease in 
the frequency of symptoms. Finally, for the 3,600 individuals reporting on daytime 
sleepiness, the majority (78.36%) reported no change in symptoms, while 9.72% 
reported an increase in symptoms, and 11.92% reported a decrease in the frequency 
of symptoms. 
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Table 34 UKHLS analysis – Arthritis subgroup: Changes in insomnia symptoms for arthritis subgroup participants 
with sleep onset latency measurements at both Wave 1 and Wave 4. 
Sleep onset latency  
 
“cannot get to sleep within 30 
minutes” 
 
Wave 4     
Not during the past 
month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
 
Wave 1 Not during the 
past month 
No change 
n=672 
Increase 
n=136 
Increase 
n=95 
Increase 
n=80 
 
n = 983 
 Less than once a 
week 
Decrease 
n=299 
No change 
n=129 
Increase 
n=99 
Increase 
n=58 
 
n = 585 
 Once or twice a 
week 
Decrease 
n=154 
Decrease 
n=98 
No change 
n=112 
Increase 
n=105 
 
n = 469 
 Three or more 
times a week 
Decrease 
n=70 
Decrease 
n=30 
Decrease 
n=80 
No change 
n=107 
 
n = 287 
   
n = 1195 
 
n = 393 
 
n = 386 
 
n = 350 
 
n = 2,324 
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Table 35 UKHLS analysis – Arthritis subgroup: Changes in insomnia symptoms for arthritis subgroup participants 
with awakenings measurements at both Wave 1 and Wave 4. 
Awakenings 
 
“woke up in the middle of the 
night or early in the morning” 
 
Wave 4     
Not during the past 
month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
 
Wave 1 Not during the 
past month 
No change 
n=173 
Increase 
n=61 
Increase 
n=61 
Increase 
n=50 
 
n = 345 
 Less than once a 
week 
Decrease 
n=109 
No change 
n=73 
Increase 
n=68 
Increase 
n=82 
 
n = 332 
 Once or twice a 
week 
Decrease 
n=133 
Decrease 
n=79 
No change 
n=120 
Increase 
n=128 
 
n = 460 
 Three or more 
times a week 
Decrease 
n=132 
Decrease 
n=70 
Decrease 
n=105 
No change 
n=203 
 
n = 510 
   
n = 547 
 
n = 283 
 
n = 354 
 
n = 463 
 
n = 1,647 
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Table 36 UKHLS analysis – Arthritis subgroup: Changes in insomnia symptoms for arthritis subgroup participants 
with daytime sleepiness measurements at both Wave 1 and Wave 4. 
Daytime sleepiness 
 
“trouble staying awake while 
driving, eating meals, or 
engaging in social activities” 
 
Wave 4     
Not during the past 
month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
 
Wave 1 Not during the 
past month 
No change 
n=2,750 
Increase 
n=100 
Increase 
n=98 
Increase 
n=94 
 
n = 3,042 
 Less than once a 
week 
Decrease 
n=209 
No change 
n=28 
Increase 
n=20 
Increase 
n=19 
 
n = 276 
 Once or twice a 
week 
Decrease 
n=114 
Decrease 
n=18 
No change 
n=22 
Increase 
n=19 
 
n = 173 
 Three or more 
times a week 
Decrease 
n=68 
Decrease 
n=8 
Decrease 
n=12 
No change 
n=21 
 
n = 109  
   
n = 3141 
 
n = 154 
 
n = 152 
 
n = 153 
 
n = 3,600 
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Arthritis subgroup – Changes in insomnia symptoms and Wave 4 GHQ-12 
 
Table 37 presents a summary of the parameter estimates (β) of all the sleep 
exposure variables included in the multivariable regression models for imputed 
datasets assessing the association with Wave 4 GHQ-12 score in the arthritis 
subgroup, controlling for Wave 1 GHQ score, and all potential confounders. An 
increase in the frequency of sleep onset latency problems was associated with higher 
GHQ scores at Wave 4 (β = 1.035 [95% CI 0.241, 1.828]), indicative of greater 
psychiatric symptoms and mental distress. Increase in the frequency of awakening 
was associated with higher Wave 4 GHQ scores (β = 1.539 [95% CI 0.616, 2.462]). An 
increase in frequency of daytime sleepiness symptoms (β = 2.031 [95% CI 1.280, 
2.783]) was significantly associated with higher Wave 4 GHQ scores. A decrease in the 
frequency of all of the symptoms was not significant. Of the three parameters, change 
in daytime sleepiness had the greater effect and yielded a small effect size of 𝑓2 = 0.03. 
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Table 37 UKHLS analysis – Arthritis subgroup: Summary of regression models in arthritis subgroup of associations with Wave 4 GHQ 
score by potential confounders and changes in frequency of insomnia symptoms (analysis combining results from imputed dataset) 
 Model 1 
Wave 1 GHQ 
+ confounders 
+ change in sleep onset latency 
(n = 4,120) 
Parameter estimate (β) 
Model 2 
Wave 1 GHQ 
+ confounders 
+ change in awakenings 
(n = 4,120) 
Parameter estimate (β) 
Model 3 
Wave 1 GHQ 
+ confounders 
+ change in daytime sleepiness 
(n = 4,120) 
Parameter estimate (β) 
Wave 1 GHQ 0.441 (0.381, 0.502) 0.460 (0.402, 0.517) 0.431 (0.389, 0.473) 
Male -0.689 (-1.135, -0.244) -0.864 (-1.299, -0.429) -0.977 (-1.408, -0.547) 
Age -0.066 (-0.086, -0.046) -0.072 (-0.093, -0.050) -0.067 (-0.086, -0.047) 
Asian -0.399 (-1.886, 1.088) -0.319 (-2.103, 1.465) -0.518 (-1.959, 0.923) 
Black -0.821 (-2.251, 0.608) -0.388 (-1.997, 1.221) -1.138 (-2.654, 0.378) 
Mixed 0.905 (-1.999, 3.809) 0.613 (-2.355, 3.582) 0.589 (-2.361, 3.539) 
Other 1.486 (-1.855, 4.827) 2.011 (-1.266, 5.288) 1.547 (-1.506, 4.600) 
BMI 0.058 (0.022, 0.094) 0.053 (0.017, 0.090) 0.051 (0.011, 0.091) 
Any other qualification 0.065 (-0.446, 0.577) 0.174 (-0.385, 0.733) 0.133 (-0.371, 0.636) 
No qualification 0.020 (-0.569, 0.609) 0.172 (-0.427, 0.772) 0.105 (-0.484, 0.694) 
Part-time employment -0.196 (-0.973, 0.581) -0.085 (-0.856, 0.685) -0.182 (-0.957, 0.593) 
Not in employment 0.853 (0.234, 1.467) 0.974 (0.385, 1.563) 0.844 (0.256, 1.432) 
Sleep onset latency – Increase 1.035 (0.241, 1.828)   
Sleep onset latency – Decrease 0.251 (-0.625, 1.128)   
Awakenings – Increase  1.539 (0.616, 2.462)  
Awakenings – Decrease  0.351 (-1.114, 0.412)  
Daytime sleepiness –  Increase    2.031 (1.280, 2.783) 
Daytime sleepiness – Decrease   -0.846 (-2.730, 1.038) 
 Mean effect size (𝑓2) 0.02 Mean effect size (𝑓2) 0.02 Mean effect size (𝑓2) 0.03 
 
Notes: Model parameter estimates (β) and low/high 95% confidence intervals (CI) in parentheses for each of the considered models in the datasets imputed using multivariate imputation by chained 
equation (mice). Significant results in bold. A higher GHQ score indicates more psychological distress, hence risk factors = positive estimates and protective factors = negative estimates. Effect size = mean 
local effect size (Cohen’s 𝑓2) for the imputed datasets - proportion of variance explained by adding a sleep exposure variable to the model with confounders alone. 
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Arthritis subgroup – Changes in insomnia symptoms and Wave 4 PCS 
Table 38 presents a summary of the parameter estimates β) of all the sleep 
exposure variables included in the multivariable regression models for imputed 
datasets assessing the association with Wave 4 PCS scores in the arthritis subgroup, 
controlling for Wave 1 PCS score and all potential confounders. An increase in the 
frequency of sleep onset latency problems was associated with lower PCS scores at 
Wave 4 (β = -1.066 [95% CI (-2.068, -0.064]), indicative of poorer physical health status 
and functioning. An increase in frequency of daytime sleepiness symptoms was also 
associated with lower PCS scores at Wave 4 (β = --1.514 [95% CI (-3.201, 0.173]). A 
decrease in sleep onset latency symptoms and daytime sleepiness and changes in 
frequency of problems with awakenings were not significantly associated with Wave 
4 PCS scores. Of the three parameters, change in sleep onset latency and daytime 
sleepiness had the greater effect and both yielded a small effect size of 𝑓2 = 0.01. 
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Table 38 UKHLS analysis – Arthritis subgroup: Summary of regression models in arthritis subgroup of associations with Wave 4 PCS 
score by potential confounders and changes in frequency of insomnia symptoms (analysis combining results from imputed dataset) 
 Model 1 
Wave 1 PCS 
+ confounders  
+ change in sleep onset latency 
(n = 4,120) 
Parameter estimate (β) 
Model 2  
Wave 1 PCS  
+ confounders  
+ change in awakenings  
(n = 4,120) 
Parameter estimate (β) 
Model 3 
Wave 1 PCS 
+ confounders  
+ change in daytime sleepiness 
(n = 4,120) 
Parameter estimate (β) 
Wave 1 PCS  -0.386 (-0.416, -0.356) -0.382 (-0.413, -0.351) -0.389 (-0.419, -0.359) 
Male -0.037 (-0.949, 0.875) 0.215 (-0.683, 1.112) 0.349 (-0.540, 1.238) 
Age -0.025 (-0.064, 0.013) -0.018 (-0.055, 0.020) -0.026 (-0.064, 0.012) 
Asian -2.598 (-5.041, -0.155) -2.702 (-5.236, -0.169) -2.499 (-5.258, 0.260) 
Black -1.101 (-4.490, 2.287) -1.318 (-4.878, 2.243) -0.870 (-3.998, 2.258) 
Mixed 2.030 (-4.130, 8.190) 1.909 (-3.965, 7.784) 2.409 (-3.558, 8.375) 
Other 1.694 (-2.940, 6.328) 1.155 (-3.298, 5.608) 1.498 (-3.026, 6.021) 
BMI -0.131 (-0.203, -0.059)  -0.124 (-0.195, -0.054) -0.116 (-0.189, -0.043) 
Any other qualification -0.446 (-1.626, 0.733) -0.578 (-1.816, 0.661) -0.578 (-1.755, 0.599) 
No qualification -1.976 (-3.244, -0.709) -2.101 (-3.313, -0.890)  -2.033 (-3.334, -0.732) 
Part-time employment -1.019 (-2.424, 0.387) -1.032 (-2.464, 0.401) -1.060 (-2.465, 0.345) 
Not in employment -3.791 (-4.934, -2.648) -3.908 (-5.034, -2.782) -3.845 (-4.955, -2.735) 
Sleep onset latency – Increase -1.066 (-2.068, -0.064)   
Sleep onset latency – Decrease -0.408 (-1.769, 0.953)   
Awakenings – Increase    0.006 (-2.032, 2.043)  
Awakenings – Decrease  0.559 (-0.745, 1.862)  
Daytime sleepiness – Increase   -1.514 (-3.201, 0.173) 
Daytime sleepiness – Decrease   1.008 (-1.647, 3.663) 
 Mean effect size (𝑓2) 0.01 Mean effect size (𝑓2) 0.005 Mean effect size (𝑓2) 0.01 
 
Notes: Model parameter estimates (β) and low/high 95% confidence intervals (CI) in parentheses for each of the considered models in the datasets imputed using multivariate imputation by chained 
equation (mice). Significant results in bold. A higher PCS score indicates better physical health/functioning, hence protective factors = positive estimates and risk factors = negative estimates. Effect size = 
mean local effect size (Cohen’s 𝑓2) for the imputed datasets - proportion of variance explained by adding a sleep exposure variable to the model with confounders alone.
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Arthritis subgroup – Changes in insomnia symptoms and Wave 4 MCS 
 
Table 39 presents a summary of the parameter estimates (β) of all the sleep 
exposure variables included in the multivariable regression models for imputed 
datasets assessing the association with Wave 4 MCS scores in the arthritis subgroup, 
controlling for Wave 1 MCS score and all potential confounders. An increase in the 
frequency of sleep onset latency problems was associated with lower MCS scores at 
Wave 4 (β = -2.539 [95% CI -4.366, -0.713]) indicative of poorer mental health status 
and psychological functioning. Decrease in the frequency of sleep onset latency 
problems was also associated with lower Wave 4 MCS scores (β = -1.566 [95% CI -
2.776, -0.356]). Increase in the frequency of awakening was associated with lower 
MCS scores (β = -1.980 [95% CI -3.402, -0.558]), and a decrease in symptoms was not 
significant. An increase in frequency of daytime sleepiness symptoms (β = -4.143 [95% 
CI -5.748, -2.537]) was associated with Wave 4 MCS scores and a decrease in 
symptoms was not significant. Of the three parameters, change in sleep onset latency 
and daytime sleepiness had the greater effect and both yielded a small effect size of 
𝑓2 = 0.03. 
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Table 39 UKHLS analysis – Arthritis subgroup: Summary of regression models in arthritis subgroup of associations with Wave 4 MCS 
score by potential confounders and changes in frequency of insomnia symptoms (analysis combining results from imputed dataset) 
 Model 1 
Wave 1 MCS 
+ confounders  
+ change in sleep onset latency 
(n = 4,120) 
Parameter estimate (β) 
Model 2  
Wave 1 MCS 
+ confounders  
+ change in awakenings  
(n = 4,120) 
Parameter estimate (β) 
Model 3 
Wave 1 MCS  
+ confounders  
+ change in daytime sleepiness  
(n = 4,120) 
Parameter estimate (β) 
Wave 1 MCS -0.605 (-0.639, -0.571) -0.585 (-0.619, -0.551) -0.607 (-0.641, -0.572) 
Male  0.152 (-0.790, 1.094) 0.569 (-0.453, 1.590) 0.870 (-0.100, 1.840) 
Age 0.121 (0.084, 0.158) 0.132 (0.090, 0.174) 0.123 (0.083, 0.163) 
Asian -0.438 (-3.399, 2.523) -0.697 (-3.356, 1.963) -0.071 (-2.733, 2.591) 
Black 0.114 (-2.823, 3.052) -0.564 (-3.619, 2.491) 0.695 (-2.173, 3.564) 
Mixed -0.544 (-6.387, 5.299) -0.572 (-6.571, 5.428) 0.015 (-5.725, 5.755) 
Other -1.355 (-6.072, 3.361) -2.380 (-7.066, 2.305) -1.299 (-5.898, 3.230) 
BMI -0.052 (-0.121, 0.018) -0.046 (-0.125, 0.034) -0.034 (-0.107, 0.040) 
Any other qualification 0.664 (-0.238, 1.565) 0.438 (-0.510, 1.385)  0.452 (-0.467, 1.371) 
No qualification -0.087 (-1.235, 1.061) -0.380 (-1.530, 0.770) -0.225 (-1.393, 0.943) 
Part-time employment 0.493 (-0.977, 1.962) 0.302 (-1.180, 1.784) -0.225 (-1.393, 0.943) 
Not in employment -1.481 (-2.647, -0.314) -1.824 (-2.995, -0.654) -1.474 (-2.640, -0.307) 
Sleep onset latency – Increase -2.539 (-4.366, -0.713)   
Sleep onset latency – Decrease -1.566 (-2.776, -0.356)   
Awakenings – Increase    -1.980 (-3.402, -0.558)  
Awakenings – Decrease  -0.159 (-1.275, 0.956)  
Daytime Sleepiness –  Increase   -4.143 (-5.748, -2.537) 
Daytime Sleepiness – Decrease   -0.051, (-2.479, 2.376) 
 Mean effect size (𝑓2) 0.03 Mean effect size (𝑓2) 0.01 Mean effect size (𝑓2) 0.03 
 
Notes: Model parameter estimates (β) and low/high 95% confidence intervals (CI) in parentheses for each of the considered models in the datasets imputed using multivariate imputation by chained 
equation (mice). Significant results in bold. A higher MCS score indicates better mental health/functioning, hence protective factors = positive estimates and risk factors = negative estimates. Effect size = 
mean local effect size (Cohen’s 𝑓2) for the imputed datasets - proportion of variance explained by adding a sleep exposure variable to the model with confounders alone. 
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7.4 Discussion 
 
7.4.1 Summary of findings  
 
Findings from this study provided some evidence for the differential 
association of changes in different insomnia symptoms with perceived health status 
in the general population and an arthritis chronic pain subgroup within this 
population. The most prevalent insomnia symptoms were problems with prolonged 
sleep onset latency and overnight/early morning awakenings, both of which are key 
criteria in diagnosing insomnia disorder.  Certain demographics variables were also 
consistently associated with mental and physical health outcomes in the analysis. 
Across all analysis, male sex and older age tended to be associated with better 
outcomes, whereas Asian race, increased BMI, and unemployment were associated 
with worse outcomes.  
 
Table 40 provides a summary and comparison of the pattern of results for 
changes in insomnia symptoms across the full sample and arthritis subgroup. The 
results suggest that overall, worsening of insomnia symptoms over a 4-year period 
was associated with poorer health outcomes, especially perceived mental health and 
psychological well-being. A weaker effect was observed for association between 
increase in frequency of all insomnia symptoms and poorer physical health outcome 
at Wave 4. In the arthritis group, an increase in sleep onset latency and daytime 
sleepiness symptoms were associated with poorer physical health outcome at Wave 
4. Generally, associations of improvement in insomnia symptoms with better mental 
and physical health outcomes were of lesser magnitude, and often not significant 
compared to worse symptoms at Wave 4. As shown in Figure 19, changes in sleep 
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onset latency seems to be a key insomnia symptom driving the association with  
mental health outcomes, functioning and well-being, and yielded the biggest effect 
size for the associations with mental health outcomes for the full sample and arthritis 
subgroup. Changes in daytime sleepiness symptoms were also particularly relevant 
within the arthritis subgroup.  
 
 
Figure 19 UKHLS analysis – Local effect sizes of changes in insomnia symptoms 
 
 
 
 
Notes: Graphical summary of the local effect sizes of changes in insomnia symptoms 
between Wave 1 and Wave 4 assessments, by mental and physical health outcomes 
at Wave 4. The local effect sizes shown above quantify the proportion of variance 
explained by adding a sleep-change exposure variable to the model with 
confounders alone. 
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Table 40 UKHLS analysis – Summary of pattern of results for full sample and 
arthritis subgroup 
 
 Full sample Arthritis subgroup 
Increase in frequency 
of insomnia symptoms: 
 
Sleep onset latency 
Overnight awakenings 
Daytime sleepiness 
 
 
Sleep onset latency 
Overnight awakenings 
Daytime sleepiness   
 
 
Mental health outcomes 
Worse GHQ + MCS at Wave 4 
Worse GHQ + MCS at Wave 4 
Worse GHQ + MCS at Wave 4 
 
Physical health outcomes 
Worse PCS at Wave 4 
Worse PCS at Wave 4 
Worse PCS at Wave 4  
 
 
Mental health outcomes 
Worse GHQ + MCS at Wave 4 
Worse GHQ + MCS at Wave 4 
Worse GHQ + MCS at Wave 4 
 
Physical health outcomes 
Worse PCS at Wave 4 
No significant association 
Worse PCS at Wave 4 
Reduction in frequency 
of insomnia symptoms: 
 
 
Sleep onset latency 
Overnight awakenings 
Daytime sleepiness 
 
 
Sleep onset latency 
Overnight awakenings 
Daytime sleepiness 
 
 
 
Mental health outcomes 
Better GHQ + MCS at Wave 4 
Better GHQ + MCS at Wave 4 
Better MCS at Wave 4 
 
Physical health outcomes 
No significant association  
Better PCS at Wave 4 
No significant effect 
 
 
 
Mental health outcomes 
Worse MCS at Wave 4 
No significant association 
No significant association 
 
Physical health outcomes 
No significant association 
No significant association 
Better PCS at Wave 4 
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7.4.2 Change in insomnia symptoms and perceived mental health 
 
The finding that change in insomnia symptoms were associated with perceived 
mental health was similar to Silva et al. (2009). They found that worsening of difficulty 
in initiating and maintaining sleep over five years was most strongly associated with 
lower mental health-related quality of life assessed with MCS scores.  A similar pattern 
emerges here, not only for MCS scores but also for GHQ scores, another validated 
measure of psychological well-being that has not been commonly assessed in relation 
to sleep and changes in insomnia symptoms.  
 
Poor self-rated mental health as captured in the GHQ and MCS are perhaps a 
contributing factor in how poor sleep and insomnia are risk factor for mental health 
problems such as depression and anxiety. Baglioni et al. (2011) meta-analysis of 21 
longitudinal studies revealed that healthy individuals with no depression and insomnia 
symptoms at baseline were at greater risk (OR 2.10 95% CI 1.86 – 2.38) of developing 
depression over time. Li, Wu, Gan, Qu, and Lu (2016) updated this meta-analysis to 34 
cohort longitudinal studies with over 172,007 participants and average follow-up of 5 
years (range 3.5 months – 34 years) again found this risk to be almost doubled (pooled 
RR 2.27, 95% CI 1.89 – 2.71). The risk was prevalent even across subgroups analysis by 
gender, location, insomnia definition, type of depression measure used, follow-up 
duration, sample size, and controlling for age, socioeconomic status, smoking, alcohol 
consumption, and body mass index. On a day-to-day level, poor sleep can affect mood 
and contribute to dysfunctional emotional reactivity and impaired socio-emotional 
functioning (Beattie, Kyle, Espie, & Biello, 2015; Dinges et al., 1997; Franzen, Siegle, & 
Buysse, 2008). The current findings provided additional insights into the associations 
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of changes in problems with sleep onset, awakenings, and daytime sleepiness in the 
long-term, which may in ways impact perceived mental well-being and risk for 
subsequent depression.  
 
This relationship between sleep and mental functioning was also observed in 
the chronic pain subgroup which also further corroborate previous findings. These 
findings highlight the pervasive and interactive nature of sleep and emotional 
disturbances in those with chronic pain and supports evidence for the daily influence 
of negative affect on daytime disabilities and impaired functioning associated with 
insomnia and poor sleep (Kothari, Davis, Yeung, & Tennen, 2015). O'Brien et al. (2011) 
assessed three chronic pain groups with back pain, facial pain, and fibromyalgia using 
daily monitoring of mood, pain rating and sleep with actigraphy and sleep diaries and 
found a relationship between self-reported poor sleep and increased pain ratings. 
Importantly, they found that negative mood was a moderator influencing this 
association. Poor sleep can have an impact on daily thoughts and the contents of those 
thoughts, leading to a tendency for brain processing to become skewed towards loops 
of repetitive negative thinking. These short-term sleep disruptions if they continue 
could contribute and lay the stage for long-term negative thinking, depressive and 
anxiety provoking thoughts, emotional problems, and general dissatisfaction with 
mental health (Gruber & Cassoff, 2014; Harvey, Murray, Chandler, & Soehner, 2011; 
Neckelmann, Mykletun, & Dahl, 2007; Palmer & Alfano, 2017). The longer the sleep 
problems persist, the greater the psychological consequences. The current findings 
illustrate that even in a general population, prolonged sleep problems or worsening 
of sleep problems may consequently be associated with general life satisfaction and 
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mental well-being. In addition, once insomnia symptom is present, an improvement 
over a period of four years was associated with only some improvement in mental 
well-being and not by as much magnitude as worsening of symptoms. As sleep 
difficulties may further be a contributory causal factor in the long-term occurrence of 
mental health problems and other comorbidities, recent trials have found that even 
in those with chronic pain conditions, improving sleep could benefit psychological 
health of the population by improving symptoms of depression and anxiety (Freeman 
et al., 2017; Luik et al., 2017).  
 
7.4.3 Difficulty getting to sleep and mental health in the general population  
 
In this current study, problems with sleep onset latency had the greatest 
association with mental health (GHQ and MCS scores) in the general population. In 
differentiating the effects of varying insomnia symptoms, Yokoyama et al. (2010) 
compared three sub symptoms of insomnia – they also found that difficulty initiating 
sleep was more associated with depression symptoms compared with early morning 
awakenings and difficulty maintaining sleep in their analysis of Japanese older adults 
over 65 years old and living in the community. These findings are possibly reflective of 
the presleep thoughts and cognitions that usually accompanies insomnia and sleep 
disturbance. People dissatisfied with their sleep or presenting with insomnia 
symptoms usually tend to report greater mental activities near bedtime. For example, 
it has been hypothesised that insomnia patients tend to overestimate how long it 
takes them to fall asleep because of enhanced sensory and information processing 
around sleep onset, leading to elevated cortical arousal and inability to disengage 
from sleep disruptive sensory and cognitive processes (Perlis, Giles, Mendelson, 
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Bootzin, & Wyatt, 1997). Cognitive models of insomnia further highlight these 
cognitive-behavioural mechanisms and explains how these psychosocial and 
physiological processes maintain insomnia disorder by prompting excessive negative-
toned cognitive activity, psychological arousal, distress, worrying, and rumination 
(Espie, Broomfield, MacMahon, Macphee, & Taylor, 2006; Harvey, 2002; Riemann et 
al., 2010).   
 
These excessive negative thinking centred around getting to sleep may 
contribute to problems with insomnia and related health outcomes. This current 
analysis highlights the potential relevance of sleep onset latency problems and need 
for further research to explore this association. Especially since it was not possible to 
directly compare these findings with other studies due to paucity of analysis on 
associations of sleep onset difficulties with perceived mental health. Problems with 
sleep onset latency may also be a prominent symptom of a certain type of insomnia 
that is particularly vulnerable to poorer physical and mental health, in comparison 
with other types of insomnia or sleep disorders featured by awakenings and excessive 
daytime sleepiness (e.g., sleep apnoea) (Chung, 2005).  
 
7.4.4 Improvements of insomnia symptoms in the general population  
 
This current study found the greatest associations of health outcomes with 
worsening than improvement of insomnia symptoms. Worsening of insomnia 
symptoms was associated with lower MCS scores of almost 3 points indicating ‘some 
more’ mental and emotional role limitation compared to baseline. On the other hand, 
improvement of symptoms was associated with higher scores by 1 – 2 points 
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indicating ‘a little less’ limitation (Ware, 1993; Ware et al., 1996). For GHQ scores, the 
results show deterioration of health status and reduction by 1.6 points when 
symptoms get worse and increase of 1.0 points when improvements in symptoms 
were observed. This GHQ score compare with those observed in a trial where mental 
health professionals who underwent an 8-week mindfulness based cognitive therapy 
showed increased psychological well-being at 20-week follow-up and experienced a 
GHQ score increase of 1.6 points (Ruths et al., 2012).  
  
As observed, there is already some associations of  ‘natural’ improvements in 
sleep, this also conveys that there could be some value in exploring the curative effect 
of improving sleep in the general population by investigating public health strategies 
to boost sleep and identifying avenue to implement these strategies. There are 
established CBT-I effective to tackle chronic insomnia in clinical populations (Trauer et 
al., 2015) but it is yet to be seen how this can be translated into meaningful strategies 
to reduce insomnia symptoms in non-clinical populations, and raise public awareness 
to the consequences and prevalence of disturbed sleep and symptoms of insomnia.  
There is some evidence to support the use of this manner of therapy in a community 
setting for those with sub-clinical and mild insomnia symptoms.  
 
There may be some value for CBT-I approaches to be delivered in an adapted 
manner as a public health strategy to address the prevalence and burden of mild 
insomnia symptoms. Swift et al. (2012) reported the effects of a 1-day intensive 
psychoeducational CBT sleep workshop. Participants from the general public were 
randomly assigned to attend an experimental workshop and follow up sessions 
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immediately (n=75), or to the waitlist control group (n=76). The CBT-I workshops were 
significantly effective in reducing insomnia symptoms among participants at a 3-
month follow-up. According to ratings on the insomnia severity index, symptoms 
reduced 17.6% in the experimental group, but only 3.5% in the control group. The 
workshops were delivered in large groups of around 30 participants and were easily 
accessible by the public. Adapting sleep management approaches in such manners 
means it can be readily delivered quickly and effectively in communities, does not 
require as much specialist knowledge as CBT-I for insomnia and thus bypasses the 
issue of lack of readily available health care professionals extensively trained to deliver 
more dedicated one-to-one non-pharmacological therapy for insomnia. It may help 
remediate mild symptoms such as problems initiating sleep and hereby then prevent 
development of clinical levels of insomnia. However, further trials with longer follow-
up and a broader set of outcome measures are still warranted to establish the 
effectiveness and efficiency of such a community-based therapy. There is also a need 
to explore which aspects of the broad construct of insomnia and sleep quality can be 
successfully addressed and improved and how this will impact on risk of developing 
clinical insomnia, health-related quality of life, and overall well-being of the 
population.   
 
7.4.5 Daytime sleepiness and perceived health outcomes in chronic pain 
 
In the arthritis subgroup, as well as sleep onset latency, it was changes in 
daytime sleepiness that translated to greater associations with health outcomes. As 
well as being related to chronic sleep loss, daytime sleepiness is often linked with 
organic sleep disorders like sleep apnoea, circadian rhythm sleep disorders, sleep 
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related movement disorders, hypersomnias (e.g., narcolepsy), and it could also be 
symptoms of underlying medical conditions such as stroke, brain injuries, other 
neurological disorder or use of medications and illicit substances (Tsai, 2010). In this 
chronic pain group, daytime sleepiness symptoms may reflect the dissatisfaction with 
daytime impairment not just related to sleep but also to their pain condition such as 
changes in pain intensity, flare-ups, and consequent decline in social and physical 
activity. In addition, those with chronic pain may also misperceive fatigue and physical 
exhaustion associated with their pain condition for sleepiness (Ancoli-Israel & Martin, 
2006; Shekleton, Rogers, & Rajaratnam, 2010).  It may be helpful to assess separately 
and tease apart the respective contribution of sleep problems, physical pain 
symptoms, and fatigue in contributing to daytime sleepiness. Consequently, targeting 
this symptom and improving sleep in this population may help in drawing attention as 
to how sleep affects not only pain but also daily functioning, mood, engagement in 
physical activity, pain appraisal and coping (Gerhart et al., 2016; Kothari et al., 2015; 
Tang & Sanborn, 2014). 
 
7.4.6 Preventing worsening of insomnia symptoms in chronic pain  
 
It is also worth noting that in the arthritis subgroup, the associations of natural 
improvement in sleep was not as prominent compared to the patterns of findings in 
the full sample. Even an improvement in sleep onset latency problems over time was 
still associated with worse health outcome. However, this analysis was carried out on 
imputed datasets, so this may have contributed to the result. Although, it may also be 
possible that a history of sleep disturbance in this group predicts stronger 
impairments in health status even if symptoms remits and resolves. The combined 
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effect of a chronic pain condition comorbid with poor sleep could lead to a 
predisposition to heightened sleep reactivity, sleep system sensitisation, increased 
vulnerability to insomnia symptoms, and psychological distress (Kalmbach, Pillai, 
Arnedt, Anderson, & Drake, 2016; Smith & Haythornthwaite, 2004). Hence, for those 
with a chronic pain condition, there may be a need for more targeted hybrid 
interventions that considers aspects of pain and sleep management to improve sleep 
in the long-term. Vitiello et al. (2014) were already able to show that 6 weekly sessions 
of CBT-I in those with arthritis led to short-term improvements in sleep measures 2 
months later across measures of insomnia severity, sleep quality and fatigue. 
Furthermore, for those showing improvement in sleep, the improvements further 
predicted sustained long-term improvement in sleep quality 18-months later, 
compared to those whose sleep did not initially improve.    
 
7.4.7 Limitations  
 
The current study highlights the associations of changes in insomnia symptoms 
with physical and mental health outcomes and is strengthened by the UKHLS large 
representative sample, availability of repeated assessment of measures in same 
individuals, derived weighting to control for sample attrition, and the measures of 
sleep and validated health outcomes. However, some limitations of the current 
analysis should also be noted. Whilst the study provided further investigation of the 
association of changes in sleep (i.e. a sustained exposure) with health outcomes, it 
lacked the specific longitudinal design (measurement of the outcome measure only 
prospectively) which would have further strengthened the causal relationship 
between sleep symptoms and health outcomes. Further longitudinal studies and 
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analyses of further waves of the UKHLS panel cohort data are required to establish if 
there is a temporal and causal prospective association between changes in sleep and 
these outcomes.  
 
The current analysis is also unable to provide an insight into what drove the 
changes in insomnia symptoms, it could be a case of reverse causality and that it was 
actually changes in the physical and mental outcomes and associated psychological 
distress and depression leading to worse or better sleep (Phelan, Love, Ryff, Brown, & 
Heidrich, 2010). To combat this, the current analysis controlled for Wave 1 measure 
of health outcomes, however, it was not possible to control for other changes in 
health outcomes during the 4-year period. In addition, each of the insomnia symptoms 
(sleep latency, awakenings and daytime sleepiness) were assessed independently for 
their relationship with health outcome at Wave 4 and whilst each analysis was 
adjusted for various confounding variables, the remaining insomnia symptoms were 
not included in the model and this may affect the specificity of the observed results.  
 
Furthermore, for the full sample analysis there was a difference noted for the 
MCS and sleep onset latency analysis for the imputed analysis. When comparing the 
imputed and complete case analysis, the association of decrease in frequency of sleep 
onset latency problems with Wave 4 MCS score was no longer significant.  This 
inconsistency suggests that perhaps missingness may be an issue for this analysis and 
begs the question of why responses for these particular items were missing in the first 
place. Missingness is often a common issue in panel studies with substantial follow-
up assessments. Attention should be paid to methods to deal with missingness and 
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consequent results should be interpreted with caution. Here for the full sample, the 
imputed data sets and complete cases analysis were compared to highlight any 
potential inconsistencies in estimates, confidence intervals and interferences. Further 
efficient techniques and statistical methods to address and appropriately interpret the 
issue of missing data in these types of studies would be a worthwhile research effort. 
 
Notably, assessment of sleep, outcomes, and even report of arthritis in the 
current analysis was based on self-report which is subject to recall and reporting 
biases. Some of items embedded within outcome measures (for example the sleep 
item in the GHQ-12) may also have an undetected impact on the observed 
associations between changes in sleep and the GHQ-12 outcome measure. In addition, 
Arthritis was not determined by clinical diagnosis and this arthritis subgroup within 
the general population were also as healthy as the population except for differences 
in PCS scores. This suggests they may present with less comorbidity with sleep issues 
compared with other clinical chronic pain patients. The current analysis also did not 
explore comorbidity with other health conditions reported in UKHLS (diabetes, 
asthma, cancer, epilepsy, depression, coronary heart disease etc.) and use of 
medications which may all contribute to different health states and differential effect 
on sleep. Furthermore, the comparison between the full sample and the arthritis 
subgroup was not as distinct since the full and subgroup sample were still overlapping 
to some extent.  
 
For assessment of insomnia symptoms, the UKHLS also does not have 
information on other organic sleep disorder such as sleep apnoea, hypersomnia, REM 
    
 289 
behaviour disorders, and the sleep assessment did not include items on duration of 
insomnia symptoms beyond the past month. Absence of other potential confounding 
sleep disorders, short period for report of insomnia symptoms, and lack of information 
on impact of sleep impairment on work and social participation and daytime 
functioning does not allow the assessment to meet full insomnia diagnostic criteria as 
per DSM-5 (2013) and ICSD-3 (2014).  This may reduce the specificity of the current 
assessment of insomnia symptoms and associations to capture the full spectrum of 
insomnia trajectories and health outcomes. Perhaps, future research or cohort study 
design can add a few further questions on self-reported assessment of sleep and sleep 
disorders to get an elaborate measure of clinical insomnia.  
 
7.5 Conclusion 
 
The current analysis revealed the association between changes in insomnia 
symptoms (both worsening and improvement) and perceived mental and physical 
functional well-being in the general population, and an arthritis subgroup. As new 
waves of data are released for the UKHLS, future analysis can perhaps also use 
advanced statistical techniques like latent modelling and latent class cluster analysis 
to follow insomnia symptoms over more than 2 – 3 time points, examine the rate of 
change in sleep over time and from this analysis determine further detailed curvilinear 
relationships between sleep and health outcomes. Fine-tuned latent class analysis can 
also explore the pattern and change in prevalence of different symptoms and relative 
contribution to different dimensions of physical and psychological well-being and 
pain-related health outcomes (Collins & Lanza, 2010).  
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8 General discussion  
 
 
“Sleep is that golden chain that ties health and our bodies together” 
 
Thomas Dekker (1577–1632) 
 
 
8.1 Summary of main findings 
 
This thesis sought to explore the interrelationship between sleep disturbance 
and the experience of pain. In particular, it considered the associations between sleep 
and pain and the mechanisms and factors underlying the association between the two 
processes. A brief summary of the relevant findings from the studies presented in the 
preceding chapters of the thesis is below.  
 
Chapter 4 – This experimental study supported the utility of conditioned pain 
modulation as a marker of pain inhibitory processes by exploring the reliability and 
validity of the procedures to elicit conditioned pain modulation response.  It 
considered factors such as the type of conditioning stimuli used to elicit pain, 
distraction, pain catastrophising, and sleep that could impact the efficiency of 
endogenous pain inhibitory response. Findings support the validity of CPM as a 
process relatively independent of cognitive distraction. Importantly, this study also 
revealed that less efficient CPM response may be associated with self-reported day-
to-day sleep disruptions (less total sleep time and longer sleep onset latency) in a 
sample of healthy young adults.  
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Chapter 5 – This quasi-experimental study further explored the associations between 
sleep disturbances and pain by comparing sleep and pain-related parameters in 
clinical chronic pain groups with healthy controls. Whilst the chronic pain groups 
reported poor self-reported sleep, findings did not find distinct differences in 
characteristics of sleep disturbance assessed using actigraphy, and polysomnography 
between two chronic pain conditions (fibromyalgia and chronic back pain) compared 
with healthy controls. However, the study offered some extension of the aims from 
Chapter 4. Namely that objective sleep disturbance (less total sleep time, more 
overnight arousals, and longer sleep onset latency) may be associated with less 
efficient CPM response and pain inhibitory processes in individuals with fibromyalgia 
and chronic back pain.  
 
Whilst Chapter 4 extended evidence of the validity of CPM as a marker of pain 
inhibition response, it also coveys the potential association of CPM with self-reported 
sleep. Chapter 5 did not reveal substantial differences in characteristics between 
chronic pain and non-chronic pain controls and pain inhibition processes. 
Nevertheless, these experimental chapters explored the potential associations of 
sleep disturbances with pain and provide a basis to further consider the role of pain 
inhibition and inflammation as possible mechanisms underlying the associations. 
Taken together, Chapter 4 and 5 provide an insight into the short-term cross-sectional 
relationship between sleep and pain variables and in small specific samples. To expand 
on this, this thesis moved on to examine the interrelationship between sleep and pain-
related variables over time in the general population. A systematic review and further 
epidemiological analyses were carried out and it was hoped this would add another 
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layer of perspective to deepen understanding of the potential long-term associations 
between sleep and pain outcomes.  
 
Chapter 6 – This systematic review and exploratory meta-analysis consolidates 
extant evidence that changes in sleep are associated with several dimensions of the 
pain experience (risk of developing a pain condition, elevations in levels of 
inflammatory markers, and a decline in self-reported physical health status). Findings 
from this review suggest that deterioration in sleep and persistent poor sleep are 
key risk factors of poor health. However, the findings do not provide sufficient 
evidence that an improvement in sleep quality has a reverse protective function. The 
review highlighted key issues that suggest that there is room for further longitudinal 
studies with longer and more frequent follow-up assessments, allowing for a proper 
evaluation of the impact of dynamic changes in sleep on long-term pain outcomes.  
 
Several methodological considerations arising from the systematic review 
also formed the focus of the analysis presented in Chapter 7. The review in Chapter 6 
revealed considerable variations across studies in the way changes in insomnia 
symptoms, sleep quality and quantity were measured, which limited interpretability 
and generalisation.  Hence, the need for an investigation into how changes in 
different sleep parameters may have differential associations with health outcomes. 
The studies reviewed also focused mainly on general populations. This leaves room 
to consider incorporating subgroup analyses (e.g., those with chronic pain) in future 
studies to dissect how change in sleep is associated with the pain-related physical 
and mental health functioning in a high risk clinical group.  
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Chapter 7 – This analysis using the UKHLS dataset revealed an association between 
changes in sleep and different insomnia symptoms over a 4-year period from Wave 1 
– Wave 4 (prolonged sleep onset latency, overnight and early morning awakenings, 
and daytime sleepiness) and perceived physical and psychological well-being at Wave 
4. In both the general population and people with arthritis, worsening of insomnia 
symptoms over the 4-year period was associated with subsequent poorer health 
outcomes, especially perceived mental health and psychological well-being. 
Associations with improvement in insomnia symptoms on health outcomes were, 
however, of lesser magnitude and often not significant compared to worsening of 
symptoms. These findings suggest that poorer sleep may be associated with worse 
psychological well-being and pain-related comorbidities in the general population and 
in those living with a chronic pain condition. 
 
8.2 Emerging findings, implications, and research recommendations 
 
Overall, the findings of this thesis provide further support for the associations 
between sleep and pain outcomes and offer some ideas on the processes through 
which this happens. The studies reported in this thesis assessed the relationship from 
two different angles (experimental and observational). These different but 
complementary research methodologies enrich and contextualise our understanding 
of the interrelationship between sleep, pain, and related health outcomes.   
 
Specifically, from the two experimental studies, we see the possible associations 
of sleep disturbance with pain response through several possible mechanisms 
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including central pain processing and inflammation. The exact roles of these 
mechanisms remain unspecified and further empirical investigations are warranted to 
establish their role in the causal links between sleep and pain. That said, the 
systematic review and analysis of the UKHLS dataset provided some evidence to 
support both the long-term associations between sleep and pain problems and the 
mechanisms involved from an epidemiological point of view. Further research into 
understanding the temporal effects and long-term relationship between the two may 
subsequently be used to determine and predict disease prognosis of these problems 
and impact on population health.  
 
Sleep disturbances and pain inhibition processes    
 
From the experimental studies discussed in this thesis, sleep disruptions seem 
to be associated with enhanced responses to pain and diminish the efficacy of 
descending pain inhibitory pathway. As reported in Chapter 4, self-reported total 
sleep time was correlated with CPM response and shorter in CPM non-responders 
than non-responders. Other markers of sleep disturbance, namely, sleep onset latency 
and wake after sleep onset were also longer in CPM non-responders but were not 
statistically significant possibly due to lack of statistical power and mismatch in the 
cell sizes of responders (n = 44; n = 91) and non-responders (n = 10; n = 12). 
 
The study presented in Chapter 5 combined self-reported sleep assessment 
with objective PSG sleep parameters and the findings of this study further revealed 
potential association of patterns of sleep disturbances with measures of pain 
threshold and pain inhibition. Here, we see that objective sleep disturbance may also 
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be associated with pain inhibitory processes in a chronic pain population. Less total 
sleep time may be associated with lower CPM response and greater arousal index with 
lower pressure pain threshold assessed the next morning in chronic back pain patient. 
In the fibromyalgia group, longer sleep onset latency and increased arousal index 
overnight may also be related to lower pressure pain thresholds and next day CPM 
response. Of course, these are only correlations which were no longer significant after 
Bonnferroni corrections and coming from a study of a small sample size. Further 
clarification of the causal link is required in larger studies in both healthy and clinical 
populations.  
 
Nevertheless, one cannot discount the possibility that short-term sleep 
disruptions may not only be associated with acute pain responses but could also 
contribute to an increased risk for future chronic pain conditions (Iacovides, George, 
Kamerman, & Baker, 2017).  If self-reported poor sleep quality and even objectively 
measures sleep are associated with insufficient CPM, it raises the question whether 
interventions that aim to improve sleep quality and protect sleep duration could alter 
pain inhibition response? Roehrs, Harris, Randall, and Roth (2012) for example, 
randomised 18 healthy participants with mild sleep disturbance (sleep efficiencies < 
85% on screening PSG) to either extended bedtime over 4 nights to 10 hours or 4 
nights of sleep diary reported habitual times. The extended bedtime group showed an 
increase in total sleep time and reduced sleepiness as assessed by daytime multiple 
sleep latency tests (MSLT) and this was correlated with reduced pain sensitivity and 
greater pain threshold to a heat pain stimulus. These findings highlight the need for 
further work both in healthy and clinical population to determine how and if changes 
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in sleep can lead to better pain and health outcomes. The finding from this thesis point 
to insufficient sleep quantity as a factor associated with pain inhibition impairments. 
Future investigations may further assess the feasibility of protecting or extending 
sleep duration or addressing sleep continuity disturbances on pain inhibition 
impairments in pain conditions.  
 
This would also ideally provide a platform to assess the temporal relationship 
between the processes of sleep and pain over a period of a couple of weeks for 
example, by combining ambulatory PSG, self-reported sleep, and daytime lab visits for 
quantitative sensory testing and to assess CPM response. Combining assessments of 
sleep and pain parameters may have clinical utility in enabling the development of 
personalised assessment of sleep disturbance, inflammation, and psychophysical pain 
modulation profile. It has been suggested that greater pro-nociceptive profile may be 
linked with higher risk of pain acquisition, intense pain syndrome and greater 
resistance to therapeutic methods, and greater impairments in the overall 
psychosocial experience of pain. Whereas an anti-nociceptive profile may be more 
indicative of lower chances of acquiring pain, and lower intensity of pain syndromes 
and symptoms (Granovsky & Yarnitsky, 2013; Yarnitsky, 2015). This has implications 
for pain therapy as it may provide predictive indicators of the individual’s 
psychophysical pain behaviour and response to medications and other preventive 
treatments. Essentially, by establishing differential pain profiles, research can explore 
if sleep disturbance is a risk factor for a pro-nociceptive or anti-nociceptive profile and 
if this association is also mediated by factors such as inflammation. In addition, the 
concurrent presence of sleep disturbances and pain syndrome may further facilitate 
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a change in pain modulation state and profile, shifting it towards pro-nociception 
(Granovsky & Yarnitsky, 2013). The effect of addressing sleep continuity disturbances 
may thus differ based on the presenting pain profile or pain inhibition impairments in 
an individual presenting with a pain condition. Knowledge of how sleep influences an 
individual’s pain experience may promote personalised integrated interventions and 
management by sleep phenotype. As the systematic review in Chapter 6 also revealed, 
these associations between sleep and pain inhibition profiles have also not yet been 
explored from a longitudinal perspective. This would further inform the 
epidemiological evidence on the development, perpetuation, or alleviation of pain 
experience.  
 
Sleep disturbances and pain-related disease risk  
The systematic review in Chapter 6 illuminated that a decline in sleep quality 
and sleep quantity over time was generally associated with a greater risk of developing 
a pain condition, small elevations of inflammatory markers, and a decline in self-
reported physical health status. Levels of inflammatory cytokine consistently emerges 
as one of the potential mechanisms through which sleep influences short- and long-
term disease risk. The study in Chapter 5 also suggested that profiles of inflammation 
and levels of cytokines may differ and be elevated in those with chronic pain and poor 
sleep compared with pain-free controls.  Other studies have suggested that subclinical 
elevations in inflammation cytokine levels such as hs-CRP are often related to 
increased pain sensitivity, suggesting a potential role of inflammation in experimental 
pain and which may be of importance for the development of clinical pain (Schistad, 
Stubhaug, Furberg, Engdahl, & Nielsen, 2017).  
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The studies included in the systematic review tend to evaluate findings related 
to sleep and these physiological biomarkers either in isolation or in relation to 
mortality risk or another health conditions such as cardiovascular disease (Cappuccio 
et al., 2011; Miller & Cappuccio, 2007) but not specifically in relation to pain or even 
specifically within a chronic pain population. Evidence from further epidemiological 
studies is required to substantiate how sleep could trigger and activate stress 
response, stimulate pro-inflammatory markers, and consequently facilitate and 
worsen pain experience (Smith et al., 2009). Much of the included studies lacked the 
specificity and research design required to clarify the underlying direction of the 
association between sleep and pain and how sleep alters physiological biomarkers and 
influences pain experience. To pin down the role of these biomarkers, future 
investigations would need to expand on the relevance of these biomarkers and how 
they specifically relate to aspects of the physiological and psychological sleep and pain 
experience (e.g., pain inhibition, conditioned pain modulation, pain catastrophising, 
quality of life), in both short- and long-term.  
 
Sleep disturbances and long-term physical and mental health 
The evidence from the experimental studies in this thesis focused primarily on 
examining the within-person association between sleep and pain within relatively 
healthy and small clinical groups. Although the studies provide in-depth explorations 
and support for a relationship between sleep disturbances and pain. The 
generalisability of the findings from such studies to the general population needs to 
be further reinforced by prospective studies with longer follow-up periods. By 
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considering an epidemiological perspective, this thesis generated further insight on 
the trajectory of sleep deterioration and sleep improvement and associations with 
pain related outcomes. Evaluating changes in sleep allowed for simulation of sleep 
deterioration and improvement and different sleep trajectories over time, enabling a 
better gauge of the potential value of sleep interventions in the prevention and 
management of chronic pain in the general population.  
 
The exploratory meta-analysis from the systematic review presented in 
Chapter 6 and the UKHLS analysis results in Chapter 7 suggested that new incidence 
and persistence of sleep problems may be associated with poor perceived physical 
and mental health over time. Whereas, the remission of sleep disturbances was only 
associated with a slight improvement in health outcomes. Such findings suggest that 
it is logical to hypothesise that improvements in sleep may help to mitigate pain-
related health factors. Hence, future studies should not only focus on the negative 
effect of sleep on pain or the association between sleep problems and propensity 
towards the risk of developing a pain condition. It is equally important to characterise 
these dynamic natural improvements in sleep and determine why and how they are 
associated with positive pain-related health outcomes.  
 
Promoting good sleep and well-being within clinical pain and general population  
In clinical settings, sleep is increasingly gaining relevance as an assessment and 
treatment target within pain management. The growing body of evidence on the 
specifics of the relationship between the two garnered from this thesis supports 
further development of ongoing non-pharmacological treatments for sleep problems 
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such as hybrid cognitive behavioural therapy for insomnia and pain to tackle sleep and 
pain problems (Tang, Goodchild, & Salkovskis, 2012). Further experimental work 
would provide insight and further conceptualisation of the sleep and pain relationship 
and relevant bio-psychological mechanisms at play as well as their role in the inception 
in sleep problems and other physical and functional impairments in chronic pain.  At 
the general population level, there may also be some value for CBT-I approaches to 
be delivered in an adapted manner as a strategy to address the burden of mild 
insomnia symptoms prevalent within the population and targeting at-risk population 
groups. Indeed, further work is needed on how this can impact the health of the 
population positively.  
 
Future studies can also look into differences between those with worsening 
and improvement of sleep problems to gain further understanding of what triggers 
these changes in sleep. Different lifestyle factors such as day-to-day activities, 
exercise, and diet could be conducive to better sleep or predictive of different 
patterns of change and thus indicative of how to promote better sleep and health-
related quality of life. Studies have suggested that behavioural interventions and 
approaches (e.g. Tai Chi) that target sleep may not only improve sleep, but also 
improve physical health and wellbeing (Irwin et al., 2015). Currently, we do not know 
what produces these effects and a key and interesting extension of this work could 
possibly focus on the mechanisms through which these approaches (exercise, diet 
etc.) impact on biologic processes and interactions between sleep and pain (Davidson, 
2015). Consequently, the goal of further sleep and pain epidemiological studies in this 
area is to inform understanding of the development, evolution and progression of 
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these problems in the population and use this epidemiological knowledge to enhance 
societal health and well-being. 
 
8.3 Looking forward 
 
 
Poor sleep and chronic pain conditions both contribute largely in determining 
societal health and present a major public health challenge due to their pervasive 
impact on daily functioning and well-being. Further experimental studies are needed 
to verify the specific causal links between sleep, inflammatory processes, and the 
experience of pain and the interaction between these processes in causing the altered 
pain perception and hyperalgesia induced by sleep disturbances. In addition, 
screening for sleep disturbances and psychological risk factors and addressing acute 
insomnia and sleep problems in the short-term may lessen the risk and transition to 
long-term chronic pain comorbidity. It has been suggested that timely identification 
and response to acute insomnia to lessen the aggravation and development 
occurrence of chronic insomnia is possible and feasible (Ellis, Cushing, & Germain, 
2015; Ellis, Gehrman, Espie, Riemann, & Perlis, 2012). This could be carried out for 
example during hospitalisation for pain surgery or whenever symptoms of acute 
insomnia are first identified by the primary care giver. Although, it is also reliant on 
the availability of a treatment infrastructure which recognises acute insomnia as a 
problem, and knowledgeable health-care providers with the expertise to assess and 
treat the problem (Ellis, Gehrman, et al., 2012).  
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 It would also be desirable to further investigate the effectiveness of 
interventions, e.g., cognitive behavioural therapies and exercise programmes as 
possible tools to enhance pain-related health outcomes and quality of life in general 
via promoting sleep. This can serve as further tests of the causal association between 
sleep, pain, and wellbeing. Although, in order to implement interventions and 
strategies to promote better sleep and good sleep quality, there is a need to 
disentangle and examine which aspects of sleep fluctuates and is also most feasibly 
amenable to changes and improvements that would lead to better quality of life.   
 
The need for more longitudinal research and knowledge of the processes 
underlying sleep and pain is also consistently emphasised throughout the thesis (Lee, 
2016). Importantly, further evidence is required to understand the trajectory of sleep 
characteristics and health outcomes in the general population and in those with a 
chronic pain condition. Longitudinal studies enable understanding of the natural 
evolution of poor sleep, its symptoms, development and progression from acute to 
chronic insomnia, transition from good sleep to poor sleep and vice-versa and causal 
consequences and associations of these trajectories and transitions with pain-related 
health outcomes (Ellis, Perlis, Neale, Espie, & Bastien, 2012; Kyle, Morgan, & Espie, 
2010; Morin et al., 2009). Longitudinal studies with more than two follow-up 
assessments and appropriate corresponding cross-lagged analysis would provide a 
suitable platform to substantiate the temporal relationship between changes in sleep 
and pain outcomes and to provide a framework to examine the trajectories of health 
status over time across individuals with different patterns of sleep changes. 
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8.4 Limitations of the thesis  
 
The studies and findings presented in this thesis are limited by a number of 
factors that require consideration:   
i. The scope of this thesis did not cover in detail other domains of sleep-wake 
behaviour for example, the role of chronotypes and biological circadian 
rhythms in the association between sleep and pain. There is limited but 
emerging evidence concerning the involvement of chronotypes and diurnal 
variations in pain syndromes, pain perception, related inflammatory 
processes, and pain management (Junker & Wirz, 2010; Keller et al., 2009).  
Circadian variations have also been observed in chronic pain conditions; the 
pain intensity and pain perception is often dependent on time of day (Junker 
& Wirz, 2010). Chronotypes are also often linked to circadian rhythms and 
diurnal variations. Some cross-sectional studies have revealed that both early 
and late chronotypes type with fibromyalgia reported poorer sleep quality and 
subjective pain than intermediate types and that late chronotypes had 
amplified fibromyalgia related symptoms (Kantermann, Theadom, 
Roenneberg, & Cropley, 2012). In terms of pain perceptions, evening types also 
tend to show lower pain thresholds and greater sensitivity to pain than 
morning types all day long and this could also be partially associated with 
affective functioning, negative affect, differences in cortisol, and sleep debts 
(Jankowski, 2013).  This could have implications for the findings reported in 
this thesis related to the assessment of pain inhibition, inflammatory markers, 
sleep disturbances, and affective variables. On the other hand, these existing 
studies are also few and often limited either by small restricted sample sizes 
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or cross-sectional designs. Further studies should seek to further clarify the 
interrelationship between subjective and objective pain assessment and sleep 
disturbances and also individual chronotypes. Considering the role of 
biological rhythms may be another part of the puzzle in understanding the links 
between sleep and better individualized pain assessment and management. 
 
ii. Findings from the experimental studies in the chronic pain population is 
limited by small sample size, mismatch between groups, recruitment 
difficulties, and subsequent lack of control in some aspects of the design. 
Although studies using PSG sleep assessment do not usually tend to have 
extremely large sample size. As encountered during the course of recruitment 
for this study, it may often be hard to recruit patients for extensive overnight 
sleep studies solely for research purposes. In addition, academic research 
department may also be constrained by the scope of how many participants 
can be tested at once due to limited resources, compared to dedicated sleep 
disorders clinics within hospitals. Looking forward, and with the emergence 
and popularity of ‘big data’ analysis, there could be scope for building a 
database of experimental PSG studies within and across sleep laboratories 
(Bianchi et al., 2017). This would then inform a collation of sleep data to be 
assessed for microstructural features to distinguish pain-free healthy with 
those with pain conditions. 
 
iii. Despite the multi-methodological approach used in this thesis and given that 
perception of sleep quality and pain are inherently subjective experiences, the 
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thesis lacked some exploration of the participants’ and patients’ 
phenomenological perspective.  For example, some chronic pain patients do 
not report sleep problem, or their sleep difficulty was not a cause of great 
burden or interference. Why this is the case would be interesting to know. 
When the thesis explored self-reported change in sleep, it may have also been 
informative to qualitatively consider how the changes in sleep are important 
or meaningful to participants and how the changes contribute to the 
perception of functioning and well-being. It may also have been the reverse 
and that it was changes in perceived health and functioning that contributed 
to these changes. Further studies may further elaborate if it is sleep pattern 
and behaviours that fundamentally change in the long-term and lead to 
changes in health outcomes or if individuals learn to cope better with poor 
sleep and adapt their function accordingly. Future studies incorporating 
qualitative analyses and utilising mixed-methods approaches as used in health 
sciences research may provide further insight into this (Ostlund, Kidd, 
Wengstrom, & Rowa-Dewar, 2011).  
 
8.5 Concluding remarks  
 
The strength of this thesis was the exploration of the interaction between the 
sleep and pain experience using several methodological approaches and providing 
different levels of empirical evidence. From observational quasi-experimental studies 
to a systematic review and analysis of a cohort dataset; these approaches 
complemented each other and enabled the utilisation of different empirical 
methodologies to explore the influence of sleep fluctuations on pain in both the short 
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and long-term and the underlying relationship between the two.  The thesis also 
highlighted future research needs crucial to the implementation and translation of 
scientific knowledge of sleep to improve pain and related health outcomes. These 
include investigations into beneficial interventions aimed at addressing the negative 
health outcomes associated with poor sleep, and the need to incorporate sleep 
assessment into pain management approaches.  
 
Emerging recommendations from the thesis also include the need for 
epidemiological investigations to understand the evolution and consequences of 
changes in sleep quality and the impact of this on pain conditions and the health of 
the population. For example, given accumulating evidence to support the importance 
of sleep in influencing cardiovascular health (Cappuccio et al., 2011), it has been 
suggested that poor sleep could be included in the list of leading modifiable 
cardiovascular disease risk factors (Lallukka & Kronholm, 2017; Redline & Foody, 
2011). A similar conceptualisation can perhaps be applied to pain research to establish 
the importance of sleep as a health attribute integral to many physiological and 
behavioural factors implicated in pain and related health outcomes. Subsequently, 
this would enable the prioritisation of sleep as an important health issue and help 
target interventions to promote better sleep, reduce pain-related disease risks, and 
improve population health.  
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